1 00:00:07,137 --> 00:00:08,572 >> Joni Rutter: THANK YOU, 2 00:00:08,572 --> 00:00:10,207 EVERYONE FOR JOINING TODAY. 3 00:00:10,207 --> 00:00:13,076 OUR 36th MEETING OF THE 4 00:00:13,076 --> 00:00:16,780 NATIONAL CENTER FOR ADD VAPS GS 5 00:00:16,780 --> 00:00:17,414 TRANSLATIONAL SCIENCE ADVISORY 6 00:00:17,414 --> 00:00:18,482 COUNCIL TODAY. 7 00:00:18,482 --> 00:00:20,117 I WILL GAVEL US IN. 8 00:00:20,117 --> 00:00:21,418 YOU MAY COMMENCE. 9 00:00:21,418 --> 00:00:24,221 I THINK I JUST BROKE THE GAVEL. 10 00:00:24,221 --> 00:00:26,690 [LAUGHTER] 11 00:00:26,690 --> 00:00:29,393 IT'S A GOOD START, YES. 12 00:00:29,393 --> 00:00:31,495 OKAY, WELL, I DON'T HAVE REALLY 13 00:00:31,495 --> 00:00:33,163 ANY OPENING STATEMENTS, JUST TO 14 00:00:33,163 --> 00:00:35,065 INVITE YOU HERE TODAY TO HEAR A 15 00:00:35,065 --> 00:00:38,602 LITTLE BIT MORE ABOUT WHAT 16 00:00:38,602 --> 00:00:40,504 NCATS HAS BEEN DOING OVER THE 17 00:00:40,504 --> 00:00:42,439 COURSE SINCE WE LAST MET. 18 00:00:42,439 --> 00:00:43,907 ANNA WILL GO OVER OUR AGENDA. 19 00:00:43,907 --> 00:00:45,876 AND THEN WE WILL GO AHEAD AND 20 00:00:45,876 --> 00:00:46,343 GET STARTED WITH THE 21 00:00:46,343 --> 00:00:48,278 PROCEEDINGS. 22 00:00:48,278 --> 00:00:49,079 ANNA, WE WILL TURN IT OVER TO 23 00:00:49,079 --> 00:00:49,913 YOU. 24 00:00:49,913 --> 00:00:50,747 >> Anna Ramsey-Ewing: THANK 25 00:00:50,747 --> 00:00:55,485 YOU, JONI. 26 00:00:55,485 --> 00:00:57,187 WE WILL COMMENCE WITH OUR ROLL 27 00:00:57,187 --> 00:00:59,523 CALL. 28 00:00:59,523 --> 00:01:00,123 MEMBERS IN ATTENDANCE PLEASE 29 00:01:00,123 --> 00:01:04,561 INDICATE SO. 30 00:01:04,561 --> 00:01:05,495 SERGIO? 31 00:01:05,495 --> 00:01:06,663 >> HERE. 32 00:01:06,663 --> 00:01:10,100 >> PAUL HARRIS? 33 00:01:10,100 --> 00:01:14,037 >> ANNI KENNEDY. 34 00:01:14,037 --> 00:01:14,638 >> KELLY McVERNY? 35 00:01:14,638 --> 00:01:17,908 >> HERE. 36 00:01:17,908 --> 00:01:20,277 >> KEITH MULLER. 37 00:01:20,277 --> 00:01:26,983 >> THE ONLY NOT IN ATTENDANCE 38 00:01:26,983 --> 00:01:28,719 TODAY IS PAULA SHARMIN. 39 00:01:28,719 --> 00:01:29,619 THE OPEN SESSION WILL TAKE 40 00:01:29,619 --> 00:01:30,887 PLACE OVER ONE DAY. 41 00:01:30,887 --> 00:01:33,023 AS YOU CAN SEE WE WILL BEGIN 42 00:01:33,023 --> 00:01:34,157 WITH OUR DIRECTOR'S REPORT. 43 00:01:34,157 --> 00:01:36,326 AFTER THAT WE HAVE A 44 00:01:36,326 --> 00:01:37,461 PRESENTATION BY PETER MARKS BY 45 00:01:37,461 --> 00:01:38,995 THE FDA. 46 00:01:38,995 --> 00:01:41,498 WE WILL HAVE A SHORT LUNCH 47 00:01:41,498 --> 00:01:42,632 BREAK TODAY, FOLLOW BY TWO 48 00:01:42,632 --> 00:01:44,434 PROGRAM UPDATES. 49 00:01:44,434 --> 00:01:46,069 ONE FROM DIVISION OF RARE 50 00:01:46,069 --> 00:01:49,506 DISEASES RESEARCH INNOVATION. 51 00:01:49,506 --> 00:01:50,107 THEN DIVISION OF PRECLINICAL 52 00:01:50,107 --> 00:01:51,441 INNOVATION. 53 00:01:51,441 --> 00:01:53,844 THEN A VERY SHORT BREAK AND 54 00:01:53,844 --> 00:01:54,778 MOVE INTO OUR CLEARANCE OF 55 00:01:54,778 --> 00:01:56,580 CONCEPTS. 56 00:01:56,580 --> 00:01:59,950 THIN A SHORT DECISION FOR OUR 57 00:01:59,950 --> 00:02:01,184 WRAP-UP AND FINALLY ADJOURN. 58 00:02:01,184 --> 00:02:02,319 NEXT SLIDE, PLEASE. 59 00:02:02,319 --> 00:02:03,920 ALL RIGHT. 60 00:02:03,920 --> 00:02:08,892 SO BECAUSE WE ARE MEETING IN 61 00:02:08,892 --> 00:02:12,329 PERSON AND WE ARE ALSO 62 00:02:12,329 --> 00:02:13,063 PARTICIPATING BY ZOOM, THE 63 00:02:13,063 --> 00:02:16,266 FOLKS ARE IN THE ROOM ARE NOT 64 00:02:16,266 --> 00:02:16,867 REQUIRED TO BE CONNECTED TO 65 00:02:16,867 --> 00:02:19,069 ZOOM. 66 00:02:19,069 --> 00:02:20,670 IT'S ALSO IMPORTANT TO TURN 67 00:02:20,670 --> 00:02:21,838 YOUR TABLE MICROPHONE ON WHEN 68 00:02:21,838 --> 00:02:23,440 YOU ARE SPEAKING TO MAKE SURE 69 00:02:23,440 --> 00:02:25,275 EVERYONE CAN HEAR YOU. 70 00:02:25,275 --> 00:02:26,676 IF YOU ARE PARTICIPATING 71 00:02:26,676 --> 00:02:28,478 VIRTUALLY, PLEASE USE THE RAISE 72 00:02:28,478 --> 00:02:30,147 HAND OR CHAT FEATURE AND WAIT 73 00:02:30,147 --> 00:02:33,016 UNTIL WE CALL UPON YOU TO 74 00:02:33,016 --> 00:02:34,251 PROVIDE YOUR INPUT. 75 00:02:34,251 --> 00:02:36,052 ALL PARTICIPANTS ALLOW SPEAKERS 76 00:02:36,052 --> 00:02:37,354 TO MOVE THROUGH THEIR 77 00:02:37,354 --> 00:02:38,588 PRESENTATIONS NOTING YOUR 78 00:02:38,588 --> 00:02:39,790 COMMENTS OR QUESTIONS AND 79 00:02:39,790 --> 00:02:42,225 NOTING THEM WHEN CALLED ON. 80 00:02:42,225 --> 00:02:44,661 WE MUST ENSURE DURING THE 81 00:02:44,661 --> 00:02:46,463 MEETING, DISCUSSIONS OF 82 00:02:46,463 --> 00:02:51,635 CONFIDENTIAL MATTERS ARE NOT 83 00:02:51,635 --> 00:02:53,737 INADVERTENTLY -- EXCUSE ME, 84 00:02:53,737 --> 00:02:54,638 THAT'S ACTUALLY NOT APPROPRIATE 85 00:02:54,638 --> 00:02:55,672 FOR THE OPEN SESSION. 86 00:02:55,672 --> 00:02:57,774 NEXT SLIDE. 87 00:02:57,774 --> 00:02:58,708 WE ARE USING THE VIDEOCAST 88 00:02:58,708 --> 00:03:00,811 FEATURE TODAY. 89 00:03:00,811 --> 00:03:02,112 AUDIENCE MEMBERS MAY SUBMIT 90 00:03:02,112 --> 00:03:04,347 COMMENTS UNTIL JUNE 13 BLG BY 91 00:03:04,347 --> 00:03:07,384 USING THE EMAIL FUNCTION 92 00:03:07,384 --> 00:03:08,285 AVAILABLE ON THE NIH VIDEOCAST 93 00:03:08,285 --> 00:03:10,420 WEBSITE. 94 00:03:10,420 --> 00:03:14,090 OR SEND THEM TO THE NCATS 95 00:03:14,090 --> 00:03:23,366 COUNCIL INBOX. 96 00:03:23,366 --> 00:03:25,068 FOR FUTURE MEETING DATES IN 97 00:03:25,068 --> 00:03:29,105 2024, WE WILL BE MEETING 98 00:03:29,105 --> 00:03:29,606 SEPTEMBER 19-20. 99 00:03:29,606 --> 00:03:32,475 IN 2025, WE ARE MEETING 100 00:03:32,475 --> 00:03:34,678 VIRTUALLY IN JANUARY 30-31. 101 00:03:34,678 --> 00:03:36,947 WE ARE MEETING IN PERSON MAY 102 00:03:36,947 --> 00:03:38,014 22-23rd. 103 00:03:38,014 --> 00:03:42,953 SEPTEMBER 18-19. 104 00:03:42,953 --> 00:03:46,089 AND 2026 WE ARE MEETING 105 00:03:46,089 --> 00:03:47,490 VIRTUALLY IN JANUARY, 29-30. 106 00:03:47,490 --> 00:03:48,258 IN MAY WE EXPECT TO BE IN 107 00:03:48,258 --> 00:03:49,726 PERSON. 108 00:03:49,726 --> 00:03:53,029 THE 21-22. 109 00:03:53,029 --> 00:03:55,699 AND THEN SEPTEMBER 2026 WE ARE 110 00:03:55,699 --> 00:03:59,369 LOOKING FOR AN INPERSON MEETING 111 00:03:59,369 --> 00:04:00,403 SEPTEMBER 17-19. 112 00:04:00,403 --> 00:04:02,639 WITH THAT WE ARE GOING TO HAVE 113 00:04:02,639 --> 00:04:05,075 OUR DIRECTOR'S REPORT TO THE 114 00:04:05,075 --> 00:04:06,977 COUNCIL PRESENTED BY DR. 115 00:04:06,977 --> 00:04:07,711 RUTTER, DIRECTOR OF NCATS. 116 00:04:07,711 --> 00:04:09,813 >> Joni Rutter: THANK YOU SO 117 00:04:09,813 --> 00:04:10,413 MUCH, ANNA, REALLY APPRECIATE 118 00:04:10,413 --> 00:04:11,348 THAT. 119 00:04:11,348 --> 00:04:15,185 GOOD MORNING, EVERYONE. 120 00:04:15,185 --> 00:04:16,953 WELCOME TO THE DIRECTOR'S 121 00:04:16,953 --> 00:04:17,387 REPORT OF COUNCIL. 122 00:04:17,387 --> 00:04:18,989 THERE'S A LOT TO GO THROUGH SO 123 00:04:18,989 --> 00:04:20,090 I WILL GO AHEAD AND JUMP RIGHT 124 00:04:20,090 --> 00:04:21,658 IN. 125 00:04:21,658 --> 00:04:23,560 I WANTED TO START OFF AS I 126 00:04:23,560 --> 00:04:25,495 USUALLY DO WITH A SUMMARY OF 127 00:04:25,495 --> 00:04:27,297 WHAT WE PREPTED LAST COUNCIL SO 128 00:04:27,297 --> 00:04:28,798 YOU REMEMBER KIND OF WHAT WE 129 00:04:28,798 --> 00:04:30,133 TALKED ABOUT LAST TIME. 130 00:04:30,133 --> 00:04:32,035 WHEN WE MET LAST TIME WE DIDN'T 131 00:04:32,035 --> 00:04:34,070 QUITE HAVE THE BUDGET IN PLACE. 132 00:04:34,070 --> 00:04:37,507 WE DIDN'T QUITE HAVE OUR NCAT 133 00:04:37,507 --> 00:04:38,842 SENIOR LEADERSHIP FINALIZED. 134 00:04:38,842 --> 00:04:40,610 NOW I HAVE LOTS OF VIEWS ON 135 00:04:40,610 --> 00:04:42,045 THIS FRONT AND I'M EXCITED TO 136 00:04:42,045 --> 00:04:43,780 TALK TO YOU ABOUT THAT. 137 00:04:43,780 --> 00:04:45,682 WE HAD TALKED ABOUT A VARIETY 138 00:04:45,682 --> 00:04:47,817 OF OTHER PROGRAMS WE ARE MAKING 139 00:04:47,817 --> 00:04:53,156 ADD VAPSES IN LIKE THE ACTIV-6 140 00:04:53,156 --> 00:04:53,857 CLINICAL TRIAL WHICH IS NOW 141 00:04:53,857 --> 00:04:56,259 COMPLETE. 142 00:04:56,259 --> 00:04:57,527 ENROLLMENT IS COMPLETE. 143 00:04:57,527 --> 00:05:00,196 WE ARE IN THE PROCESS OF DOING 144 00:05:00,196 --> 00:05:06,102 ANALYSIS. 145 00:05:06,102 --> 00:05:08,438 WE ARE HOPING IT DO BE 146 00:05:08,438 --> 00:05:10,140 PUBLISHED IN THE NEW YEAR OR 147 00:05:10,140 --> 00:05:11,041 PERHAPS END OF THE YEAR. 148 00:05:11,041 --> 00:05:14,577 THAT'S EXCITING. 149 00:05:14,577 --> 00:05:16,479 WE HAVE NEW APPROACH 150 00:05:16,479 --> 00:05:17,614 METHODOLOGIES OR NAMS, I WILL 151 00:05:17,614 --> 00:05:20,250 TALK ABOUT THAT TOO. 152 00:05:20,250 --> 00:05:21,418 EDITING IS ANOTHER AREA THAT 153 00:05:21,418 --> 00:05:23,586 MOVED INTO PHASE 2. 154 00:05:23,586 --> 00:05:24,788 ANOTHER PROGRAM WE ARE INVOLVED 155 00:05:24,788 --> 00:05:27,524 IN, WE TALKED A LITTLE ABOUT 156 00:05:27,524 --> 00:05:28,992 DATA SCIENCE AND LARGE LANGUAGE 157 00:05:28,992 --> 00:05:32,562 MODELS AND THE WORK IN THAT 158 00:05:32,562 --> 00:05:34,064 SPACE, INCLUDING THE LITCOIN. 159 00:05:34,064 --> 00:05:36,566 SOME OF THE WORK THAT'S BEEN 160 00:05:36,566 --> 00:05:40,203 GOING ON IN DPI RELATED TO THE 161 00:05:40,203 --> 00:05:41,371 IND'S AND NDA SUBMISSIONS. 162 00:05:41,371 --> 00:05:43,139 AND I THINK WE WILL HEAR A 163 00:05:43,139 --> 00:05:44,941 LITTLE MORE ABOUT THAT LATER 164 00:05:44,941 --> 00:05:45,308 TODAY AS WELL. 165 00:05:45,308 --> 00:05:47,110 WE TALKED ABOUT A VARIETY OF 166 00:05:47,110 --> 00:05:48,945 INTERACTIONS. 167 00:05:48,945 --> 00:05:50,847 THE DISCUSSION AROUND THAT 168 00:05:50,847 --> 00:05:52,615 TOPIC SPECIFICALLY PROMPTED US 169 00:05:52,615 --> 00:05:55,185 TO INVITE THE FDA TODAY. 170 00:05:55,185 --> 00:05:56,653 BY THE FDA, I DO MEAN PETER 171 00:05:56,653 --> 00:05:58,421 MARKS. 172 00:05:58,421 --> 00:06:00,623 I GUESS HE ISN'T "THE" FDA BUT 173 00:06:00,623 --> 00:06:03,026 HE IS A MEMBER OF THE FDA AND 174 00:06:03,026 --> 00:06:04,661 WE ARE EXCITED TO HAVE HIM HERE 175 00:06:04,661 --> 00:06:06,763 GIVING AN UPDATE. 176 00:06:06,763 --> 00:06:10,767 WE ALSO HAD DR. MONICA 177 00:06:10,767 --> 00:06:12,268 BERTAGNOLLI GIVE AN UPDATE LAST 178 00:06:12,268 --> 00:06:17,140 TIME AND UP ZAIT FROM DR. BALKI 179 00:06:17,140 --> 00:06:20,877 BALIKRISHNAN. 180 00:06:20,877 --> 00:06:22,679 AND DAN TAGLE. 181 00:06:22,679 --> 00:06:24,147 AND WE WILL HEAR MORE FROM 182 00:06:24,147 --> 00:06:25,949 DOMINIQUE AS WELL. 183 00:06:25,949 --> 00:06:26,816 A LOT GOING ON SINCE THEN AS 184 00:06:26,816 --> 00:06:27,917 WELL. 185 00:06:27,917 --> 00:06:30,153 IT TURNS OUT WE DID GET A 186 00:06:30,153 --> 00:06:32,956 BUDGET SINCE WE HAVE SPOKEN 187 00:06:32,956 --> 00:06:33,223 LAST TIME. 188 00:06:33,223 --> 00:06:37,027 WHAT IS EXCITING, I THINK, 189 00:06:37,027 --> 00:06:38,962 ABOUT THIS IS THAT NCATS WE 190 00:06:38,962 --> 00:06:40,397 WERE PLANNING FOR A DECREASE IN 191 00:06:40,397 --> 00:06:42,265 SUPPORT JUST BECAUSE OF THE 192 00:06:42,265 --> 00:06:45,068 BUDGET SCENARIOS WE WERE 193 00:06:45,068 --> 00:06:46,136 ANTICIPATING. 194 00:06:46,136 --> 00:06:48,304 HOWEVER, NCATS GOT A $5 MILLION 195 00:06:48,304 --> 00:06:49,939 INCREASE. 196 00:06:49,939 --> 00:06:51,808 THIS INDICATES IT'S POSSIBLE TO 197 00:06:51,808 --> 00:06:55,311 GET AN INCREASE EVEN IN BUDGET 198 00:06:55,311 --> 00:06:55,912 MORE AUSTERE BUDGET 199 00:06:55,912 --> 00:06:58,281 ENVIRONMENTS *. I THINK THAT'S 200 00:06:58,281 --> 00:06:59,849 REALLY ATTRIBUTED TO A LOT OF 201 00:06:59,849 --> 00:07:01,484 THE WORK YOU, AS OUR 202 00:07:01,484 --> 00:07:02,886 STAKEHOLDERS DO AND INVOLVED IN 203 00:07:02,886 --> 00:07:05,021 AND HELPING SUPPORT THE WORK WE 204 00:07:05,021 --> 00:07:06,022 DO AT NCATS. 205 00:07:06,022 --> 00:07:07,824 REALLY THIS IS A THANK YOU TO 206 00:07:07,824 --> 00:07:09,192 YOU FOR ALL YOUR HELP AND 207 00:07:09,192 --> 00:07:11,094 SUPPORT. 208 00:07:11,094 --> 00:07:12,328 OUR SPENDING ENVELOPE INCREASED 209 00:07:12,328 --> 00:07:12,996 BY $5 MILLION. 210 00:07:12,996 --> 00:07:15,098 THIS IS ONE OF THE FIRST TIMES 211 00:07:15,098 --> 00:07:18,468 WE HAVE EVER SEEN THIS INCREASE 212 00:07:18,468 --> 00:07:20,470 IN CAN-SPECIFIC LANGUAGE. 213 00:07:20,470 --> 00:07:23,506 WHERE PRIMARILY THEY HAVE GIVEN 214 00:07:23,506 --> 00:07:24,908 SUPPORT TO NCATS BUT NOT 215 00:07:24,908 --> 00:07:26,242 SPECIFICALLY CAN. 216 00:07:26,242 --> 00:07:28,044 THIS IS A NEW CHANGE. 217 00:07:28,044 --> 00:07:30,780 THE LANGUAGE MENTIONED IS WE 218 00:07:30,780 --> 00:07:32,582 COULD DO, WE COULD SUPPORT CAN 219 00:07:32,582 --> 00:07:34,918 UP TO, THAT'S WHAT THE LANGUAGE 220 00:07:34,918 --> 00:07:36,286 HAD SAID BEFORE IN OUR REPORT 221 00:07:36,286 --> 00:07:38,254 LANGUAGE. 222 00:07:38,254 --> 00:07:40,957 NOW IT SAYS $75 SHALL BE 223 00:07:40,957 --> 00:07:43,927 AVAILABLE FOR CAN SUPPORT. 224 00:07:43,927 --> 00:07:45,395 SO THIS IS SOMETHING THAT, 225 00:07:45,395 --> 00:07:48,164 WON'T BE TOO HARD TO GET USED 226 00:07:48,164 --> 00:07:48,331 TO. 227 00:07:48,331 --> 00:07:50,300 I THINK WE ARE EXCITED TO GET 228 00:07:50,300 --> 00:07:52,001 USED TO THIS IDEA AND EXCITED 229 00:07:52,001 --> 00:07:53,036 HOW TO MOVE FORWARD IN THE 230 00:07:53,036 --> 00:07:53,703 SPACE TOO. 231 00:07:53,703 --> 00:07:57,740 I WILL GIVE YOU A LITTLE 232 00:07:57,740 --> 00:08:00,677 INKLING WHAT WE ARE PLANNING. 233 00:08:00,677 --> 00:08:03,113 AT NIH MORE BROADLY THERE HAD 234 00:08:03,113 --> 00:08:05,515 BEEN A $300 MILLION INCREASE IN 235 00:08:05,515 --> 00:08:07,450 DISCRETIONARY FUNDING. 236 00:08:07,450 --> 00:08:17,961 OVERALL THE BUDGET DECREASED. 237 00:08:19,863 --> 00:08:21,297 THERE ARE CERTAIN AREAS 238 00:08:21,297 --> 00:08:24,334 RECEIVING A FEW MORE DOLLARS. 239 00:08:24,334 --> 00:08:25,435 YOU MIGHT BE WONDERING, WELL 240 00:08:25,435 --> 00:08:27,036 YOU DID GET A $5 MILLION 241 00:08:27,036 --> 00:08:28,104 INCREASE, SO WHAT ARE YOU DOING 242 00:08:28,104 --> 00:08:29,572 WITH THAT? 243 00:08:29,572 --> 00:08:32,342 WE WERE PLANNING MORE FOR THE 244 00:08:32,342 --> 00:08:36,146 OTHER SCENARIO TO HAPPEN. 245 00:08:36,146 --> 00:08:38,648 HOWEVER, WE ARE ALWAYS PLANNING 246 00:08:38,648 --> 00:08:40,083 FOR DIFFERENT BUDGET SCENARIOS, 247 00:08:40,083 --> 00:08:42,085 FROM THE POTENTIAL OF YOU KNOW, 248 00:08:42,085 --> 00:08:45,822 PERHAPS MORE OF AN INCREASE AT 249 00:08:45,822 --> 00:08:46,823 DIFFERENT LEVELS, SORRY, 250 00:08:46,823 --> 00:08:48,158 DECREASE OF PARTICULAR LEVELS 251 00:08:48,158 --> 00:08:49,359 WITHIN THE BUDGET WE MIGHT HAVE 252 00:08:49,359 --> 00:08:51,361 TO BE PLANNING FOR. 253 00:08:51,361 --> 00:08:52,695 ALSO TWO AREAS WHERE WE MIGHT 254 00:08:52,695 --> 00:08:55,965 HAVE AN INCREASE. 255 00:08:55,965 --> 00:08:57,867 WE HAVE BEEN TALKING ABOUT THE 256 00:08:57,867 --> 00:08:59,235 IDEAS OF ALL THESE SCENARIOS 257 00:08:59,235 --> 00:09:00,970 THAT COULD TAKE PLACE. 258 00:09:00,970 --> 00:09:01,771 WE ARE ALWAYS FLEXIBLE IN THAT 259 00:09:01,771 --> 00:09:02,805 REGARD. 260 00:09:02,805 --> 00:09:04,207 WE HAVE A STRONG PLANNING 261 00:09:04,207 --> 00:09:05,542 PROCESS SO WE CAN ADAPT TO ANY 262 00:09:05,542 --> 00:09:07,644 SCENARIO. 263 00:09:07,644 --> 00:09:09,846 WE ARE STILL WORKING OUT THE 264 00:09:09,846 --> 00:09:11,481 DETAILS FOR THE $5 MILLION BUT, 265 00:09:11,481 --> 00:09:13,149 ONE OF THE THINGSES WE ARE 266 00:09:13,149 --> 00:09:15,418 GOING TO DO IS SUPPORT 267 00:09:15,418 --> 00:09:17,520 ADDITIONAL AREAS RELATED TO 268 00:09:17,520 --> 00:09:18,555 RARE DISEASES AND TISSUE CHIPS 269 00:09:18,555 --> 00:09:20,056 AND I WILL TALK ABOUT MORE 270 00:09:20,056 --> 00:09:21,691 PROGRAMS LATER TODAY. 271 00:09:21,691 --> 00:09:23,526 BUT WE ARE ALSO TALKING ABOUT 272 00:09:23,526 --> 00:09:25,295 JOINING THE FIGHT FOR MMA. 273 00:09:25,295 --> 00:09:28,364 YOU MAY NOT THINK WE ARE VERY 274 00:09:28,364 --> 00:09:29,866 GOOD KICK BOXERS OR MARSHAL 275 00:09:29,866 --> 00:09:30,700 ARTISTS BUT THAT'S NOT REALLY 276 00:09:30,700 --> 00:09:31,701 WHAT THIS IS ABOUT. 277 00:09:31,701 --> 00:09:36,940 AS I DID MY RHODE -- 278 00:09:36,940 --> 00:09:38,441 RESEARCH AND TYPED IN MMA, IT 279 00:09:38,441 --> 00:09:41,477 CAME UP WITH THIS, WHAT WAS 280 00:09:41,477 --> 00:09:43,479 FASCINATING, ONE OF THE MMA 281 00:09:43,479 --> 00:09:45,748 CHAMPIONS, JOHN HOWARD, HE SAID 282 00:09:45,748 --> 00:09:47,016 HE ZOPT CONSIDER HIMSELF 283 00:09:47,016 --> 00:09:49,285 DISABLED BUT HE HAS AUTISM. 284 00:09:49,285 --> 00:09:50,453 HE SAID THROUGHOUT HIS WHOLE 285 00:09:50,453 --> 00:09:52,789 LIFE HE HAD TO OVERCOME A LOT 286 00:09:52,789 --> 00:09:54,724 OF DIFFERENT THINGS GOING ON IN 287 00:09:54,724 --> 00:09:57,060 HIS LIFE RELATED TO THAT 288 00:09:57,060 --> 00:09:57,794 PARTICULAR CONDITION. 289 00:09:57,794 --> 00:10:01,698 AND SO HE WAS ALWAYS LABELD AS 290 00:10:01,698 --> 00:10:02,799 SOMEONE WHO HAD A DISABILITY. 291 00:10:02,799 --> 00:10:05,301 WHAT HE SAID I THOUGHT WAS VERY 292 00:10:05,301 --> 00:10:09,072 POIGNANT WHAT I WILL TALK ABOUT 293 00:10:09,072 --> 00:10:10,173 LATER TODAY. 294 00:10:10,173 --> 00:10:11,374 HE LABELED HIS DISABILITY NOW 295 00:10:11,374 --> 00:10:13,343 IS REALLY AN ADVANTAGE. 296 00:10:13,343 --> 00:10:15,111 BECAUSE ONCE YOU BEAT THE 297 00:10:15,111 --> 00:10:17,046 ADVANTAGE, WHAT'S GOING TO STOP 298 00:10:17,046 --> 00:10:17,847 YOU NOW? 299 00:10:17,847 --> 00:10:19,682 EVEN THOUGH I WASN'T REALLY 300 00:10:19,682 --> 00:10:21,517 LOOKING FOR MMA, I WAS REALLY 301 00:10:21,517 --> 00:10:24,053 EXCITED TO FIND THIS QUOTE FROM 302 00:10:24,053 --> 00:10:28,958 JOHN HOWARD, ALSO KNOWN AS 303 00:10:28,958 --> 00:10:29,492 "DOOMSDAY", MMA CHAMPION. 304 00:10:29,492 --> 00:10:39,369 BUT REALLY WHAT WE ARE TALKING 305 00:10:39,369 --> 00:10:40,403 ABOUT IS METHYLMALONIC 306 00:10:40,403 --> 00:10:42,905 ACIDEMIA, MMA A BODY CAN'T 307 00:10:42,905 --> 00:10:45,141 BREAK DOWN PROTEINS AND FATS 308 00:10:45,141 --> 00:10:45,541 PROPERLY. 309 00:10:45,541 --> 00:10:47,910 THIS RESULTS IN HIGH LEVELS OF 310 00:10:47,910 --> 00:10:53,182 ACID IN THE BLOOD, ACIDEMIA AND 311 00:10:53,182 --> 00:10:54,550 BODY TISSUES. 312 00:10:54,550 --> 00:10:56,686 CHUCK VENDITTI HAS BEEN WORKING 313 00:10:56,686 --> 00:10:59,856 ON MMA AND WORKING ON A GENE 314 00:10:59,856 --> 00:11:01,724 THERAPY. 315 00:11:01,724 --> 00:11:04,661 HE NEEDED AN EXTRA BOOST IN THE 316 00:11:04,661 --> 00:11:06,663 WORK CONDUCTED TO FINALIZE THIS 317 00:11:06,663 --> 00:11:07,997 GENE THERAPY INTO HUMANS. 318 00:11:07,997 --> 00:11:09,599 BECAUSE OF THE SUPPORT WE HAVE 319 00:11:09,599 --> 00:11:11,734 THROUGH CAN, WE ARE GOING TO BE 320 00:11:11,734 --> 00:11:16,973 ABLE TO HELP SUPPORT MOVE THIS 321 00:11:16,973 --> 00:11:21,944 GENE THERAPY IN HUMAN FOR MMA, 322 00:11:21,944 --> 00:11:23,546 THE CLINICAL CENTER, NICHD, 323 00:11:23,546 --> 00:11:27,317 CHILD HEALTH AND HUMAN 324 00:11:27,317 --> 00:11:29,018 DEVELOPMENT AND NATIONAL 325 00:11:29,018 --> 00:11:30,153 INSTITUTE OF NEUROLOGICAL 326 00:11:30,153 --> 00:11:32,722 DISORDERS AND STROKE. 327 00:11:32,722 --> 00:11:37,527 THIS IS DEVELOPING A CRUX OF 328 00:11:37,527 --> 00:11:39,295 EXPERTISE AT NIH THAT CAN 329 00:11:39,295 --> 00:11:41,164 SUPPORT IDEAS LIKE THIS MOVING 330 00:11:41,164 --> 00:11:41,397 FORWARD. 331 00:11:41,397 --> 00:11:42,532 WE ARE GOING TO LEARN, I THINK, 332 00:11:42,532 --> 00:11:43,933 A GREAT DEAL ABOUT THIS. 333 00:11:43,933 --> 00:11:46,769 AS YOU KNOW WE HAVE A VARIETY 334 00:11:46,769 --> 00:11:50,340 OF PROGRAMS ABOUT GENE THERAPY. 335 00:11:50,340 --> 00:11:51,841 THE VECTOR. 336 00:11:51,841 --> 00:11:53,743 THIS IS GOING TO MOVE MORE 337 00:11:53,743 --> 00:11:55,778 QUICKLY THAN BOTH THOSE THINGS. 338 00:11:55,778 --> 00:11:58,815 THIS IS A CAN SPECIFIC ACTIVITY 339 00:11:58,815 --> 00:12:00,650 WE WILL COLLABORATE WITH WITH 340 00:12:00,650 --> 00:12:02,051 NHGRI. 341 00:12:02,051 --> 00:12:04,687 NONE OF THIS CAN HAPPEN WITH 342 00:12:04,687 --> 00:12:07,290 THAT CAN INCREASE UNTIL WE CAN 343 00:12:07,290 --> 00:12:08,491 DEVELOP THIS PARTNERSHIP AND 344 00:12:08,491 --> 00:12:09,625 GET THIS MOVE TO HELP TREAT 345 00:12:09,625 --> 00:12:10,727 KIDS. 346 00:12:10,727 --> 00:12:12,929 THAT IS ONE OF THE AREAS I 347 00:12:12,929 --> 00:12:13,796 WANTED TO MENTION ABOUT THE 348 00:12:13,796 --> 00:12:15,164 BUDGET. 349 00:12:15,164 --> 00:12:16,499 THE SECOND THING IS, DURING 350 00:12:16,499 --> 00:12:18,301 THIS TIME AS THE BUDGET CAME 351 00:12:18,301 --> 00:12:24,140 OUT, WHICH WAS RELATIVELY LATE 352 00:12:24,140 --> 00:12:24,474 IN THE CYCLE. 353 00:12:24,474 --> 00:12:25,541 AROUND THE SAME TIME, LITERALLY 354 00:12:25,541 --> 00:12:28,711 LIKE A DAY AFTER, THE FY 2025 355 00:12:28,711 --> 00:12:30,179 BUDGET CAME OUT WITH THE 356 00:12:30,179 --> 00:12:31,447 PRESIDENT'S BUMG ET. 357 00:12:31,447 --> 00:12:33,282 -- BUDGET. 358 00:12:33,282 --> 00:12:34,650 WHAT IS INTERESTING ABOUT THIS 359 00:12:34,650 --> 00:12:36,819 AND WHAT TO NOTE ABOUT THIS 360 00:12:36,819 --> 00:12:37,820 SLIDE, BECAUSE THE PRESIDENT'S 361 00:12:37,820 --> 00:12:41,524 BUDGET CAME OUT A DAY AFTER THE 362 00:12:41,524 --> 00:12:43,860 FY '24 BUDGET WAS FINALIZED, 363 00:12:43,860 --> 00:12:45,495 THE PRESIDENT'S BUDGET WASN'T 364 00:12:45,495 --> 00:12:47,897 MEASURING AGAINST FY '24, IT 365 00:12:47,897 --> 00:12:50,500 WAS MEASURING AGAINST FY '23. 366 00:12:50,500 --> 00:12:53,636 BEAR THAT IN MIND, IN A WAY THE 367 00:12:53,636 --> 00:12:54,771 PRESENT BUDGET IS ALWAYS THE 368 00:12:54,771 --> 00:12:56,939 FIRST PLACE TO START IN BUDGET 369 00:12:56,939 --> 00:12:57,507 NEGOTIATIONS. 370 00:12:57,507 --> 00:13:01,644 BUT THIS IS A LITTLE NUANCE 371 00:13:01,644 --> 00:13:03,479 THAT IS ATYPICAL WHEN WE TALK 372 00:13:03,479 --> 00:13:05,381 ABOUT THESE BUDGETS. 373 00:13:05,381 --> 00:13:07,316 AND AS IT TURNS OUT THE 374 00:13:07,316 --> 00:13:08,317 APPROPRIATION HEARINGS FOR THAT 375 00:13:08,317 --> 00:13:11,120 BUDGET ARE HAPPENING TODAY. 376 00:13:11,120 --> 00:13:13,790 SO THE QR CODE IS HERE. 377 00:13:13,790 --> 00:13:16,125 WE OBSCURED IT A LITTLE 378 00:13:16,125 --> 00:13:17,126 APPARENTLY SO YOU CAN'T PORT 379 00:13:17,126 --> 00:13:18,127 OVER TO HEAR THAT. 380 00:13:18,127 --> 00:13:19,796 I KNOW I WILL BE CATCHING UP 381 00:13:19,796 --> 00:13:22,331 WITH THAT LATER ON IN THE WEEK. 382 00:13:22,331 --> 00:13:26,636 SO THIS IS WHERE WE STAND NOW 383 00:13:26,636 --> 00:13:28,171 AND CERTAINLY EXCITED TO HEAR 384 00:13:28,171 --> 00:13:29,005 ABOUT WHAT THE HEARINGS WILL DO 385 00:13:29,005 --> 00:13:31,140 NEXT. 386 00:13:31,140 --> 00:13:33,476 FY '25 IS ALSO THOUGHT TO BE AN 387 00:13:33,476 --> 00:13:36,012 AREA WHERE THERE MAY BE MORE 388 00:13:36,012 --> 00:13:36,679 DIFFICULT BUDGET SCENARIOS BUT 389 00:13:36,679 --> 00:13:38,080 WE WILL SEE. 390 00:13:38,080 --> 00:13:40,950 WE ARE KIND OF USED TO 391 00:13:40,950 --> 00:13:41,584 DIFFICULT SCENARIOS AND THAT'S 392 00:13:41,584 --> 00:13:42,318 OKAY. 393 00:13:42,318 --> 00:13:43,352 WE WILL BE READY FOR WHATEVER 394 00:13:43,352 --> 00:13:45,455 HAPPENS. 395 00:13:45,455 --> 00:13:49,392 SO NOW, IN TERMS OF COMINGS AND 396 00:13:49,392 --> 00:13:50,993 GOINGS AT NCATS AS I MENTIONED 397 00:13:50,993 --> 00:13:52,795 WE HAVE BEEN DOING A LOT IN 398 00:13:52,795 --> 00:13:53,429 TERMS OF PUTTING THE LEADERSHIP 399 00:13:53,429 --> 00:13:54,497 TOGETHER. 400 00:13:54,497 --> 00:13:57,366 AS I HAVE SHOWN YOU THE SLIDE 401 00:13:57,366 --> 00:13:59,101 IN THE PAST THERE'S BEEN LOTS 402 00:13:59,101 --> 00:14:00,570 OF RED INSTEAD OF GREEN IN 403 00:14:00,570 --> 00:14:02,505 THESE CATEGORIES BUT YOU WILL 404 00:14:02,505 --> 00:14:04,207 NOTICE THEY ARE ALL GREEN NOW. 405 00:14:04,207 --> 00:14:05,241 I'M EXCITED TO TELL YOU ABOUT 406 00:14:05,241 --> 00:14:07,243 THE LEADERSHIP WE HAVE. 407 00:14:07,243 --> 00:14:10,246 LATER TODAY YOU WILL BE HEARING 408 00:14:10,246 --> 00:14:11,380 FROM MATT HULL AND DOMINIQUE 409 00:14:11,380 --> 00:14:13,916 BUSHARD. 410 00:14:13,916 --> 00:14:16,319 MATT IS NEW SCIENTIFIC DIRECTOR 411 00:14:16,319 --> 00:14:21,424 FROM THE DIVISION OF 412 00:14:21,424 --> 00:14:23,626 PRECLINICAL INNOVATION, AND 413 00:14:23,626 --> 00:14:25,728 DOMINIQUE FROM DISEASE AND RARE. 414 00:14:25,728 --> 00:14:28,464 SPEAKING OF NEW ACTIVITIES I 415 00:14:28,464 --> 00:14:30,733 WILL START WITH NCATS 416 00:14:30,733 --> 00:14:31,334 LEADERSHIP IN DEPUTY DIRECTOR 417 00:14:31,334 --> 00:14:35,938 POSITION. 418 00:14:35,938 --> 00:14:39,775 IT HAS BEEN FABULOUS TO HAVE 419 00:14:39,775 --> 00:14:41,444 ANTON SIMEONOV TO STEP IN THE 420 00:14:41,444 --> 00:14:42,178 ROLE OF THE ACTING DEPUTY 421 00:14:42,178 --> 00:14:44,080 DIRECTOR. 422 00:14:44,080 --> 00:14:47,116 HE HAS DONE IT FLAWLESSLY, 423 00:14:47,116 --> 00:14:48,117 AMAZINGLY, WITHOUT SKIPPING A 424 00:14:48,117 --> 00:14:49,619 STEP AND BROUGHT THE SCIENTIFIC 425 00:14:49,619 --> 00:14:51,020 KNOWLEDGE TO THE TABLE. 426 00:14:51,020 --> 00:14:52,622 I CAN'T THANK HIM ENOUGH FOR 427 00:14:52,622 --> 00:14:55,691 SERVING IN THIS ROLE. 428 00:14:55,691 --> 00:14:57,994 AND HE IS PROBABLY MOST EXCITED 429 00:14:57,994 --> 00:15:00,162 TOO NOW THAT HE DOESN'T HAVE TO 430 00:15:00,162 --> 00:15:02,198 SERVE IN THIS ROLE ANY LONGER, 431 00:15:02,198 --> 00:15:05,034 BUT WE WON'T LET HIM GO SO 432 00:15:05,034 --> 00:15:05,701 EASILY. 433 00:15:05,701 --> 00:15:07,703 I'M EXCITED TO SAY, IT'S MY 434 00:15:07,703 --> 00:15:12,575 PLEASURE TO SHARE TODAY THAT 435 00:15:12,575 --> 00:15:14,477 DR. ANNICA WAYMAN HAS BEEN 436 00:15:14,477 --> 00:15:16,245 SELECTED AS OUR DEPUTY IT 437 00:15:16,245 --> 00:15:16,512 DIRECTOR. 438 00:15:16,512 --> 00:15:18,414 MANY OF YOU KNOW BECAUSE SHE 439 00:15:18,414 --> 00:15:19,615 WAS SITTING AT THE TABLE LAST 440 00:15:19,615 --> 00:15:20,850 COUNCIL AS WELL. 441 00:15:20,850 --> 00:15:22,952 WE ARE EXCITED TO HAVE HER NOW. 442 00:15:22,952 --> 00:15:26,022 SHE IS REALLY THIS RARE AND 443 00:15:26,022 --> 00:15:27,089 HIGHLY TUNED INDIVIDUAL WITH 444 00:15:27,089 --> 00:15:29,625 HER ROLE AS A RESEARCH 445 00:15:29,625 --> 00:15:30,660 SCIENTIST, A SCIENTIST 446 00:15:30,660 --> 00:15:32,061 ADMINISTRATOR, AN EDUCATOR AND 447 00:15:32,061 --> 00:15:35,398 A CHAMPION FOR ADVANCING 448 00:15:35,398 --> 00:15:36,499 TRANSLATIONAL SCIENCES. 449 00:15:36,499 --> 00:15:39,936 SHE HAS BEEN A GREAT MENTOR AND 450 00:15:39,936 --> 00:15:42,271 DEVELOPED THE FUTURE OF 451 00:15:42,271 --> 00:15:44,240 STUDENTS IN TRANSLATIONAL 452 00:15:44,240 --> 00:15:48,144 SCIENCE IN HER FIELD. 453 00:15:48,144 --> 00:15:48,978 CLINICIANS TRANSLATIONAL 454 00:15:48,978 --> 00:15:50,212 SCIENCE, RESEARCHERS. 455 00:15:50,212 --> 00:15:52,949 SO HER DEPTH AND BREADTH IS 456 00:15:52,949 --> 00:15:53,416 REALLY QUITE MASS. 457 00:15:53,416 --> 00:15:54,884 SO WE ARE EXCITED TO BRING THAT 458 00:15:54,884 --> 00:16:03,192 EXPERIENCE HERE AS WELL. 459 00:16:03,192 --> 00:16:05,294 SHE WILL SHARE A VARIETY OF 460 00:16:05,294 --> 00:16:06,596 EXPERIENCES I HAVE, AND SHE 461 00:16:06,596 --> 00:16:08,130 WILL BE CERTAINLY VERY 462 00:16:08,130 --> 00:16:09,565 IMPORTANT FOR GUIDING OUR 463 00:16:09,565 --> 00:16:10,566 STRATEGIC DIRECTION, OUR 464 00:16:10,566 --> 00:16:12,101 STRATEGIC PLANNING AND SETTING 465 00:16:12,101 --> 00:16:13,336 OUT OUR ACTIVITIES OVER THE 466 00:16:13,336 --> 00:16:20,509 NEXT MANY YEARS AHEAD. 467 00:16:20,509 --> 00:16:21,210 I'M LOOKING FORWARD TO HORE 468 00:16:21,210 --> 00:16:23,245 LEADERSHIP. 469 00:16:23,245 --> 00:16:25,114 HER LEADERSHIP. 470 00:16:25,114 --> 00:16:27,650 SHE WILL BE STARTING JUNE 17 471 00:16:27,650 --> 00:16:29,852 AND I WILL GOING ON VACATION 472 00:16:29,852 --> 00:16:34,156 JUNE 22nd, I THINK IT WILL WORK 473 00:16:34,156 --> 00:16:36,192 OUT OKAY, I APOLOGIZED 474 00:16:36,192 --> 00:16:37,660 PROFUSELY FOR THAT. 475 00:16:37,660 --> 00:16:41,230 ANTON WILL BE HELPING OUT. 476 00:16:41,230 --> 00:16:44,200 EXCITED TO HAVE ANNICA AS OUR 477 00:16:44,200 --> 00:16:46,268 DEPUTY DIRECTOR NOW. 478 00:16:46,268 --> 00:16:48,671 NEXT, ANTON HAS BEEN THE 479 00:16:48,671 --> 00:16:51,207 SCIENTIFIC DIRECTOR FOR MANY 480 00:16:51,207 --> 00:16:52,975 YEARS AT NCATS BEFORE HE BECAME 481 00:16:52,975 --> 00:16:54,777 THE ACTING DEPUTY DIRECTOR. 482 00:16:54,777 --> 00:16:56,879 SO IT'S SORT OF A LENGTHY 483 00:16:56,879 --> 00:16:57,680 PROCESS, BECAUSE HE STEPPED 484 00:16:57,680 --> 00:17:00,616 DOWN TO BE IN A LAB AND 485 00:17:00,616 --> 00:17:01,250 CONTINUING WITH HIS SCIENTIFIC 486 00:17:01,250 --> 00:17:02,418 ACTIVITIES. 487 00:17:02,418 --> 00:17:04,153 WE WENT THROUGH A PROCESS WITH 488 00:17:04,153 --> 00:17:06,155 OUR SCIENTIFIC DIRECTOR AS WELL. 489 00:17:06,155 --> 00:17:08,190 I'M ALSO EXCITED TO ANNOUNCE 490 00:17:08,190 --> 00:17:11,560 THAT MATT HALL IS OUR NEW 491 00:17:11,560 --> 00:17:13,262 SCIENTIFIC DIRECTOR AT NCATS. 492 00:17:13,262 --> 00:17:14,730 WE SELECTED HIM THE DAY AFTER 493 00:17:14,730 --> 00:17:16,932 COUNCIL LAST TIME. 494 00:17:16,932 --> 00:17:18,067 THE TIMING WASN'T QUITE RIGHT. 495 00:17:18,067 --> 00:17:21,037 BUT NOW HE IS AN OLD HAT. 496 00:17:21,037 --> 00:17:22,338 SO NO PROBLEM AT ALL. 497 00:17:22,338 --> 00:17:24,440 WE HAVE SORT OF PUT HIM IN 498 00:17:24,440 --> 00:17:25,975 FRONT OF, AND HE WILL BE ABLE 499 00:17:25,975 --> 00:17:27,877 TO TELL YOU MORE ABOUT HIMSELF, 500 00:17:27,877 --> 00:17:30,179 SO I WON'T DWELL ON HIM HERE, 501 00:17:30,179 --> 00:17:31,480 BUT I'M REALLY EXCITED TO HAVE 502 00:17:31,480 --> 00:17:36,786 HIM AT THE TABLE AS WELL TO 503 00:17:36,786 --> 00:17:40,022 CONSIDER HOW WE CAN SET THE 504 00:17:40,022 --> 00:17:42,558 STAGE FOR NCATS LABS AND MOVE 505 00:17:42,558 --> 00:17:43,526 FORWARD IN STRATEGIC PLANNING 506 00:17:43,526 --> 00:17:46,062 IN THE DECADE AS HEAD. 507 00:17:46,062 --> 00:17:47,563 HE HAS DONE HIS LISTENING 508 00:17:47,563 --> 00:17:49,031 SESSIONS AS WELL AND I'M SURE 509 00:17:49,031 --> 00:17:49,899 HE WILL TALK TO YOU MORE ABOUT 510 00:17:49,899 --> 00:17:51,133 THAT. 511 00:17:51,133 --> 00:17:53,269 IN ADDITION WE HAVE A NEW 512 00:17:53,269 --> 00:17:54,737 POSITION AT NCATS. 513 00:17:54,737 --> 00:17:57,006 CHIEF OF STAFF, THIS IS A 514 00:17:57,006 --> 00:17:58,607 POSITION GROWING I WOULD SAY 515 00:17:58,607 --> 00:18:00,009 ACROSS THE NIH. 516 00:18:00,009 --> 00:18:02,511 THIS IS SOMETHING WE DIDN'T 517 00:18:02,511 --> 00:18:04,914 REALLY HAVE AT NCATS IN TERMS 518 00:18:04,914 --> 00:18:06,449 OF INDIVIDUALS SUPPORTING THIS 519 00:18:06,449 --> 00:18:08,818 SORT OF DEFINED ROLE. 520 00:18:08,818 --> 00:18:10,286 AND WHAT, IF YOU LOOK AT CHIEF 521 00:18:10,286 --> 00:18:13,923 OF STAFF POSITION THEY HAVE 522 00:18:13,923 --> 00:18:15,725 VERY DIFFERENT ACROSS THE NIH. 523 00:18:15,725 --> 00:18:18,360 FOR US, GIVE ESPECIALLY THAT WE 524 00:18:18,360 --> 00:18:28,904 ARE THE DOT CONNECTORS, WE WORK 525 00:18:29,839 --> 00:18:31,474 ACROSS DOT-COM, DOT-EDU, 526 00:18:31,474 --> 00:18:34,410 DOT-GOV AND DOT-ORG. 527 00:18:34,410 --> 00:18:37,313 SHE REPRESENTS OD AND NCATS AT 528 00:18:37,313 --> 00:18:42,017 LARGE FOR THESE VARIOUS 529 00:18:42,017 --> 00:18:44,420 OUTREACH ACTIVITIES AND 530 00:18:44,420 --> 00:18:47,656 COLLABORATIONS WORKING ACROSS 531 00:18:47,656 --> 00:18:48,991 NIH, DIFFERENT GOVERNMENT 532 00:18:48,991 --> 00:18:49,992 AGENCIES, ACADEMIA AND INDUSTRY. 533 00:18:49,992 --> 00:18:52,128 SHE HAS HIT THE GROUND RUNNING. 534 00:18:52,128 --> 00:18:53,929 LEADING THE EFFORTS WITH THE 535 00:18:53,929 --> 00:19:00,102 ARPA H FOLKS AS WELL. 536 00:19:00,102 --> 00:19:01,604 BRINGING IN SOMEONE DEDICATED 537 00:19:01,604 --> 00:19:03,239 TO THOSE EFFORTS IS GREAT FOR 538 00:19:03,239 --> 00:19:04,907 US AND I THINK WILL HELP US 539 00:19:04,907 --> 00:19:06,108 MATURE AS AN ORGANIZATION AS 540 00:19:06,108 --> 00:19:08,077 WELL. 541 00:19:08,077 --> 00:19:11,380 SHE SERVED IN A VARIETY OF 542 00:19:11,380 --> 00:19:14,817 CAPACITIES AT NIH. 543 00:19:14,817 --> 00:19:21,190 SHE STARTED AT NCI, FOCUSING ON 544 00:19:21,190 --> 00:19:22,892 BACTERIA POST RNA 545 00:19:22,892 --> 00:19:23,959 TRANSCRIPTIONAL, AND THEN 546 00:19:23,959 --> 00:19:24,527 STRATEGIC PREPAREDNESS AND 547 00:19:24,527 --> 00:19:25,327 RESPONSE. 548 00:19:25,327 --> 00:19:26,662 AND THAT'S WHERE SHE WAS 549 00:19:26,662 --> 00:19:29,765 INVOLVED IN DEVELOPING A LOT OF 550 00:19:29,765 --> 00:19:30,499 THERAPEUTIC AND VACCINE 551 00:19:30,499 --> 00:19:37,039 STRATEGIES FOR THE RESPONSE TO 552 00:19:37,039 --> 00:19:38,874 MONKEY POX OUTBREAK, EBOLA 553 00:19:38,874 --> 00:19:40,776 PREPAREDNESS AND COVID-19 AS 554 00:19:40,776 --> 00:19:40,976 WELL. 555 00:19:40,976 --> 00:19:43,646 SHE IS TRAINED AS CHEMIST AND 556 00:19:43,646 --> 00:19:52,021 MICRO BIOLOGIST AND RECEIVED 557 00:19:52,021 --> 00:19:56,225 HER BACHELOR AT UNIVERSITY OF 558 00:19:56,225 --> 00:19:57,059 NORTH CAROLINA, CHARLOTTE AND 559 00:19:57,059 --> 00:19:58,794 DOCTORATE AT -- 560 00:19:58,794 --> 00:20:02,298 AND THEN NEXT I WOULD LIKE TO 561 00:20:02,298 --> 00:20:03,499 INTRODUCE DR. JOSH FESSEL. 562 00:20:03,499 --> 00:20:05,968 HE IS ALSO NOT A NEW FACE 563 00:20:05,968 --> 00:20:07,169 WITHIN NCATS. 564 00:20:07,169 --> 00:20:10,906 HE HAS BEEN A SENIOR DIVISOR 565 00:20:10,906 --> 00:20:13,442 BUT NOW SERVING IN THE ROLE OF 566 00:20:13,442 --> 00:20:14,376 OFFICE OF TRANSLATIONAL 567 00:20:14,376 --> 00:20:15,010 MEDICINE AND THE DIRECTOR IN 568 00:20:15,010 --> 00:20:15,845 THAT ROLE. 569 00:20:15,845 --> 00:20:18,480 THIS IS SORT OF A NEW-ISH 570 00:20:18,480 --> 00:20:19,715 OFFICE, IT'S BEEN IN PLACE NOW 571 00:20:19,715 --> 00:20:21,183 ABOUT FOUR YEARS. 572 00:20:21,183 --> 00:20:23,953 HE IS THE SECOND DIRECTOR IN 573 00:20:23,953 --> 00:20:25,754 THIS ROLE. 574 00:20:25,754 --> 00:20:30,526 HE BRINGS A WEALTH OF CLINICAL 575 00:20:30,526 --> 00:20:31,293 RESEARCH EXPERIENCE AND REAL 576 00:20:31,293 --> 00:20:32,728 WORLD EXPERIENCE AND WE ARE 577 00:20:32,728 --> 00:20:35,164 EXCITED TO HAVE THAT EXPERTISE 578 00:20:35,164 --> 00:20:37,366 AT THE TABLE, SORRY, I'M 579 00:20:37,366 --> 00:20:41,036 HEARING AN ECHO, HOPEFULLY THAT 580 00:20:41,036 --> 00:20:41,403 WILL -- OKAY. 581 00:20:41,403 --> 00:20:51,780 SHE IS WORKING ON IT. 582 00:20:58,654 --> 00:21:00,589 YOU MIGHT HAVE TO LOG OUT. 583 00:21:00,589 --> 00:21:02,224 SOUNDS LIKE IT RESOLVED? 584 00:21:02,224 --> 00:21:03,359 IT HAS. 585 00:21:03,359 --> 00:21:07,763 GOOD. 586 00:21:07,763 --> 00:21:10,900 OKAY, WITH JOSH FESSEL NOW AT 587 00:21:10,900 --> 00:21:14,036 AS THE HEAD OF THE OTM HE WILL 588 00:21:14,036 --> 00:21:23,012 BE ABLE TO FOSTER HOW WE THINK 589 00:21:23,012 --> 00:21:24,880 OF INTEGRATING PROGRAMS AND 590 00:21:24,880 --> 00:21:26,448 INNOVATING ACROSS NCATS. 591 00:21:26,448 --> 00:21:28,183 SO REALLY BRINGING SOME OF THAT 592 00:21:28,183 --> 00:21:29,985 GLUE TO THE TABLE. 593 00:21:29,985 --> 00:21:34,423 IN ADDITION TO THAT, HE WILL BE 594 00:21:34,423 --> 00:21:37,092 WORKING VERY CLOSELY WITHIN OUR 595 00:21:37,092 --> 00:21:40,195 INTRAMURAL PROGRAM. 596 00:21:40,195 --> 00:21:41,597 STRENGTHENING INTERACTIONS WITH 597 00:21:41,597 --> 00:21:43,732 THE CLINICAL CENTER AND 598 00:21:43,732 --> 00:21:44,833 CLINICAL COUNTERPARTS. 599 00:21:44,833 --> 00:21:47,369 SO THERE'S A VARIETY OF THINGS 600 00:21:47,369 --> 00:21:49,705 ON HIS PLATE ALREADY. 601 00:21:49,705 --> 00:21:53,075 HE ALSO HAS WITHIN HIS PURVIEW 602 00:21:53,075 --> 00:21:56,145 TOPICS OF HUMAN SUBJECTS 603 00:21:56,145 --> 00:21:56,679 RESEARCH, DIVISION EQUITY 604 00:21:56,679 --> 00:21:58,213 INCLUSION SENSIBILITY. 605 00:21:58,213 --> 00:22:00,316 DRUG DEVELOPMENT, AS WELL AS 606 00:22:00,316 --> 00:22:01,016 CLINICAL TRIALS AND 607 00:22:01,016 --> 00:22:02,751 ENVIRONMENTAL ICS. 608 00:22:02,751 --> 00:22:04,386 IC -- ETHICS. 609 00:22:04,386 --> 00:22:07,189 WE HAVE A PROGRAM IN 610 00:22:07,189 --> 00:22:08,624 TRANSLATIONAL SCIENCE, ETHICS 611 00:22:08,624 --> 00:22:11,694 OF TRANSLATIONAL SCIENCE THAT 612 00:22:11,694 --> 00:22:12,161 ELAINE COLLIER LEADS. 613 00:22:12,161 --> 00:22:14,697 THE A SMALL BUT MIGHTY PROGRAM. 614 00:22:14,697 --> 00:22:16,799 UNDER THE PURVIEW OF OTM. 615 00:22:16,799 --> 00:22:19,635 SO JOSH, ALSO IN ADDITION TO 616 00:22:19,635 --> 00:22:22,671 ALL THAT, HE SERVES AS,S HE IS 617 00:22:22,671 --> 00:22:24,673 CO-CHAIRING A SUBGROUP ON 618 00:22:24,673 --> 00:22:26,342 LOOKING AT ELECTRONIC HEALTH 619 00:22:26,342 --> 00:22:28,944 RECORDS FOR NIH AND HOW WE DO 620 00:22:28,944 --> 00:22:30,646 THIS MORE BROADLY. 621 00:22:30,646 --> 00:22:33,449 BEING MORE COORDINATED IN OUR 622 00:22:33,449 --> 00:22:34,883 GOALS OF PURSUING REAL-WORLD 623 00:22:34,883 --> 00:22:40,255 DATA AND ELECTRONIC HEALTH, I 624 00:22:40,255 --> 00:22:42,858 SERVE AS THE CO-CHAIR OF ONE OF 625 00:22:42,858 --> 00:22:45,260 THESE COMMITTEES, CALLED THE 626 00:22:45,260 --> 00:22:47,696 DATA SCIENCE POLICY COUNCIL. 627 00:22:47,696 --> 00:22:51,633 THIS IS AN IMPORTANT ACTIVE IN 628 00:22:51,633 --> 00:22:52,835 THAT SPACE AND JOSH IS 629 00:22:52,835 --> 00:22:54,870 COORDINATING. 630 00:22:54,870 --> 00:22:56,672 SO THAT IS EXCITING, BECAUSE HE 631 00:22:56,672 --> 00:23:00,209 HAS ALSO DONE THIS FOR THE CTSA 632 00:23:00,209 --> 00:23:00,576 PROGRAM. 633 00:23:00,576 --> 00:23:04,279 SO THERE'S A WEALTH OF 634 00:23:04,279 --> 00:23:04,847 EXPERTISE HE BRINGS TO THE 635 00:23:04,847 --> 00:23:05,781 TABLE. 636 00:23:05,781 --> 00:23:08,050 I THINK THIS IS THE LAST CHANGE 637 00:23:08,050 --> 00:23:11,120 I WILL MENTION TODAY. 638 00:23:11,120 --> 00:23:12,521 VEPA IS THE SENIOR LICENSING 639 00:23:12,521 --> 00:23:16,492 PATENT MANAGER IN THE OFFICE OF 640 00:23:16,492 --> 00:23:17,292 STRATEGIC ALLIANCES, WORKING 641 00:23:17,292 --> 00:23:19,228 WITH BALKI. 642 00:23:19,228 --> 00:23:21,830 HE JOINED NIH IN 2005, SERVED 643 00:23:21,830 --> 00:23:24,166 IN A VARIETY OF CAPACITIES IN 644 00:23:24,166 --> 00:23:25,200 THAT TIMEFRAME. 645 00:23:25,200 --> 00:23:27,736 HE KIND OF TOOK A BREAK AND WAS 646 00:23:27,736 --> 00:23:29,271 TEACHING AT THE UNIVERSITY OF 647 00:23:29,271 --> 00:23:31,607 MARYLAND SCHOOL OF LAW AND 648 00:23:31,607 --> 00:23:35,110 SUPERVISED ATTORNEYS ENROLLED 649 00:23:35,110 --> 00:23:36,345 IN THE MARYLAND INTELLECTUAL 650 00:23:36,345 --> 00:23:38,247 PROPERTY AND LEGAL RESEARCH. 651 00:23:38,247 --> 00:23:41,383 AND HE CAME BACK TO NCATS AND 652 00:23:41,383 --> 00:23:42,918 WORKING IN OUR OFFICE OF 653 00:23:42,918 --> 00:23:44,686 STRATEGIC ALLIANCES AND WE ARE 654 00:23:44,686 --> 00:23:46,522 DELIGHTED TO HAVE HIS EXPERTISE 655 00:23:46,522 --> 00:23:49,425 AS WELL AND BE AT THE LEVEL OF 656 00:23:49,425 --> 00:23:51,894 SENIOR LEADERSHIP AT O.S.I. 657 00:23:51,894 --> 00:23:56,698 HE RECEIVED J.V. WITH HONORS 658 00:23:56,698 --> 00:24:03,772 UNIVERSITY OF MARYLAND AND 659 00:24:03,772 --> 00:24:06,742 BIOCHEMISTRY IN BANGALORE. 660 00:24:06,742 --> 00:24:09,044 HE HAS THE CHOPS, AND THAT 661 00:24:09,044 --> 00:24:09,445 SHOWS. 662 00:24:09,445 --> 00:24:12,481 HE IS REALLY GREAT TO HAVE. 663 00:24:12,481 --> 00:24:14,750 ALL RIGHT, ONE OTHER THING I 664 00:24:14,750 --> 00:24:19,388 WANTED TO HIGHLIGHT, OUR 665 00:24:19,388 --> 00:24:20,789 EXECUTIVE OFFICER, KEITH 666 00:24:20,789 --> 00:24:21,790 LAMIRANDE RECEIVED ONE OF THESE 667 00:24:21,790 --> 00:24:24,193 LIFE AWARDS. 668 00:24:24,193 --> 00:24:29,765 THIS IS A VERY PRESTIGIOUS 669 00:24:29,765 --> 00:24:30,399 AWARD, THE PRESIDENTAL RANK 670 00:24:30,399 --> 00:24:31,733 AWARD. 671 00:24:31,733 --> 00:24:33,102 CONFERRED TO A FEW INDIVIDUALS 672 00:24:33,102 --> 00:24:35,637 ACROSS THE GOVERNMENT. 673 00:24:35,637 --> 00:24:37,739 THEY RECOGNIZE OUTSTANDING 674 00:24:37,739 --> 00:24:39,708 LEADERS WHO CONSISTENTLY 675 00:24:39,708 --> 00:24:40,609 DEMONSTRATE, STRENGTH, 676 00:24:40,609 --> 00:24:41,610 INTEGRITY, INDUSTRY AND MADE 677 00:24:41,610 --> 00:24:44,646 SIGNIFICANT CONTRIBUTIONS TO 678 00:24:44,646 --> 00:24:45,247 UNITED STATES U.S. GOVERNMENT. 679 00:24:45,247 --> 00:24:47,049 SO KEITH HAS SPENT ABOUT 35 680 00:24:47,049 --> 00:24:48,817 YEARS WITHIN THE NIH WORKING IN 681 00:24:48,817 --> 00:24:50,018 LABS AND MOVING OVER TO 682 00:24:50,018 --> 00:24:51,520 ADMINISTRATION. 683 00:24:51,520 --> 00:24:54,189 AND I CAN'T THINK OF ANYONE 684 00:24:54,189 --> 00:24:55,891 MORE WORTHY THAN KEITH TO GET 685 00:24:55,891 --> 00:24:56,959 THIS HONOR. 686 00:24:56,959 --> 00:24:59,261 SO I WANTED TO TAKE A MOMENT TO 687 00:24:59,261 --> 00:25:00,529 CONGRATULATE KEITH ON THIS WORK. 688 00:25:00,529 --> 00:25:02,831 I WILL SAY THAT OVER THE PAST 689 00:25:02,831 --> 00:25:06,068 FOUR YEARS SINCE I HAVE BEEN AT 690 00:25:06,068 --> 00:25:08,070 NCATS, KEITH HAS REALLY WORKED 691 00:25:08,070 --> 00:25:12,374 VERY HARD TO HELP GROW NCATS. 692 00:25:12,374 --> 00:25:13,008 WE HAVE HIRED OVER 150 PEOPLE 693 00:25:13,008 --> 00:25:14,543 LAST YEAR. 694 00:25:14,543 --> 00:25:17,946 WE ARE GROWING, LARGELY BECAUSE 695 00:25:17,946 --> 00:25:19,114 OF THE SMOOTH ADMINISTRATION 696 00:25:19,114 --> 00:25:26,054 OPERATIONS WE HAVE WITH KEITH 697 00:25:26,054 --> 00:25:27,489 ADD OFFICE OF ADMINISTRATIVE 698 00:25:27,489 --> 00:25:27,756 SCIENCES. 699 00:25:27,756 --> 00:25:30,659 I WANT TO SAY THANK YOU TO 700 00:25:30,659 --> 00:25:33,762 KEITH AND CONGRATULATE HIM. 701 00:25:33,762 --> 00:25:35,197 WHILE I'M CONGRATULATING HIM, 702 00:25:35,197 --> 00:25:36,698 I'M ALSO KURTSING HIM. 703 00:25:36,698 --> 00:25:38,700 -- CURSING HIM. 704 00:25:38,700 --> 00:25:43,338 HE DECIDED 35 YEARS IS A LONG 705 00:25:43,338 --> 00:25:44,840 TIME, SO HE RECENTLY ANNOUNCED 706 00:25:44,840 --> 00:25:45,874 HIS RETIREMENT AS WELL. 707 00:25:45,874 --> 00:25:48,777 I WANT TO TAKE A MOMENT TO SAY 708 00:25:48,777 --> 00:25:50,712 TO THE COUNCIL HE WILL BE 709 00:25:50,712 --> 00:25:51,680 RETIRING, I BELIEVE AT THE END 710 00:25:51,680 --> 00:25:53,448 OF JUNE. 711 00:25:53,448 --> 00:25:55,450 AND SO THIS IS OUR LAST 712 00:25:55,450 --> 00:25:58,120 OPPORTUNITY TO WISH HIM A 713 00:25:58,120 --> 00:25:59,955 FAREWELL HERE WITHIN COUNCIL. 714 00:25:59,955 --> 00:26:07,029 NOW AT THE SAME TIME, WE HAVE 715 00:26:07,029 --> 00:26:13,468 ANNOUNCED THIS WEEK THAT BEKAH 716 00:26:13,468 --> 00:26:15,871 GEIGER WILL BE ACTING EXECUTIVE 717 00:26:15,871 --> 00:26:17,606 OFFICER, SHE HAS BEEN DEPUTY 718 00:26:17,606 --> 00:26:19,007 EXECUTIVE OFFICER NOW FOR A FEW 719 00:26:19,007 --> 00:26:21,643 MONTHS AND SHE WILL BE STEPPING 720 00:26:21,643 --> 00:26:23,145 INTO THIS ROLE, VERY ABLY, VERY 721 00:26:23,145 --> 00:26:24,980 MUCH LOOKING FORWARD TO WORKING 722 00:26:24,980 --> 00:26:26,181 WITH BEKAH AS WELL. 723 00:26:26,181 --> 00:26:27,349 I KNOW WE ARE IN VERY GOOD 724 00:26:27,349 --> 00:26:28,483 HANDS. 725 00:26:28,483 --> 00:26:32,321 SHE HAS BEEN ALSO A LONG-TERM 726 00:26:32,321 --> 00:26:36,725 CHAMPION IN NIH AND SERVED IN A 727 00:26:36,725 --> 00:26:39,027 VARIETY OF CAPACITIES. 728 00:26:39,027 --> 00:26:40,162 HELPING AT THE DEPUTY EXECUTIVE 729 00:26:40,162 --> 00:26:44,399 LEVEL AND I LOOK FORWARD TO HER 730 00:26:44,399 --> 00:26:46,535 LEADERSHIP AS WE DO AN ACTIVE 731 00:26:46,535 --> 00:26:47,703 SEARCH FOR THIS POSITION. 732 00:26:47,703 --> 00:26:49,438 WE ARE KIND OF DONE WITH 733 00:26:49,438 --> 00:26:50,439 LEADERSHIP, NOT QUITE BUT WE 734 00:26:50,439 --> 00:26:51,540 ARE GOING TO GET THERE. 735 00:26:51,540 --> 00:26:52,941 ALL RIGHT. 736 00:26:52,941 --> 00:26:54,576 JUST A FEW OTHER THINGS I 737 00:26:54,576 --> 00:26:56,945 WANTED TO MENTION TOO, AT THE 738 00:26:56,945 --> 00:26:58,180 NIH LEVEL WE ARE RECRUITING NOW 739 00:26:58,180 --> 00:27:00,148 FOR A DIRECTOR OF THE NATIONAL 740 00:27:00,148 --> 00:27:03,485 LIBRARY OF MEDICINE. 741 00:27:03,485 --> 00:27:05,387 PATTY BRENNAN STEPPED DOWN 742 00:27:05,387 --> 00:27:07,222 ABOUT 6-9 MONTHS AGO NOW. 743 00:27:07,222 --> 00:27:09,358 AND THE APPLICATION PERIOD FOR 744 00:27:09,358 --> 00:27:11,260 THIS CHOICES ON MONDAY JULY 1st. 745 00:27:11,260 --> 00:27:13,262 SO IF YOU KNOW ANYONE WHO MIGHT 746 00:27:13,262 --> 00:27:14,696 BE INTERESTED IN THIS 747 00:27:14,696 --> 00:27:15,897 PARTICULAR POSITION, PLEASE 748 00:27:15,897 --> 00:27:17,699 RELAY THIS ANNOUNCEMENT TO THEM. 749 00:27:17,699 --> 00:27:20,269 THIS POSITION OFFERS A VERY 750 00:27:20,269 --> 00:27:24,506 UNIQUE, I THINK EXCITING 751 00:27:24,506 --> 00:27:25,707 OPPORTUNITY BECAUSE THE NLM, I 752 00:27:25,707 --> 00:27:26,942 THINK IT'S A LIBRARY, BUT IT'S 753 00:27:26,942 --> 00:27:28,310 MORE THAN A LIBRARY. 754 00:27:28,310 --> 00:27:30,612 I THINK THERE'S A LOT OF 755 00:27:30,612 --> 00:27:34,950 ACTIVITY THE NLM IS DOING NOW, 756 00:27:34,950 --> 00:27:36,084 BUT ALSO WITH DR. BERTAGNOLLI 757 00:27:36,084 --> 00:27:37,786 AND HER VISION, I SEE IT AS 758 00:27:37,786 --> 00:27:40,822 REALLY THINKING MORE OF A DATA 759 00:27:40,822 --> 00:27:43,058 HUB AND CONVENING RELEVANT DATA 760 00:27:43,058 --> 00:27:44,960 FOR SCIENCE AND ANALYTICS IN 761 00:27:44,960 --> 00:27:45,527 THE FUTURE TOO. 762 00:27:45,527 --> 00:27:47,162 THERE MAY BE REALLY GREAT 763 00:27:47,162 --> 00:27:48,363 OPPORTUNITIES FOR PEOPLE WHO 764 00:27:48,363 --> 00:27:51,867 MAY BE INTERESTED IN THIS 765 00:27:51,867 --> 00:27:53,001 POSITION. 766 00:27:53,001 --> 00:27:55,771 I SHOULD SAY TOO, WE HAVE BEEN 767 00:27:55,771 --> 00:27:57,906 PRETTY SUCCESSFUL BRINGING 768 00:27:57,906 --> 00:28:01,576 PEOPLE INVOLVED IN NCATS 769 00:28:01,576 --> 00:28:02,878 SUPPORTED ACTIVITIES, 770 00:28:02,878 --> 00:28:08,650 ESPECIALLY THE CTSA *. JOSHUA 771 00:28:08,650 --> 00:28:10,052 LEVY JOINED THE NIDCD RECENTLY, 772 00:28:10,052 --> 00:28:15,757 HE IS THE CLINICAL DIRECTOR 773 00:28:15,757 --> 00:28:18,760 THERE, AND SEAN MOONEY WAS 774 00:28:18,760 --> 00:28:21,129 HIRED AND CAME FROM A CTSA 775 00:28:21,129 --> 00:28:22,130 PROGRAM. 776 00:28:22,130 --> 00:28:23,832 WHO KNOWS MAYBE WE WILL SEE 777 00:28:23,832 --> 00:28:30,372 ANOTHER LEADERSHIP. 778 00:28:30,372 --> 00:28:33,141 DR. DEB TUCEY, SHE WAS FROM THE 779 00:28:33,141 --> 00:28:33,742 CTSA. 780 00:28:33,742 --> 00:28:36,845 WENDY IS THE DIRECTOR OF NIAM, 781 00:28:36,845 --> 00:28:38,580 SHE WAS FROM CTSA. 782 00:28:38,580 --> 00:28:41,583 YOU NEVER KNOW, WE MAY GET MORE 783 00:28:41,583 --> 00:28:43,452 FOLKS FROM CTSA JOINING AT THE 784 00:28:43,452 --> 00:28:49,091 NIH LEVEL TOO. 785 00:28:49,091 --> 00:28:50,392 HE IS MOVING VERY QUICKLY. 786 00:28:50,392 --> 00:28:52,127 I WANTED TO SAY ONE OF THE 787 00:28:52,127 --> 00:28:54,062 THINGS HE HAS DONE SINCE HE HAS 788 00:28:54,062 --> 00:28:58,166 BEEN AT CIT. 789 00:28:58,166 --> 00:28:59,368 NIH HAS GREATLY BENEFITED FROM 790 00:28:59,368 --> 00:29:01,136 THE STRIDES PROGRAM. 791 00:29:01,136 --> 00:29:01,770 THIS IS A CLOUD-BASED PROGRAM 792 00:29:01,770 --> 00:29:03,405 WE HAVE. 793 00:29:03,405 --> 00:29:06,041 IT'S REALLY BEEN FOCUSED ON THE 794 00:29:06,041 --> 00:29:08,076 INTRAMURAL PROGRAMS AT NIH. 795 00:29:08,076 --> 00:29:10,011 NOW HE IS OPENING THIS TO THE 796 00:29:10,011 --> 00:29:10,846 EXTRAMURAL COMMUNITY. 797 00:29:10,846 --> 00:29:12,647 I WANT TO MAKE SURE YOU ARE ALL 798 00:29:12,647 --> 00:29:13,749 AWARE OF THIS. 799 00:29:13,749 --> 00:29:16,618 THIS IS AN OPPORTUNITY TO GET 800 00:29:16,618 --> 00:29:17,219 CLOUD-BASED EXPERIENCE AT NO 801 00:29:17,219 --> 00:29:27,329 COST. 802 00:29:28,029 --> 00:29:29,698 THIS IS KIND OF A TRY BEFORE 803 00:29:29,698 --> 00:29:32,934 YOU BUY AND YOU GET $500 IN 804 00:29:32,934 --> 00:29:33,168 CREDITS. 805 00:29:33,168 --> 00:29:34,302 YOU CAN LEARN THE ROPES AND SEE 806 00:29:34,302 --> 00:29:35,303 IF THE SOMETHING YOU WANT TO DO 807 00:29:35,303 --> 00:29:38,473 MORE OF. 808 00:29:38,473 --> 00:29:40,776 THIS IS ONE OF THE ACTIVITIES 809 00:29:40,776 --> 00:29:43,278 HE HAS BROUGHT TO THE TABLE 810 00:29:43,278 --> 00:29:44,546 SINCE HE JOINED THE NIH AND I 811 00:29:44,546 --> 00:29:45,480 WANTED TO MAKE SURE YOU WERE 812 00:29:45,480 --> 00:29:47,249 AWARE OF THAT. 813 00:29:47,249 --> 00:29:48,984 A FEW MORE PIECES OF ACTIVITIES 814 00:29:48,984 --> 00:29:51,486 WE HAVE BEEN DOING. 815 00:29:51,486 --> 00:29:53,889 THIS YEAR RARE DISEASE DAY FELL 816 00:29:53,889 --> 00:29:55,424 ON FEBRUARY 29th AND THAT IS A 817 00:29:55,424 --> 00:29:57,526 RARE, RARE DAY. 818 00:29:57,526 --> 00:29:59,161 ON FEBRUARY 28th THE WHITE 819 00:29:59,161 --> 00:30:01,263 HOUSE HELD FOR THE FIRST TIME A 820 00:30:01,263 --> 00:30:02,798 RARE DISEASE FORUM, AND I WAS 821 00:30:02,798 --> 00:30:07,169 HONOR TODAY BE A PART AS WELL 822 00:30:07,169 --> 00:30:09,104 AS ANNIE KENNEDY. 823 00:30:09,104 --> 00:30:09,805 SHE WAS ALSO MODERATING A 824 00:30:09,805 --> 00:30:11,273 SESSION THAT DAY. 825 00:30:11,273 --> 00:30:13,408 I HOPE THIS IS SOMETHING THE 826 00:30:13,408 --> 00:30:15,444 WHITE HOUSE DID DO, IT RAISED 827 00:30:15,444 --> 00:30:17,145 AWARENESS OF RARE DISEASES. 828 00:30:17,145 --> 00:30:18,346 I AM GRATEFUL FOR THEIR 829 00:30:18,346 --> 00:30:24,519 RECOGNITION OF DOING THAT. 830 00:30:24,519 --> 00:30:26,888 IN ADDITION ON THE RARE DISEASE 831 00:30:26,888 --> 00:30:29,224 DAY AT NIH WAS THE DAY AFTER. 832 00:30:29,224 --> 00:30:31,059 AGAIN, IT WAS A VERY RARE DAY. 833 00:30:31,059 --> 00:30:33,128 ONE HIGHLIGHT I WANT TO 834 00:30:33,128 --> 00:30:34,496 MENTION, DOMINIQUE WILL TALK 835 00:30:34,496 --> 00:30:36,131 MORE ABOUT RARE DISEASE DAY, SO 836 00:30:36,131 --> 00:30:38,667 I DON'T WANT TO STEAL HER 837 00:30:38,667 --> 00:30:38,900 THUNDER. 838 00:30:38,900 --> 00:30:43,004 ONE THING THAT HAPPENED ON THIS 839 00:30:43,004 --> 00:30:47,342 DAY, IT WAS PRETTY SPECIAL, THE 840 00:30:47,342 --> 00:30:49,110 CURE JM ADVOCATE PRESENTED 841 00:30:49,110 --> 00:30:52,180 PROCLAMATION AND THANKS TO 842 00:30:52,180 --> 00:30:52,380 NCATS. 843 00:30:52,380 --> 00:30:53,648 I WAS PRESENTED THIS PLAQUE AND 844 00:30:53,648 --> 00:30:56,184 HONORED TO RECEIVE IT. 845 00:30:56,184 --> 00:30:58,053 JAMES BEST WAS ONE PRESENTING 846 00:30:58,053 --> 00:31:00,956 IT TO ME, SOMEONE I REALLY LOOK 847 00:31:00,956 --> 00:31:01,423 UP TO, LITERALLY AND 848 00:31:01,423 --> 00:31:02,357 FIGURATIVELY. 849 00:31:02,357 --> 00:31:03,792 [LAUGHTER] 850 00:31:03,792 --> 00:31:06,928 BUT TAKE A LOOK AT THIS. 851 00:31:06,928 --> 00:31:09,030 THEIR PROCLAMATION OF THANKS 852 00:31:09,030 --> 00:31:11,766 WAS OVER 600 SIGNATORIES FROM 853 00:31:11,766 --> 00:31:13,235 THE CURE JM COMMUNITY. 854 00:31:13,235 --> 00:31:16,037 JUST A QUOTE FROM ONE OF THE 855 00:31:16,037 --> 00:31:17,405 FRIENDS OF SOMEONE WITH JM, SHE 856 00:31:17,405 --> 00:31:19,174 SAID I'M SO PROUD OF YOUR 857 00:31:19,174 --> 00:31:21,109 ABILITY TO WAKE UP EACH DAY AND 858 00:31:21,109 --> 00:31:22,410 GIVE IT YOUR BEST NO MATTER 859 00:31:22,410 --> 00:31:24,746 WHAT. 860 00:31:24,746 --> 00:31:26,414 I HOPE NIH WILL EARMARK MORE 861 00:31:26,414 --> 00:31:30,352 FUNDING FOR THE VITAL RESEARCH 862 00:31:30,352 --> 00:31:31,786 AND DEVELOPMENT OF LIFE-SAVING 863 00:31:31,786 --> 00:31:33,688 TREATMENTS FOR RARE DISEASES. 864 00:31:33,688 --> 00:31:35,190 THIS WAS HEART WARMING TO 865 00:31:35,190 --> 00:31:38,960 RECEIVE A DEEP NOTE LIKE THIS 866 00:31:38,960 --> 00:31:40,061 FROM PATIENTS, PARENTS, 867 00:31:40,061 --> 00:31:42,464 GRANDPARENT AND FRIENDS OF JM. 868 00:31:42,464 --> 00:31:43,798 I AM PLEASED TO SHARE THIS SO 869 00:31:43,798 --> 00:31:45,200 YOU CAN SEE IT. 870 00:31:45,200 --> 00:31:47,836 WE SENT IT AROUND THE NCATS 871 00:31:47,836 --> 00:31:49,604 COMMUNITY SO THEY WOULD ALL BE 872 00:31:49,604 --> 00:31:50,972 AWARE OF IT. 873 00:31:50,972 --> 00:31:51,706 THIS WAS A DEEPLY TOUCHING 874 00:31:51,706 --> 00:31:55,143 MOMENT FOR US. 875 00:31:55,143 --> 00:31:59,080 IN ADDITION TO SOME OF THOSE 876 00:31:59,080 --> 00:31:59,948 ACTIVITIES ON RARE DISEASE DAY, 877 00:31:59,948 --> 00:32:03,618 WE HAVE A VARIETY OF CHORES. 878 00:32:03,618 --> 00:32:07,422 SO WE HAVE A VARIETY OF PEOPLE 879 00:32:07,422 --> 00:32:09,891 COMING THROUGH TO DO TOURS. 880 00:32:09,891 --> 00:32:14,329 I WANT TO SHOW THE TOURS. 881 00:32:14,329 --> 00:32:16,598 THIS IS ED MANACHURIAN, THE 882 00:32:16,598 --> 00:32:21,303 FOUNDER OF ACT FOR NIH ALONG 883 00:32:21,303 --> 00:32:22,170 WITH RICHARD TURMAN, THE KRRKTS 884 00:32:22,170 --> 00:32:22,871 EO. 885 00:32:22,871 --> 00:32:24,573 THEY WERE ABLE TO COME IN AND 886 00:32:24,573 --> 00:32:34,883 TAKE A NICE TOUR. 887 00:32:37,018 --> 00:32:38,353 THAT'S ALWAYS A NICE THING TO 888 00:32:38,353 --> 00:32:41,890 GIVE THEM A SENSE HOW WE DO 889 00:32:41,890 --> 00:32:43,191 DRUG DEVELOPMENT AND WE 890 00:32:43,191 --> 00:32:43,792 PIXELATE DRUG DEVELOPMENT IN 891 00:32:43,792 --> 00:32:45,727 THAT WAY. 892 00:32:45,727 --> 00:32:49,364 IN ADDITION TO THE ACT FOR NIH, 893 00:32:49,364 --> 00:32:51,466 WE HAD THE EUROPEAN MEDICINES 894 00:32:51,466 --> 00:32:51,700 AGENCY. 895 00:32:51,700 --> 00:32:53,501 WE HAVE BEEN ENGAGING QUITE A 896 00:32:53,501 --> 00:32:57,105 BIT WITH THE FDA BUT ALSO WITH 897 00:32:57,105 --> 00:33:00,175 THE EUROPEAN MEDICINES AGENCY 898 00:33:00,175 --> 00:33:00,408 AS WELL. 899 00:33:00,408 --> 00:33:01,977 WE HAD THE CHIEF MEDICAL 900 00:33:01,977 --> 00:33:05,513 OFFICER COME TO VISIT US. 901 00:33:05,513 --> 00:33:06,948 WE WERE ABLE TO EXPLAIN SOME OF 902 00:33:06,948 --> 00:33:11,286 THE WORK WE HAVE BEEN DOING AT 903 00:33:11,286 --> 00:33:14,956 THE NCATS LABS, TALKING ABOUT 904 00:33:14,956 --> 00:33:17,192 DRUG REPURPOSING, RARE 905 00:33:17,192 --> 00:33:17,859 DISEASES, NEW APPROACH 906 00:33:17,859 --> 00:33:18,793 METHODOLOGIES, ALL THESE THINGS 907 00:33:18,793 --> 00:33:20,395 WE HAVE BEEN TALKING ABOUT, 908 00:33:20,395 --> 00:33:22,731 THEY ARE ALSO INTERESTED IN. 909 00:33:22,731 --> 00:33:24,366 FORMING INTERACTIONS AND 910 00:33:24,366 --> 00:33:27,469 PARTNERSHIPS WITH THE EMA AND 911 00:33:27,469 --> 00:33:29,204 FDA IS INCREDIBLY IMPORTANT FOR 912 00:33:29,204 --> 00:33:29,504 US. 913 00:33:29,504 --> 00:33:31,806 IN ADDITION WE HAVE BEEN DOING 914 00:33:31,806 --> 00:33:33,808 QUITE A NUMBER OF CONGRESSIONAL 915 00:33:33,808 --> 00:33:35,143 BRIEFINGS AND ACTIVITIES. 916 00:33:35,143 --> 00:33:37,178 THIS IS A VERY BUSY SLIDE AND 917 00:33:37,178 --> 00:33:38,446 SOME OF THE IMAGES OVERLAP WITH 918 00:33:38,446 --> 00:33:39,981 SOME OF THE IMPORTANT THINGS 919 00:33:39,981 --> 00:33:40,181 HERE. 920 00:33:40,181 --> 00:33:46,554 I WILL SEE IF I CAN GET RID OF 921 00:33:46,554 --> 00:33:48,323 THE, MAYBE I CAN'T. 922 00:33:48,323 --> 00:33:49,057 ANYWAY, HOPEFULLY YOU WILL GET 923 00:33:49,057 --> 00:33:50,325 THE IDEA. 924 00:33:50,325 --> 00:33:53,161 WE HAVE DONE QUITE A NUMBER OF 925 00:33:53,161 --> 00:33:56,297 CONGRESSIONAL BRIEFINGS WITH 926 00:33:56,297 --> 00:33:57,365 STAFFERS AND WITH DIFFERENT 927 00:33:57,365 --> 00:34:00,568 MEMBERS AROUND CONGRESS. 928 00:34:00,568 --> 00:34:02,771 FOLKS IN DRUG REPURPOSING, RARE 929 00:34:02,771 --> 00:34:05,607 DISEASES, WE TALK A LOT ABOUT 930 00:34:05,607 --> 00:34:07,075 N3C AND ARTIFICIAL INTELLIGENCE 931 00:34:07,075 --> 00:34:08,576 AND QUANTUM RESEARCH. 932 00:34:08,576 --> 00:34:10,945 AND SO THIS IS, WE WERE 933 00:34:10,945 --> 00:34:13,081 ACTUALLY DOWNTOWN YESTERDAY AT 934 00:34:13,081 --> 00:34:15,250 A DEMONSTRATION FOR THE 935 00:34:15,250 --> 00:34:16,818 NATIONAL AI RESEARCH RESOURCES. 936 00:34:16,818 --> 00:34:20,021 THIS IS A PROGRAM THAT NSF RUNS 937 00:34:20,021 --> 00:34:22,857 BUT WE ARE A PART OF IT, AND 938 00:34:22,857 --> 00:34:33,334 N3C IS A PART OF IT, NIAED. 939 00:34:36,071 --> 00:34:38,606 SUSAN GREGURICK IS WITH ODSS. 940 00:34:38,606 --> 00:34:40,642 SAM HAS A TIE ON, HE IS TURNED 941 00:34:40,642 --> 00:34:42,577 AROUND HERE, TALKING WITH THE 942 00:34:42,577 --> 00:34:45,213 LEGISLATIVE FELLOW. 943 00:34:45,213 --> 00:34:50,552 SENATOR HEINRICH'S OFFICE. 944 00:34:50,552 --> 00:34:58,560 WASEM GAWISH AND TALK WITH 945 00:34:58,560 --> 00:34:59,194 REPRESENTATIVE HALEY STEVENS, 946 00:34:59,194 --> 00:35:01,696 ANNA ESHOO, BILL FOSTER. 947 00:35:01,696 --> 00:35:05,800 THEY ARE INCREDIBLY EXCITED 948 00:35:05,800 --> 00:35:07,702 ABOUT A.I. AND HEARING ABOUT 949 00:35:07,702 --> 00:35:08,369 N3C, THEY ASKED A LOT OF 950 00:35:08,369 --> 00:35:10,071 QUESTION. 951 00:35:10,071 --> 00:35:12,674 THAT'S FANTASTIC TO SEE. 952 00:35:12,674 --> 00:35:14,409 SORT OF LAST IN THIS SESSION, I 953 00:35:14,409 --> 00:35:17,412 WANT TO MENTION WE ARE MOVING. 954 00:35:17,412 --> 00:35:20,982 NCATS WILL NO LONGER BE IN THE 955 00:35:20,982 --> 00:35:22,083 DEMOCRACY BOULEVARD SPACE. 956 00:35:22,083 --> 00:35:29,257 THEY WILL PROBABLY BE IN THE 957 00:35:29,257 --> 00:35:29,791 NATIONAL CANCER INSTITUTE 958 00:35:29,791 --> 00:35:30,592 FACILITIES. 959 00:35:30,592 --> 00:35:32,293 LATER IN JUNE. 960 00:35:32,293 --> 00:35:34,295 WE HAVE ANOTHER MONTH OR SO. 961 00:35:34,295 --> 00:35:36,698 WE LOOK FORWARD TO MOVING. 962 00:35:36,698 --> 00:35:37,832 KIND OF BEING CO-LOCATED IN THE 963 00:35:37,832 --> 00:35:38,933 SAME SPACE. 964 00:35:38,933 --> 00:35:41,269 NOT ONLY WILL WE BE IN THE SAME 965 00:35:41,269 --> 00:35:43,505 SPACE AND BUILDING FOR 966 00:35:43,505 --> 00:35:46,207 EXTRAMURAL, WE WILL BE 15 967 00:35:46,207 --> 00:35:48,243 MINUTES AWAY FROM THE NCATS LAB 968 00:35:48,243 --> 00:35:52,213 BY FOOT, YOU DON'T HAVE TO 969 00:35:52,213 --> 00:35:52,413 DRIVE. 970 00:35:52,413 --> 00:35:54,449 JUST WANT TO BRIEFLY RUN 971 00:35:54,449 --> 00:35:56,718 THROUGH SOME PROGRAMMATIC 972 00:35:56,718 --> 00:35:56,951 UPDATES. 973 00:35:56,951 --> 00:35:58,153 YOU WON'T SPEND TOO MUCH TIME. 974 00:35:58,153 --> 00:36:00,855 WE ARE STILL WORKING THROUGH 975 00:36:00,855 --> 00:36:02,323 THE NOVEL APPROACH IN THE 976 00:36:02,323 --> 00:36:06,528 COMPLIMENTARY. 977 00:36:06,528 --> 00:36:13,868 THIS IS THE COMPLEMENT ANIMAL 978 00:36:13,868 --> 00:36:19,240 RESEARCH IN EXPERIMENTATION. 979 00:36:19,240 --> 00:36:22,544 BRING IN DIGITAL AND LOOKING AT 980 00:36:22,544 --> 00:36:24,345 mRNA AND OTHER ASSAYS. 981 00:36:24,345 --> 00:36:26,881 WE HOPE THIS WILL BE A VERY 982 00:36:26,881 --> 00:36:28,883 EFFECTIVE WAY OF DEVELOPING 983 00:36:28,883 --> 00:36:30,585 BETTER TOOLS THAT ARE 984 00:36:30,585 --> 00:36:33,822 PREDICTIVE TOOLS FOR MORE 985 00:36:33,822 --> 00:36:34,556 EFFICIENT EFFECTIVE RESEARCH IN 986 00:36:34,556 --> 00:36:35,924 BIO MEDICINE. 987 00:36:35,924 --> 00:36:37,025 STAY TUNED FOR MORE WORK IN 988 00:36:37,025 --> 00:36:38,459 THIS SPACE. 989 00:36:38,459 --> 00:36:39,327 HOPEFULLY AT OUR NEXT COUNCIL 990 00:36:39,327 --> 00:36:40,962 WE WILL BE ABLE TO GIVE YOU A 991 00:36:40,962 --> 00:36:42,530 LITTLE MORE ABOUT THAT. 992 00:36:42,530 --> 00:36:45,333 I WANT TO HIGHLIGHT ONE OF THE 993 00:36:45,333 --> 00:36:46,134 PROGRAMS CHRISTINED TOUCHED ON 994 00:36:46,134 --> 00:36:47,702 EARLIER WHEN WE WERE IN OUR 995 00:36:47,702 --> 00:36:51,406 CLOSED SESSION TODAY. 996 00:36:51,406 --> 00:36:58,847 THIS IS AN INITIATIVE ON THE 997 00:36:58,847 --> 00:36:59,914 PRE-CLINICAL PROOF OF CONCEPT 998 00:36:59,914 --> 00:37:04,118 STUDIES FOR RARE DISEASES. 999 00:37:04,118 --> 00:37:06,221 THANKS, STEVE. 1000 00:37:06,221 --> 00:37:07,288 THIS HAS CREATED A MASSIVE 1001 00:37:07,288 --> 00:37:09,023 RESPONSE FROM THE COMMUNITY. 1002 00:37:09,023 --> 00:37:12,160 SO MUCH WE AREN'T ABLE TO FUND 1003 00:37:12,160 --> 00:37:12,660 THE REALLY GOOD SCIENCE. 1004 00:37:12,660 --> 00:37:16,764 OUR GOAL IS TO PROVIDE FUNDING 1005 00:37:16,764 --> 00:37:19,400 TO TEST EFFICACY OF NOVEL 1006 00:37:19,400 --> 00:37:21,603 AGENTS IN ESTABLISHED RARE 1007 00:37:21,603 --> 00:37:22,070 DISEASES, ESPECIALLY 1008 00:37:22,070 --> 00:37:24,806 PRECLINICAL MODELS. 1009 00:37:24,806 --> 00:37:27,342 SUPPORT EFFICACY TESTING FOR 1010 00:37:27,342 --> 00:37:28,776 REPURPOSING OF APPROVED 1011 00:37:28,776 --> 00:37:30,378 THYROPUET ICS TO TREAT RARE 1012 00:37:30,378 --> 00:37:32,247 DISEASES. 1013 00:37:32,247 --> 00:37:34,449 THIS REQUIRES PARTNERSHIP PLAN 1014 00:37:34,449 --> 00:37:36,651 WITH RARE DISEASE STEERING AND 1015 00:37:36,651 --> 00:37:38,786 OVERSIGHT COMMIT EYES 1016 00:37:38,786 --> 00:37:39,654 CONSISTING OF EXPERTS, 1017 00:37:39,654 --> 00:37:47,896 PATIENTS, PATIENT ADVOCATE. 1018 00:37:47,896 --> 00:37:50,131 TR-24-023. 1019 00:37:50,131 --> 00:37:52,233 HERE IS YOUR QR CODE IF YOU ARE 1020 00:37:52,233 --> 00:37:54,202 INTERESTED IN THIS, WE HOPE YOU 1021 00:37:54,202 --> 00:37:54,869 APPLY. 1022 00:37:54,869 --> 00:37:57,171 YOU CAN SEE THE BREAK DOWN OF 1023 00:37:57,171 --> 00:37:57,839 THE MODALITIES WE ARE LOOKING 1024 00:37:57,839 --> 00:37:59,307 AT HERE. 1025 00:37:59,307 --> 00:38:01,209 QUITE A NUMBER OF MODALITIES, 1026 00:38:01,209 --> 00:38:02,510 INDICATION AREAS. 1027 00:38:02,510 --> 00:38:04,712 AS WELL AS THE REPURPOSING OR 1028 00:38:04,712 --> 00:38:08,549 NOT APPROACHES HERE TOO. 1029 00:38:08,549 --> 00:38:12,153 QUITE A SMATTERING OF 1030 00:38:12,153 --> 00:38:12,654 ACTIVITIES IN RESEARCH. 1031 00:38:12,654 --> 00:38:14,656 A GREAT PROGRAM. 1032 00:38:14,656 --> 00:38:17,659 EARLIER THIS YEAR WE HAD THE 1033 00:38:17,659 --> 00:38:18,826 ASSOCIATION FOR CLINICAL AND 1034 00:38:18,826 --> 00:38:19,394 TRANSLATIONAL SCIENCE AWARD 1035 00:38:19,394 --> 00:38:20,929 MEETING. 1036 00:38:20,929 --> 00:38:21,930 THIS IS THE TRANSLATIONAL 1037 00:38:21,930 --> 00:38:22,764 SCIENCE 2024 IS WHAT IT IS 1038 00:38:22,764 --> 00:38:23,965 KNOWN AS. 1039 00:38:23,965 --> 00:38:25,566 THIS WAS HELD IN LAS VEGAS. 1040 00:38:25,566 --> 00:38:28,303 WE WERE STANDING IN FRONT OF 1041 00:38:28,303 --> 00:38:29,771 THE FAMOUS FOUNTAINS BUT IT 1042 00:38:29,771 --> 00:38:32,140 WASN'T GOING OFF BECAUSE IT WAS 1043 00:38:32,140 --> 00:38:36,077 WINDY SO WE HAVE OUR SAD FACES 1044 00:38:36,077 --> 00:38:36,244 ON. 1045 00:38:36,244 --> 00:38:38,713 THIS IS AN INCREDIBLE INSPIRING 1046 00:38:38,713 --> 00:38:39,180 AND ENGAGING MEETING. 1047 00:38:39,180 --> 00:38:41,849 I WANTED TO START THIS OFF AS 1048 00:38:41,849 --> 00:38:43,718 HIGHLIGHTING KEY AREA OF 1049 00:38:43,718 --> 00:38:44,118 SCIENCE MENTIONED. 1050 00:38:44,118 --> 00:38:45,887 THIS IS ONE AREA OF SCIENCE 1051 00:38:45,887 --> 00:38:48,089 THAT RECEIVED A CLINICAL 1052 00:38:48,089 --> 00:38:48,656 RESEARCH ACHIEVEMENT AWARD. 1053 00:38:48,656 --> 00:38:50,224 TOP TEN. 1054 00:38:50,224 --> 00:39:00,735 S THIS IS A PROGRAM KNOWN AS 1055 00:39:01,402 --> 00:39:04,539 GEMINI OUT OF TUFTS UNIVERSITY. 1056 00:39:04,539 --> 00:39:05,440 THEY TOOK TARGET SEQUENCING 1057 00:39:05,440 --> 00:39:07,976 SPECIFIC GENES THAT MAY BE 1058 00:39:07,976 --> 00:39:08,843 RELATED TO SPECIFIC DISEASES 1059 00:39:08,843 --> 00:39:10,712 AND HOLDING. 1060 00:39:10,712 --> 00:39:11,779 AND THEY COMPARED THE TWO 1061 00:39:11,779 --> 00:39:12,714 APPROACHES. 1062 00:39:12,714 --> 00:39:15,450 WHAT THEY FOUND WAS ESSENTIALLY 1063 00:39:15,450 --> 00:39:18,019 WHEN YOU COMPARE WHOLE GENOME 1064 00:39:18,019 --> 00:39:20,321 SEQUENCING, WHEN YOU DID IT, IT 1065 00:39:20,321 --> 00:39:22,824 DIDN'T REPORT 19 OF THE 1066 00:39:22,824 --> 00:39:23,358 VARIANTS FOUND BY TARGET 1067 00:39:23,358 --> 00:39:25,860 SEQUENCING. 1068 00:39:25,860 --> 00:39:29,097 ON THE OTHER HAND TARGET 1069 00:39:29,097 --> 00:39:32,100 SEQUENCING DIDN'T REPORT 164 1070 00:39:32,100 --> 00:39:32,900 VARIANTS THAT WHOLE GENOME 1071 00:39:32,900 --> 00:39:34,969 SEQUENCING IDENTIFIED. 1072 00:39:34,969 --> 00:39:38,506 SO WHOLE GENOME SEQUENCING WITH 1073 00:39:38,506 --> 00:39:39,874 THE WIN HERE IDENTIFYING MORE 1074 00:39:39,874 --> 00:39:41,142 IMPORTANT VARIANTS. 1075 00:39:41,142 --> 00:39:42,243 NOW THE OTHER INTERESTING THING 1076 00:39:42,243 --> 00:39:44,178 THEY LOOKED AT WAS THE MEDIAN 1077 00:39:44,178 --> 00:39:47,782 TIME TO RETURN THE TEST RESULTS. 1078 00:39:47,782 --> 00:39:52,320 IT TOOK ABOUT FOUR DAYS TO GET 1079 00:39:52,320 --> 00:39:53,454 THE TARGETED GENE SEQUENCING 1080 00:39:53,454 --> 00:39:55,656 RESULTS AND A LITTLE OVER SIX 1081 00:39:55,656 --> 00:39:57,258 DAYS TO GET THE WHOLE GENOME 1082 00:39:57,258 --> 00:39:59,727 SEQUENCING RESULTS. 1083 00:39:59,727 --> 00:40:00,828 THE NUMBER OF VARIANTS 1084 00:40:00,828 --> 00:40:02,430 IDENTIFIED, PERHAPS A LITTLE 1085 00:40:02,430 --> 00:40:03,164 BIT LONGER ISN'T A BHATT BAD 1086 00:40:03,164 --> 00:40:05,466 THING. 1087 00:40:05,466 --> 00:40:06,968 -- BAD THING. 1088 00:40:06,968 --> 00:40:09,070 I WOULD ONLY IMAGINE THAT WOULD 1089 00:40:09,070 --> 00:40:11,339 GET BETTER OVER TIME. 1090 00:40:11,339 --> 00:40:18,312 THIS IS PROVIDING EVIDENCE HOW 1091 00:40:18,312 --> 00:40:19,847 IMPORTANT WHOLE GENOME 1092 00:40:19,847 --> 00:40:21,983 SEQUENCING IS ESPECIALLY IN THE 1093 00:40:21,983 --> 00:40:25,086 RARE DISEASES SPACE. 1094 00:40:25,086 --> 00:40:26,421 THIS IS A PROGRAM CALLED EARLY 1095 00:40:26,421 --> 00:40:28,456 CHECK. 1096 00:40:28,456 --> 00:40:32,894 ALSO OUT OF THE CPSA PROGRAM TO 1097 00:40:32,894 --> 00:40:33,661 ASSIST THE IA, COLLABORATIVE 1098 00:40:33,661 --> 00:40:36,264 INNOVATION AWARD. 1099 00:40:36,264 --> 00:40:40,301 THIS IS A LARGE SCALE PROGRAM 1100 00:40:40,301 --> 00:40:40,701 IN NORTH CAROLINA. 1101 00:40:40,701 --> 00:40:41,335 THEY DO THREE SCREENING 1102 00:40:41,335 --> 00:40:43,604 RESEARCH PROGRAMS HERE. 1103 00:40:43,604 --> 00:40:45,540 THE DESIGNED TO IDENTIFY 1104 00:40:45,540 --> 00:40:47,275 CHILDREN WITH RARE HEALTH 1105 00:40:47,275 --> 00:40:47,842 CONDITIONS BEFORE SYMPTOMS 1106 00:40:47,842 --> 00:40:54,615 APPEAR. 1107 00:40:54,615 --> 00:40:56,317 THEY STARTED BY SPINAL 1108 00:40:56,317 --> 00:40:58,686 HUFF-THEY STARTED THIS IN 2018. 1109 00:40:58,686 --> 00:41:00,788 AS OF SEPTEMBER EARLY CHECK 1110 00:41:00,788 --> 00:41:03,324 SCREENED MORE THAN 10,000 BABY 1111 00:41:03,324 --> 00:41:05,460 AS CROSS NORTH CAROLINA AND THE 1112 00:41:05,460 --> 00:41:06,727 FAMILIES WERE INVOLVED IN THIS 1113 00:41:06,727 --> 00:41:08,062 VIRTUAL RECRUITMENT. 1114 00:41:08,062 --> 00:41:09,263 SO THIS IS ALL DONE RIGHT 1115 00:41:09,263 --> 00:41:10,665 BEFORE THE PANDEMIC HIT. 1116 00:41:10,665 --> 00:41:12,900 BUT I THINK REALLY SET THE 1117 00:41:12,900 --> 00:41:13,768 STAGE WELL FOR HAVING THIS MOVE 1118 00:41:13,768 --> 00:41:14,936 FORWARD. 1119 00:41:14,936 --> 00:41:17,038 AS A RESULT OF THE PROJECT, 1120 00:41:17,038 --> 00:41:22,110 BECAUSE THEY HAD BEEN LOOKING 1121 00:41:22,110 --> 00:41:23,511 FOR FRAGILE X AND SMA, THEY 1122 00:41:23,511 --> 00:41:26,447 WERE ABLE TO ADD THOSE TO THE 1123 00:41:26,447 --> 00:41:28,149 STANDARD NEWBORN SCREENINGS IN 1124 00:41:28,149 --> 00:41:28,816 NORTH CAROLINA WHICH IT WASN'T 1125 00:41:28,816 --> 00:41:30,551 ON BEFORE. 1126 00:41:30,551 --> 00:41:31,986 THIS IS MAKING A DIFFERENCE 1127 00:41:31,986 --> 00:41:34,622 ADDING THE RARE DISEASES TO THE 1128 00:41:34,622 --> 00:41:37,792 TABLE BUT ALSO GARNERING A LOT 1129 00:41:37,792 --> 00:41:40,094 OF EVIDENCE NEEDED FOR WHOLE 1130 00:41:40,094 --> 00:41:41,696 GENOME SEQUENCES AND HOW 1131 00:41:41,696 --> 00:41:42,263 IMPORTANT IT IS FOR NEWBORN 1132 00:41:42,263 --> 00:41:43,297 SCREENING. 1133 00:41:43,297 --> 00:41:45,466 SOMETHING TO KEEP YOUR EYE ON. 1134 00:41:45,466 --> 00:41:48,069 I WOULD SAY EARLY CHECK 1135 00:41:48,069 --> 00:41:50,404 SPECIFICALLY ALSO LOOKS FOR 1136 00:41:50,404 --> 00:41:52,006 TYPE I DIABETES AND PROVIDES 1137 00:41:52,006 --> 00:41:53,941 COUNSELING FOR THE CASES WHERE 1138 00:41:53,941 --> 00:41:55,643 THEY IDENTIFY THOSE. 1139 00:41:55,643 --> 00:41:57,545 I WANT TO BRIEFLY MENTION THIS, 1140 00:41:57,545 --> 00:41:58,379 THE KIND OF A DIFFERENT 1141 00:41:58,379 --> 00:42:01,949 TECHNOLOGY. 1142 00:42:01,949 --> 00:42:03,885 THIS IS OUT OF WASH-U. 1143 00:42:03,885 --> 00:42:06,387 ST. LOUIS TEAM, USED A 1144 00:42:06,387 --> 00:42:09,624 STREAMLINE WHOLE GENOME 1145 00:42:09,624 --> 00:42:11,959 SEQUENCING TO OBTAIN GENETIC 1146 00:42:11,959 --> 00:42:17,298 PROFILES FOR PATIENTS WITH 1147 00:42:17,298 --> 00:42:18,866 MYELOID CANCERS. 1148 00:42:18,866 --> 00:42:21,903 WHEN THEY DID THIS, THEY DID 1149 00:42:21,903 --> 00:42:24,272 WHOLE GENOME SEQUENCING. 1150 00:42:24,272 --> 00:42:27,608 ALL 40 AND 91 COPY NUMBER 1151 00:42:27,608 --> 00:42:31,445 ALTERATIONS THAT HAD BEEN 1152 00:42:31,445 --> 00:42:32,146 IDENTIFIED THROUGH CYTOGENETIC 1153 00:42:32,146 --> 00:42:33,581 PROCESSES AS WELL SORT OF THE 1154 00:42:33,581 --> 00:42:34,682 STANDARD PRACTICE. 1155 00:42:34,682 --> 00:42:36,217 BECAUSE THEY WERE ABLE TO GET 1156 00:42:36,217 --> 00:42:38,386 AT ALL OF THOSE, IT GAVE US 1157 00:42:38,386 --> 00:42:39,921 HIGH CONFIDENCE THIS MAY BE 1158 00:42:39,921 --> 00:42:43,157 ANOTHER TOOL TO USE IN 1159 00:42:43,157 --> 00:42:45,893 IDENTIFYING THOSE SPECIFIC 1160 00:42:45,893 --> 00:42:46,527 GENETIC ABNORMALITIES 1161 00:42:46,527 --> 00:42:48,129 ASSOCIATED WITH THESE DISEASES. 1162 00:42:48,129 --> 00:42:52,066 IT COULD HELP US IDENTIFY MORE 1163 00:42:52,066 --> 00:42:53,201 ACCURATE TREATMENTS FOR THESE 1164 00:42:53,201 --> 00:42:54,969 VERY SPECIFIC DISEASES. 1165 00:42:54,969 --> 00:42:57,705 SO IT LOOKS VERY PROMISING. 1166 00:42:57,705 --> 00:42:59,006 ONE MORE PROGRAM, ACTUALLY TWO 1167 00:42:59,006 --> 00:43:02,543 MORE PROGRAMS I WANT TO MENTION. 1168 00:43:02,543 --> 00:43:03,644 THESE ARE TWO COLLABORATIVE 1169 00:43:03,644 --> 00:43:04,812 CTSA GENOMES PROGRAMS. 1170 00:43:04,812 --> 00:43:07,415 ON THE LEFT SIDE THIS IS 1171 00:43:07,415 --> 00:43:12,453 LOOKING AT SORT OF A REAL-WORLD 1172 00:43:12,453 --> 00:43:14,255 RANDOMIZED CLINICAL TRIAL STUDY 1173 00:43:14,255 --> 00:43:17,091 ON IMPACT OF WHOLE GENOME 1174 00:43:17,091 --> 00:43:20,228 SEQUENCING IN ETHNICALLY AND 1175 00:43:20,228 --> 00:43:21,629 RACIALLY DIVERSE POPULATION OF 1176 00:43:21,629 --> 00:43:22,964 HEALTHY INFANTS. 1177 00:43:22,964 --> 00:43:24,198 THIS IS ROBERT GREEN AND HIS 1178 00:43:24,198 --> 00:43:25,800 COLLEAGUES. 1179 00:43:25,800 --> 00:43:28,102 THEY DEVELOPED THIS IDEA OF 1180 00:43:28,102 --> 00:43:29,237 DOING GENOME SEQUENCING IN 1181 00:43:29,237 --> 00:43:32,673 THESE KIDS AS A WAY TO SCREEN 1182 00:43:32,673 --> 00:43:34,375 IN UNDERSERVED COMMUNITIES WITH 1183 00:43:34,375 --> 00:43:36,410 THE GOAL IN MIND TO DETERMINE 1184 00:43:36,410 --> 00:43:38,346 HOW IT COULD BECOME MORE 1185 00:43:38,346 --> 00:43:40,381 ROUTINE IN PEDIATRIC CARE. 1186 00:43:40,381 --> 00:43:43,084 LEARNING ESSENTIALLY THIS IS A 1187 00:43:43,084 --> 00:43:44,285 PRETTY STRAIGHT-FORWARD 1188 00:43:44,285 --> 00:43:46,020 APPROACH AND HIGHLY REGARDED AS 1189 00:43:46,020 --> 00:43:48,422 A WAY OF MOVING FORWARD OR 1190 00:43:48,422 --> 00:43:49,023 IDENTIFYING DISEASES IN THESE 1191 00:43:49,023 --> 00:43:51,158 KIDS. 1192 00:43:51,158 --> 00:43:53,160 ONE MORE OF THESE COLLABORATIVE 1193 00:43:53,160 --> 00:43:56,731 PROGRAMS I WANT TO MENTION IS 1194 00:43:56,731 --> 00:43:58,165 ON THE RIGHT-HAND SIDE WITH KEN 1195 00:43:58,165 --> 00:43:59,233 MENDEL. 1196 00:43:59,233 --> 00:44:02,303 HE IS OUT OF BOSTON. 1197 00:44:02,303 --> 00:44:03,104 THIS IS THE GENOME INFORMATION 1198 00:44:03,104 --> 00:44:07,308 COMMON. 1199 00:44:07,308 --> 00:44:09,410 FIND DATA WITH BIO SPECIMEN 1200 00:44:09,410 --> 00:44:10,745 DATA AT THIS SCALE. 1201 00:44:10,745 --> 00:44:14,282 I WANT TO HIGHLIGHT THAT AS A 1202 00:44:14,282 --> 00:44:15,049 RESOURCE THAT'S PROVEN HIGHLY 1203 00:44:15,049 --> 00:44:18,019 VALUABLE IN THIS SPACE. 1204 00:44:18,019 --> 00:44:25,326 AND WITH JUST SORT OF RIFFING 1205 00:44:25,326 --> 00:44:26,427 OFF WHAT DR. BERTAGNOLLI 1206 00:44:26,427 --> 00:44:28,262 PRESENTED, THIS IS A VISION SHE 1207 00:44:28,262 --> 00:44:31,065 HAS BEEN BRINGING TO THE NIH 1208 00:44:31,065 --> 00:44:32,333 ESTABLISHING A RESEARCH NETWORK 1209 00:44:32,333 --> 00:44:35,603 IN PRIMARY CARE SETTINGS. 1210 00:44:35,603 --> 00:44:36,304 I'M EXCITED ABOUT PLAYING IN 1211 00:44:36,304 --> 00:44:39,240 THIS ROLE. 1212 00:44:39,240 --> 00:44:40,574 I'M ACTUALLY CO-CHAIRING SOME 1213 00:44:40,574 --> 00:44:41,676 ACTIVITIES RELATED TO THIS 1214 00:44:41,676 --> 00:44:44,011 PARTICULAR PROGRAM AND PROJECT. 1215 00:44:44,011 --> 00:44:45,379 SO I WILL RUN THROUGH IT VERY 1216 00:44:45,379 --> 00:44:47,948 QUICKLY HERE. 1217 00:44:47,948 --> 00:44:53,120 AS YOU PROBABLY ARE ALL AWARE, 1218 00:44:53,120 --> 00:44:55,589 OUR LIFE SPAN IN THE U.S. IS 1219 00:44:55,589 --> 00:44:56,190 ACTUALLY GETTING SHORTER OVER 1220 00:44:56,190 --> 00:44:58,259 TIME. 1221 00:44:58,259 --> 00:45:00,995 AND AS WE RANK IN FIRST WORLD 1222 00:45:00,995 --> 00:45:03,197 COUNTRIES WE ARE AROUND 35. 1223 00:45:03,197 --> 00:45:03,831 THE ACTUALLY GOING DOWN EVEN 1224 00:45:03,831 --> 00:45:05,132 MORE. 1225 00:45:05,132 --> 00:45:07,435 SO THIS IS ONE OF THOSE THINGS 1226 00:45:07,435 --> 00:45:09,437 WE ARE TRYING TO UNDERSTAND 1227 00:45:09,437 --> 00:45:11,372 WHAT THE REAL ISSUES ARE. 1228 00:45:11,372 --> 00:45:12,907 BUT WE KNOW WHAT SOME OF THEM 1229 00:45:12,907 --> 00:45:16,711 ARE FOR SURE. 1230 00:45:16,711 --> 00:45:19,046 THAT IS DESPITE HAVING HIGHEST 1231 00:45:19,046 --> 00:45:22,416 HEALTH EXPENDITURES IN THE 1232 00:45:22,416 --> 00:45:24,885 WORLD, WE ARE SEEING MORE AND 1233 00:45:24,885 --> 00:45:26,687 MORE GAPS IN HEALTH DISPARITIES 1234 00:45:26,687 --> 00:45:27,221 AND THOSE IN UNDERSERVED 1235 00:45:27,221 --> 00:45:28,255 COMMUNITIES. 1236 00:45:28,255 --> 00:45:30,791 THE GOAL OF THIS PROGRAM IS 1237 00:45:30,791 --> 00:45:32,493 STARTING TO ADDRESS THOSE 1238 00:45:32,493 --> 00:45:33,060 DISPARITIES, SPECIFICALLY 1239 00:45:33,060 --> 00:45:34,095 MOVING MORE INTO THE PRIMARY 1240 00:45:34,095 --> 00:45:36,931 CARE SPACE. 1241 00:45:36,931 --> 00:45:37,631 THAT'S WHAT THESE ACTIVITIS ARE 1242 00:45:37,631 --> 00:45:39,033 MEANT TO DO. 1243 00:45:39,033 --> 00:45:42,269 THE APPROACH IS SHOWN HERE TO 1244 00:45:42,269 --> 00:45:44,872 EXPAND ENROLLMENT EFFORTS IN 1245 00:45:44,872 --> 00:45:46,107 EXISTING NIH STUDIES AND PILOT 1246 00:45:46,107 --> 00:45:47,408 WAYS TO GET INTO THE PRIMARY 1247 00:45:47,408 --> 00:45:48,642 CARE COMMUNITIES. 1248 00:45:48,642 --> 00:45:51,278 WE WANT TO PARTNER WITH 1249 00:45:51,278 --> 00:45:52,380 EXISTING CLINICAL RESEARCH 1250 00:45:52,380 --> 00:45:53,080 NETWORKS AND RESOURCES TO 1251 00:45:53,080 --> 00:45:55,316 EXPAND THAT GROWTH. 1252 00:45:55,316 --> 00:45:56,050 ENGAGE WITH MORE SITES IN THIS 1253 00:45:56,050 --> 00:45:57,251 WORK. 1254 00:45:57,251 --> 00:45:59,820 AS YOU GO TO THE DOCTOR YOU 1255 00:45:59,820 --> 00:46:01,622 PROBABLY SPEND 15 MINUTES WHEN 1256 00:46:01,622 --> 00:46:03,457 YOUR PRIMARY CARE DOCTOR, THIS 1257 00:46:03,457 --> 00:46:04,959 WON'T BE AN EASY OR STRAIGHT 1258 00:46:04,959 --> 00:46:06,861 FORWARD THING TO DO, WE DON'T 1259 00:46:06,861 --> 00:46:08,396 WANT TO ADD BURDEN TO THE 1260 00:46:08,396 --> 00:46:09,830 PRIMARY CARE ENVIRONMENT OR THE 1261 00:46:09,830 --> 00:46:11,031 PHYSICIANS WHO HAVE LITTLE TIME. 1262 00:46:11,031 --> 00:46:14,268 THE MORE WE CAN DO TO 1263 00:46:14,268 --> 00:46:15,870 STREAMLINE ACTIVITIES, YET 1264 00:46:15,870 --> 00:46:18,205 AGAIN MAKE ADVANCES TO MOVE 1265 00:46:18,205 --> 00:46:20,141 INTO THAT PRIMARY CARE SPACE, 1266 00:46:20,141 --> 00:46:21,575 THIS IS WHERE WE ARE TRYING TO 1267 00:46:21,575 --> 00:46:23,177 MAKE THE CHANGES. 1268 00:46:23,177 --> 00:46:25,579 WE ARE TRYING TO IMPLEMENT THE 1269 00:46:25,579 --> 00:46:26,981 STUDY DESIGN, WORKING WITH 1270 00:46:26,981 --> 00:46:27,782 THESE NETWORK PARTNERS TO 1271 00:46:27,782 --> 00:46:30,851 FIGURE OUT HOW TO DO SUSTAINED 1272 00:46:30,851 --> 00:46:33,154 COMMUNITY ENGAGEMENT AND 1273 00:46:33,154 --> 00:46:34,588 IMPROVE ON CLINICAL INNOVATIONS 1274 00:46:34,588 --> 00:46:37,625 WITHIN THE PRIMARY CARE SETTING. 1275 00:46:37,625 --> 00:46:42,463 WE RECEPTLY CAME OUT WITH A 1276 00:46:42,463 --> 00:46:43,097 ROA, ANOTHER TRANSACTION AWARD 1277 00:46:43,097 --> 00:46:53,340 ANNOUNCEMENT. 1278 00:46:58,312 --> 00:47:01,782 WE WANT TO MAKE SURE IT'S AT 1279 00:47:01,782 --> 00:47:03,717 LEAST OUT OF THE GATE. 1280 00:47:03,717 --> 00:47:06,020 MORE OF A PILOT STAGE ACTIVITY. 1281 00:47:06,020 --> 00:47:07,621 WITH THE ROA WE HOPE TO LAUNCH 1282 00:47:07,621 --> 00:47:09,156 THIS BY END OF THE YEAR. 1283 00:47:09,156 --> 00:47:10,658 WE ARE ON A QUICK TIMELINE TO 1284 00:47:10,658 --> 00:47:11,692 DO THIS. 1285 00:47:11,692 --> 00:47:14,261 WE ARE STARTING OFF WITH $5 1286 00:47:14,261 --> 00:47:15,963 MILLION IN FY '24. 1287 00:47:15,963 --> 00:47:17,431 WE WILL EXPAND THIS, WE HOPE, 1288 00:47:17,431 --> 00:47:18,532 IN YEARS TO COME. 1289 00:47:18,532 --> 00:47:22,269 I HOPE YOU HAVE HAD A CHANCE TO 1290 00:47:22,269 --> 00:47:22,736 LOOK AT THIS RESEARCH 1291 00:47:22,736 --> 00:47:23,671 OPPORTUNITY. 1292 00:47:23,671 --> 00:47:25,105 HERE IS THE LINK TO THAT 1293 00:47:25,105 --> 00:47:26,707 OPPORTUNITY. 1294 00:47:26,707 --> 00:47:28,442 AND THE NUMBER SO YOU CAN 1295 00:47:28,442 --> 00:47:29,477 GOOGLE IT AND FIND OUT A LITTLE 1296 00:47:29,477 --> 00:47:30,377 BIT MORE. 1297 00:47:30,377 --> 00:47:32,713 I WANT TO TAKE A SPECIFIC NOTE 1298 00:47:32,713 --> 00:47:36,617 ON THE ELIGIBILITY. 1299 00:47:36,617 --> 00:47:38,853 THIS IS LOCATED IN STATE 1300 00:47:38,853 --> 00:47:44,792 JURISDICTIONS AT LEAST 25% OF 1301 00:47:44,792 --> 00:47:47,528 CENSUS TRACT DEFINED AS RURAL. 1302 00:47:47,528 --> 00:47:50,598 THIS IS DEFINED BY OUR RUCA 1303 00:47:50,598 --> 00:47:50,798 CODES. 1304 00:47:50,798 --> 00:47:51,966 THIS IS WHERE WE START, 1305 00:47:51,966 --> 00:47:53,901 PROBABLY NOT WHERE WE END, BUT 1306 00:47:53,901 --> 00:47:55,169 WHERE IT WILL START IN TERMS OF 1307 00:47:55,169 --> 00:47:56,637 ELIGIBILITY. 1308 00:47:56,637 --> 00:47:59,840 THERE ALSO HAS TO BE FUNDING TO 1309 00:47:59,840 --> 00:48:01,942 THE NIH INSTITUTIONAL 1310 00:48:01,942 --> 00:48:03,677 DEVELOPMENT ALWARD, CLINICAL 1311 00:48:03,677 --> 00:48:06,647 AND TRANSLATIONAL LAB. 1312 00:48:06,647 --> 00:48:10,384 AND THE NHL CLINICAL AND 1313 00:48:10,384 --> 00:48:10,985 TRANSLATIONAL SCIENCE PROGRAM 1314 00:48:10,985 --> 00:48:14,622 AS WELL. 1315 00:48:14,622 --> 00:48:15,289 OUR CTSA PLEASE STAY TUNED FOR 1316 00:48:15,289 --> 00:48:17,725 THAT. 1317 00:48:17,725 --> 00:48:18,359 AND RESEARCH INSTITUTE NETWORK 1318 00:48:18,359 --> 00:48:20,261 AS WELL. 1319 00:48:20,261 --> 00:48:23,864 THESE ARE THE INITIAL ELIGIBLE 1320 00:48:23,864 --> 00:48:24,565 INSTITUTIONS THAT WILL BE 1321 00:48:24,565 --> 00:48:25,599 CONSIDERED FOR THIS. 1322 00:48:25,599 --> 00:48:28,702 AND THEN IF WE HOPE TO EXPAND 1323 00:48:28,702 --> 00:48:30,471 IT GOING FORWARD. 1324 00:48:30,471 --> 00:48:32,206 ALL RIGHT, SO I WILL END WITH A 1325 00:48:32,206 --> 00:48:33,908 LITTLE BIT OF A TEASER. 1326 00:48:33,908 --> 00:48:35,910 WE WILL HAVE KIND A GAP BETWEEN 1327 00:48:35,910 --> 00:48:37,011 NOW AND A LATER COUNCIL 1328 00:48:37,011 --> 00:48:38,679 DISCUSSION WE WILL HAVE THAT I 1329 00:48:38,679 --> 00:48:40,414 HOPE YOU HAVE ALL RECEIVED OUR 1330 00:48:40,414 --> 00:48:41,916 STRATEGIC PLAN AND HAVE YOU HAD 1331 00:48:41,916 --> 00:48:43,417 A LOOK AT THE STRATEGIC PLAN 1332 00:48:43,417 --> 00:48:44,718 AND WILL BE READY TO ENGAGE IN 1333 00:48:44,718 --> 00:48:45,719 THIS CONVERSATION. 1334 00:48:45,719 --> 00:48:47,855 BUT WE ARE NOW AT THE POINT IN 1335 00:48:47,855 --> 00:48:50,024 TIME THIS IS YOUR LAST CHANCE 1336 00:48:50,024 --> 00:48:51,191 TO PROVIDE THAT INPUT. 1337 00:48:51,191 --> 00:48:52,760 AND I LOOK FORWARD TO 1338 00:48:52,760 --> 00:48:54,228 DISCUSSING THIS WITH YOU. 1339 00:48:54,228 --> 00:48:55,896 AS YOU KNOW, WE HAVE FIVE GOALS 1340 00:48:55,896 --> 00:48:57,064 WE ARE OUTLINING. 1341 00:48:57,064 --> 00:48:58,532 AND WE WILL HAVE A LITTLE BIT 1342 00:48:58,532 --> 00:49:02,303 OF A DISCUSSION TODAY. 1343 00:49:02,303 --> 00:49:03,504 AND THEN THAT WILL FINALIZE 1344 00:49:03,504 --> 00:49:04,838 SORT OF OUR INPUT. 1345 00:49:04,838 --> 00:49:07,875 WE ARE ASKING FOR PEOPLE TO 1346 00:49:07,875 --> 00:49:08,409 INPUT UNTIL JUNE 14th, I 1347 00:49:08,409 --> 00:49:09,209 BELIEVE. 1348 00:49:09,209 --> 00:49:10,277 SO YOU STILL HAVE A LITTLE BIT 1349 00:49:10,277 --> 00:49:11,612 OF TIME. 1350 00:49:11,612 --> 00:49:13,914 BUT WE HOPE TO CAPTURE A LOT OF 1351 00:49:13,914 --> 00:49:16,083 YOUR THINKING AT LEAST TODAY TO 1352 00:49:16,083 --> 00:49:18,185 REALLY GET THAT KICKED OFF. 1353 00:49:18,185 --> 00:49:19,687 ACTUALLY, THAT'S MY LAST SLIDE 1354 00:49:19,687 --> 00:49:20,588 I THINK, THE SUMMARY DISCUSSION 1355 00:49:20,588 --> 00:49:21,622 IS HERE. 1356 00:49:21,622 --> 00:49:23,924 I WON'T GO THROUGH ALL OF THIS, 1357 00:49:23,924 --> 00:49:26,360 I LOOK FORWARD TO HAVING PETER 1358 00:49:26,360 --> 00:49:27,761 MARKS HERE AND UPDATES FROM 1359 00:49:27,761 --> 00:49:29,129 DOMINIQUE AND MATT AS WE GO 1360 00:49:29,129 --> 00:49:29,496 FORWARD. 1361 00:49:29,496 --> 00:49:31,599 I THINK I WILL STOP HERE. 1362 00:49:31,599 --> 00:49:32,600 AND SEE IF THERE ARE ANY 1363 00:49:32,600 --> 00:49:42,776 QUESTIONS? 1364 00:49:45,946 --> 00:49:46,513 NO QUESTIONS, EXCELLENT. 1365 00:49:46,513 --> 00:49:47,915 EASY. 1366 00:49:47,915 --> 00:49:49,350 IF THERE ARE NO QUESTIONS, HOW 1367 00:49:49,350 --> 00:49:52,987 ARE WE DOING ON TIME FOR PETER? 1368 00:49:52,987 --> 00:49:53,687 AS YOU ARE THINKING ABOUT 1369 00:49:53,687 --> 00:49:54,922 QUESTIONS. 1370 00:49:54,922 --> 00:50:00,861 >> WE ARE OKAY ON TIME BUT WE 1371 00:50:00,861 --> 00:50:03,897 HAVEN'T CONFIRMED -- HE IS ON. 1372 00:50:03,897 --> 00:50:05,165 >> Joni Rutter: HI, PETER, IF 1373 00:50:05,165 --> 00:50:08,969 YOU ARE ON. 1374 00:50:08,969 --> 00:50:10,237 >> Peter Marks: I'M ON. 1375 00:50:10,237 --> 00:50:11,772 >> Joni Rutter: I KNOW WHAT 1376 00:50:11,772 --> 00:50:13,507 HAPPENS WITH THIS COUNCIL. 1377 00:50:13,507 --> 00:50:14,642 WE ALSO GET WOUND UP IN 1378 00:50:14,642 --> 00:50:16,744 QUESTIONS. 1379 00:50:16,744 --> 00:50:17,945 WE CAN PERHAPS ALSO SAVE IT FOR 1380 00:50:17,945 --> 00:50:19,546 LATER TODAY. 1381 00:50:19,546 --> 00:50:23,684 IF YOU HAVE A QUESTION, ANNIE? 1382 00:50:23,684 --> 00:50:24,818 >> I JUST WANTED TO SAY THANK 1383 00:50:24,818 --> 00:50:25,819 YOU. 1384 00:50:25,819 --> 00:50:27,821 THIS IS JUST AN ENORMOUS BODY 1385 00:50:27,821 --> 00:50:29,156 OF WORK YOU JUST PRESENTED TO 1386 00:50:29,156 --> 00:50:31,392 US, I JUST WANT TO MAKE SURE WE 1387 00:50:31,392 --> 00:50:33,060 ACKNOWLEDGE THAT AND SAY THANK 1388 00:50:33,060 --> 00:50:33,427 YOU. 1389 00:50:33,427 --> 00:50:37,631 ACKNOWLEDGE THE MEMBERS AND 1390 00:50:37,631 --> 00:50:39,366 TEAM MEMBERS WHO ARE LEAVING. 1391 00:50:39,366 --> 00:50:45,406 AND WELCOME THOSE WHO ARE 1392 00:50:45,406 --> 00:50:48,242 JOINING, SO JUST A THANK YOU ON 1393 00:50:48,242 --> 00:50:50,077 BEHALF OF THE COUNCIL FOR THAT. 1394 00:50:50,077 --> 00:50:51,712 >> Joni Rutter: THANK YOU. 1395 00:50:51,712 --> 00:50:52,312 WE APPRECIATE THAT. 1396 00:50:52,312 --> 00:50:54,548 ANYTHING ELSE? 1397 00:50:54,548 --> 00:50:56,450 OKAY, WELL, IF NOT, I'M GOING 1398 00:50:56,450 --> 00:51:02,623 TO DO ONE MORE SLIDE HERE. 1399 00:51:02,623 --> 00:51:04,958 IT IS A GREAT OPPORTUNITY, 1400 00:51:04,958 --> 00:51:05,959 PETER. 1401 00:51:05,959 --> 00:51:09,263 I'M SORRY, SERGIO? 1402 00:51:09,263 --> 00:51:10,998 >> SERGIO: I'M SORRY I JUST 1403 00:51:10,998 --> 00:51:12,099 RAISED MY HAND AT THE LAST 1404 00:51:12,099 --> 00:51:15,235 MINUTE. 1405 00:51:15,235 --> 00:51:17,071 JUST TO ASK YOU IF WE ARE GOING 1406 00:51:17,071 --> 00:51:20,708 TO HAVE SOME TIME TO DISCUSS 1407 00:51:20,708 --> 00:51:21,909 THE NATIONAL STRATEGIC PLAN? 1408 00:51:21,909 --> 00:51:23,711 >> Joni Rutter: YES, THERE WILL 1409 00:51:23,711 --> 00:51:25,345 BE A DEDICATED SESSION AT THE 1410 00:51:25,345 --> 00:51:27,281 END OF THE DAY TODAY AFTER 1411 00:51:27,281 --> 00:51:30,484 PRESENTATIONS SO THAT WE CAN 1412 00:51:30,484 --> 00:51:30,951 HAVE THAT DISCUSSION, 1413 00:51:30,951 --> 00:51:34,855 ABSOLUTELY. 1414 00:51:34,855 --> 00:51:36,690 >> SERGIO: THANK YOU. 1415 00:51:36,690 --> 00:51:37,991 >> Joni Rutter: WONDERFUL, 1416 00:51:37,991 --> 00:51:39,927 THANK YOU, SERGIO. 1417 00:51:39,927 --> 00:51:41,829 NOW, PETER, REALLY GLAD TO HAVE 1418 00:51:41,829 --> 00:51:45,265 DR. PETER MARKS HERE TODAY. 1419 00:51:45,265 --> 00:51:47,401 AND PETER, I'VE BEEN TALKING A 1420 00:51:47,401 --> 00:51:49,636 LOT ABOUT OUR INTERACTIONS WITH 1421 00:51:49,636 --> 00:51:50,370 THE FDA OVER MANY COUNCIL 1422 00:51:50,370 --> 00:51:52,840 ROUNDS. 1423 00:51:52,840 --> 00:51:55,209 AND AT THE LAST COUNCIL ROUND 1424 00:51:55,209 --> 00:51:56,577 WE REALLY TALKED SPECIFICALLY 1425 00:51:56,577 --> 00:52:00,948 ABOUT THE IMPORTANCE OF THOSE 1426 00:52:00,948 --> 00:52:02,549 INTERACTIONS WITH NCATS AND THE 1427 00:52:02,549 --> 00:52:04,184 FDA BECAUSE OF THE CLOSE 1428 00:52:04,184 --> 00:52:05,786 RELATIONSHIP WE HAVE IN THE 1429 00:52:05,786 --> 00:52:07,387 SCIENCE WE SUPPORT AND HOW 1430 00:52:07,387 --> 00:52:10,657 CRITICAL IT IS TO FIND A WAY TO 1431 00:52:10,657 --> 00:52:11,658 STREAMLINE THOSE ACTIVITIES, 1432 00:52:11,658 --> 00:52:14,561 UNDERSTANDING WHERE THE HOLES 1433 00:52:14,561 --> 00:52:17,397 ARE, ET CETERA, HOW TO FILL THE 1434 00:52:17,397 --> 00:52:20,467 HOLES BETTER AND ALSO HELP THE 1435 00:52:20,467 --> 00:52:21,301 COMMUNITY WITH THEIR 1436 00:52:21,301 --> 00:52:22,836 APPLICATIONS AND THE SCIENCE 1437 00:52:22,836 --> 00:52:25,005 THEY DO AS IT MOVES FORWARD 1438 00:52:25,005 --> 00:52:26,173 INTO MORE REGULATORY SPACE. 1439 00:52:26,173 --> 00:52:28,008 WE THOUGHT IT WOULD BE 1440 00:52:28,008 --> 00:52:29,309 FANTASTIC TO HAVE DR. PETER 1441 00:52:29,309 --> 00:52:30,744 MARKS HERE TODAY TO TALK MORE 1442 00:52:30,744 --> 00:52:32,346 ABOUT WHAT HE IS THINKING ABOUT. 1443 00:52:32,346 --> 00:52:33,947 AS MANY OF YOU KNOW, PETER IS 1444 00:52:33,947 --> 00:52:37,417 THE HEAD OF THE CENTER ON 1445 00:52:37,417 --> 00:52:38,786 BIOLOGICS WHICH IS RESPONSIBLE 1446 00:52:38,786 --> 00:52:42,489 FOR ASSURING THE SAFETY AND 1447 00:52:42,489 --> 00:52:45,092 EFFECTIVENESS OF BIOLOGICAL 1448 00:52:45,092 --> 00:52:47,394 PRODUCTS, INCLUDING VACCINES, 1449 00:52:47,394 --> 00:52:48,495 ALLERGENIC PRODUCTS, BLOOD 1450 00:52:48,495 --> 00:52:51,632 PRODUCTS, CELLULAR TISSUE AND 1451 00:52:51,632 --> 00:52:51,999 GENE THERAPIES. 1452 00:52:51,999 --> 00:52:57,971 DR. MARKS RECEIVED HIS GRADUATE 1453 00:52:57,971 --> 00:53:02,643 DEGREE IN CELLULAR MOLECULAR. 1454 00:53:02,643 --> 00:53:05,379 COMPLETED INTERNAL MEDICINE 1455 00:53:05,379 --> 00:53:06,180 RESIDENCY AT BRIGHAM HOSPITAL 1456 00:53:06,180 --> 00:53:07,514 IN BOSTON. 1457 00:53:07,514 --> 00:53:10,918 WHERE HE THEN JOINED THEIR 1458 00:53:10,918 --> 00:53:11,752 ATTENDING STAFF, CLINICIAN 1459 00:53:11,752 --> 00:53:13,754 SCIENTIST, EVENTUALLY SERVED AS 1460 00:53:13,754 --> 00:53:14,288 THE CLINICAL DIRECTOR OF 1461 00:53:14,288 --> 00:53:15,989 HEMATOLOGY. 1462 00:53:15,989 --> 00:53:20,561 HE THEN WENT ONTO WORK SEVERAL 1463 00:53:20,561 --> 00:53:21,128 YEARS IN THE PHARMACEUTICAL 1464 00:53:21,128 --> 00:53:22,563 INDUSTRY. 1465 00:53:22,563 --> 00:53:24,998 PRIOR TO RETURNING TO ACADEMIC 1466 00:53:24,998 --> 00:53:27,601 MEDICINE AT YALE UNIVERSITY 1467 00:53:27,601 --> 00:53:30,537 WHERE HE LED THE ADULT 1468 00:53:30,537 --> 00:53:32,472 LEUKEMIA, THE CHIEF CLINICAL 1469 00:53:32,472 --> 00:53:34,875 OFFICER OF -- CANCER HOSPITAL. 1470 00:53:34,875 --> 00:53:40,581 HE JOINED THE FDA IN 2012 AS 1471 00:53:40,581 --> 00:53:42,950 DEPUTY DIRECTOR OF CBER. 1472 00:53:42,950 --> 00:53:48,121 DR. MARKS IS BOARD CERTIFIED IN 1473 00:53:48,121 --> 00:53:50,123 INTERNAL MEDICINE, FELLOW OF 1474 00:53:50,123 --> 00:53:50,757 AMERICAN COLLEGE OF PHYSICIANS 1475 00:53:50,757 --> 00:53:52,059 AS WELL. 1476 00:53:52,059 --> 00:53:54,595 AND IN 2022 HE BECAME A MEMBER 1477 00:53:54,595 --> 00:53:55,462 OF THE NATIONAL ACADEMY OF 1478 00:53:55,462 --> 00:53:56,730 MEDICINE. 1479 00:53:56,730 --> 00:53:58,398 AND THAT'S ONE OF THE HIGHEST 1480 00:53:58,398 --> 00:54:00,167 HONORS IN THE FIELD OF HEALTH 1481 00:54:00,167 --> 00:54:02,870 SCIENCE AND MEDICINE. 1482 00:54:02,870 --> 00:54:04,104 SO, SUPER HONORED TO HAVE PETER 1483 00:54:04,104 --> 00:54:05,572 HERE TODAY. 1484 00:54:05,572 --> 00:54:10,844 I WILL SAY TOO, BECAUSE I 1485 00:54:10,844 --> 00:54:11,445 COULDN'T RESIST SHOWING THIS 1486 00:54:11,445 --> 00:54:13,380 SLIDE. 1487 00:54:13,380 --> 00:54:14,581 THREE VERY DIFFERENT PHOTOS, 1488 00:54:14,581 --> 00:54:15,916 TOO BAD THE PICTURES ON THE 1489 00:54:15,916 --> 00:54:18,619 SCREEN ARE COVERING THIS UP. 1490 00:54:18,619 --> 00:54:19,453 PETER IS VERY STUDIOUSLY 1491 00:54:19,453 --> 00:54:20,354 THINKING ABOUT WHAT HE IS GOING 1492 00:54:20,354 --> 00:54:27,594 TO SAY. 1493 00:54:27,594 --> 00:54:30,631 JANET IS NO LONGER AT THE FDA 1494 00:54:30,631 --> 00:54:33,000 AND ABLE TO SAY WHATEVER SHE 1495 00:54:33,000 --> 00:54:34,334 WANTS, I DON'T KNOW IF THAT 1496 00:54:34,334 --> 00:54:35,903 STOPPED HER BEFORE. 1497 00:54:35,903 --> 00:54:37,604 THE ALWAYS GOOD TO HEAR WHAT 1498 00:54:37,604 --> 00:54:39,973 PETER IS THINKING, HE IS AN 1499 00:54:39,973 --> 00:54:42,175 INCREDIBLY INSPIRING PERSON. 1500 00:54:42,175 --> 00:54:43,377 I'M OFTEN INSPIRED BY WHAT 1501 00:54:43,377 --> 00:54:45,612 PETER IS DOING AND WHAT HE SAYS. 1502 00:54:45,612 --> 00:54:47,114 IT'S THRILLING TO HAVE HIM HERE 1503 00:54:47,114 --> 00:54:48,782 TODAY TO GIVE A LITTLE BIT A 1504 00:54:48,782 --> 00:54:49,816 PRESENTATION. 1505 00:54:49,816 --> 00:54:51,251 PETER, I WILL TURN IT OVER TO 1506 00:54:51,251 --> 00:54:51,418 YOU. 1507 00:54:51,418 --> 00:54:52,986 >> Peter Marks: THANK YOU SO 1508 00:54:52,986 --> 00:54:55,889 MUCH, I WILL SHARE MY SLIDES. 1509 00:54:55,889 --> 00:54:56,690 IT'S WONDERFUL TO HAVE 1510 00:54:56,690 --> 00:54:58,091 COLLEAGUES LIKE YOU AND TO BE 1511 00:54:58,091 --> 00:55:00,027 ABLE TO PARTICIPATE HERE. 1512 00:55:00,027 --> 00:55:01,028 LET'S SEE, SOMEONE NEEDS TO 1513 00:55:01,028 --> 00:55:02,963 STOP SHARING. 1514 00:55:02,963 --> 00:55:04,798 SO STOP YOUR SHARING. 1515 00:55:04,798 --> 00:55:06,300 OKAY, THAT'S OKAY, I THINK. 1516 00:55:06,300 --> 00:55:16,843 BECAUSE YOU DO WANT ME TO SHARE. 1517 00:55:17,411 --> 00:55:20,280 YOU SHOULD HOPEFULLY BE ABLE TO 1518 00:55:20,280 --> 00:55:22,182 SEE MY SLIDES FULL SCREEN? 1519 00:55:22,182 --> 00:55:23,750 >> Joni Rutter: YES. 1520 00:55:23,750 --> 00:55:25,419 >> Peter Marks: MUCH OF THIS 1521 00:55:25,419 --> 00:55:26,653 WILL BE THINGS YOU ARE VERY 1522 00:55:26,653 --> 00:55:28,322 FAMILIAR WITH. 1523 00:55:28,322 --> 00:55:30,123 THIS PUTS IT TOGETHER KIND OF 1524 00:55:30,123 --> 00:55:31,625 FROM OUR REGULATORY PERSPECTIVE. 1525 00:55:31,625 --> 00:55:32,759 THIS WON'T BE A TYPICAL 1526 00:55:32,759 --> 00:55:34,194 REGULATORY TALK. 1527 00:55:34,194 --> 00:55:38,432 BECAUSE I'M NOT GOING TO CITE 1528 00:55:38,432 --> 00:55:39,833 FDA REGULATIONS FROM THE 21CFR. 1529 00:55:39,833 --> 00:55:41,635 I'M GOING TO TRY TO TALK ABOUT 1530 00:55:41,635 --> 00:55:44,404 WHAT WE ARE ACTUALLY TRYING TO 1531 00:55:44,404 --> 00:55:50,844 DO TO ACTUALLY HELP MOVE THINGS 1532 00:55:50,844 --> 00:55:52,045 THROUGH THE PROCESS TO GET THEM 1533 00:55:52,045 --> 00:55:53,480 TO PATIENTS. 1534 00:55:53,480 --> 00:55:54,881 TALK ABOUT CURRENT PROGRESS IN 1535 00:55:54,881 --> 00:55:57,417 THE FIELD OF GENE THERAPY. 1536 00:55:57,417 --> 00:55:59,119 TALK ABOUT EXISTING CHALLENGES 1537 00:55:59,119 --> 00:56:00,454 IN PRODUCT DEVELOPMENT, WHAT WE 1538 00:56:00,454 --> 00:56:01,755 ARE DOING TO ADDRESS THE 1539 00:56:01,755 --> 00:56:02,990 CHALLENGES AND WHAT WE ARE 1540 00:56:02,990 --> 00:56:04,524 TRYING TO PUT IN PLACE IN TERMS 1541 00:56:04,524 --> 00:56:07,928 OF POLICIES. 1542 00:56:07,928 --> 00:56:11,631 THE GENE THERAPY HAS SOME 1543 00:56:11,631 --> 00:56:13,200 REALLY EXCITING PROSPECTS HERE 1544 00:56:13,200 --> 00:56:16,703 OF HAVING ONE DOSE OF SOMETHING 1545 00:56:16,703 --> 00:56:20,507 THAT COULD LEAD TO LONG TERM 1546 00:56:20,507 --> 00:56:22,509 CLINICAL BENEFIT, PERHAPS SOME 1547 00:56:22,509 --> 00:56:24,478 CIRCUMSTANCES EVEN CURE. 1548 00:56:24,478 --> 00:56:27,714 THIS CONCEPT OF ONE DOSE HAVING 1549 00:56:27,714 --> 00:56:29,649 AN EFFECT IS VERY EXCITING. 1550 00:56:29,649 --> 00:56:31,151 NOT JUST IN HIGH INCOME 1551 00:56:31,151 --> 00:56:32,452 COUNTRIES LIKE THE UNITED 1552 00:56:32,452 --> 00:56:34,354 STATES BUT AROUND THE WORLD 1553 00:56:34,354 --> 00:56:36,823 WHERE DELIVERING MEDICINES ON A 1554 00:56:36,823 --> 00:56:39,226 REGULAR BASIS WOULD BE 1555 00:56:39,226 --> 00:56:41,962 CHALLENGING, WHERE AS GENE 1556 00:56:41,962 --> 00:56:43,296 THERAPY COULD BE GAME-CHANGING. 1557 00:56:43,296 --> 00:56:45,532 I THINK ONE OF THE EXCITING 1558 00:56:45,532 --> 00:56:50,270 THINGS FOR ME, YOU HAVE YOUR 1559 00:56:50,270 --> 00:56:51,271 WORK DIRECTLY, THERE'S A HIGH 1560 00:56:51,271 --> 00:56:54,374 PROBABILITY OF SUCCESS WITH 1561 00:56:54,374 --> 00:56:56,410 YOUR CONSTRUCT THAN YOU WOULD 1562 00:56:56,410 --> 00:56:59,546 HAVE WITH SOME OTHER PRODUCTS, 1563 00:56:59,546 --> 00:57:01,982 SUCH AS SMALL MOLECULES, THAT'S 1564 00:57:01,982 --> 00:57:03,917 NOT TO SAY SMALL MOLECULES 1565 00:57:03,917 --> 00:57:06,686 AREN'T WONDERFUL, BUT USING THE 1566 00:57:06,686 --> 00:57:08,855 POWER OF GENETICS AND 1567 00:57:08,855 --> 00:57:09,623 THOUGHTFULNESS YOU CAN 1568 00:57:09,623 --> 00:57:12,492 HOPEFULLY STACK THE DECK IN 1569 00:57:12,492 --> 00:57:13,560 FAVOR OF ANY CANDIDATE BEING 1570 00:57:13,560 --> 00:57:14,661 SUCCESSFUL. 1571 00:57:14,661 --> 00:57:16,596 IF YOU USE A PLATFORM APPROACH 1572 00:57:16,596 --> 00:57:19,166 YOU CAN ADDRESS A LOT OF 1573 00:57:19,166 --> 00:57:21,034 DIFFERENT DISEASES USING THE 1574 00:57:21,034 --> 00:57:24,371 SAME BACKBONE OF A PLATFORM. 1575 00:57:24,371 --> 00:57:25,305 NOW THERE ARE SOME 1576 00:57:25,305 --> 00:57:28,241 DISADVANTAGES RIGHT NOW, ONE IS 1577 00:57:28,241 --> 00:57:30,210 THE COMPLEXITY AND COST OF 1578 00:57:30,210 --> 00:57:31,578 MANUFACTURER OF THESE PRODUCTS. 1579 00:57:31,578 --> 00:57:34,281 WE WILL TALK ABOUT HOW WE MAY 1580 00:57:34,281 --> 00:57:34,948 SEE THINGS TO ADDRESS SOME OF 1581 00:57:34,948 --> 00:57:37,717 THAT. 1582 00:57:37,717 --> 00:57:38,351 POTENTIAL FOR IRREVERSIBLE SIDE 1583 00:57:38,351 --> 00:57:45,092 EFFECTS. 1584 00:57:45,092 --> 00:57:46,026 THAT OBVIOUSLY, GENOTOXICITY IS 1585 00:57:46,026 --> 00:57:46,793 SOMETHING WE HAVE TO KEEP IN 1586 00:57:46,793 --> 00:57:50,864 MIND. 1587 00:57:50,864 --> 00:57:54,334 GENE THERAPIES IN THE CURRENT 1588 00:57:54,334 --> 00:57:57,170 EMBODIMENT THINGS REASONABLY 1589 00:57:57,170 --> 00:57:57,604 COMPLICATED TO GIVE. 1590 00:57:57,604 --> 00:57:59,873 GIVING LARGE DOSES OF AN 1591 00:57:59,873 --> 00:58:02,209 ASSOCIATED VIRUS, ASSOCIATED 1592 00:58:02,209 --> 00:58:03,410 WITH AN INFLAMMATORY RESPONSE 1593 00:58:03,410 --> 00:58:04,811 THAT HAS TO BE MANAGED. 1594 00:58:04,811 --> 00:58:09,583 RIGHT NOW YOU WON'T SEE THEM 1595 00:58:09,583 --> 00:58:10,684 GIVEN AT THE LOCAL HEALTH STOP. 1596 00:58:10,684 --> 00:58:13,019 THEY WILL BE IN THE HANDS OF 1597 00:58:13,019 --> 00:58:14,221 SPECIALIZED PHYSICIAN. 1598 00:58:14,221 --> 00:58:16,123 THIS IS A NEW BUSINESS MODEL 1599 00:58:16,123 --> 00:58:17,057 AND EVERYONE IS KIND OF 1600 00:58:17,057 --> 00:58:19,059 STRUGGLING WITH IT. 1601 00:58:19,059 --> 00:58:20,961 BOTH THE COMPANIES MAKING THESE 1602 00:58:20,961 --> 00:58:22,996 PRODUCTS AS WELL AS 1603 00:58:22,996 --> 00:58:23,897 PARTICULARLY PAYERS AND 1604 00:58:23,897 --> 00:58:25,432 GOVERNMENTS WHO ARE TRYING TO 1605 00:58:25,432 --> 00:58:27,734 UNDERSTAND HOW TO DEAL WITH 1606 00:58:27,734 --> 00:58:29,369 THESE VERY EXPENSIVE PRODUCTS 1607 00:58:29,369 --> 00:58:31,571 THAT CAN SOMETIMES BRING A LOT 1608 00:58:31,571 --> 00:58:32,272 OF ISSUES. 1609 00:58:32,272 --> 00:58:36,810 OKAY. 1610 00:58:36,810 --> 00:58:41,615 SO IN TERMS OF DELIVERING GENE 1611 00:58:41,615 --> 00:58:42,916 THERAPIES, THERE ARE TWO 1612 00:58:42,916 --> 00:58:46,052 GENERAL WAYS WE SEE THEM 1613 00:58:46,052 --> 00:58:49,055 DELIVERED, EITHER EX VIVO OR 1614 00:58:49,055 --> 00:58:59,199 INVIVO. 1615 00:59:02,636 --> 00:59:07,007 THE CHIMERIC, SOMETIMES WITH 1616 00:59:07,007 --> 00:59:08,742 LENTIVIRAL VECTORS. 1617 00:59:08,742 --> 00:59:11,978 OR USING SOME OTHER MEANS OF 1618 00:59:11,978 --> 00:59:13,313 INTRODUCING, OR CELL DISRUPTION 1619 00:59:13,313 --> 00:59:18,852 TO GET THE CONSTRUCT IN. 1620 00:59:18,852 --> 00:59:24,224 THE OTHER WAY IS DIRECTLY 1621 00:59:24,224 --> 00:59:29,262 ADMINISTERED GENE THERAPIES, 1622 00:59:29,262 --> 00:59:30,463 THROUGH ADENO -- WE ARE 1623 00:59:30,463 --> 00:59:32,999 STARTING TO SEE THE DEVELOPMENT 1624 00:59:32,999 --> 00:59:34,601 OF LIPID NANO PARTICLES AS A 1625 00:59:34,601 --> 00:59:36,136 WAY OF GETTING THESE IN AND I 1626 00:59:36,136 --> 00:59:37,637 WILL SAY MORE ABOUT THAT LATER. 1627 00:59:37,637 --> 00:59:41,074 ONE THING I WOULD WE REMISS IS 1628 00:59:41,074 --> 00:59:43,009 NOT INTRODUCING THE FACT GENE 1629 00:59:43,009 --> 00:59:44,511 THERAPY IS NOW UNDERGOING A 1630 00:59:44,511 --> 00:59:46,780 TRANSITION WHERE WE ARE 1631 00:59:46,780 --> 00:59:48,682 STARTING TO SEE GENOME EDITING, 1632 00:59:48,682 --> 00:59:50,383 IN OTHER WORDS FIXING THE BASE 1633 00:59:50,383 --> 00:59:52,953 PAIRS THAT ARE NOT CORRECT IN 1634 00:59:52,953 --> 00:59:56,590 THE GENOME. 1635 00:59:56,590 --> 00:59:58,091 BECOMING INCREASING MODALITY. 1636 00:59:58,091 --> 01:00:00,627 NOW, THIS IS NOT TO SAY GENOME 1637 01:00:00,627 --> 01:00:02,395 EDITING TOOLS HAVE BEEN AROUND 1638 01:00:02,395 --> 01:00:12,639 FOR YEARS AND INCLUDED THINGS 1639 01:00:12,639 --> 01:00:21,014 LIKE ZINC FINGER NUCLEASES. 1640 01:00:21,014 --> 01:00:21,615 TRANSCRIPTION ACTIVATOR-LIKE 1641 01:00:21,615 --> 01:00:28,255 EFFECTOR NUCLEASES. 1642 01:00:28,255 --> 01:00:30,924 WE NOW HAVE CRISPR BASED 1643 01:00:30,924 --> 01:00:34,227 EDITORS THAT GETS OVER PROBLEMS 1644 01:00:34,227 --> 01:00:35,562 WITH THE FIRST GENERATION 1645 01:00:35,562 --> 01:00:36,630 CRISPR THEY DON'T REQUIRE 1646 01:00:36,630 --> 01:00:37,964 DOUBLE STRANDED BREAKS. 1647 01:00:37,964 --> 01:00:40,133 AND NOT ABLE TO JUST CLIP BUT 1648 01:00:40,133 --> 01:00:41,134 POTENTIALLY REPLACE. 1649 01:00:41,134 --> 01:00:43,637 WE ARE STARTING TO SEE THIS 1650 01:00:43,637 --> 01:00:47,274 EVOLUTION IN GENE THERAPY. 1651 01:00:47,274 --> 01:00:49,743 WE HAVE SEEN NOW PRODUCTS THAT 1652 01:00:49,743 --> 01:00:52,145 ARE COMING ALONG. 1653 01:00:52,145 --> 01:00:55,949 IN 2023 WE HAD SIX PRODUCTS 1654 01:00:55,949 --> 01:01:06,493 APPROVED AND THIS IS, I THINK, 1655 01:01:10,964 --> 01:01:19,372 SHOWING THE PACE OF PROGRESS. 1656 01:01:19,372 --> 01:01:21,308 ONE WAS CASGEVY. 1657 01:01:21,308 --> 01:01:24,844 QUITE EXCITING. 1658 01:01:24,844 --> 01:01:27,080 I THINK THIS ABILITY TO HAVE 1659 01:01:27,080 --> 01:01:31,318 PRODUCTS NOW, WE NOW HAVE TWO 1660 01:01:31,318 --> 01:01:34,454 PRODUCTS FOR SICKLE-CELL 1661 01:01:34,454 --> 01:01:36,056 DISEASE AND BETA THALASSEMIA IS 1662 01:01:36,056 --> 01:01:41,695 QUITE EXCITING. 1663 01:01:41,695 --> 01:01:43,930 BUT TO SEE EDITED CELL-BASED 1664 01:01:43,930 --> 01:01:46,232 THERAPY COME ALONG A LITTLE 1665 01:01:46,232 --> 01:01:48,368 MORE THAN A DECADE THAN THE 1666 01:01:48,368 --> 01:01:50,103 IDENTIFICATION OF CRISPR I 1667 01:01:50,103 --> 01:01:53,440 THINK IS QUITE EXCITING. 1668 01:01:53,440 --> 01:01:55,842 WITH ALL THAT SAID, GENE 1669 01:01:55,842 --> 01:01:58,511 THERAPY IS AT A CRITICAL 1670 01:01:58,511 --> 01:02:00,680 JUNCTURE DUE TO COMBINATION OF 1671 01:02:00,680 --> 01:02:02,415 FACTORS, MANUFACTURING KHAL 1672 01:02:02,415 --> 01:02:03,450 LEPGS, CLINICAL DEVELOPMENT 1673 01:02:03,450 --> 01:02:05,852 TIMELINES, AND DIFFERENT GLOBAL 1674 01:02:05,852 --> 01:02:06,886 REGULATORY REQUIREMENTS WHICH 1675 01:02:06,886 --> 01:02:08,388 IS SLOWING DOWN PROGRESS OF 1676 01:02:08,388 --> 01:02:09,622 PRODUCTS GETTING TO THE BENEFIT 1677 01:02:09,622 --> 01:02:11,591 OF PATIENTS. 1678 01:02:11,591 --> 01:02:13,927 SO WE ARE TRYING TO DO WHAT WE 1679 01:02:13,927 --> 01:02:17,664 CAN AT CENTER FOR BIOLOGICS, 1680 01:02:17,664 --> 01:02:18,231 SOME IN COLLABORATION WITH 1681 01:02:18,231 --> 01:02:19,366 NCATS. 1682 01:02:19,366 --> 01:02:20,467 I THINK WE REALLY VALUE THAT 1683 01:02:20,467 --> 01:02:24,237 COLLABORATION. 1684 01:02:24,237 --> 01:02:25,739 IN TERMS OF ADVANCING 1685 01:02:25,739 --> 01:02:26,973 MANUFACTURING OF GENE THERAPIES 1686 01:02:26,973 --> 01:02:28,441 AND GETTING THEM THROUGH THE 1687 01:02:28,441 --> 01:02:33,113 PROCESS, THAT'S IN PART THROUGH 1688 01:02:33,113 --> 01:02:34,347 THE SPOKE GENE THERAPY 1689 01:02:34,347 --> 01:02:36,783 CONSORTIUM WORK BUT ALSO OTHER 1690 01:02:36,783 --> 01:02:38,485 COLLABORATIONS, SUCH AS PAY GT 1691 01:02:38,485 --> 01:02:40,720 WITH NCATS. 1692 01:02:40,720 --> 01:02:41,921 SO ADVANCING MANUFACTURING, WE 1693 01:02:41,921 --> 01:02:44,657 ARE TRYING TO APPLY THE 1694 01:02:44,657 --> 01:02:46,326 PLATFORM TECHNOLOGY PROVISION 1695 01:02:46,326 --> 01:02:47,694 IN THE 2023 OMNIBUS. 1696 01:02:47,694 --> 01:02:50,397 WE ARE WORKING TO MORE CLEARLY 1697 01:02:50,397 --> 01:02:54,434 DEFINE THE USE OF ACCELERATOR 1698 01:02:54,434 --> 01:02:55,902 APPROVAL FOR GENE THERAPY, 1699 01:02:55,902 --> 01:02:57,904 EXPLORING AND REVIEW WITH OTHER 1700 01:02:57,904 --> 01:02:59,205 REGULATORY AUTHORITIES AND 1701 01:02:59,205 --> 01:03:00,039 MOVING FORWARD COMMUNICATION 1702 01:03:00,039 --> 01:03:01,007 PILOT FOR RARE DISEASES. 1703 01:03:01,007 --> 01:03:02,742 I WILL TELL YOU ABOUT ONE 1704 01:03:02,742 --> 01:03:04,778 MINUTE OF EACH OF THESE AND TRY 1705 01:03:04,778 --> 01:03:06,146 TO GET YOU, GIVE YOU BACK A 1706 01:03:06,146 --> 01:03:08,214 LITTLE TIME. 1707 01:03:08,214 --> 01:03:09,916 IN TERMS OF MANUFACTURING 1708 01:03:09,916 --> 01:03:11,217 SOLUTIONS, IT'S BEEN RECOGNIZED 1709 01:03:11,217 --> 01:03:14,287 THAT A LOT OF INNOVATION COMES 1710 01:03:14,287 --> 01:03:16,289 OUT OF ACADEMIC LABORATORIS. 1711 01:03:16,289 --> 01:03:19,826 THE PROBLEM IS, HAVING BEEN AN 1712 01:03:19,826 --> 01:03:23,463 ACADEMIC MYSELF, WE TEND TO DO 1713 01:03:23,463 --> 01:03:25,565 IT THE WAY OUR COLLEAGUE DID IT 1714 01:03:25,565 --> 01:03:26,833 IN OUR LOCAL INSTITUTIONMENT 1715 01:03:26,833 --> 01:03:30,970 WHEN YOU WANT TO TRANSFER A 1716 01:03:30,970 --> 01:03:32,472 PROCESS TO A CONTRACT 1717 01:03:32,472 --> 01:03:34,541 MANUFACTURER TO A COMPANY, 1718 01:03:34,541 --> 01:03:35,775 OFTEN TIMES THOSE PROCESSES 1719 01:03:35,775 --> 01:03:37,644 HAVE TO BE REWORKED. 1720 01:03:37,644 --> 01:03:38,678 AND THAT REWORK COSTS A LOT OF 1721 01:03:38,678 --> 01:03:39,979 MONEY. 1722 01:03:39,979 --> 01:03:41,681 WE ARE TALKING MILLIONS OF 1723 01:03:41,681 --> 01:03:42,282 DOLLARS SOMETIMES, AS WELL AS 1724 01:03:42,282 --> 01:03:44,083 TIME. 1725 01:03:44,083 --> 01:03:47,554 AND SO, WE ARE THINKING THAT 1726 01:03:47,554 --> 01:03:48,822 STANDARDIZING THESE PROTOCOLS 1727 01:03:48,822 --> 01:03:50,190 USED BY ACADEMICS COULD 1728 01:03:50,190 --> 01:03:50,857 POTENTIALLY BE HELPFUL. 1729 01:03:50,857 --> 01:03:57,831 THIS IS ONE OF THE THINGS THE 1730 01:03:57,831 --> 01:03:59,098 SPOKANE GENE THERAPY CONSORTIUM 1731 01:03:59,098 --> 01:04:00,800 IS DOING BY TRYING TO CREATE A 1732 01:04:00,800 --> 01:04:06,039 PLAY BOOK. 1733 01:04:06,039 --> 01:04:07,240 ADENO ASSOCIATED VIRUSES ARE 1734 01:04:07,240 --> 01:04:09,642 THINGS THAT COULD BE AUTOMATED. 1735 01:04:09,642 --> 01:04:10,577 THEY SIMPLY HAVEN'T BEEN 1736 01:04:10,577 --> 01:04:12,679 BECAUSE NOBODY HAS HAD THE 1737 01:04:12,679 --> 01:04:14,047 IMPETUS TO, THERE HASN'T BEEN A 1738 01:04:14,047 --> 01:04:16,516 LARGE ENOUGH MARKET. 1739 01:04:16,516 --> 01:04:17,617 THIS CONCEPT OF AUTOMATION 1740 01:04:17,617 --> 01:04:18,852 COULD BE VERY HELPFUL. 1741 01:04:18,852 --> 01:04:22,589 IF NOT FOR THE ENTIRE PROCESS 1742 01:04:22,589 --> 01:04:24,824 AT LEAST THE DOWNSTREAM PROCESS. 1743 01:04:24,824 --> 01:04:27,827 THIS IS A SCHEMATIC TO SAY, WE 1744 01:04:27,827 --> 01:04:30,663 ACTUALLY HAVE MACHINES THAT DO 1745 01:04:30,663 --> 01:04:31,865 THIS IN MANUFACTURING ALREADY, 1746 01:04:31,865 --> 01:04:32,966 IT JUST HASN'T BEEN APPLIED TO 1747 01:04:32,966 --> 01:04:36,503 THIS PROCESS. 1748 01:04:36,503 --> 01:04:38,571 IT COULD HELP IMPROVE 1749 01:04:38,571 --> 01:04:39,172 REPRODUCABILITY AND DECREASE 1750 01:04:39,172 --> 01:04:39,372 COST. 1751 01:04:39,372 --> 01:04:41,674 GOOD THINGS. 1752 01:04:41,674 --> 01:04:43,676 IDEALLY YOU WOULD WANT 1753 01:04:43,676 --> 01:04:47,347 SOMETHING TO REPLACE THIS SODA 1754 01:04:47,347 --> 01:04:49,349 DISPENSER AS A GENE THERAPY 1755 01:04:49,349 --> 01:04:53,653 DISPENSER, THE A NICE MODEL FOR 1756 01:04:53,653 --> 01:04:58,191 SOMEONE IN THE MANUFACTURE 1757 01:04:58,191 --> 01:05:00,927 WORLD, IT'S A FABRICATION 1758 01:05:00,927 --> 01:05:01,494 DEVICE WITH DISPOSABLES AND 1759 01:05:01,494 --> 01:05:03,530 CONSUMABLES. 1760 01:05:03,530 --> 01:05:04,464 MOVING ON,SPEAKING OF PLATFORMS 1761 01:05:04,464 --> 01:05:06,232 WHERE WE THINK WE CAN MAKE SOME 1762 01:05:06,232 --> 01:05:08,501 REAL PROGRESS HERE. 1763 01:05:08,501 --> 01:05:10,637 GENE THERAPIES HAVE SOMETHING 1764 01:05:10,637 --> 01:05:11,804 ABOUT THEM THAT MANY OTHER 1765 01:05:11,804 --> 01:05:14,274 PRODUCTS DO NOT HAVE. 1766 01:05:14,274 --> 01:05:16,276 WHICH IS, OFTEN TIMES THE 1767 01:05:16,276 --> 01:05:17,610 VECTOR BACKBONE IS THE SAME 1768 01:05:17,610 --> 01:05:18,912 BETWEEN DIFFERENT CONSTRUCTS. 1769 01:05:18,912 --> 01:05:20,246 NOW IT'S NOT THE SAME FOR EVERY 1770 01:05:20,246 --> 01:05:22,081 CONSTRUCT. 1771 01:05:22,081 --> 01:05:25,451 BUT THAT SAID, FOR A GIVEN 1772 01:05:25,451 --> 01:05:27,554 GROUP OF AV8'S WITH INSERTS OF 1773 01:05:27,554 --> 01:05:28,888 A CERTAIN SIZE RANGE WE WOULD 1774 01:05:28,888 --> 01:05:31,591 LIKE TO SEE IF WE COULD MAKE 1775 01:05:31,591 --> 01:05:32,425 MORE PROGRESS QUICKLY BY 1776 01:05:32,425 --> 01:05:34,561 ALLOWING SWAPPING OUT OF THE 1777 01:05:34,561 --> 01:05:38,264 INSERT AGAIN WITHIN A GIVEN 1778 01:05:38,264 --> 01:05:39,866 SIZE RANGE WHILE MAINTAINING 1779 01:05:39,866 --> 01:05:40,900 THE SAME MANUFACTURING PROCESS, 1780 01:05:40,900 --> 01:05:46,973 THE SAME CONTROLS AND 1781 01:05:46,973 --> 01:05:49,175 LEVERAGING THE TOXICOLOGY. 1782 01:05:49,175 --> 01:05:51,110 THAT MAY ALLOW MORE 1783 01:05:51,110 --> 01:05:54,781 STREAMLINING AND MOVE FROM ONE 1784 01:05:54,781 --> 01:05:55,882 PRODUCT TO THE NEXT WITH LESS 1785 01:05:55,882 --> 01:05:59,686 BURDEN. 1786 01:05:59,686 --> 01:06:02,155 CONGRESS PASSED THE PLATFORM 1787 01:06:02,155 --> 01:06:04,324 TECHNOLOGIES ACT AS PART OF 1788 01:06:04,324 --> 01:06:04,924 OMNIBUS APPROPRIATIONS ACT OF 1789 01:06:04,924 --> 01:06:07,160 2023. 1790 01:06:07,160 --> 01:06:08,595 ONE PRODUCT, HAVE THEIR 1791 01:06:08,595 --> 01:06:10,396 PLATFORM DESIGNATED SO THEY CAN 1792 01:06:10,396 --> 01:06:11,297 USE CROSS-REFERENCE AND NOT 1793 01:06:11,297 --> 01:06:14,334 HAVE TO GO BACK AND REDO ALL OF 1794 01:06:14,334 --> 01:06:15,668 THE TOXICOLOGY, MANUFACTURING 1795 01:06:15,668 --> 01:06:19,405 INFORMATION FOR SUBMISSION WHEN 1796 01:06:19,405 --> 01:06:21,040 THEY COME IN WITH THESE 1797 01:06:21,040 --> 01:06:22,208 PLATFORM PRODUCTS. 1798 01:06:22,208 --> 01:06:26,045 WE ARE IN THE PROCESS OF 1799 01:06:26,045 --> 01:06:27,880 ISSUING GUIDANCE BUT WE THINK 1800 01:06:27,880 --> 01:06:29,315 IT WILL BE PARTICULARLY 1801 01:06:29,315 --> 01:06:30,617 IMPORTANT, PARTICULARLY BECAUSE 1802 01:06:30,617 --> 01:06:34,220 WHEN WE COME TO CRISPR, IT'S 1803 01:06:34,220 --> 01:06:36,155 THE POSTER CHILD OF A PLATFORM 1804 01:06:36,155 --> 01:06:36,389 THERAPY. 1805 01:06:36,389 --> 01:06:37,790 WHEN YOU THINK ABOUT IT, WHEN 1806 01:06:37,790 --> 01:06:41,494 YOU LOOK AT THE RIGHT AT THE 1807 01:06:41,494 --> 01:06:42,595 PRIME EDITOR, WHICH ARE 1808 01:06:42,595 --> 01:06:43,830 REMARKABLY VERSATILE. 1809 01:06:43,830 --> 01:06:46,432 IF YOU THINK OF A PRIME EDITOR 1810 01:06:46,432 --> 01:06:48,134 THAT WANTS TO TARGET THINGS IN 1811 01:06:48,134 --> 01:06:50,503 THE LIVER FOR INSTANCE. 1812 01:06:50,503 --> 01:06:55,775 BY A LIPID NANOPARTICLE YOU CAN 1813 01:06:55,775 --> 01:06:58,911 PROBABLY DO WITH A NON-STUDDED 1814 01:06:58,911 --> 01:07:00,413 LIPID NANO PARTICLE, WHETHER 1815 01:07:00,413 --> 01:07:06,552 YOU ARE TARGETING A METABOLIC 1816 01:07:06,552 --> 01:07:07,954 DISORDER OF ONE SORT OR ANOTHER 1817 01:07:07,954 --> 01:07:09,956 YOU ARE GOING TO HAVE A VERY 1818 01:07:09,956 --> 01:07:13,526 SIMILAR CONSTRUCT WITH THE 1819 01:07:13,526 --> 01:07:15,161 EXCEPTION OF A SMALL SEGMENT OF 1820 01:07:15,161 --> 01:07:16,362 RNA. 1821 01:07:16,362 --> 01:07:19,065 SO THE ABILITY TO USE THIS 1822 01:07:19,065 --> 01:07:21,701 PLATFORM APPROACH MAY ALLOW US 1823 01:07:21,701 --> 01:07:23,936 TO REALLY MOVE THROUGH 1824 01:07:23,936 --> 01:07:26,339 DIFFERENT PRODUCTS BY HAVING A 1825 01:07:26,339 --> 01:07:27,840 WHOLE HOST OF PRODUCTS 1826 01:07:27,840 --> 01:07:28,341 REFERENCE ONE SERIES OF 1827 01:07:28,341 --> 01:07:30,476 MANUFACTURING. 1828 01:07:30,476 --> 01:07:34,414 YOU CAN JUST FOCUS IN ON 1829 01:07:34,414 --> 01:07:35,882 OFF-TARGET EFFECTS AND SPECIFIC 1830 01:07:35,882 --> 01:07:37,383 CLINICAL EFFECTIVENESS FOR EACH 1831 01:07:37,383 --> 01:07:39,552 OF THE PRODUCTS. 1832 01:07:39,552 --> 01:07:40,887 FINALLY, THE LAST COUPLE THINGS 1833 01:07:40,887 --> 01:07:44,891 WE WANT TO TRY TO LEVERAGE 1834 01:07:44,891 --> 01:07:45,558 ACCELERATED APPROVAL AS MUCH AS 1835 01:07:45,558 --> 01:07:47,627 WE CAN. 1836 01:07:47,627 --> 01:07:48,961 IN THE GENETIC MEDICINE SPACE, 1837 01:07:48,961 --> 01:07:50,263 WE HOPE AT LEAST SOME OF THE 1838 01:07:50,263 --> 01:07:53,933 TIME WE WILL BE ABLE TO 1839 01:07:53,933 --> 01:07:55,535 LEVERAGE ENZYME ACTIVITY 1840 01:07:55,535 --> 01:07:56,335 LEVELS, STRUCTURAL PROTEIN 1841 01:07:56,335 --> 01:07:59,272 LEVELS, THINGS WE CAN MEASURE 1842 01:07:59,272 --> 01:08:00,873 THAT WILL REASONABLY LIKELY 1843 01:08:00,873 --> 01:08:03,843 PREDICT CLINICAL BENEFIT SO WE 1844 01:08:03,843 --> 01:08:05,111 CAN MOVE THESE PRODUCTS FORWARD 1845 01:08:05,111 --> 01:08:06,045 MORE PERFECTLY. 1846 01:08:06,045 --> 01:08:08,781 WHEN YOU THINK ABOUT IT NOT ALL 1847 01:08:08,781 --> 01:08:11,117 ANIMAL MODELS ARE PERFECT, BUT 1848 01:08:11,117 --> 01:08:12,418 WHERE WE HAVE GOOD ANIMAL 1849 01:08:12,418 --> 01:08:15,154 MODELS WE CAN USE THEM TO HELP 1850 01:08:15,154 --> 01:08:16,756 US PREDICT BENEFIT BASED ON 1851 01:08:16,756 --> 01:08:18,157 LEVELS SEEN IN HUMANS OF A GENE 1852 01:08:18,157 --> 01:08:20,493 THERAPY. 1853 01:08:20,493 --> 01:08:23,096 OR WE CAN SOMETIMES DERIVE THAT 1854 01:08:23,096 --> 01:08:24,097 INFORMATION FROM HUMAN 1855 01:08:24,097 --> 01:08:25,965 OBSERVATIONS WHERE IN SOME 1856 01:08:25,965 --> 01:08:29,068 CASES HUMANS ARE PARTIALLY 1857 01:08:29,068 --> 01:08:30,536 DEFICIENT IN PROTEINS YET SHOW 1858 01:08:30,536 --> 01:08:31,871 NO ADVERSE EFFECTS. 1859 01:08:31,871 --> 01:08:33,606 IF WE CAN REACH THOSE LEVELS 1860 01:08:33,606 --> 01:08:35,341 WITH A GENE THERAPY WE HAVE 1861 01:08:35,341 --> 01:08:38,377 SOMETHING THAT IS LESS LIKELY 1862 01:08:38,377 --> 01:08:39,579 TO PREDICT CLINICAL BENEFIT, WE 1863 01:08:39,579 --> 01:08:42,215 CAN GET THINGS OVER TO THE 1864 01:08:42,215 --> 01:08:43,750 APPROVED PRODUCTS, COMPANIES 1865 01:08:43,750 --> 01:08:46,652 GET A REVENUE STREAM, BUT MORE 1866 01:08:46,652 --> 01:08:47,386 IMPORTANTLY, PATIENTS GET 1867 01:08:47,386 --> 01:08:50,323 ACCESS SOONER AND THEN WE GET 1868 01:08:50,323 --> 01:08:51,724 THE CONFIRMATORY EVIDENCE IN 1869 01:08:51,724 --> 01:08:54,026 THE COURSE OF TIME AFTERWARDS. 1870 01:08:54,026 --> 01:08:55,762 IT MEANS OCCASIONALLY THINGS 1871 01:08:55,762 --> 01:08:57,063 WON'T CONFIRM BUT WE CAN LIVE 1872 01:08:57,063 --> 01:08:58,598 WITH THAT IF WE ARE HELPING 1873 01:08:58,598 --> 01:09:01,100 MORE PEOPLE OVERALL. 1874 01:09:01,100 --> 01:09:02,935 AND THEN THE LAST TWO AREAS I 1875 01:09:02,935 --> 01:09:04,470 WOULD LIKE TO SPEAK ABOUT, ONE 1876 01:09:04,470 --> 01:09:08,608 IS THE FACT WE DO RECOGNIZE 1877 01:09:08,608 --> 01:09:12,945 THAT GLOBAL, OR LACK OF GLOBAL 1878 01:09:12,945 --> 01:09:15,181 HARMONIZATION AROUND THIS GENE 1879 01:09:15,181 --> 01:09:16,682 THERAPY SPACE LEADS TO 1880 01:09:16,682 --> 01:09:18,584 PROBLEMS, PARTICULARLY FOR RARE 1881 01:09:18,584 --> 01:09:20,119 DISEASES, WHERE IN SOME CASES 1882 01:09:20,119 --> 01:09:24,357 THE BARRIERS TO ENTRY AND NEW 1883 01:09:24,357 --> 01:09:26,759 REGULATORY ENVIRONMENT PREVENT 1884 01:09:26,759 --> 01:09:28,594 PEOPLE FROM BRINGING A 1885 01:09:28,594 --> 01:09:29,662 WELL-DOCUMENTED SAFE AND 1886 01:09:29,662 --> 01:09:31,297 EFFECTIVE THERAPY TO A NEW 1887 01:09:31,297 --> 01:09:32,965 REGULATORY ENVIRONMENT. 1888 01:09:32,965 --> 01:09:36,169 SO WE ARE TRYING TO WORK WITH 1889 01:09:36,169 --> 01:09:37,069 OUR COLLEAGUES, PARTICULARLY AT 1890 01:09:37,069 --> 01:09:39,505 EMA RIGHT NOW BUT WE WILL 1891 01:09:39,505 --> 01:09:41,774 EXPAND THIS PILOTING WAYS TO 1892 01:09:41,774 --> 01:09:43,209 BOTH GET TO CONVERGENT 1893 01:09:43,209 --> 01:09:45,244 REGULATORY APPROACHES BUT ALSO 1894 01:09:45,244 --> 01:09:47,480 TO DO COLLABORATIVE REVIEW AND 1895 01:09:47,480 --> 01:09:49,081 HOPEFULLY THAT WILL AGAIN MOVE 1896 01:09:49,081 --> 01:09:51,384 PRODUCTS THROUGH THE PROCESS. 1897 01:09:51,384 --> 01:09:52,385 IMPORTANTLY HERE JUST THE 1898 01:09:52,385 --> 01:09:55,221 BOTTOM LINE HERE IS IF WE HAVE 1899 01:09:55,221 --> 01:09:56,455 A POPULATION OF 30-50 PEOPLE IN 1900 01:09:56,455 --> 01:09:58,024 THE UNITED STATES WITH A RARE 1901 01:09:58,024 --> 01:10:00,560 DISEASE TO BE TREATED IN A 1902 01:10:00,560 --> 01:10:01,260 GIVEN YEAR, THAT'S NOT 1903 01:10:01,260 --> 01:10:02,929 COMMERCIALLY VIABLE. 1904 01:10:02,929 --> 01:10:06,566 BUT IF YOU MELD THAT WITH A 1905 01:10:06,566 --> 01:10:09,969 POPULATION OF 70-80 PATIENTS IN 1906 01:10:09,969 --> 01:10:11,604 EUROPE, AND ANOTHER 70-80 1907 01:10:11,604 --> 01:10:13,706 PATIENTS IN ASIA, SUDDENLY 1908 01:10:13,706 --> 01:10:14,640 THERE'S A VERY COMMERCIALLY 1909 01:10:14,640 --> 01:10:16,142 VIABLE PRODUCT. 1910 01:10:16,142 --> 01:10:17,810 IF WE CAN GET THERE, THAT MIGHT 1911 01:10:17,810 --> 01:10:20,179 BE VERY GOOD FOR ALL OF OUR 1912 01:10:20,179 --> 01:10:26,485 DIFFERENT PATIENT POPULATIONS. 1913 01:10:26,485 --> 01:10:27,320 THE LAST INITIATIVE OUR START 1914 01:10:27,320 --> 01:10:28,921 PILOT. 1915 01:10:28,921 --> 01:10:31,357 BASICALLY TRYING TO APPLY WHAT 1916 01:10:31,357 --> 01:10:32,658 WE LEARNED DURING THE COVID-19 1917 01:10:32,658 --> 01:10:34,894 PANDEMIC TO THE BENEFIT OF RARE 1918 01:10:34,894 --> 01:10:36,929 DISEASE THERAPY PRODUCTS *. THE 1919 01:10:36,929 --> 01:10:38,531 IDEA HERE IS WE FOUND THAT 1920 01:10:38,531 --> 01:10:43,269 BEING ABLE TO HAVE VERY 1921 01:10:43,269 --> 01:10:45,705 CONSTANT COMMUNICATION, ONGOING 1922 01:10:45,705 --> 01:10:47,907 COMMUNICATION WITH SPONSORS WAS 1923 01:10:47,907 --> 01:10:50,710 VERY HELPFUL FOR THEM, AS THEY 1924 01:10:50,710 --> 01:10:52,778 DEVELOP PRODUCTS IN THE 1925 01:10:52,778 --> 01:10:53,980 COVID-19 SPACE, IT PROBABLY 1926 01:10:53,980 --> 01:10:56,482 SHAVED AT LEAST 25% OF THE 1927 01:10:56,482 --> 01:10:58,317 TOTAL TIME OF DEVELOPMENT OF 1928 01:10:58,317 --> 01:10:59,752 THE VACCINES, PROBABLY MORE 1929 01:10:59,752 --> 01:11:00,686 THAN THAT, BECAUSE PEOPLE 1930 01:11:00,686 --> 01:11:02,488 DIDN'T HAVE TO WAIT AROUND FOR 1931 01:11:02,488 --> 01:11:04,724 MEETINGS TO OCCUR, WE JUST 1932 01:11:04,724 --> 01:11:05,324 ANSWERED QUESTIONS WHEN THEY 1933 01:11:05,324 --> 01:11:06,626 CAME UP. 1934 01:11:06,626 --> 01:11:09,228 WE HAVE A PILOT WE INTEND TO DO 1935 01:11:09,228 --> 01:11:10,863 THE SAME THING FOR SEVERAL RARE 1936 01:11:10,863 --> 01:11:13,065 DISEASE PRODUCTS. 1937 01:11:13,065 --> 01:11:14,333 WE WILL PICK PROBABLY THREE 1938 01:11:14,333 --> 01:11:15,701 ELIGIBLE PRODUCTS. 1939 01:11:15,701 --> 01:11:17,570 KEEP YOUR EARS OPEN BECAUSE THE 1940 01:11:17,570 --> 01:11:19,672 ANNOUNCEMENTS WILL BE SOON. 1941 01:11:19,672 --> 01:11:23,709 AND HOPEFULLY, WE WILL BE ABLE 1942 01:11:23,709 --> 01:11:25,711 TO SHOW USING METRICS BETWEEN 1943 01:11:25,711 --> 01:11:27,046 VARIOUS STAGES OF DEVELOPMENT 1944 01:11:27,046 --> 01:11:28,014 THIS ACTUALLY MAKES A 1945 01:11:28,014 --> 01:11:29,282 DIFFERENCE, IF IT DOES, WE WILL 1946 01:11:29,282 --> 01:11:31,684 EXPAND THE PILOT. 1947 01:11:31,684 --> 01:11:34,520 ULTIMATELY CENTER FOR BIOLOGICS 1948 01:11:34,520 --> 01:11:37,123 WE ARE TRYING TO ADVANCE THE 1949 01:11:37,123 --> 01:11:38,524 REGULATORY FRAMEWORK FOR GENE 1950 01:11:38,524 --> 01:11:40,459 THERAPY AND UP AND COMING FIELD 1951 01:11:40,459 --> 01:11:41,294 OF GENOME EDITING BECAUSE WE 1952 01:11:41,294 --> 01:11:43,195 WOULD LIKE TO SEE THE BENEFITS 1953 01:11:43,195 --> 01:11:43,930 BROUGHT TO THE GREATEST NUMBER 1954 01:11:43,930 --> 01:11:44,697 OF PEOPLE. 1955 01:11:44,697 --> 01:11:49,869 SO THANKS VERY MUCH. 1956 01:11:49,869 --> 01:11:52,371 >> Joni Rutter: THANK YOU, 1957 01:11:52,371 --> 01:11:54,273 PETER, THAT WAS TERRIFIC. 1958 01:11:54,273 --> 01:11:56,108 THANK YOU FOR THE PRESENTATION. 1959 01:11:56,108 --> 01:11:57,343 WE DO HAVE SOME TIME FOR 1960 01:11:57,343 --> 01:11:58,344 QUESTIONS. 1961 01:11:58,344 --> 01:11:59,845 AND I HAVE A LOT. 1962 01:11:59,845 --> 01:12:01,080 WELL, MAYBE NOT A LOT. 1963 01:12:01,080 --> 01:12:03,616 BUT I HAVE SOME. 1964 01:12:03,616 --> 01:12:06,752 SO I'M HAPPY TO GET US STARTED, 1965 01:12:06,752 --> 01:12:08,087 WHILE I'M STARTING I HOPE OWNS 1966 01:12:08,087 --> 01:12:10,690 THINK OF QUESTIONS. 1967 01:12:10,690 --> 01:12:12,692 PETER, YOU MENTIONED COGENT AND 1968 01:12:12,692 --> 01:12:14,894 HOW IMPORTANT IT IS FOR 1969 01:12:14,894 --> 01:12:17,129 THINKING ABOUT MORE GLOBALLY 1970 01:12:17,129 --> 01:12:17,630 ADDRESSING THE ISSUE OF 1971 01:12:17,630 --> 01:12:19,465 COMMERCIALIZATION. 1972 01:12:19,465 --> 01:12:21,600 I COULDN'T HELP BUT THINK ABOUT 1973 01:12:21,600 --> 01:12:24,537 TOO IN THE OTHER APPROACH YOU 1974 01:12:24,537 --> 01:12:28,207 TALKED ABOUT IN TERMS OF THE 1975 01:12:28,207 --> 01:12:30,109 PLATFORM TECHNOLOGY IN HOW, 1976 01:12:30,109 --> 01:12:35,748 JUST THE IDEA OF THE PLATFORM 1977 01:12:35,748 --> 01:12:40,419 BASED APPROVALS COULD ALSO 1978 01:12:40,419 --> 01:12:41,520 POTENTIALLY HELP 1979 01:12:41,520 --> 01:12:42,188 COMMERCIALIZATION AS WELL, 1980 01:12:42,188 --> 01:12:44,156 BECAUSE THERE MIGHT BE, IT 1981 01:12:44,156 --> 01:12:45,658 WOULD SEEM TO CUT NOT ONLY THE 1982 01:12:45,658 --> 01:12:47,994 TIME IT TAKES TO DEVELOP THE 1983 01:12:47,994 --> 01:12:49,929 THERAPIES BUT ALSO POTENTIALLY 1984 01:12:49,929 --> 01:12:51,831 THE COSTS ASSOCIATED WITH THE 1985 01:12:51,831 --> 01:12:52,431 DEVELOPMENT OF THE THERAPIES 1986 01:12:52,431 --> 01:12:53,432 TOO. 1987 01:12:53,432 --> 01:12:55,368 SO THERE MIGHT BE MORE 1988 01:12:55,368 --> 01:12:57,803 COMMERCIAL INTEREST FROM JUST 1989 01:12:57,803 --> 01:13:03,042 THAT PLATFORM-BASED APPROACHES. 1990 01:13:03,042 --> 01:13:05,177 IS IT, I'M ASSUMING THAT, YOU 1991 01:13:05,177 --> 01:13:06,846 PROBABLY CAN'T REMARK ON THIS, 1992 01:13:06,846 --> 01:13:08,581 BUT ARE THERE GROUPS YOU KNOW 1993 01:13:08,581 --> 01:13:10,583 ABOUT WHO ARE BEGINNING TO 1994 01:13:10,583 --> 01:13:11,817 GENERATE THOSE KINDS OF 1995 01:13:11,817 --> 01:13:12,852 PLATFORM TECHNOLOGIES THAT 1996 01:13:12,852 --> 01:13:16,956 MIGHT BE VERY HELPFUL FOR THAT, 1997 01:13:16,956 --> 01:13:18,090 REALLY GETTING AT THAT 1998 01:13:18,090 --> 01:13:19,825 COMMERCIALIZATION FOR RARE 1999 01:13:19,825 --> 01:13:20,459 DISEASES IN THE GENE THERAPY 2000 01:13:20,459 --> 01:13:21,127 SPACE? 2001 01:13:21,127 --> 01:13:22,928 >> Peter Marks: I'M AWARE OF 2002 01:13:22,928 --> 01:13:24,030 VARIOUS GROUPS TALKING ABOUT 2003 01:13:24,030 --> 01:13:26,465 HOW TO GO ABOUT THIS. 2004 01:13:26,465 --> 01:13:28,067 BECAUSE I THINK THE ECONOMY OF 2005 01:13:28,067 --> 01:13:31,303 SCALE OF BEING ABLE TO MOVE 2006 01:13:31,303 --> 01:13:33,639 HERE, AND BEING ABLE TO PUT 2007 01:13:33,639 --> 01:13:36,442 TOGETHER WHAT MIGHT BE A 2008 01:13:36,442 --> 01:13:37,777 PORTFOLIO OF PRODUCTS, THAT 2009 01:13:37,777 --> 01:13:41,881 EACH OF WHICH MIGHT NOT BE 2010 01:13:41,881 --> 01:13:42,715 ROBUSTLY COMMERCIALLY VIABLE 2011 01:13:42,715 --> 01:13:45,484 BUT TOGETHER FORM SOMETHING 2012 01:13:45,484 --> 01:13:47,953 THAT IS COMMERCIALLY VERY 2013 01:13:47,953 --> 01:13:49,555 VIABLE, I THINK IS SOMETHING 2014 01:13:49,555 --> 01:13:51,223 THAT IS ATTRACTIVE. 2015 01:13:51,223 --> 01:13:53,159 IN SOME WAYS IT'S A LITTLE BIT, 2016 01:13:53,159 --> 01:13:55,361 IT'S WEIRD TO SAY THIS, IT'S A 2017 01:13:55,361 --> 01:13:57,196 LITTLE LIKE THE GENERIC MODEL. 2018 01:13:57,196 --> 01:14:00,099 YOU AREN'T GOING TO MAKE AS 2019 01:14:00,099 --> 01:14:01,934 INCREDIBLE AMOUNT OF MONEY FROM 2020 01:14:01,934 --> 01:14:03,436 EACH OF THESE PRODUCTS BUT FROM 2021 01:14:03,436 --> 01:14:05,671 HAVING THEM TOGETHER THEY CAN 2022 01:14:05,671 --> 01:14:06,238 CREATE A ROBUST COMMERCIAL 2023 01:14:06,238 --> 01:14:07,206 VENTURE. 2024 01:14:07,206 --> 01:14:09,508 >> Joni Rutter: GRIT. 2025 01:14:09,508 --> 01:14:10,709 -- GREAT. 2026 01:14:10,709 --> 01:14:12,311 THANK YOU FOR THAT. 2027 01:14:12,311 --> 01:14:14,380 I SEE PAUL, GO AHEAD. 2028 01:14:14,380 --> 01:14:15,781 >> PAUL: PETER, THANK YOU, THAT 2029 01:14:15,781 --> 01:14:17,183 WAS A GREAT PRESENTATION. 2030 01:14:17,183 --> 01:14:19,518 ON THE LAST SLIDE YOU PRESENTED 2031 01:14:19,518 --> 01:14:21,153 YOU WERE TALKING ABOUT 2032 01:14:21,153 --> 01:14:21,720 INNOVATION IN COMMUNICATION 2033 01:14:21,720 --> 01:14:23,322 EFFICIENCY. 2034 01:14:23,322 --> 01:14:24,323 AND PILOTS YOU ARE WANTING TO 2035 01:14:24,323 --> 01:14:25,858 SORT OF ROLL OUT. 2036 01:14:25,858 --> 01:14:27,593 CAN YOU TALK A LITTLE BIT MORE 2037 01:14:27,593 --> 01:14:29,128 ABOUT THE MECHANISMS FOR THAT 2038 01:14:29,128 --> 01:14:29,628 EFFICIENT COMMUNICATION? 2039 01:14:29,628 --> 01:14:31,730 >> Peter Marks: YEAH. 2040 01:14:31,730 --> 01:14:33,432 SO THE WAY WE PLAN TO DO THIS, 2041 01:14:33,432 --> 01:14:35,534 I THINK IF THAT'S WHAT YOU ARE 2042 01:14:35,534 --> 01:14:36,669 ASK, HOW ARE WE ACTUALLY GOING 2043 01:14:36,669 --> 01:14:38,971 TO MAKE IT WORK. 2044 01:14:38,971 --> 01:14:40,372 THE IDEA HERE, THE REASON WHY 2045 01:14:40,372 --> 01:14:42,508 WE CAN'T JUST SAY WE WILL DO 2046 01:14:42,508 --> 01:14:44,844 THIS FOR EVERYONE, WE WILL 2047 01:14:44,844 --> 01:14:45,945 ASSIGN A PROJECT MANAGER AND 2048 01:14:45,945 --> 01:14:49,381 THE COMPANY WILL HAVE THE 2049 01:14:49,381 --> 01:14:50,516 PROJECT MANAGER'S PHONE NUMBER 2050 01:14:50,516 --> 01:14:53,319 AND EMAIL AND WE WILL SAY OKAY, 2051 01:14:53,319 --> 01:14:55,421 WHEN AN ISSUE COMES UP, LET THE 2052 01:14:55,421 --> 01:14:58,257 PROJECT MANAGER KNOW, IF IT'S A 2053 01:14:58,257 --> 01:15:02,194 CMC MINOR ISSUE WE WILL GET ONE 2054 01:15:02,194 --> 01:15:02,995 OF OUR CMC REVIEWERS ON THE 2055 01:15:02,995 --> 01:15:04,230 PHONE. 2056 01:15:04,230 --> 01:15:06,165 IF IT'S A MAJOR ISSUE WE WILL 2057 01:15:06,165 --> 01:15:07,867 ARRANGE A MEETING IN A WEEK'S 2058 01:15:07,867 --> 01:15:11,337 TIME BUT WE WON'T ASK THEM TO 2059 01:15:11,337 --> 01:15:12,938 SUBMIT A BRIEFING, USUALLY IT'S 2060 01:15:12,938 --> 01:15:14,840 SUBMIT A BRIEFING BOOK. 2061 01:15:14,840 --> 01:15:16,275 HERE SUMMARIZE THE ISSUE IN 2062 01:15:16,275 --> 01:15:17,576 EMAIL SO OUR FOLKS CAN 2063 01:15:17,576 --> 01:15:19,078 UNDERSTAND IT AND LET'S GET ON 2064 01:15:19,078 --> 01:15:23,916 PHONE AND WORK IT OUT. 2065 01:15:23,916 --> 01:15:29,588 THE IDEA HERE IS NOT TO GET 2066 01:15:29,588 --> 01:15:31,924 STUCK AT EACH PLACE WHERE WE 2067 01:15:31,924 --> 01:15:35,594 OFTEN HAVE THINGS GET STUCK. 2068 01:15:35,594 --> 01:15:37,163 MY HYPOTHESIS, ESPECIALLY WITH 2069 01:15:37,163 --> 01:15:39,465 SMALLER COMPANIES, SOMETIMES 2070 01:15:39,465 --> 01:15:40,733 WHEN WE HAVE FORMAL 2071 01:15:40,733 --> 01:15:41,734 CORRESPONDENCE WITH THEM, THEY 2072 01:15:41,734 --> 01:15:42,434 DON'T UNDERSTAND WHAT WE ARE 2073 01:15:42,434 --> 01:15:43,636 SAYING. 2074 01:15:43,636 --> 01:15:45,171 BECAUSE THEY DON'T, THEY DO 2075 01:15:45,171 --> 01:15:46,372 SOMETHING DIFFERENT THAN WHAT 2076 01:15:46,372 --> 01:15:48,073 WE THOUGHT WE WERE TELLING THEM. 2077 01:15:48,073 --> 01:15:50,109 THEY COME BACK TO US. 2078 01:15:50,109 --> 01:15:51,810 WE SAID NO, NO, WE DIDN'T MEAN 2079 01:15:51,810 --> 01:15:53,546 FOR YOU TO DO THAT, DO THIS. 2080 01:15:53,546 --> 01:15:54,880 AND THIS WAY, THE NICE THING 2081 01:15:54,880 --> 01:15:56,916 ABOUT THIS, I CAN SAY TO YOU, 2082 01:15:56,916 --> 01:15:59,084 YOU KNOW, I'M GOING TO GET OFF 2083 01:15:59,084 --> 01:16:00,119 THIS CALL IN FIVE MINUTES, DO 2084 01:16:00,119 --> 01:16:01,520 YOU UNDERSTAND THAT. 2085 01:16:01,520 --> 01:16:02,922 AND YOU CAN SAY OH YES, I 2086 01:16:02,922 --> 01:16:05,024 UNDERSTAND YOU ARE GOING TO GET 2087 01:16:05,024 --> 01:16:08,460 OFF IN FIVE MINUTES AND I CAN 2088 01:16:08,460 --> 01:16:09,995 NOD MY HEAD, WE HAVE GONE 2089 01:16:09,995 --> 01:16:10,462 THROUGH THE CYCLE OF 2090 01:16:10,462 --> 01:16:11,297 COMMUNICATION. 2091 01:16:11,297 --> 01:16:12,898 THAT'S PART OF THE IDEA HERE, 2092 01:16:12,898 --> 01:16:16,535 WE CAN MAKE SURE THAT WHEN WE 2093 01:16:16,535 --> 01:16:18,204 CONVEY ADVICE, THAT IT'S REALLY 2094 01:16:18,204 --> 01:16:18,971 UNDERSTOOD. 2095 01:16:18,971 --> 01:16:21,073 IT SEEMS SO SIMPLE. 2096 01:16:21,073 --> 01:16:22,775 YOU KNOW, THIS IS LIKE, IT 2097 01:16:22,775 --> 01:16:24,310 SHOULD BE ELEMENTARY SCHOOL. 2098 01:16:24,310 --> 01:16:26,845 BUT I CAN'T TELL YOU. 2099 01:16:26,845 --> 01:16:29,381 THERE ARE PROGRAMS THAT HAVE 2100 01:16:29,381 --> 01:16:30,482 NEARLY BEEN TERMINATED BECAUSE 2101 01:16:30,482 --> 01:16:31,917 OF ISSUES WITH COMMUNICATION 2102 01:16:31,917 --> 01:16:36,956 LIKE THIS WITH FDA. 2103 01:16:36,956 --> 01:16:39,391 >> SOUNDS LIKE A GOOD LIGHT 2104 01:16:39,391 --> 01:16:39,925 WEIGHT INITIATIVE TO MOVE 2105 01:16:39,925 --> 01:16:40,159 FORWARD. 2106 01:16:40,159 --> 01:16:40,893 THANK. 2107 01:16:40,893 --> 01:16:44,697 >> Peter Marks: I APPRECIATE IT. 2108 01:16:44,697 --> 01:16:47,666 >> Joni Rutter: ANNIE KENNEDY. 2109 01:16:47,666 --> 01:16:50,502 >> HI DR. MARKS, THANK YOU FOR 2110 01:16:50,502 --> 01:16:53,539 BEING HERE AND WONDERFUL TO SIT 2111 01:16:53,539 --> 01:16:55,541 AT AN NCATS ADVISORY COUNCIL 2112 01:16:55,541 --> 01:16:56,375 MEETING AND INTERACTING WITH 2113 01:16:56,375 --> 01:16:57,009 YOU, SO THANK YOU FOR BEING 2114 01:16:57,009 --> 01:16:59,345 HERE. 2115 01:16:59,345 --> 01:17:04,083 I STARTED MY CAREER IN INTRA 2116 01:17:04,083 --> 01:17:05,017 MUSCULAR CLINIC, I NEVER 2117 01:17:05,017 --> 01:17:08,520 THOUGHT I WOULD SEE A DAY WHEN 2118 01:17:08,520 --> 01:17:10,689 GENE THERAPY ARE BENEFITING THE 2119 01:17:10,689 --> 01:17:11,523 PATIENTS AND FAMILIES I'M 2120 01:17:11,523 --> 01:17:12,791 SERVING, MUCH OF THAT IS DUE TO 2121 01:17:12,791 --> 01:17:14,326 THE LEADERSHIP OF YOU AND YOUR 2122 01:17:14,326 --> 01:17:16,161 TEAM BUT ALSO THE LEADERSHIP OF 2123 01:17:16,161 --> 01:17:17,763 THOSE ON THIS CAMPUS WHERE WE 2124 01:17:17,763 --> 01:17:20,399 ARE TODAY, WHO MOVED SO MANY OF 2125 01:17:20,399 --> 01:17:22,034 THOSE PROGRAMS FORWARD AND 2126 01:17:22,034 --> 01:17:22,668 PIPELINES MOVED INTO REGULATORY 2127 01:17:22,668 --> 01:17:25,237 REVIEW. 2128 01:17:25,237 --> 01:17:28,173 SO MY FACEBOOK FEEDS ARE RIGHT 2129 01:17:28,173 --> 01:17:29,808 NOW FLOODED WITH PHOTOS OF 2130 01:17:29,808 --> 01:17:32,811 INDIVIDUALS WHO ARE DIAGNOSED 2131 01:17:32,811 --> 01:17:35,714 WITH SMA TYPE I GRADUATING FROM 2132 01:17:35,714 --> 01:17:36,482 PRE-SCHOOL WITH THEIR LITTLE 2133 01:17:36,482 --> 01:17:37,650 CAPS AND GOWNS. 2134 01:17:37,650 --> 01:17:39,785 I THINK OF THE FAMILIES I SPENT 2135 01:17:39,785 --> 01:17:41,720 TIME WITH THEM IN CLINIC YEARS 2136 01:17:41,720 --> 01:17:44,456 AGO AS WE DEVELOPED THE 2137 01:17:44,456 --> 01:17:45,524 DIAGNOSES AND THEIR OUTCOMES 2138 01:17:45,524 --> 01:17:46,125 WERE QUITE DIFFERENT AT THAT 2139 01:17:46,125 --> 01:17:47,092 TIME. 2140 01:17:47,092 --> 01:17:47,726 THAT'S WHAT THE PROMISE OF 2141 01:17:47,726 --> 01:17:49,295 SCIENCE IS. 2142 01:17:49,295 --> 01:17:52,931 BUT I ALSO THANK THE TEAMS WHO 2143 01:17:52,931 --> 01:17:54,566 UNDERSTAND THAT ENDPOINTS ARE 2144 01:17:54,566 --> 01:17:56,335 DIFFERENT IN DIFFERENT DISEASES 2145 01:17:56,335 --> 01:17:58,871 AND FAMILIES TO WHOM A 2146 01:17:58,871 --> 01:18:00,706 MEANINGFUL BENEFIT IS GOING UP 2147 01:18:00,706 --> 01:18:06,078 A STAIR, SO PATIENTS WHO NOW 2148 01:18:06,078 --> 01:18:07,780 BENEFIT FROM THE DUCHEN GENE 2149 01:18:07,780 --> 01:18:09,982 THERAPY AND CAN NOW RIDE BIKES 2150 01:18:09,982 --> 01:18:13,619 OR GO TO A FRIEND'S HOUSE FOR A 2151 01:18:13,619 --> 01:18:15,954 SLEEP OVER, THEY CAN CROSS THE 2152 01:18:15,954 --> 01:18:17,056 THRESHOLD OF THAT FRIEND'S HOME 2153 01:18:17,056 --> 01:18:19,491 BECAUSE OF THAT THERAPY. 2154 01:18:19,491 --> 01:18:22,161 EVEN THOUGH WE BENEFITED FROM 2155 01:18:22,161 --> 01:18:22,995 THESE ROBUST GENE THERAPY 2156 01:18:22,995 --> 01:18:24,830 PROGRAMS THERE ARE STILL THOSE 2157 01:18:24,830 --> 01:18:26,098 WHO ARE BEING LEFT BEHIND. 2158 01:18:26,098 --> 01:18:28,801 FOR MANY REASONS. 2159 01:18:28,801 --> 01:18:29,768 AND YOU ARTICULATED SOME THAT 2160 01:18:29,768 --> 01:18:32,004 ARE BEING DEALT WITH. 2161 01:18:32,004 --> 01:18:36,442 THERE ARE FAMILIES WHO, NOT 2162 01:18:36,442 --> 01:18:39,244 BECAUSE OF REDOSING BUT DON'T 2163 01:18:39,244 --> 01:18:42,581 MEET INCLUSION CRITERIA BECAUSE 2164 01:18:42,581 --> 01:18:45,718 OF PREEXISTING ANTIBODIES AND 2165 01:18:45,718 --> 01:18:48,253 THEY HAVE THE AB TO BEGIN WITH. 2166 01:18:48,253 --> 01:18:50,522 THIS COULD BE A QUESTION FOR 2167 01:18:50,522 --> 01:18:52,291 NCATS OR YOU. 2168 01:18:52,291 --> 01:18:52,991 I APPRECIATE UNDERSTANDING 2169 01:18:52,991 --> 01:18:56,228 WHAT'S BEING DONE AT THIS POINT 2170 01:18:56,228 --> 01:18:59,164 TO ENABLE THOSE WHO CURRENTLY 2171 01:18:59,164 --> 01:19:01,767 HAVE THE ANTIBODIES TO AB AND 2172 01:19:01,767 --> 01:19:04,036 ARE EXCLUDED FROM CLINICAL 2173 01:19:04,036 --> 01:19:05,804 TRIAL OR APPROVED THERAPIES, IS 2174 01:19:05,804 --> 01:19:08,574 THERE WORK BEING DONE TO HELP 2175 01:19:08,574 --> 01:19:10,042 OVERCOME THAT ENTRY BARRIER 2176 01:19:10,042 --> 01:19:11,377 INTO THE GENE THERAPY PROGRAMS 2177 01:19:11,377 --> 01:19:12,344 BEING WORKED ON? 2178 01:19:12,344 --> 01:19:14,313 >> Peter Marks: I WILL TELL YOU 2179 01:19:14,313 --> 01:19:15,114 THREE QUICK AREAS OF RESEARCH 2180 01:19:15,114 --> 01:19:17,750 GOING ON. 2181 01:19:17,750 --> 01:19:19,385 SIMPLEST THERE ARE INDIVIDUALS 2182 01:19:19,385 --> 01:19:22,321 LOOKING AT WAYS TO CLEAR THE 2183 01:19:22,321 --> 01:19:23,789 ANTIBODIES AND MAKE GENE 2184 01:19:23,789 --> 01:19:25,858 THERAPY POSSIBLE, OR AT LEAST 2185 01:19:25,858 --> 01:19:27,793 REDUCE TO POSSIBILITIES YOU CAN 2186 01:19:27,793 --> 01:19:29,161 ESSENTIALLY OVERWHELM AND HAVE 2187 01:19:29,161 --> 01:19:30,362 THE GENE THERAPY OCCUR. 2188 01:19:30,362 --> 01:19:31,463 THAT'S SOMETHING WE HAVE KNOWN 2189 01:19:31,463 --> 01:19:33,265 HOW TO DO. 2190 01:19:33,265 --> 01:19:35,167 WE HAVE DONE FOR OTHER THINGSES. 2191 01:19:35,167 --> 01:19:36,769 THAT'S ONE WAY. 2192 01:19:36,769 --> 01:19:44,643 THE OTHER IS PEOPLE ARE 2193 01:19:44,643 --> 01:19:45,744 OBVIOUSLY DEVELOPING NOVEL 2194 01:19:45,744 --> 01:19:47,679 CAPSIDS THAT MAY EVADE. 2195 01:19:47,679 --> 01:19:50,082 BUT THE OTHER DECIDING TO MOVE 2196 01:19:50,082 --> 01:19:57,256 ON FROM AEV TO CONSTRUCTS TO 2197 01:19:57,256 --> 01:20:00,292 USING NANO PARTICLES FOR 2198 01:20:00,292 --> 01:20:01,994 CRISPR, FOR THOSE WITH 2199 01:20:01,994 --> 01:20:02,895 ANTIBODIES, IT IS SIDE STEPPING 2200 01:20:02,895 --> 01:20:03,796 THE ISSUE. 2201 01:20:03,796 --> 01:20:06,331 THERE ARE A VARIETY OF 2202 01:20:06,331 --> 01:20:08,133 DIFFERENT THINGS GOING ON. 2203 01:20:08,133 --> 01:20:10,803 I AGREE, I WISH THERE WOULD BE 2204 01:20:10,803 --> 01:20:12,504 MORE RAPID PROGRESS IN SOME OF 2205 01:20:12,504 --> 01:20:14,640 THESE AREAS BUT THERE ARE 2206 01:20:14,640 --> 01:20:17,676 OBVIOUSLY SERIOUS EFFORTS GOING 2207 01:20:17,676 --> 01:20:18,811 ON IN ALL THREE OF THOSE 2208 01:20:18,811 --> 01:20:19,678 EXAMPLES. 2209 01:20:19,678 --> 01:20:21,213 THERE ARE MORE BUT AT LEAST 2210 01:20:21,213 --> 01:20:27,753 THREE EXAMPLES. 2211 01:20:27,753 --> 01:20:29,054 >> ANNIE: THANK YOU. 2212 01:20:29,054 --> 01:20:30,722 >> Joni Rutter: PETER, I HAVE 2213 01:20:30,722 --> 01:20:32,324 ANOTHER QUESTION BECAUSE I 2214 01:20:32,324 --> 01:20:34,059 DON'T SEE OTHERS JUST YET. 2215 01:20:34,059 --> 01:20:36,728 ANOTHER QUESTION ALONG THE SAME 2216 01:20:36,728 --> 01:20:38,664 LINES AROUND SORT OF INITIATING 2217 01:20:38,664 --> 01:20:39,998 THE RESEARCH NEEDED TO SUPPORT 2218 01:20:39,998 --> 01:20:42,601 SORT OF THE NEXT PHASE WE ARE 2219 01:20:42,601 --> 01:20:45,537 MOVING INTO, I AM WONDERING IF 2220 01:20:45,537 --> 01:20:47,072 THIS IS A GOOD OPPORTUNITY TO 2221 01:20:47,072 --> 01:20:49,508 THINK HARD HOW WE CAN USE THE 2222 01:20:49,508 --> 01:20:50,709 SMALL BUSINESS PROGRAMS TO 2223 01:20:50,709 --> 01:20:52,845 SUPPORT RESEARCH TO GET IN THE 2224 01:20:52,845 --> 01:20:54,079 MANUFACTURING SPACE AND PERHAPS 2225 01:20:54,079 --> 01:20:54,680 OTHER ISSUES YOU WERE TALKING 2226 01:20:54,680 --> 01:20:55,848 ABOUT. 2227 01:20:55,848 --> 01:20:58,417 AND YOUR THOUGHTS ON PERHAPS 2228 01:20:58,417 --> 01:21:01,820 THAT VERY SPECIFIC APPROACH OF 2229 01:21:01,820 --> 01:21:02,454 WORKING WITH COMPANIES, BIOTECH 2230 01:21:02,454 --> 01:21:03,655 COMPANIES. 2231 01:21:03,655 --> 01:21:05,457 >> Peter Marks: JONI, I THINK 2232 01:21:05,457 --> 01:21:08,093 THAT IS PROBABLY ONE OF THE 2233 01:21:08,093 --> 01:21:08,961 GREATEST FOCUSES WE NEED TO GET 2234 01:21:08,961 --> 01:21:10,229 INTO. 2235 01:21:10,229 --> 01:21:12,631 HOW ARE WE GOING TO 2236 01:21:12,631 --> 01:21:14,533 MANUFACTURER THESE THINGS MORE 2237 01:21:14,533 --> 01:21:15,767 EFFICIENT AND EFFECTIVELY. 2238 01:21:15,767 --> 01:21:16,935 I THINK THAT IS AN IMPORTANT 2239 01:21:16,935 --> 01:21:19,705 PLACE. 2240 01:21:19,705 --> 01:21:23,408 I THINK IT'S NOT JUST WITH THE 2241 01:21:23,408 --> 01:21:24,443 TRADITIONAL GENE THERAPY 2242 01:21:24,443 --> 01:21:26,979 COMPANIES, IT'S WITH COMPANIES 2243 01:21:26,979 --> 01:21:28,113 THAT MAKE MANUFACTURING 2244 01:21:28,113 --> 01:21:29,414 EQUIPMENT TO ACTUALLY HAVE THEM 2245 01:21:29,414 --> 01:21:30,549 DEVELOP THE TOOLS THAT COULD BE 2246 01:21:30,549 --> 01:21:35,254 APPLIED HERE. 2247 01:21:35,254 --> 01:21:36,755 IT'S UNFORTUNATE, ACADEMICS 2248 01:21:36,755 --> 01:21:38,590 DON'T GET PAPERS OUT OF, I MEAN 2249 01:21:38,590 --> 01:21:41,426 THERE ARE SOME THAT DO. 2250 01:21:41,426 --> 01:21:43,428 MANUFACTURING EQUIPMENT IS NOT 2251 01:21:43,428 --> 01:21:45,864 REALLY EXCITING TO DESIGN FROM 2252 01:21:45,864 --> 01:21:47,866 AN ACADEMIC STANDPOINT BUT IT 2253 01:21:47,866 --> 01:21:50,669 IS ABSOLUTELY CRUCIAL IF WE ARE 2254 01:21:50,669 --> 01:21:53,739 GOING TO HAVE GENE THERAPIES 2255 01:21:53,739 --> 01:21:54,406 FOR MANY DIFFERENT RARE 2256 01:21:54,406 --> 01:21:55,674 DISEASES AND WE HAVE TO GET 2257 01:21:55,674 --> 01:21:57,075 MORE EFFICIENT. 2258 01:21:57,075 --> 01:21:59,144 THE KIND OF BENCH TOP APPROACH 2259 01:21:59,144 --> 01:22:00,612 WILL NOT BE SUSTAINABLE. 2260 01:22:00,612 --> 01:22:04,016 SO I THINK THIS APPLICATION OF 2261 01:22:04,016 --> 01:22:05,651 KIND OF GETTING SMALL 2262 01:22:05,651 --> 01:22:06,685 BUSINESSES INTERESTED IN THIS, 2263 01:22:06,685 --> 01:22:09,021 IT'S TRUE, THERE ARE A LOT OF 2264 01:22:09,021 --> 01:22:10,322 ENGINEERS IN SMALL BUSINESSES 2265 01:22:10,322 --> 01:22:12,224 WHO MIGHT BE VERY WILLING TO 2266 01:22:12,224 --> 01:22:14,793 TAKE THIS CHALLENGE UP. 2267 01:22:14,793 --> 01:22:16,595 >> Joni Rutter: YEAH. 2268 01:22:16,595 --> 01:22:18,397 IT SEEMS LIKE WE NEED TO DO A 2269 01:22:18,397 --> 01:22:19,731 LOT IN THE MANUFACTURING SPACE 2270 01:22:19,731 --> 01:22:20,933 TO GET US TO WHERE WE NEED TO 2271 01:22:20,933 --> 01:22:23,435 BE. 2272 01:22:23,435 --> 01:22:25,771 SO I THINK FIRING ON ALL 2273 01:22:25,771 --> 01:22:27,406 CYLINDERS WE HAVE THE ABILITY 2274 01:22:27,406 --> 01:22:30,108 TO DO SO WOULD BE GREAT. 2275 01:22:30,108 --> 01:22:33,111 ANY OTHER QUESTIONS FOR PETER? 2276 01:22:33,111 --> 01:22:37,382 ANNIE, GO AHEAD. 2277 01:22:37,382 --> 01:22:40,319 >> ANNIE KENNEDY: IT'S ME AGAIN. 2278 01:22:40,319 --> 01:22:41,119 THERE'S ANOTHER IMPORTANT 2279 01:22:41,119 --> 01:22:43,255 INTERSECTION MAYBE NOT ALL MY 2280 01:22:43,255 --> 01:22:46,491 COUNCILMEMBERS ARE AWARE, THE 2281 01:22:46,491 --> 01:22:49,328 WORK THAT NCATS AND FDA AND 2282 01:22:49,328 --> 01:22:53,665 PERHAPS CBER IS WORKING ON. 2283 01:22:53,665 --> 01:22:55,767 THE INTERSECTION OF PATIENTS 2284 01:22:55,767 --> 01:22:56,802 NOT AVAILABLE FOR CLINICAL 2285 01:22:56,802 --> 01:22:59,371 TRIALS THE POINT OF WHICH THEY 2286 01:22:59,371 --> 01:23:00,839 ARE IDENTIFIED AND DIAGNOSED 2287 01:23:00,839 --> 01:23:02,975 AND ELIGIBILITY CRITERIA ON A 2288 01:23:02,975 --> 01:23:04,343 LABEL FOR PRODUCTS THAT'S 2289 01:23:04,343 --> 01:23:04,610 APPROVED. 2290 01:23:04,610 --> 01:23:07,913 THAT'S BECAUSE OF THE CRITERIA 2291 01:23:07,913 --> 01:23:10,382 NECESSARY TO HAVE THE CONDITION 2292 01:23:10,382 --> 01:23:12,551 IN THE NEWBORN SCREENING NOW. 2293 01:23:12,551 --> 01:23:14,486 WE JUST, A LITTLE WHILE AGO 2294 01:23:14,486 --> 01:23:16,688 HEAR DR. RUTTER GIVE A 2295 01:23:16,688 --> 01:23:20,525 PRESENTATION ABOUT SOME WORK IN 2296 01:23:20,525 --> 01:23:22,260 DIAGNOSTICS NCATS IS DOING AND 2297 01:23:22,260 --> 01:23:26,565 OTHERS ARE DOING TO REALLY HELP 2298 01:23:26,565 --> 01:23:28,000 INNOVATE IN OUR DIAGNOSTICS 2299 01:23:28,000 --> 01:23:30,202 THROUGHOUT THE U.S., SO WE CAN 2300 01:23:30,202 --> 01:23:33,505 BETTER DETECT PATIENTS, 2301 01:23:33,505 --> 01:23:34,640 ESPECIALLY FOR DISEASES EARLIER. 2302 01:23:34,640 --> 01:23:38,110 I KNOW THIS IS AN AREA, DR. 2303 01:23:38,110 --> 01:23:38,744 MARKS, YOU ARE ALSO CONCERNED 2304 01:23:38,744 --> 01:23:40,445 ABOUT. 2305 01:23:40,445 --> 01:23:44,850 WE HAVE PRODUCTS NOW APPROVED 2306 01:23:44,850 --> 01:23:46,518 THAT ARE LIFE-ALTERING, NOT 2307 01:23:46,518 --> 01:23:49,021 LIFE-SAVING BUT NOT GETTING TO 2308 01:23:49,021 --> 01:23:51,957 PATIENTS SOON ENOUGH, FAST 2309 01:23:51,957 --> 01:23:53,759 ENOUGH BECAUSE THE PATIENTS 2310 01:23:53,759 --> 01:23:56,261 ELIGIBLE AREN'T IDENTIFIED AT 2311 01:23:56,261 --> 01:24:00,632 THE OPTIMUM THERAPEUTIC WINDOW. 2312 01:24:00,632 --> 01:24:02,434 >> Peter Marks: THERE ARE 2313 01:24:02,434 --> 01:24:06,505 MULTIPLE ISSUES HERE, RIGHT? 2314 01:24:06,505 --> 01:24:07,906 THERE'S THE ISSUE OF PROPER, 2315 01:24:07,906 --> 01:24:08,907 EARLY DIAGNOSIS. 2316 01:24:08,907 --> 01:24:10,742 THAT HAS TO DO WITH THE FACT WE 2317 01:24:10,742 --> 01:24:13,779 NEED TO DO A BETTER JOB AT 2318 01:24:13,779 --> 01:24:14,479 ESSENTIALLY NEWBORN SCREENING 2319 01:24:14,479 --> 01:24:16,214 IN THE COUNTRY. 2320 01:24:16,214 --> 01:24:17,115 BUT THEN ALSO THERE'S THE 2321 01:24:17,115 --> 01:24:20,552 ABILITY TO GET OUT THE TESTS 2322 01:24:20,552 --> 01:24:23,555 THAT ARE NECESSARY SO THAT, AND 2323 01:24:23,555 --> 01:24:26,324 GET OUT THE WORD OF THESE 2324 01:24:26,324 --> 01:24:29,795 THERAPIES AS THEY COME ALONG. 2325 01:24:29,795 --> 01:24:33,365 AND SO I THINK WE WILL NEED TO 2326 01:24:33,365 --> 01:24:34,366 CONTINUE TO WORK ALONG THESE, 2327 01:24:34,366 --> 01:24:36,535 AS WE HAVE, I THINK WE ARE 2328 01:24:36,535 --> 01:24:39,805 GOING TO HAVE INCREASING NUMBER 2329 01:24:39,805 --> 01:24:41,940 OF THERAPEUTIC OPTIONS, BUT AN 2330 01:24:41,940 --> 01:24:43,575 INCREASING NUMBER OF OPTIONS 2331 01:24:43,575 --> 01:24:46,712 FOR PEOPLE WHO PREVIOUSLY 2332 01:24:46,712 --> 01:24:50,048 DIDN'T HAVE ANY OPTIONS WHERE 2333 01:24:50,048 --> 01:24:50,916 IDENTIFYING THOSE WHO MIGHT 2334 01:24:50,916 --> 01:24:52,651 BENEFIT WILL BE CRITICAL. 2335 01:24:52,651 --> 01:24:55,587 WE WILL ALSO HAVE TO IDENTIFY 2336 01:24:55,587 --> 01:24:56,722 WAYS POTENTIALLY OF HAVING 2337 01:24:56,722 --> 01:24:59,257 ACCESS FOR THOSE WHO MIGHT BE 2338 01:24:59,257 --> 01:25:02,861 DIAGNOSED LATE. 2339 01:25:02,861 --> 01:25:05,263 WHERE THEY MAY NOT HAVE FALLEN 2340 01:25:05,263 --> 01:25:05,764 INTO THE CLINICAL TRIAL 2341 01:25:05,764 --> 01:25:06,598 POPULATIONS. 2342 01:25:06,598 --> 01:25:08,734 I THINK THAT IS WHAT YOU ARE 2343 01:25:08,734 --> 01:25:18,210 TRYING TO GET AT, ANNIE AS WELL. 2344 01:25:18,210 --> 01:25:20,212 THAT'S SOMETHING WE WILL HAVE 2345 01:25:20,212 --> 01:25:22,047 TO THINK ABOUT DOING 2346 01:25:22,047 --> 01:25:22,948 EFFECTIVELY AND EFFICIENTLY. 2347 01:25:22,948 --> 01:25:24,182 >> Joni Rutter: YES, GO AHEAD, 2348 01:25:24,182 --> 01:25:26,785 MIKE. 2349 01:25:26,785 --> 01:25:28,386 >> MIKE: PETER, YOU MENTIONED 2350 01:25:28,386 --> 01:25:32,357 YOU KNOW, THE POTENTIAL FOR A 2351 01:25:32,357 --> 01:25:34,559 GLOBAL DEMAND WOULD REALLY MAKE 2352 01:25:34,559 --> 01:25:36,294 IT MORE COMMERCIALLY ATTRACTIVE. 2353 01:25:36,294 --> 01:25:38,096 BUT I'M JUST WONDERING IF YOU 2354 01:25:38,096 --> 01:25:43,769 CAN SPEAK TO THE EXTENT OF THE 2355 01:25:43,769 --> 01:25:44,870 GLOBAL REGULATORY HARMONIZATION 2356 01:25:44,870 --> 01:25:48,840 WE HAVE SEEN IN VACCINES, THIS 2357 01:25:48,840 --> 01:25:53,478 IS REALLY AN OBSTACLES FOR 2358 01:25:53,478 --> 01:25:55,547 MANUFACTURERS TO GO THROUGH THE 2359 01:25:55,547 --> 01:25:56,114 REGULATORY ENVIRONMENTS. 2360 01:25:56,114 --> 01:25:58,950 >> Peter Marks: WE HAVE BEEN 2361 01:25:58,950 --> 01:26:02,053 WORKING WITH WHO ON CELL 2362 01:26:02,053 --> 01:26:04,089 THERAPY REGULATORY CONVERGENCE, 2363 01:26:04,089 --> 01:26:13,064 THERE WAS A MEETING HELD LAST 2364 01:26:13,064 --> 01:26:16,134 WEEK IN MUSCOT, OMAN ON THIS. 2365 01:26:16,134 --> 01:26:18,770 FOR VACCINES, YOU ARE FAMILIAR 2366 01:26:18,770 --> 01:26:22,174 WITH WHO LISTING WHEN A MAJOR 2367 01:26:22,174 --> 01:26:26,645 REGULATORY AUTHORITY APPROVES A 2368 01:26:26,645 --> 01:26:27,612 VACCINE, THE MANUFACTURER CAN 2369 01:26:27,612 --> 01:26:32,150 APPLY TO BE LISTED WITH WHO AND 2370 01:26:32,150 --> 01:26:33,285 OTHER REGULATORS WITH OTHER 2371 01:26:33,285 --> 01:26:36,121 COMPANIES DON'T HAVE THE 2372 01:26:36,121 --> 01:26:39,624 CAPACITY JUST KEY IN ON THAT 2373 01:26:39,624 --> 01:26:40,859 WHO-LISTED VACCINE. 2374 01:26:40,859 --> 01:26:43,195 I THINK WE WILL NEED SOMETHING 2375 01:26:43,195 --> 01:26:45,397 VERY SIMILAR IN THE GENE 2376 01:26:45,397 --> 01:26:46,765 THERAPY SPACE, PARTICULARLY THE 2377 01:26:46,765 --> 01:26:49,534 GENE THERAPY SPACE. 2378 01:26:49,534 --> 01:26:51,636 WE HAVE COUNTRIES THAT ARE 2379 01:26:51,636 --> 01:26:53,471 AFFLUENT ENOUGH TO BE ABLE TO 2380 01:26:53,471 --> 01:26:54,439 AFFORD THESE PRODUCTS. 2381 01:26:54,439 --> 01:26:56,875 IF YOU LOOK AT THE MIDDLE EAST, 2382 01:26:56,875 --> 01:26:58,376 THAT'S A GREAT EXAMPLE. 2383 01:26:58,376 --> 01:27:00,645 YET, THEY DON'T HAVE THE 2384 01:27:00,645 --> 01:27:01,246 REGULATORY CAPACITY TO REVIEW 2385 01:27:01,246 --> 01:27:02,314 THEM. 2386 01:27:02,314 --> 01:27:04,349 THEY ARE PERFECTLY WILLING TO 2387 01:27:04,349 --> 01:27:07,185 KEY OFF AN FDA OR EMA APPROVAL. 2388 01:27:07,185 --> 01:27:09,187 WE NEED TO HELP THEM FIND THE 2389 01:27:09,187 --> 01:27:10,822 PATHWAY TO DO SO. 2390 01:27:10,822 --> 01:27:12,524 THAT'S WHERE WE MAY NEED TO 2391 01:27:12,524 --> 01:27:14,059 HEAD HERE, THE FASTER WE CAN 2392 01:27:14,059 --> 01:27:15,060 GET THERE, THE BETTER OFF WE 2393 01:27:15,060 --> 01:27:23,535 MAY BE. 2394 01:27:23,535 --> 01:27:24,336 >> Joni Rutter: THANK YOU VERY 2395 01:27:24,336 --> 01:27:24,870 MUCH. 2396 01:27:24,870 --> 01:27:31,910 ANY OTHER QUESTIONS? 2397 01:27:31,910 --> 01:27:32,744 ALL RIGHT. 2398 01:27:32,744 --> 01:27:34,546 SEEING NONE. 2399 01:27:34,546 --> 01:27:35,680 PETER, IT'S BEEN A REAL 2400 01:27:35,680 --> 01:27:36,715 PLEASURE TO HAVE YOU HERE AT 2401 01:27:36,715 --> 01:27:38,316 THE COUNCIL TODAY. 2402 01:27:38,316 --> 01:27:39,384 PERHAPS THIS SHOULDN'T BE THE 2403 01:27:39,384 --> 01:27:40,619 ONLY OCCURRENCE FOR THAT. 2404 01:27:40,619 --> 01:27:41,653 WE MIGHT HAVE TO INVITE YOU 2405 01:27:41,653 --> 01:27:42,854 BACK AGAIN. 2406 01:27:42,854 --> 01:27:44,789 BUT WE WILL GIVE YOU A LITTLE 2407 01:27:44,789 --> 01:27:45,624 BIT A BREAK BETWEEN NOW AND 2408 01:27:45,624 --> 01:27:47,392 THEN. 2409 01:27:47,392 --> 01:27:48,693 THANK YOU FOR BEING HERE, I 2410 01:27:48,693 --> 01:27:50,328 APPRECIATE YOU TAKING TIME OUT 2411 01:27:50,328 --> 01:27:51,329 OF YOUR BUSY SCHEDULE TODAY. 2412 01:27:51,329 --> 01:27:53,198 >> Peter Marks: THANK YOU, I 2413 01:27:53,198 --> 01:27:54,165 THINK WE HAVE REALLY ENJOYED 2414 01:27:54,165 --> 01:27:55,600 COLLABORATING. 2415 01:27:55,600 --> 01:27:56,601 IT'S JUST SUCH AN IMPORTANT 2416 01:27:56,601 --> 01:27:58,603 PART OF WHAT WE DO, SO THANK 2417 01:27:58,603 --> 01:27:58,904 YOU, NCATS. 2418 01:27:58,904 --> 01:28:00,438 THANK YOU. 2419 01:28:00,438 --> 01:28:02,774 >> Joni Rutter: ALL RIGHT. 2420 01:28:02,774 --> 01:28:05,810 THANK YOU VERY MUCH. 2421 01:28:05,810 --> 01:28:08,446 OKAY, WITH THAT, WE ARE 2422 01:28:08,446 --> 01:28:09,848 ACTUALLY AHEAD OF SCHEDULE, 2423 01:28:09,848 --> 01:28:11,049 WHICH RARELY HAPPENS, SO I 2424 01:28:11,049 --> 01:28:12,784 THINK WE NEED TO SEIZE THE 2425 01:28:12,784 --> 01:28:13,685 OPPORTUNITY HERE AND TAKE 2426 01:28:13,685 --> 01:28:16,021 ADVANTAGE OF THE FACT THAT WE 2427 01:28:16,021 --> 01:28:17,222 HAVE A LITTLE BIT MORE TIME. 2428 01:28:17,222 --> 01:28:19,357 SO WHAT I WOULD LIKE TO DO IS 2429 01:28:19,357 --> 01:28:21,259 ACTUALLY GIVE YOU A LITTLE BIT 2430 01:28:21,259 --> 01:28:23,361 MORE TIME TO HAVE SOME LUNCH. 2431 01:28:23,361 --> 01:28:29,401 AND THEN WE WILL GO AHEAD AND 2432 01:28:29,401 --> 01:28:33,171 CONVENE AT 12:45. 2433 01:28:33,171 --> 01:28:35,707 12:40? 2434 01:28:35,707 --> 01:28:38,777 WE NEED TO CONVENE AT 12:40 SO 2435 01:28:38,777 --> 01:28:41,746 THAT WE CAN GET STARTED 2436 01:28:41,746 --> 01:28:42,981 PROMPTLY AT 12:45, I KNOW WE 2437 01:28:42,981 --> 01:28:44,282 ARE GOING TO HAVE A GOOD 2438 01:28:44,282 --> 01:28:45,717 DISCUSSION AT THE END WHEN WE 2439 01:28:45,717 --> 01:28:46,251 TALK ABOUT THE STRATEGIC 2440 01:28:46,251 --> 01:28:48,153 PLANNING. 2441 01:28:48,153 --> 01:28:50,655 SO HAPPY TO TALK ABOUT ANY 2442 01:28:50,655 --> 01:28:51,756 QUESTIONS ALONG THE WAY, I HOPE 2443 01:28:51,756 --> 01:28:52,958 YOU ARE SAVING THEM FOR THE END 2444 01:28:52,958 --> 01:28:54,793 OF THE DAY WHEN WE CAN HAVE A 2445 01:28:54,793 --> 01:28:56,528 LITTLE MORE OPEN DISCUSSION AS 2446 01:28:56,528 --> 01:28:56,728 WELL. 2447 01:28:56,728 --> 01:28:57,362 WITH THAT, LET US CONVENE FOR 2448 01:28:57,362 --> 01:28:57,562 LUNCH. 2449 01:28:57,562 --> 01:28:58,767 THANK YOU. 2450 01:29:00,244 --> 01:29:01,045 IN THAT CASE, WE WILL GET 2451 01:29:01,045 --> 01:29:01,845 STARTED. 2452 01:29:01,845 --> 01:29:04,481 I WILL TELL YOU, WE HAVE OUR 2453 01:29:04,481 --> 01:29:06,283 CLOCK ON THE SCREEN IS ONE TIME 2454 01:29:06,283 --> 01:29:07,584 OUR CLOCKS IN THE ROOM. 2455 01:29:07,584 --> 01:29:11,422 THERE ARE A COUPLE, THEY ARE ON 2456 01:29:11,422 --> 01:29:14,391 DIFFERENT TIMES. 2457 01:29:14,391 --> 01:29:16,493 FOLLOW THE ONE ON YOUR SCREEN 2458 01:29:16,493 --> 01:29:18,195 IF ALL ELSE FAILS. 2459 01:29:18,195 --> 01:29:21,432 THANK YOU FOR A GOOD LUNCH. 2460 01:29:21,432 --> 01:29:22,966 I HOPE EVERYBODY HAD A CHANCE 2461 01:29:22,966 --> 01:29:25,703 TO CATCH UP WITH ONE ANOTHER. 2462 01:29:25,703 --> 01:29:28,238 I WANT TO INTRODUCE DR. 2463 01:29:28,238 --> 01:29:29,907 DOMINIQUE BUSHARD, SHE WILL 2464 01:29:29,907 --> 01:29:39,516 GIVE AN UPDATE. 2465 01:29:39,516 --> 01:29:49,960 >> I'M DOMINIQUE BUSHARD. 2466 01:29:54,131 --> 01:29:58,836 I'M THE DIRECTOR OF THE 2467 01:29:58,836 --> 01:29:59,636 DIVISION OF RARE DISEASES 2468 01:29:59,636 --> 01:30:00,938 RESEARCH INNOVATION. 2469 01:30:00,938 --> 01:30:02,673 WE WILL GO THROUGH SOME OF THE 2470 01:30:02,673 --> 01:30:04,808 PROGRAMMATIC UPDATES. 2471 01:30:04,808 --> 01:30:06,477 I WISH WE COULD TALK ABOUT ALL 2472 01:30:06,477 --> 01:30:07,911 OF THE WONDERFUL THINGS THE 2473 01:30:07,911 --> 01:30:10,647 DIVISION HAS BEEN UP TO, BUT 2474 01:30:10,647 --> 01:30:12,583 THERE'S JUST NOT ENOUGH TIME 2475 01:30:12,583 --> 01:30:12,783 TODAY. 2476 01:30:12,783 --> 01:30:13,884 THIS WILL BE SOME HIGHLIGHTS. 2477 01:30:13,884 --> 01:30:15,686 BEFORE I BEGIN, I WOULD BE 2478 01:30:15,686 --> 01:30:16,587 REMISS IF I DIDN'T ACTUALLY 2479 01:30:16,587 --> 01:30:24,061 SHOW YOU WHO IT IS THAT MAKES 2480 01:30:24,061 --> 01:30:24,895 UP THIS EXCELLENT TEAM RUNNING 2481 01:30:24,895 --> 01:30:26,063 ALL THE WORK I WILL BE TALKING 2482 01:30:26,063 --> 01:30:28,031 ABOUT TODAY. 2483 01:30:28,031 --> 01:30:29,633 THIS IS THE DRDRI STAFF. 2484 01:30:29,633 --> 01:30:31,869 AND IN THE RARE DISEASE 2485 01:30:31,869 --> 01:30:33,771 COMMUNITY WE OFTEN SAY RARE 2486 01:30:33,771 --> 01:30:36,173 DISEASES ARE SMALL BUT MIGHTY. 2487 01:30:36,173 --> 01:30:40,077 I SAY THE SAME THING ABOUT 2488 01:30:40,077 --> 01:30:41,779 DRDRI. 2489 01:30:41,779 --> 01:30:44,581 WE ARE A SMALL BUT MIGHTY TEAM. 2490 01:30:44,581 --> 01:30:46,083 IT'S THESE INDIVIDUALS WHO WORK 2491 01:30:46,083 --> 01:30:47,818 HARD EVERY DAY TO ACCOMPLISH 2492 01:30:47,818 --> 01:30:50,254 ALL OF THE PROGRAMS WE RUN AND 2493 01:30:50,254 --> 01:30:52,356 ADMINISTER AS WELL AS THE ONES 2494 01:30:52,356 --> 01:30:54,792 WE WILL JUST BE HIGHLIGHTING 2495 01:30:54,792 --> 01:30:56,593 TODAY. 2496 01:30:56,593 --> 01:30:58,796 BEFORE WE BEGIN, I THINK IT'S 2497 01:30:58,796 --> 01:31:01,031 IMPORTANT TO JUST TALK ABOUT 2498 01:31:01,031 --> 01:31:02,633 WHY RARE DISEASE RESEARCH IS SO 2499 01:31:02,633 --> 01:31:04,067 IMPORTANT. 2500 01:31:04,067 --> 01:31:05,736 THIS IS A SLIDE THAT MANY OF 2501 01:31:05,736 --> 01:31:10,441 YOU MAY KNOW SOME OF THE 2502 01:31:10,441 --> 01:31:11,809 EFFECTS ON HERE. 2503 01:31:11,809 --> 01:31:15,646 THERE ARE NOW MORE THAN 10,000 2504 01:31:15,646 --> 01:31:17,181 RARE KNOWN DISEASES. 2505 01:31:17,181 --> 01:31:19,583 THIS IS A STAGGERING NUMBER. 2506 01:31:19,583 --> 01:31:20,884 WE DON'T KNOW HOW MANY 2507 01:31:20,884 --> 01:31:22,186 AMERICANS ARE AFFECTED. 2508 01:31:22,186 --> 01:31:24,121 WE KNOW IT'S MILLIONS. 2509 01:31:24,121 --> 01:31:25,489 MILLIONS OF AMERICANS ARE 2510 01:31:25,489 --> 01:31:26,123 AFFECTED BY RARE DISEASES EVERY 2511 01:31:26,123 --> 01:31:27,891 DAY. 2512 01:31:27,891 --> 01:31:29,393 ONLY 5% OF THOSE DISEASES HAVE 2513 01:31:29,393 --> 01:31:34,565 TREATMENT. 2514 01:31:34,565 --> 01:31:39,503 IT'S A HUGE UNMET NEED. 2515 01:31:39,503 --> 01:31:40,103 IT'S REALLY AN UNFATHOMABLE 2516 01:31:40,103 --> 01:31:41,138 UNMET NEED. 2517 01:31:41,138 --> 01:31:42,840 YOU PARTNER THAT WITH THE RIGHT 2518 01:31:42,840 --> 01:31:44,475 SIDE OF THE SLIDE, THE TIME 2519 01:31:44,475 --> 01:31:46,743 FROM EARLY DEVELOPMENT TO THE 2520 01:31:46,743 --> 01:31:47,344 MEDICINE CABINET TAKES 10-15ER 2521 01:31:47,344 --> 01:31:51,014 >>S. 2522 01:31:51,014 --> 01:31:53,851 -- YEARS. 2523 01:31:53,851 --> 01:31:56,987 AND NINE OUT OF TOUCHDOWN OF 2524 01:31:56,987 --> 01:31:58,689 THOSE PROMISING THERAPEUTIC 2525 01:31:58,689 --> 01:31:59,490 CANDIDATES THAT ENTER CLINICAL 2526 01:31:59,490 --> 01:32:00,924 TRIALS WILL FAIL. 2527 01:32:00,924 --> 01:32:02,426 WITH A TREMENDOUS NUMBER OF 2528 01:32:02,426 --> 01:32:05,863 RARE DISEASES WITH NO 2529 01:32:05,863 --> 01:32:07,130 THERAPEUTICS, A 10-15 TIMELINE 2530 01:32:07,130 --> 01:32:10,834 TO GET A CANDIDATE IN THE 2531 01:32:10,834 --> 01:32:11,768 MEDICINE CABINET AND 90% OF 2532 01:32:11,768 --> 01:32:14,371 THOSE WILL FAIL. 2533 01:32:14,371 --> 01:32:15,806 THIS SHOWS THE COMPOUNDING 2534 01:32:15,806 --> 01:32:18,909 PROBLEM WE HAVE IN RARE DISEASE 2535 01:32:18,909 --> 01:32:20,077 THERAPEUTIC DEVELOPMENT AND WHY 2536 01:32:20,077 --> 01:32:22,379 MORE RESEARCH IS NEEDED. 2537 01:32:22,379 --> 01:32:24,548 THEN WE ADD TO THAT, WHAT IS 2538 01:32:24,548 --> 01:32:25,883 THE BURDEN OF RARE DISEASES, 2539 01:32:25,883 --> 01:32:27,851 THIS IS REALLY JUST LOOKING AT 2540 01:32:27,851 --> 01:32:30,053 ECONOMIC BURDEN. 2541 01:32:30,053 --> 01:32:38,795 THIS SLIDE SHOWS WORK DONE LED 2542 01:32:38,795 --> 01:32:42,966 BY ANNIE KENNEDY. 2543 01:32:42,966 --> 01:32:45,269 THE EVERY LIFE FOUNDATION. 2544 01:32:45,269 --> 01:32:47,704 I LIKE THIS BECAUSE IT BREAKS 2545 01:32:47,704 --> 01:32:49,706 DOWN WHAT WAS LOOKED AT. 2546 01:32:49,706 --> 01:32:51,241 THEY LOOKED AT NOT ONLY DIRECT 2547 01:32:51,241 --> 01:32:52,843 MEDICAL COSTS, WHICH IS WHAT WE 2548 01:32:52,843 --> 01:32:55,279 MIGHT THINK OF WHEN WE THINK OF 2549 01:32:55,279 --> 01:32:57,548 A BURDEN OF A HEALTH CONDITION. 2550 01:32:57,548 --> 01:32:58,815 BUT ALSO THE INDIRECT COSTS. 2551 01:32:58,815 --> 01:33:01,218 SO THERE'S QUITE A BIT OF 2552 01:33:01,218 --> 01:33:02,352 PRODUCTIVITY LOST FOR 2553 01:33:02,352 --> 01:33:02,886 INDIVIDUAL WITH THE RARE 2554 01:33:02,886 --> 01:33:04,955 DISEASE. 2555 01:33:04,955 --> 01:33:06,990 BUT POTENTIALLY ALSO CARE 2556 01:33:06,990 --> 01:33:09,026 TAKERS OR THOSE AROUND THEM 2557 01:33:09,026 --> 01:33:10,127 HELPING THEM DURING THEIR RARE 2558 01:33:10,127 --> 01:33:11,929 DISEASE JOURNEY. 2559 01:33:11,929 --> 01:33:14,131 AS WELL AS NON-MEDICAL AND 2560 01:33:14,131 --> 01:33:15,365 UNCOVERED HEALTHCARE COSTS. 2561 01:33:15,365 --> 01:33:18,201 SO WHAT THEY FOUND WAS THAT THE 2562 01:33:18,201 --> 01:33:19,469 TOTAL ECONOMIC BURDEN OF RARE 2563 01:33:19,469 --> 01:33:23,106 DISEASE IN THE U.S. IN 2019 WAS 2564 01:33:23,106 --> 01:33:28,712 ALMOST A TRILLION DOLLARS. 2565 01:33:28,712 --> 01:33:30,747 SO WITH ALL THAT SAID, WE WANT 2566 01:33:30,747 --> 01:33:35,218 TO BRING THIS BACK TO NCATS AND 2567 01:33:35,218 --> 01:33:38,889 OUR ROLE. 2568 01:33:38,889 --> 01:33:42,292 THIS HAS A HOME AT NCATS, WILL 2569 01:33:42,292 --> 01:33:43,994 HEAR FROM MY COLLEAGUE, MATT 2570 01:33:43,994 --> 01:33:45,095 HALL WILL TALK ABOUT RARE 2571 01:33:45,095 --> 01:33:47,965 DISEASE WORK IN THEIR DIVISION. 2572 01:33:47,965 --> 01:33:50,534 IT REALLY SPANS ACROSS THE 2573 01:33:50,534 --> 01:33:56,740 NCATS DIVISION AND OFFICES. 2574 01:33:56,740 --> 01:33:59,376 WE CREATE OPPORTUNITIES TO BE 2575 01:33:59,376 --> 01:34:06,049 ABLE TO FUND INNOVATIVE 2576 01:34:06,049 --> 01:34:07,884 RESEARCH TO ACCELERATE MEDICAL 2577 01:34:07,884 --> 01:34:09,653 RESEARCH ACROSS RARE DISEASES. 2578 01:34:09,653 --> 01:34:12,656 I THINK WE WILL CONTINUE TO 2579 01:34:12,656 --> 01:34:14,024 HAVE INCREASINGLY HAVE ABILITY 2580 01:34:14,024 --> 01:34:17,027 TO DATA WE CAN USE. 2581 01:34:17,027 --> 01:34:19,896 BUT WE CREATE RESOURCES TO 2582 01:34:19,896 --> 01:34:20,964 EDUCATE, ENGAGE AND EMPOWER THE 2583 01:34:20,964 --> 01:34:23,934 RARE DISEASE COMMUNITY. 2584 01:34:23,934 --> 01:34:25,535 THE RARE DISEASE COMMUNITY IS, 2585 01:34:25,535 --> 01:34:29,172 I THINK UNIQUE IN THE DRUG 2586 01:34:29,172 --> 01:34:29,806 DEVELOPMENT ECOSYSTEM BECAUSE 2587 01:34:29,806 --> 01:34:32,676 THEY ARE OFTEN PART OF THE 2588 01:34:32,676 --> 01:34:35,912 SOLUTION, IF NOT THE DRIVERS OF 2589 01:34:35,912 --> 01:34:38,081 SOLUTIONS FOR RARE DISEASES. 2590 01:34:38,081 --> 01:34:41,118 IF WITH DON'T HAVE AN EDUCATED 2591 01:34:41,118 --> 01:34:42,119 AND EMPOWERED GROUP, IT'S GOING 2592 01:34:42,119 --> 01:34:43,920 TO BE HARD FOR THEM TO BRING 2593 01:34:43,920 --> 01:34:46,223 ABOUT THE SOLUTIONS IN THE MOST 2594 01:34:46,223 --> 01:34:47,758 EFFICIENT AND EFFECTIVE WAY. 2595 01:34:47,758 --> 01:34:48,358 WE REALLY PARTNER WITH OUR 2596 01:34:48,358 --> 01:34:55,632 COMMUNITY. 2597 01:34:55,632 --> 01:35:00,404 THIS SLIDE, I GIVE YOU OVERVIEW 2598 01:35:00,404 --> 01:35:03,440 OF THE RARE DISEASES THE DRDRI 2599 01:35:03,440 --> 01:35:05,242 INVEST IN. 2600 01:35:05,242 --> 01:35:06,243 WE BREAK IT DOWN INTO THREE 2601 01:35:06,243 --> 01:35:08,779 CATEGORIES. 2602 01:35:08,779 --> 01:35:09,279 THE PATIENT SUPPORT AND 2603 01:35:09,279 --> 01:35:10,881 INFORMATION. 2604 01:35:10,881 --> 01:35:11,348 FUNDING RESEARCH AND 2605 01:35:11,348 --> 01:35:12,516 DEVELOPMENT PROGRAMS. 2606 01:35:12,516 --> 01:35:13,450 AS WELL AS CONVENING AND 2607 01:35:13,450 --> 01:35:23,660 PARTNERING. 2608 01:35:26,129 --> 01:35:27,130 THIS NEXT SLIDE HIGHLIGHTS 2609 01:35:27,130 --> 01:35:28,198 WHICH ONES WE ARE GOING TO TALK 2610 01:35:28,198 --> 01:35:31,201 ABOUT TODAY. 2611 01:35:31,201 --> 01:35:32,402 SOME OF THEM BRIEFLY, SOME OF 2612 01:35:32,402 --> 01:35:39,276 THEM IN A LITTLE MORE DEPTH. 2613 01:35:39,276 --> 01:35:39,743 THERE ARE SIGNIFICANT 2614 01:35:39,743 --> 01:35:40,477 BOTTLENECKS. 2615 01:35:40,477 --> 01:35:42,079 SOME OF WHICH WE HAVE 2616 01:35:42,079 --> 01:35:43,513 IDENTIFIED AND SOME WE HAVE YET 2617 01:35:43,513 --> 01:35:46,016 TO IDENTIFY. 2618 01:35:46,016 --> 01:35:49,653 AT NCATS WE WORK TO ADDRESS 2619 01:35:49,653 --> 01:35:50,987 THOSE LONG STANDING BOTTLENECKS 2620 01:35:50,987 --> 01:35:52,622 TO GET TO THOSE NEW TREATMENTS 2621 01:35:52,622 --> 01:35:54,691 FOR ALL PEOPLE MORE QUICKLY. 2622 01:35:54,691 --> 01:35:55,959 OVER THESE NEXT FEW SLIDES I 2623 01:35:55,959 --> 01:36:00,263 WILL TALK ABOUT SOME OF THE 2624 01:36:00,263 --> 01:36:01,798 PROGRAMS THE DRDRI IS INVOLVED 2625 01:36:01,798 --> 01:36:03,533 IN TO TRY TO TACKLE THESE 2626 01:36:03,533 --> 01:36:13,744 BOTTLENECKS. 2627 01:36:14,711 --> 01:36:17,347 THIS IS THE IMPACT OF RARE 2628 01:36:17,347 --> 01:36:18,081 DISEASES ON PATIENTS IN 2629 01:36:18,081 --> 01:36:19,883 HEALTHCARE SYSTEMS. 2630 01:36:19,883 --> 01:36:23,820 THIS IS QUANTIFYING FINANCIAL 2631 01:36:23,820 --> 01:36:25,756 AND MEDICAL UTILIZATION AND 2632 01:36:25,756 --> 01:36:26,923 COSTS WITHIN FOUR DIFFERENT 2633 01:36:26,923 --> 01:36:32,496 HEALTHCARE SYSTEM DATABASES. 2634 01:36:32,496 --> 01:36:34,498 SO PRELIMINARY ANALYSIS FOR THE 2635 01:36:34,498 --> 01:36:35,766 PATIENTS. 2636 01:36:35,766 --> 01:36:38,568 THIS WAS A COLLABORATIVE EFFORT 2637 01:36:38,568 --> 01:36:41,705 THAT WAS BETWEEN NCATS INDUSTRY 2638 01:36:41,705 --> 01:36:43,840 AS WELL AS ACADEMIC 2639 01:36:43,840 --> 01:36:44,474 INSTITUTIONS AND INTERNATIONAL 2640 01:36:44,474 --> 01:36:46,510 HEALTHCARE COMPANIES. 2641 01:36:46,510 --> 01:36:48,445 THIS WAS REALLY NEAT BECAUSE IT 2642 01:36:48,445 --> 01:36:50,113 WAS CONDUCTED IN PARALLEL WITH, 2643 01:36:50,113 --> 01:36:53,049 BUT NOT HAVING KNOWLEDGE OF THE 2644 01:36:53,049 --> 01:36:54,651 WORK BEING DONE AT EVERY LIFE. 2645 01:36:54,651 --> 01:36:55,752 REALLY WE CAME UP WITH THE SAME 2646 01:36:55,752 --> 01:36:57,587 CONCLUSION. 2647 01:36:57,587 --> 01:36:58,088 THE METHODS WERE QUITE 2648 01:36:58,088 --> 01:36:59,890 DIFFERENT. 2649 01:36:59,890 --> 01:37:03,760 WE SELECTED 14 RARE DISEASES. 2650 01:37:03,760 --> 01:37:07,464 THEY SENT DISEASES THAT HAVE 2651 01:37:07,464 --> 01:37:09,866 IC9S AND 10 CODES WE CAN LOOK 2652 01:37:09,866 --> 01:37:10,400 AT THE ELECTRONIC HEALTH 2653 01:37:10,400 --> 01:37:11,501 RECORDS. 2654 01:37:11,501 --> 01:37:14,037 WE CAME TO THE SAME CONCLUSION. 2655 01:37:14,037 --> 01:37:15,272 WHICH REALLY LET'S US KNOW THAT 2656 01:37:15,272 --> 01:37:18,475 WE ARE IN THE RIGHT BALLPARK 2657 01:37:18,475 --> 01:37:20,911 FOR THE BURDEN OF DISEASE. 2658 01:37:20,911 --> 01:37:23,947 THE OTHER ASPECT THIS STUDY 2659 01:37:23,947 --> 01:37:25,982 LOOKED AT WAS THE RARE DISEASE 2660 01:37:25,982 --> 01:37:29,686 JOURNEY OF THE PATIENT. 2661 01:37:29,686 --> 01:37:30,921 AND THIS FIGURE HERE HIGHLIGHTS 2662 01:37:30,921 --> 01:37:35,058 WHAT YOU SEE ON THE LEFT IN THE 2663 01:37:35,058 --> 01:37:39,496 GRAY AREA IS THE COST. 2664 01:37:39,496 --> 01:37:41,698 YOU HAVE DOLLARS ON THEIR 2665 01:37:41,698 --> 01:37:42,766 MEDICAL JOURNEY BEFORE 2666 01:37:42,766 --> 01:37:44,768 DIAGNOSIS. 2667 01:37:44,768 --> 01:37:48,271 AND ON THE RIGHT IS THE COSTS 2668 01:37:48,271 --> 01:37:50,574 THAT WERE AFTER DIAGNOSIS. 2669 01:37:50,574 --> 01:37:52,209 THIS PARTICULAR PATIENT THAT WE 2670 01:37:52,209 --> 01:37:59,416 FOLLOWED IN THIS PATIENT 2671 01:37:59,416 --> 01:38:09,960 JOURNEY HAS A NEURODEGENERATIVE 2672 01:38:10,861 --> 01:38:13,363 DISEASE, CALLED BATTEN DISEASE. 2673 01:38:13,363 --> 01:38:14,431 HAVING THAT DIAGNOSIS HELPS 2674 01:38:14,431 --> 01:38:15,832 THEM TO BETTER UNDERSTAND AND 2675 01:38:15,832 --> 01:38:17,267 BETTER TREAT. 2676 01:38:17,267 --> 01:38:18,068 THIS HIGHLIGHTS HOW IMPORTANT 2677 01:38:18,068 --> 01:38:20,303 IT IS TO GET TO DIAGNOSIS. 2678 01:38:20,303 --> 01:38:21,004 THIS IS SOMETHING WE MENTIONED 2679 01:38:21,004 --> 01:38:24,007 EARLIER. 2680 01:38:24,007 --> 01:38:26,376 WE REALLY NEED TO BE ABLE TO 2681 01:38:26,376 --> 01:38:29,412 GET TO DIAGNOSIS EARLIER SO WE 2682 01:38:29,412 --> 01:38:31,081 CAN THEN APPLY TREATMENT 2683 01:38:31,081 --> 01:38:31,615 FASTER, MORE APPROPRIATE 2684 01:38:31,615 --> 01:38:34,651 TREATMENT FASTER. 2685 01:38:34,651 --> 01:38:38,255 AND THIS LEADS ME TO ANOTHER 2686 01:38:38,255 --> 01:38:40,257 INITIATIVE, ONE CALLED THE 2687 01:38:40,257 --> 01:38:44,928 SHORTENING DIAGNOSTIC ODYSSEY. 2688 01:38:44,928 --> 01:38:48,698 THIS IS A GRANT THAT ALICE 2689 01:38:48,698 --> 01:38:54,437 CHEN, I'M SORRY, I FORGOT TO 2690 01:38:54,437 --> 01:38:56,172 MENTION AINLAY TINSDALE THE 2691 01:38:56,172 --> 01:39:00,510 INITIATIVE AND ALICE CHEN IS 2692 01:39:00,510 --> 01:39:01,177 LEADING THE DIAGNOSTIC ODYSSEY 2693 01:39:01,177 --> 01:39:04,347 GRANT MECHANISM. 2694 01:39:04,347 --> 01:39:06,249 WE ASKED APPLICANTS TO USE 2695 01:39:06,249 --> 01:39:07,984 ANALYSIS IN CLINICAL APPROACHS 2696 01:39:07,984 --> 01:39:12,756 TO COME UP WITH SOLUTIONS TO 2697 01:39:12,756 --> 01:39:14,824 SHORTEN THE DIAGNOSTIC ODYSSEY. 2698 01:39:14,824 --> 01:39:17,394 HERE ARE THE THREE AWARDS MADE. 2699 01:39:17,394 --> 01:39:18,995 THEY ALL USE TECHNOLOGY 2700 01:39:18,995 --> 01:39:24,034 DIFFERENTLY TO CREATE SOLUTIONS. 2701 01:39:24,034 --> 01:39:27,671 AT RARE DISEASE DAY THIS YEAR, 2702 01:39:27,671 --> 01:39:33,343 THERE WAS A HIGHLIGHT BY DR. 2703 01:39:33,343 --> 01:39:38,381 LALANI ABOUT WHAT THEY ARE 2704 01:39:38,381 --> 01:39:41,751 USING, AS WELL AS DR. MULANI. 2705 01:39:41,751 --> 01:39:44,521 I WILL GO OVER WHAT DR. LALANI 2706 01:39:44,521 --> 01:39:48,024 SHOWED ME. 2707 01:39:48,024 --> 01:39:51,861 I ENCOURAGE YOU TO WATCH THE 2708 01:39:51,861 --> 01:39:53,163 RARE DISEASE WEBCAST TO HEAR 2709 01:39:53,163 --> 01:39:56,766 FROM BOTH OF THEM. 2710 01:39:56,766 --> 01:40:00,136 DR. LALANI'S PROJECT WAS CALLED 2711 01:40:00,136 --> 01:40:02,138 PROJECT GIVE, GENETIC INCLUSION 2712 01:40:02,138 --> 01:40:04,174 BY VIRTUAL EVALUATION FOR THE 2713 01:40:04,174 --> 01:40:08,912 RIO GRANDE VALLEY. 2714 01:40:08,912 --> 01:40:10,747 THE PROJECT GIVE TEAM WAS MADE 2715 01:40:10,747 --> 01:40:12,849 UP OF INDIVIDUALS ON THE BOTTOM 2716 01:40:12,849 --> 01:40:15,051 ROW COULD SEE INDIVIDUALS FROM 2717 01:40:15,051 --> 01:40:16,519 BAYLOR COLLEGE OF MEDICINE. 2718 01:40:16,519 --> 01:40:20,190 ON THE TOP YOU SEE THE 2719 01:40:20,190 --> 01:40:22,993 INDIVIDUALS THAT UNIVERSITY OF 2720 01:40:22,993 --> 01:40:25,095 TEXAS RIO GRANDE VALLEY. 2721 01:40:25,095 --> 01:40:26,363 THESE ARE PARTNERS THEY FOUND 2722 01:40:26,363 --> 01:40:27,998 IN THE LOCAL COMMUNITY WHO WERE 2723 01:40:27,998 --> 01:40:29,466 REALLY A CRITICAL PART OF THE 2724 01:40:29,466 --> 01:40:31,468 SUCCESS OF THIS PROJECT. 2725 01:40:31,468 --> 01:40:35,805 BECAUSE WHAT THEY RECOGNIZED IS 2726 01:40:35,805 --> 01:40:37,507 THAT THEY REALLY NEEDED LOCAL 2727 01:40:37,507 --> 01:40:40,243 INDIVIDUALS WITH WHOM THEY 2728 01:40:40,243 --> 01:40:42,278 COULD HELP TO BUILD COMPETENCE 2729 01:40:42,278 --> 01:40:46,850 AND EXPERTISE TO THEN ALLOW FOR 2730 01:40:46,850 --> 01:40:48,251 BETTER INTERACTION BETWEEN 2731 01:40:48,251 --> 01:40:54,891 POPULATION IN THE RIO GRANDE 2732 01:40:54,891 --> 01:40:55,825 VALLEY AND EXPERTISE THEY ARE 2733 01:40:55,825 --> 01:40:58,194 ABLE FOUGHT FORWARD. 2734 01:40:58,194 --> 01:40:59,362 THE RIO GRANDE VALLEY IN TEXAS, 2735 01:40:59,362 --> 01:41:02,265 AS YOU CAN SEE ON THE BOTTOM OF 2736 01:41:02,265 --> 01:41:05,802 THE MAP IS KIND OF AN AREA ON 2737 01:41:05,802 --> 01:41:07,704 THE SOUTHERN TIP OF TEXAS. 2738 01:41:07,704 --> 01:41:12,742 THIS IS REALLY AN AREA THAT HAS 2739 01:41:12,742 --> 01:41:15,812 A VERY HIGH HISPANIC POPULATION. 2740 01:41:15,812 --> 01:41:17,514 94% OF THE POPULATION IS 2741 01:41:17,514 --> 01:41:19,349 HISPANIC WITH A VERY HIGH 2742 01:41:19,349 --> 01:41:21,284 UNINSURED RATE AS WELL AS A 2743 01:41:21,284 --> 01:41:24,888 VERY HIGH POVERTY RATE. 2744 01:41:24,888 --> 01:41:27,657 THIS IS A MEDICALLY UNDERSERVED 2745 01:41:27,657 --> 01:41:28,458 AND SOCIOECONOMIC DISADVANTAGED 2746 01:41:28,458 --> 01:41:30,760 AREA WHERE THERE'S A LACK OF 2747 01:41:30,760 --> 01:41:32,095 EXPERTISE IN THE PROVIDERS AS 2748 01:41:32,095 --> 01:41:34,464 WELL AS LACK OF ACCESS. 2749 01:41:34,464 --> 01:41:37,567 THIS WAS AN AREA THEY WANTED TO 2750 01:41:37,567 --> 01:41:41,271 TARGET BECAUSE THE DISEASE RATE 2751 01:41:41,271 --> 01:41:45,208 234 RARE DISEASES WAS 2752 01:41:45,208 --> 01:41:46,476 NEGLIGIBLE BECAUSE THEY DIDN'T 2753 01:41:46,476 --> 01:41:48,144 HAVE ACCESS. 2754 01:41:48,144 --> 01:41:50,413 SO THE AIMS WERE TO REDUCE THE 2755 01:41:50,413 --> 01:41:53,516 TIME OF DIAGNOSIS. 2756 01:41:53,516 --> 01:41:55,051 TO USE A MACHINE-ASSISTED 2757 01:41:55,051 --> 01:41:56,853 VIRTUAL WEB-BASED SERVICE. 2758 01:41:56,853 --> 01:41:58,922 IT ALLOWED THEM TO USE 2759 01:41:58,922 --> 01:42:01,057 TECHNOLOGY TO REACH A 2760 01:42:01,057 --> 01:42:02,192 POPULATION THEY WOULDN'T HAVE 2761 01:42:02,192 --> 01:42:05,061 OTHERWISE BEEN ABLE TO REACH, 2762 01:42:05,061 --> 01:42:09,165 BUT USING LOCAL PROVIDERS. 2763 01:42:09,165 --> 01:42:14,804 THEY WANTED TO PROVIDE GENETIC 2764 01:42:14,804 --> 01:42:15,438 DIAGNOSIS THROUGH WHOLE GENOME 2765 01:42:15,438 --> 01:42:19,576 SEQUENCING. 2766 01:42:19,576 --> 01:42:21,644 BUILDING GENOMIC COMPETENCE TO 2767 01:42:21,644 --> 01:42:23,947 EXPEDITE THE REFERRALS. 2768 01:42:23,947 --> 01:42:25,849 AND THEY COULD GET ACCESS TO 2769 01:42:25,849 --> 01:42:26,583 THE PATIENTS TO PROVIDE SERVICE 2770 01:42:26,583 --> 01:42:30,720 TO THEM. 2771 01:42:30,720 --> 01:42:32,021 THIS SHOWS THEY HAVE TARGET 2772 01:42:32,021 --> 01:42:33,590 ENROLLMENT OF 100. 2773 01:42:33,590 --> 01:42:36,860 THEY WERE ABLE TO ROLL 115. 2774 01:42:36,860 --> 01:42:38,361 71 OF WHOM RECEIVED WHOLE 2775 01:42:38,361 --> 01:42:42,832 GENOME SEQUENCING RESULT. 2776 01:42:42,832 --> 01:42:44,601 THIS STUDY SHOWS DIAGNOSTICALLY 2777 01:42:44,601 --> 01:42:46,369 HAS BEEN 35%. 2778 01:42:46,369 --> 01:42:48,705 WHICH IS A SIGNIFICANT 2779 01:42:48,705 --> 01:42:51,574 DIAGNOSTIC RATE FOR INDIVIDUALS 2780 01:42:51,574 --> 01:42:53,810 WHO HAVE BEEN WITHOUT A 2781 01:42:53,810 --> 01:42:57,447 DIAGNOSIS THEIR ENTIRE LIVES. 2782 01:42:57,447 --> 01:42:59,048 AND THIS NEXT SLIDE SHOWS YOU 2783 01:42:59,048 --> 01:43:00,316 SOME OF THE FACES. 2784 01:43:00,316 --> 01:43:03,853 YOU SEE THESE ARE NOT JUST 2785 01:43:03,853 --> 01:43:05,421 NEWBORNS WHO ARE JUST, IT'S 2786 01:43:05,421 --> 01:43:10,093 BEEN DAYS SINCE THEY HAD THEIR 2787 01:43:10,093 --> 01:43:13,029 RARE DISEASES, IT'S INDIVIDUALS 2788 01:43:13,029 --> 01:43:14,030 LIVING UNDIAGNOSED, THEREFORE 2789 01:43:14,030 --> 01:43:16,232 NOT HAVING COMMUNITY OF 2790 01:43:16,232 --> 01:43:18,368 INDIVIDUALS THEY SHARE THEIR 2791 01:43:18,368 --> 01:43:19,369 DIAGNOSIS, NOT HAVING 2792 01:43:19,369 --> 01:43:22,138 TREATMENTS THAT ARE GEARED 2793 01:43:22,138 --> 01:43:25,942 TOWARDS THEIR DIAGNOSIS. 2794 01:43:25,942 --> 01:43:27,677 THIS PROGRAM REALLY HELPS TO 2795 01:43:27,677 --> 01:43:28,978 DEMONSTRATE HOW YOU CAN SOLVE 2796 01:43:28,978 --> 01:43:30,880 THIS ISSUE. 2797 01:43:30,880 --> 01:43:31,681 EVEN IN A MEDICALLY UNDERSERVED 2798 01:43:31,681 --> 01:43:35,818 AREA. 2799 01:43:35,818 --> 01:43:37,654 I HIGHLIGHT THIS ONE EXAMPLE 2800 01:43:37,654 --> 01:43:39,255 OF, YOU KNOW, WE HAVE MANY 2801 01:43:39,255 --> 01:43:40,890 EXCELLENT AWARDS. 2802 01:43:40,890 --> 01:43:43,526 BUT THIS IS JUST ONE EXAMPLE 2803 01:43:43,526 --> 01:43:47,564 THAT SHOWS A PROGRAM THAT USES 2804 01:43:47,564 --> 01:43:48,765 TECHNOLOGY, BUILDS TRUST WITH 2805 01:43:48,765 --> 01:43:51,100 THE COMMUNITY AND SHOWS HOW TO 2806 01:43:51,100 --> 01:43:54,204 MODEL THIS AND CREATE, REACH 2807 01:43:54,204 --> 01:43:54,904 OTHER MEDICALLY UNDERSERVED 2808 01:43:54,904 --> 01:43:58,408 AREAS IF THIS WERE TO BE 2809 01:43:58,408 --> 01:44:04,414 REPLICATED IN OTHER REGIONS. 2810 01:44:04,414 --> 01:44:06,716 SO MOVING ON TO OUR NEXT HURDLE. 2811 01:44:06,716 --> 01:44:08,084 WITH RARE DISEASES WE KNOW 2812 01:44:08,084 --> 01:44:08,818 THERE ARE SMALL NUMBERS OF 2813 01:44:08,818 --> 01:44:10,587 INDIVIDUALS. 2814 01:44:10,587 --> 01:44:14,724 WE KNOW THEY MAY BE -- IT'S 2815 01:44:14,724 --> 01:44:16,426 CHALLENGING TO COLLATE THE DATA 2816 01:44:16,426 --> 01:44:18,261 AND REALLY LEARN ENOUGH ABOUT 2817 01:44:18,261 --> 01:44:20,096 THESE DISEASES TO HAVE 2818 01:44:20,096 --> 01:44:22,498 EFFECTIVE CLINICAL TRIALS. 2819 01:44:22,498 --> 01:44:26,002 ONE OF THE PROGRAMS THAT'S OUR 2820 01:44:26,002 --> 01:44:30,273 FLAGSHIP IS THE RARE DISEASE 2821 01:44:30,273 --> 01:44:31,908 CLINICAL RESEARCH NETWORK. 2822 01:44:31,908 --> 01:44:34,844 THIS WAS ESTABLISHED BY THE 2823 01:44:34,844 --> 01:44:38,448 RARE DISEASES ACT OF 2002 AND 2824 01:44:38,448 --> 01:44:41,150 BEEN IN PLACE SINCE 2003. 2825 01:44:41,150 --> 01:44:43,953 IT'S BEEN JUST OVER 20 YEARS 2826 01:44:43,953 --> 01:44:45,989 SINCE THIS HAS BEEN IN PROCESS. 2827 01:44:45,989 --> 01:44:47,457 THIS WAS THE HIGHLIGHT OF OUR 2828 01:44:47,457 --> 01:44:49,659 UPDATE LAST YEAR. 2829 01:44:49,659 --> 01:44:51,561 THERE WAS A SIGNIFICANT AMOUNT 2830 01:44:51,561 --> 01:44:54,697 OF TIME SPENT ON THE RARE 2831 01:44:54,697 --> 01:44:55,798 DISEASES CLINICAL RESEARCH 2832 01:44:55,798 --> 01:44:57,200 CENTER OF EXCELLENCE LAST YEAR. 2833 01:44:57,200 --> 01:44:58,601 I WON'T GROW THROUGH THE 2834 01:44:58,601 --> 01:45:00,403 PROGRAM AND HOW IT RUNS BUT 2835 01:45:00,403 --> 01:45:04,507 REALLY JUST SOME HIGHLIGHTS. 2836 01:45:04,507 --> 01:45:06,776 THIS CURRENT CYCLE, THE RDCRN 2837 01:45:06,776 --> 01:45:09,345 CYCLE 4, 2019-2024, BECAUSE OF 2838 01:45:09,345 --> 01:45:10,513 THE COVID NO-COST EXTENSION 2839 01:45:10,513 --> 01:45:12,682 WOULD GO INTO 2025. 2840 01:45:12,682 --> 01:45:14,317 WHAT THIS HIGHLIGHTS IS THE 2841 01:45:14,317 --> 01:45:16,219 NUMBER OF RESEARCH GROUPS AND 2842 01:45:16,219 --> 01:45:18,087 MANY OF THE METRICS ON THE 2843 01:45:18,087 --> 01:45:21,257 DISEASES AND THEIR SUCCESSES. 2844 01:45:21,257 --> 01:45:23,092 SO THERE ARE 20 RESEARCH GROUPS. 2845 01:45:23,092 --> 01:45:25,695 EACH ONE OF THESE HAS TO STUDY 2846 01:45:25,695 --> 01:45:27,063 AT LEAST THREE DISEASES. 2847 01:45:27,063 --> 01:45:31,367 HERE WE TACKLE ONE OF THE 2848 01:45:31,367 --> 01:45:34,504 PROBLEMS. 2849 01:45:34,504 --> 01:45:35,938 ASKING THE RESEARCHERS TO STUDY 2850 01:45:35,938 --> 01:45:37,940 AT LEAST THREE DISEASES AT ONCE. 2851 01:45:37,940 --> 01:45:40,076 WE ARE ENCOURAGING THEM TO LOOK 2852 01:45:40,076 --> 01:45:41,444 AT WHAT'S COMMON AMONG THE 2853 01:45:41,444 --> 01:45:44,113 DISEASES SO THAT WE CAN GET TO 2854 01:45:44,113 --> 01:45:46,382 SOLUTIONS THAT WILL BE 2855 01:45:46,382 --> 01:45:47,016 APPLICABLE BEYOND JUST ONE 2856 01:45:47,016 --> 01:45:48,651 DISEASE AT A TIME. 2857 01:45:48,651 --> 01:45:50,987 ANOTHER KEY PART OF THIS IS THE 2858 01:45:50,987 --> 01:45:51,721 PATIENT ADVOCACY PARTNER. 2859 01:45:51,721 --> 01:45:54,724 LISTED HERE. 2860 01:45:54,724 --> 01:45:57,360 THERE ARE 170 PATIENT ADVOCACY 2861 01:45:57,360 --> 01:46:01,798 PARTNERS IN THIS CURRENT CYCLE. 2862 01:46:01,798 --> 01:46:03,333 ONE OF THE REQUIREMENT FOR THE 2863 01:46:03,333 --> 01:46:06,169 APPLICATION THEY HAVE TO ENGAGE 2864 01:46:06,169 --> 01:46:07,570 A PATIENT ADVOCACY GROUP IN 2865 01:46:07,570 --> 01:46:10,506 THEIR CONSORTIUM. 2866 01:46:10,506 --> 01:46:11,874 REALLY THE PATIENT ADVOCATE ARE 2867 01:46:11,874 --> 01:46:14,744 AN IMPORTANT PART OF THIS. 2868 01:46:14,744 --> 01:46:15,945 AND SIGNIFICANTLY CONTRIBUTE TO 2869 01:46:15,945 --> 01:46:19,248 THE RESEARCH THAT IS CONDUCTED 2870 01:46:19,248 --> 01:46:20,383 THROUGH THE RDCRN. 2871 01:46:20,383 --> 01:46:24,387 I WANT TO HIGHLIGHT THIS IS A 2872 01:46:24,387 --> 01:46:24,987 VERY CROSS-NIH COLLABORATIVE 2873 01:46:24,987 --> 01:46:27,056 PROJECT. 2874 01:46:27,056 --> 01:46:30,693 THERE ARE TEN INSTITUTES AND 2875 01:46:30,693 --> 01:46:32,595 CENTERS INVOLVED IN CURRENT 2876 01:46:32,595 --> 01:46:36,366 CYCLE OF THE RDCRN. 2877 01:46:36,366 --> 01:46:38,267 IN GETTING TO SOME OF THE 2878 01:46:38,267 --> 01:46:40,169 IMPACTS OF THIS, THIS SLIDE 2879 01:46:40,169 --> 01:46:42,171 HERE REALLY JUST HIGHLIGHTS ONE 2880 01:46:42,171 --> 01:46:44,340 OF THE TRANSLATIONAL IMPACTS. 2881 01:46:44,340 --> 01:46:45,975 I THINK JONI HAD MENTIONED THIS 2882 01:46:45,975 --> 01:46:50,113 EARLIER IN HER TALK. 2883 01:46:50,113 --> 01:46:51,280 IT IS EXCELLENT TO STUDY THESE 2884 01:46:51,280 --> 01:46:54,150 RARE DISEASES. 2885 01:46:54,150 --> 01:46:58,087 ALL OF THESE CONSORTIUM HAVE TO 2886 01:46:58,087 --> 01:47:00,623 CONDUCT A NATURAL HISTORY STUDY 2887 01:47:00,623 --> 01:47:02,625 WHICH ARE GETTING THEM READY 2888 01:47:02,625 --> 01:47:04,560 FOR CLINICAL TRIALS. 2889 01:47:04,560 --> 01:47:07,196 ULTIMATELY WHAT WE WANT ARE 2890 01:47:07,196 --> 01:47:07,864 TREATMENTS FOR INDIVIDUALS WITH 2891 01:47:07,864 --> 01:47:10,733 RARE DISEASE. 2892 01:47:10,733 --> 01:47:15,138 WHAT THE TABLE SHOWS IS THE 12 2893 01:47:15,138 --> 01:47:19,308 DIFFERENT FDA INDICATIONS THAT 2894 01:47:19,308 --> 01:47:21,344 HAVE BEEN FDA APPROVED FOR 11 2895 01:47:21,344 --> 01:47:23,146 DIFFERENT RARE DISEASES. 2896 01:47:23,146 --> 01:47:24,414 THESE WERE NOT SPONSORED BY 2897 01:47:24,414 --> 01:47:25,148 NCATS. 2898 01:47:25,148 --> 01:47:27,283 AS YOU CAN SEE THERE ARE 2899 01:47:27,283 --> 01:47:33,623 COMPANIES LISTED FOR THE 2900 01:47:33,623 --> 01:47:34,123 SPONSORS OF THESE DRUG 2901 01:47:34,123 --> 01:47:36,159 APPLICATIONS. 2902 01:47:36,159 --> 01:47:39,128 THE PIVOTAL PHASE 3 STUDIES ARE 2903 01:47:39,128 --> 01:47:40,830 ALSO NOT SPONSORED BY NCATS BUT 2904 01:47:40,830 --> 01:47:43,466 IT'S REALLY ALL THE WORK THAT 2905 01:47:43,466 --> 01:47:46,669 THE RDCRN DOES TO MAKE THESE 2906 01:47:46,669 --> 01:47:51,674 DISEASES TRIAL-READY, SO THEN 2907 01:47:51,674 --> 01:47:52,975 PHARMACEUTICAL COMPANIES CAN 2908 01:47:52,975 --> 01:47:56,145 COME AND SELECT THE DISEASES 2909 01:47:56,145 --> 01:47:57,847 THAT ALREADY HAVE THE STUDY, 2910 01:47:57,847 --> 01:48:00,450 HAVE THE OUTCOME MEASURES AND 2911 01:48:00,450 --> 01:48:03,085 MAY HAVE CONDUCTED EARLY 2912 01:48:03,085 --> 01:48:04,520 CLINICAL BASED TRIALS AND TAKE 2913 01:48:04,520 --> 01:48:05,721 IT ACROSS THE FINISH LINE. 2914 01:48:05,721 --> 01:48:07,256 THE OTHER THING I WANT TO 2915 01:48:07,256 --> 01:48:08,558 HIGHLIGHT ON THIS SLIDE, IF YOU 2916 01:48:08,558 --> 01:48:10,960 LOOK AT THE TIME LINE ON THE 2917 01:48:10,960 --> 01:48:12,695 APPROVED DATES ON THE RIGHT, 2918 01:48:12,695 --> 01:48:14,530 FIVE THESE HAVE BEEN IN THE 2919 01:48:14,530 --> 01:48:23,272 LAST YEAR PLUS. 2920 01:48:23,272 --> 01:48:25,241 IT BUILDS THE UNDERLYING 2921 01:48:25,241 --> 01:48:26,142 INFRASTRUCTURE FOR THESE 2922 01:48:26,142 --> 01:48:27,643 DISEASES THAT TAKE SIGNIFICANT 2923 01:48:27,643 --> 01:48:29,145 AMOUNT OF TIME TO DEVELOP SO 2924 01:48:29,145 --> 01:48:31,380 THEN THEY ARE READY TO HAVE 2925 01:48:31,380 --> 01:48:33,182 THESE PIVOTAL STUDIES. 2926 01:48:33,182 --> 01:48:35,818 I HOPE THIS IS REALLY JUST THE 2927 01:48:35,818 --> 01:48:38,354 TIP OF THE ICEBERG THAT AS EACH 2928 01:48:38,354 --> 01:48:40,890 ONE OF THESE RESEARCH GROUPS 2929 01:48:40,890 --> 01:48:42,225 CONTINUES TO ADVANCE THEIR 2930 01:48:42,225 --> 01:48:43,493 RESEARCH, BECAUSE THOUGH EACH 2931 01:48:43,493 --> 01:48:46,562 GET FIVE YEARS TO STUDY THESE 2932 01:48:46,562 --> 01:48:47,730 DISEASES, THIS NUMBER WILL 2933 01:48:47,730 --> 01:48:57,139 CONTINUE TO ACCELERATE AND WE 2934 01:48:57,139 --> 01:48:58,007 WILL CONTINUE TO SEE MORE 2935 01:48:58,007 --> 01:48:59,775 TREATMENTS. 2936 01:48:59,775 --> 01:49:01,377 YOU WANT TO HIGHLIGHT AND THIS 2937 01:49:01,377 --> 01:49:02,712 WAS TALKED ABOUT LAST YEAR 2938 01:49:02,712 --> 01:49:04,313 DURING THE BIG HIGHLIGHT BUT WE 2939 01:49:04,313 --> 01:49:06,115 ARE A LITTLE FURTHER ALONG IN 2940 01:49:06,115 --> 01:49:07,650 THIS PROCESS. 2941 01:49:07,650 --> 01:49:16,225 WE ARE WORKING CLOSELY WITH OUR 2942 01:49:16,225 --> 01:49:17,360 COLLEAGUES IN ITRB TO SHARE THE 2943 01:49:17,360 --> 01:49:19,362 DATA. 2944 01:49:19,362 --> 01:49:22,932 WHAT THIS WILL DO, IT TAKES THE 2945 01:49:22,932 --> 01:49:25,801 CONSENTED DATA FROM THE RDCRN 2946 01:49:25,801 --> 01:49:27,637 STUDY, IDENTIFIES T THE 2947 01:49:27,637 --> 01:49:28,905 COORDINATING CENTER PROVIDES 2948 01:49:28,905 --> 01:49:31,841 THE ASSURANCE OF DATA QUALITY, 2949 01:49:31,841 --> 01:49:33,776 DATA USE LIMITATIONS, MAKING 2950 01:49:33,776 --> 01:49:36,345 SURE DATA IS AVAILABLE AND THEN 2951 01:49:36,345 --> 01:49:39,282 DATA WILL BE PASSED ONTO THE 2952 01:49:39,282 --> 01:49:39,882 NIH IN THE SHARED DATA 2953 01:49:39,882 --> 01:49:41,484 ENVIRONMENT. 2954 01:49:41,484 --> 01:49:44,020 IT WILL BE GOVERNED THROUGH AN 2955 01:49:44,020 --> 01:49:46,022 NCAT STACK. 2956 01:49:46,022 --> 01:49:46,556 AND THEN AVAILABLE TO THE 2957 01:49:46,556 --> 01:49:47,423 PUBLIC. 2958 01:49:47,423 --> 01:49:49,258 THIS WILL BE REALLY A 2959 01:49:49,258 --> 01:49:50,359 TREMENDOUS RESOURCE FOR THE 2960 01:49:50,359 --> 01:49:53,696 PUBLIC TO HAVE ACCESS TO THE 2961 01:49:53,696 --> 01:49:58,434 DATA THAT'S BEEN COLLECTED 2962 01:49:58,434 --> 01:49:59,535 THROUGH THE RDCRN. 2963 01:49:59,535 --> 01:50:03,139 I WANT TO BRING YOUR ATTENTION 2964 01:50:03,139 --> 01:50:07,610 TO THE RDCRN WEBSITE. 2965 01:50:07,610 --> 01:50:09,845 YOU COULD GO TO 2966 01:50:09,845 --> 01:50:10,346 RAREDISEASESNETWORK.ORG. 2967 01:50:10,346 --> 01:50:10,980 DISEASES THAT ARE STUDIED AND 2968 01:50:10,980 --> 01:50:13,082 WORK THAT'S BEEN DONE. 2969 01:50:13,082 --> 01:50:15,184 THE A GREAT RESOURCE FOR 2970 01:50:15,184 --> 01:50:17,019 RESEARCHERS TO LOOK TO SEE WHAT 2971 01:50:17,019 --> 01:50:18,554 DISEASES ARE IN THERE AND 2972 01:50:18,554 --> 01:50:20,790 WHAT'S BEEN DONE, AND EVEN 2973 01:50:20,790 --> 01:50:21,457 PATIENTS AND PATIENT ADVOCATE 2974 01:50:21,457 --> 01:50:23,659 TO LEARN ABOUT IT. 2975 01:50:23,659 --> 01:50:26,195 FINALLY THE LAST THING I WILL 2976 01:50:26,195 --> 01:50:29,165 MENTION ABOUT THE RDCRN WE HAVE 2977 01:50:29,165 --> 01:50:30,766 A NOFO AVAILABLE. 2978 01:50:30,766 --> 01:50:35,371 THIS FOR THE NEXT CYCLE. 2979 01:50:35,371 --> 01:50:36,806 WE RECOMPETE EVERY FIVE YEARS. 2980 01:50:36,806 --> 01:50:39,842 SO THE DUE DATES ARE IN AUGUST 2981 01:50:39,842 --> 01:50:44,580 2024. 2982 01:50:44,580 --> 01:50:46,749 WE ENCOURAGE GROUPS TO THINK 2983 01:50:46,749 --> 01:50:48,417 ABOUT YOUR CONSORTIUM AND HOW 2984 01:50:48,417 --> 01:50:50,853 TO FIND DISEASES THAT HAVE 2985 01:50:50,853 --> 01:50:51,554 COMMONALITIES AND PUT FORTH AN 2986 01:50:51,554 --> 01:50:54,890 APPLICATION. 2987 01:50:54,890 --> 01:50:56,559 THROUGH THE QR CODE GET MORE 2988 01:50:56,559 --> 01:50:57,393 INFORMATION ABOUT THE 2989 01:50:57,393 --> 01:50:59,061 APPLICATION, AND THERE'S A 2990 01:50:59,061 --> 01:51:00,129 TECHNICAL ASSISTANCE WEBINAR 2991 01:51:00,129 --> 01:51:07,603 THAT WILL BE JUNE 3rd. 2992 01:51:07,603 --> 01:51:10,539 ANOTHER WAY WE WORK TO CREATE 2993 01:51:10,539 --> 01:51:11,641 SOLUTIONS FOCUSING ON MORE THAN 2994 01:51:11,641 --> 01:51:16,012 ONE DISEASE AT A TIME IS FOCUS 2995 01:51:16,012 --> 01:51:19,615 ON GROUND BREAKING GENETIC 2996 01:51:19,615 --> 01:51:20,950 APPROACHES, AS MARK MENTIONED 2997 01:51:20,950 --> 01:51:23,519 EARLIER THAT ARE REALLY 2998 01:51:23,519 --> 01:51:25,187 AMENABLE TO BEING MORE 2999 01:51:25,187 --> 01:51:26,922 STREAMLINED AND MORE BROADLY 3000 01:51:26,922 --> 01:51:28,624 APPLICABLE. 3001 01:51:28,624 --> 01:51:32,061 RARE DISEASES, THE DATA SHOW 3002 01:51:32,061 --> 01:51:34,497 ABOUT 70-80% OF RARE DISEASES 3003 01:51:34,497 --> 01:51:36,265 ARE CAUSED BY GENE MUTATIONS 3004 01:51:36,265 --> 01:51:38,434 WHICH ARE VARIANT. 3005 01:51:38,434 --> 01:51:41,837 SO THEREFORE USING GENETIC 3006 01:51:41,837 --> 01:51:45,508 APPROACHES MAY BE RELEVANT TO A 3007 01:51:45,508 --> 01:51:46,075 SIGNIFICANT NUMBER OF RARE 3008 01:51:46,075 --> 01:51:47,343 DISEASES. 3009 01:51:47,343 --> 01:51:48,344 I WILL SHOW THREE DIFFERENT 3010 01:51:48,344 --> 01:51:49,311 PROGRAMS. 3011 01:51:49,311 --> 01:51:52,782 ALTHOUGH THE FIRST ONE I WILL 3012 01:51:52,782 --> 01:51:59,655 ONLY SHOW YOU THIS SLIDE. 3013 01:51:59,655 --> 01:52:00,189 THE PLATFORM VECTOR GENE 3014 01:52:00,189 --> 01:52:01,457 THERAPY. 3015 01:52:01,457 --> 01:52:03,492 DR. MATT HALL WILL TALK ABOUT 3016 01:52:03,492 --> 01:52:06,796 THIS IN MORE DETAIL DURING HIS 3017 01:52:06,796 --> 01:52:07,129 PRESENTATION. 3018 01:52:07,129 --> 01:52:09,165 I WANTED TO HIGHLIGHT HOW THIS 3019 01:52:09,165 --> 01:52:14,470 IS AN EXAMPLE WHERE WE WORK SO 3020 01:52:14,470 --> 01:52:15,671 CLOSELY WITHIN THE NCATS 3021 01:52:15,671 --> 01:52:17,406 ECOSYSTEM. 3022 01:52:17,406 --> 01:52:18,040 MANY DIVISIONS AND OFFICES ARE 3023 01:52:18,040 --> 01:52:19,075 INVOLVED. 3024 01:52:19,075 --> 01:52:21,043 YOU COULD SEE THE DIFFERENT 3025 01:52:21,043 --> 01:52:22,311 FACES, COMING FROM DIFFERENT 3026 01:52:22,311 --> 01:52:24,380 DIVISIONS AND OFFICES. 3027 01:52:24,380 --> 01:52:26,415 NOT JUST NCATS WE ALSO WORK 3028 01:52:26,415 --> 01:52:28,417 WITH OTHER NIH INSTITUTES. 3029 01:52:28,417 --> 01:52:29,919 I THINK THIS REALLY 3030 01:52:29,919 --> 01:52:30,986 DEMONSTRATES IT, IT TAKES BROAD 3031 01:52:30,986 --> 01:52:33,789 EXPERTISE. 3032 01:52:33,789 --> 01:52:37,026 IT HAS TO BE INDIVIDUALS THAT 3033 01:52:37,026 --> 01:52:38,027 BRING DIFFERENT EXPERTISE TO 3034 01:52:38,027 --> 01:52:41,263 THE TABLE TO BE ABLE TO CREATE 3035 01:52:41,263 --> 01:52:41,764 SOLUTIONS THAT WILL BE 3036 01:52:41,764 --> 01:52:42,965 TRANSFORMATIVE. 3037 01:52:42,965 --> 01:52:48,804 SO I WILL LET DR. HALL TELL YOU 3038 01:52:48,804 --> 01:52:50,840 MORE ABOUT PAYGT. 3039 01:52:50,840 --> 01:52:56,746 I WILL TALK MORE ABOUT TALKING 3040 01:52:56,746 --> 01:53:01,717 ABOUT THE BESPOKE GENE THERAPY 3041 01:53:01,717 --> 01:53:04,286 CONSORTIUM. 3042 01:53:04,286 --> 01:53:06,088 THIS IS A PUBLIC PRIVATE 3043 01:53:06,088 --> 01:53:08,624 PARTNERSHIP THAT IS LED BY 3044 01:53:08,624 --> 01:53:10,659 NCATS AND COORDINATED THROUGH 3045 01:53:10,659 --> 01:53:13,262 THE FOUNDATION OF NATIONAL 3046 01:53:13,262 --> 01:53:14,897 INSTITUTES OF HEALTH OR FNIH. 3047 01:53:14,897 --> 01:53:17,299 THIS IS FROM THE PUBLIC SECTOR 3048 01:53:17,299 --> 01:53:22,271 AS WELL AS NUMERATOR PRIVATE 3049 01:53:22,271 --> 01:53:27,209 SECTORS AND NONPROFITS AS WELL. 3050 01:53:27,209 --> 01:53:29,612 IT'S TO STREAMLINE THE 3051 01:53:29,612 --> 01:53:31,046 FRAMEWORK TO ACCELERATE GENE 3052 01:53:31,046 --> 01:53:33,249 THERAPIES FOR RARE DISEASES. 3053 01:53:33,249 --> 01:53:35,584 ULTIMATELY WE WANT THIS TO BE A 3054 01:53:35,584 --> 01:53:36,786 PLATFORM WHERE LEARNINGS ARE 3055 01:53:36,786 --> 01:53:40,523 SHARED ACROSS COMMUNITY WHERE 3056 01:53:40,523 --> 01:53:42,758 WE ARE IMPROVING THE PROCESS, 3057 01:53:42,758 --> 01:53:45,094 SHARING THEM WITH THE COMMUNITY 3058 01:53:45,094 --> 01:53:47,997 SO THAT FUTURE SPONSORS, IT'S 3059 01:53:47,997 --> 01:53:49,031 DE-RISKED AND POTENTIALLY, 3060 01:53:49,031 --> 01:53:50,432 KNOW, AS PETER MARKS WAS 3061 01:53:50,432 --> 01:53:53,068 SAYING, YOU KNOW, A LOT OF 3062 01:53:53,068 --> 01:53:53,969 EFFICIENCIES HAVE BEEN WORKED 3063 01:53:53,969 --> 01:53:55,571 OUT AND SHARED SO THEY CAN 3064 01:53:55,571 --> 01:53:58,174 BENEFIT FROM THE LEARNING OF 3065 01:53:58,174 --> 01:54:02,945 THIS GENE THERAPY CONSORTIUM. 3066 01:54:02,945 --> 01:54:05,981 AND P.J. BROOKS AND JAMES FROM 3067 01:54:05,981 --> 01:54:08,417 DRDRI LEAD THIS PROGRAM. 3068 01:54:08,417 --> 01:54:11,554 ONE OF THE WAYS WE ARE SHARING 3069 01:54:11,554 --> 01:54:13,689 LEARNINGS IS BY CREATING A 3070 01:54:13,689 --> 01:54:15,558 PLAYBOOK. 3071 01:54:15,558 --> 01:54:17,092 THE VERSION 1.0 WAS JUST 3072 01:54:17,092 --> 01:54:20,729 RELEASED THIS YEAR AT THE 3073 01:54:20,729 --> 01:54:21,263 ACCELERATING PARTNERSHIP 3074 01:54:21,263 --> 01:54:23,098 MEETING. 3075 01:54:23,098 --> 01:54:25,467 BY LEVERAGING THE UP TO EIGHT 3076 01:54:25,467 --> 01:54:29,004 CLINICAL TRIALS THAT WILL BE 3077 01:54:29,004 --> 01:54:30,940 PERFORMED, CONDUCTED IN THE 3078 01:54:30,940 --> 01:54:33,275 BGTC, THE COMBINED EXPERTISE OF 3079 01:54:33,275 --> 01:54:35,878 ALL THE CONSORTIUM MEMBERS, WE 3080 01:54:35,878 --> 01:54:37,313 DEVELOPED THIS PLAYBOOK FOR 3081 01:54:37,313 --> 01:54:38,414 STREAMLINING THIS PRODUCT 3082 01:54:38,414 --> 01:54:40,249 DEVELOPMENT AND REGULATION OF 3083 01:54:40,249 --> 01:54:42,218 THE REGULATORY PATHWAY FOR 3084 01:54:42,218 --> 01:54:48,023 THESE AAV GENE THERAPY. 3085 01:54:48,023 --> 01:54:49,825 THE REGULATORY PLAYBOOK IS TO 3086 01:54:49,825 --> 01:54:51,126 ACT AS AN OPERATIONAL GUIDE 3087 01:54:51,126 --> 01:54:52,661 WITH TOOLS TO EMBARK ON THE 3088 01:54:52,661 --> 01:54:55,097 REGULATORY PROCESS. 3089 01:54:55,097 --> 01:54:58,534 PART OF WHY I MENTION THE PAYGT 3090 01:54:58,534 --> 01:55:01,670 IS THE LEARNINGS WE HAVE FROM 3091 01:55:01,670 --> 01:55:02,271 THESE PROGRAMS ACTUALLY HELP 3092 01:55:02,271 --> 01:55:03,672 EACH OTHER. 3093 01:55:03,672 --> 01:55:07,176 THE ORGANIZATION SECTION OF THE 3094 01:55:07,176 --> 01:55:08,544 PLAYBOOK SECTION 1.0 CAME FROM 3095 01:55:08,544 --> 01:55:09,812 OUR LEARNINGS. 3096 01:55:09,812 --> 01:55:12,348 WE LEARN FROM THE DIFFERENT 3097 01:55:12,348 --> 01:55:15,384 PROGRAMS AND APPLY THEM TO 3098 01:55:15,384 --> 01:55:19,054 CREATE EFFICIENCIES. 3099 01:55:19,054 --> 01:55:20,789 BGTC WILL CONTINUE TO ITERATE 3100 01:55:20,789 --> 01:55:22,758 AND CREATE NEW VERSIONS OF THE 3101 01:55:22,758 --> 01:55:24,260 PLAYBOOK AS WE GET FURTHER 3102 01:55:24,260 --> 01:55:25,561 ALONG THE PROCESS AND HAVE MORE 3103 01:55:25,561 --> 01:55:27,730 LEARNINGS TO SHARE. 3104 01:55:27,730 --> 01:55:29,365 I ENCOURAGE INDIVIDUALS TO 3105 01:55:29,365 --> 01:55:31,867 FOLLOW ALONG IN THE PLAYBOOK BY 3106 01:55:31,867 --> 01:55:32,601 LEARNING HOW TO IMPROVE THE 3107 01:55:32,601 --> 01:55:34,470 PROCESS. 3108 01:55:34,470 --> 01:55:35,771 THE FINAL GENETIC TECHNOLOGY I 3109 01:55:35,771 --> 01:55:38,707 WILL TALK ABOUT IS IN OUR 3110 01:55:38,707 --> 01:55:40,075 PROGRAM THAT SOMATOIC CELL 3111 01:55:40,075 --> 01:55:43,178 GENOME EDITING PROGRAM. 3112 01:55:43,178 --> 01:55:48,050 NOW THIS IS A PROGRAM THAT IS 3113 01:55:48,050 --> 01:55:52,154 CO-LED BY NIH COMMON FUND AND 3114 01:55:52,154 --> 01:55:54,189 NCATS AND NINDS. 3115 01:55:54,189 --> 01:55:58,127 THIS AIMS TO REDUCE THE BURDEN 3116 01:55:58,127 --> 01:55:59,962 OF CHANGE CAUSED BY GENETIC 3117 01:55:59,962 --> 01:56:06,802 CHANGES. 3118 01:56:06,802 --> 01:56:10,973 FY18-FY23 THE GOAL WAS TO 3119 01:56:10,973 --> 01:56:13,175 IMPROVE EFFICACY AND 3120 01:56:13,175 --> 01:56:13,776 SPECIFICITY OF GENOME EDITING 3121 01:56:13,776 --> 01:56:18,314 APPROACHES. 3122 01:56:18,314 --> 01:56:20,683 PERFORM AND ASSESS EFFECTIVE 3123 01:56:20,683 --> 01:56:21,750 GENOME EDITING TOOLS IN 3124 01:56:21,750 --> 01:56:25,921 SOMATOIC CELLS. 3125 01:56:25,921 --> 01:56:28,357 AND THEN THIS IS WHERE WE ALL 3126 01:56:28,357 --> 01:56:32,061 REALLY WANT TO BE, PHASE 2. 3127 01:56:32,061 --> 01:56:33,996 P.J. BROOKS AND LINDA HO FROM 3128 01:56:33,996 --> 01:56:41,570 MY DIVISION LEADS THIS PROGRAM. 3129 01:56:41,570 --> 01:56:51,380 DID I LOSE MY SLIDES? 3130 01:56:51,380 --> 01:56:55,384 WHAT I WAS GOING TO SHOW YOU, 3131 01:56:55,384 --> 01:56:57,219 THERE'S A TARGETED GENOME 3132 01:56:57,219 --> 01:56:58,354 EDITOR PRIZE, CALLED TARGETED 3133 01:56:58,354 --> 01:57:04,660 THAT IS CURRENTLY OUT. 3134 01:57:04,660 --> 01:57:07,396 THIS PRIZE CHALLENGE DELIVERING 3135 01:57:07,396 --> 01:57:16,271 GENOME EDITORS TO THESE SOMATIC. 3136 01:57:16,271 --> 01:57:17,973 ONE IS PROGRAMABLE DELIVERY 3137 01:57:17,973 --> 01:57:19,475 SYSTEMS FOR GENOME EDITING IN 3138 01:57:19,475 --> 01:57:24,146 DIFFERENT ORGANS AND CELLS. 3139 01:57:24,146 --> 01:57:24,780 TWO, HIGHLY EFFICIENT NON-VIRAL 3140 01:57:24,780 --> 01:57:25,481 DELIVERY. 3141 01:57:25,481 --> 01:57:26,982 LET ME SEE IF I CAN FIND. 3142 01:57:26,982 --> 01:57:31,520 HERE WE GO. 3143 01:57:31,520 --> 01:57:33,455 HIGHLY EFFICIENT NON VIRAL 3144 01:57:33,455 --> 01:57:34,256 DELIVERY ACROSS THE BLOOD BRAIN 3145 01:57:34,256 --> 01:57:35,691 BARRIER. 3146 01:57:35,691 --> 01:57:38,627 THIS SPEAKS TO WHAT YOU BROUGHT 3147 01:57:38,627 --> 01:57:40,029 UP EARLIER, ANNIE KENNEDY, 3148 01:57:40,029 --> 01:57:41,363 THERE ARE INDIVIDUALS WHO MAY 3149 01:57:41,363 --> 01:57:43,665 NOT BE ABLE TO USE AAV. 3150 01:57:43,665 --> 01:57:47,202 AV MAY NOT BE THE BEST DELIVERY 3151 01:57:47,202 --> 01:57:48,504 SYSTEM BECAUSE OF PREEXISTING 3152 01:57:48,504 --> 01:57:50,672 IMMUNITY OR OTHER REASONS. 3153 01:57:50,672 --> 01:57:53,642 SO TARGET AREA II OF THIS PRIZE 3154 01:57:53,642 --> 01:57:55,377 CHALLENGE WAS TO IDENTIFY NON 3155 01:57:55,377 --> 01:57:57,913 VIRAL DELIVERY THAT COULD CROSS 3156 01:57:57,913 --> 01:58:00,249 THE BLOOD-BRAIN BARRIER. 3157 01:58:00,249 --> 01:58:02,117 SO PHASE ONE, THIS IS A 3158 01:58:02,117 --> 01:58:05,654 MULTI-PHASE AWARD. 3159 01:58:05,654 --> 01:58:08,924 PHASE ONE HAS COMPLETED, THERE 3160 01:58:08,924 --> 01:58:10,759 WERE 30 WINNERS ACROSS THE TWO 3161 01:58:10,759 --> 01:58:13,362 DIFFERENT TARGET AREAS. 3162 01:58:13,362 --> 01:58:14,596 SUBMISSION DEADLINE IN JANUARY 3163 01:58:14,596 --> 01:58:24,740 OF 2025. 3164 01:58:27,776 --> 01:58:28,644 THIS WILL WORK TO CREATE 3165 01:58:28,644 --> 01:58:31,647 SOLUTIONS. 3166 01:58:31,647 --> 01:58:34,950 I'M GOING TO CLOSE TALKING 3167 01:58:34,950 --> 01:58:35,451 ABOUT OUR CONVENING AND 3168 01:58:35,451 --> 01:58:37,286 PARTNERING. 3169 01:58:37,286 --> 01:58:39,588 WHERE WE KNOW IT TAKES MULTIPLE 3170 01:58:39,588 --> 01:58:41,056 DIFFERENT STAKEHOLDERS. 3171 01:58:41,056 --> 01:58:42,858 AND WE NEED TO ENGAGE THEM ALL 3172 01:58:42,858 --> 01:58:45,894 AND BRING THEM TOGETHER IN 3173 01:58:45,894 --> 01:58:48,430 ORDER TO CREATE NEW SOLUTIONS. 3174 01:58:48,430 --> 01:58:50,265 YOU WILL HIGHLIGHT TWO RECENT 3175 01:58:50,265 --> 01:58:50,866 CONFERENCES AND WORKSHOPS WE 3176 01:58:50,866 --> 01:58:53,969 HAVE HAD. 3177 01:58:53,969 --> 01:58:55,304 SO ONE WAS ABOUT TEN DAYS AGO 3178 01:58:55,304 --> 01:58:56,972 NOW. 3179 01:58:56,972 --> 01:58:58,407 WE WORKED WITH OUR COLLEAGUES 3180 01:58:58,407 --> 01:58:59,541 AT THE FDA. 3181 01:58:59,541 --> 01:59:01,043 THE RARE DISEASE TEAM FOR 3182 01:59:01,043 --> 01:59:03,378 CENTER FOR DRUG EVALUATION AND 3183 01:59:03,378 --> 01:59:05,814 RESEARCH TO PUT TOGETHER THIS 3184 01:59:05,814 --> 01:59:06,715 NATURAL HISTORY STUDIES AND 3185 01:59:06,715 --> 01:59:08,150 REGISTRIS IN THE DEVELOPMENT OF 3186 01:59:08,150 --> 01:59:11,019 RARE DISEASE TREATMENTS. 3187 01:59:11,019 --> 01:59:15,124 THIS WAS A HYBRID WORKSHOP THAT 3188 01:59:15,124 --> 01:59:16,391 THE FOUNDATION HELPED TO CO-RUN 3189 01:59:16,391 --> 01:59:18,026 WITH US. 3190 01:59:18,026 --> 01:59:20,062 THIS WAS AN EXAMPLE HOW WE CAN 3191 01:59:20,062 --> 01:59:21,763 WORK TO EDUCATE THE COMMUNITY. 3192 01:59:21,763 --> 01:59:25,167 NOT ONLY THE PATIENTS AND 3193 01:59:25,167 --> 01:59:26,835 ADVOCATE WHO ARE OFTEN THE ONES 3194 01:59:26,835 --> 01:59:28,537 TRYING TO LEAD THE DEVELOPMENT. 3195 01:59:28,537 --> 01:59:32,641 SOMETIMES THEY ARE THE ONES 3196 01:59:32,641 --> 01:59:36,311 THAT ARE FUNDING AND RUNNING 3197 01:59:36,311 --> 01:59:38,413 THE REGISTRIES AS WELL AS 3198 01:59:38,413 --> 01:59:39,748 RESEARCHERS OR SPONSORS WHO 3199 01:59:39,748 --> 01:59:40,883 REALLY NEED TO UNDERSTAND WHAT 3200 01:59:40,883 --> 01:59:46,388 IS THE BEST WAY TO COLLECT DATA 3201 01:59:46,388 --> 01:59:47,956 TO USE IT FOR REGULATORY 3202 01:59:47,956 --> 01:59:49,625 PURPOSES. 3203 01:59:49,625 --> 01:59:51,660 IT'S ONE THING TO COLLECT 3204 01:59:51,660 --> 01:59:53,362 NATURAL HISTORY STUDIES DATA TO 3205 01:59:53,362 --> 01:59:55,063 LEARN ABOUT RARE DISEASES FROM 3206 01:59:55,063 --> 01:59:56,532 A CLINICAL CARE PERSPECTIVE. 3207 01:59:56,532 --> 01:59:58,834 AND DIFFERENT IF YOU WANT TO 3208 01:59:58,834 --> 02:00:00,102 USE IT FOR REGULATORY PURPOSES, 3209 02:00:00,102 --> 02:00:01,036 THERE ARE CONSIDERATIONS YOU 3210 02:00:01,036 --> 02:00:03,272 HAVE TO TAKE IN ORDER TO MAKE 3211 02:00:03,272 --> 02:00:04,640 SURE IT COULD BE USED IN THE 3212 02:00:04,640 --> 02:00:06,008 WAY YOU ARE INTENDING. 3213 02:00:06,008 --> 02:00:08,143 SO ONE OF THE THEMES THAT CAME 3214 02:00:08,143 --> 02:00:09,411 OUT THERE WAS START WITH THE 3215 02:00:09,411 --> 02:00:10,646 END IN MIND. 3216 02:00:10,646 --> 02:00:11,246 SOMETIMES YOU DON'T KNOW THE 3217 02:00:11,246 --> 02:00:12,581 END. 3218 02:00:12,581 --> 02:00:15,384 BUT CERTAINLY IF YOU ARE 3219 02:00:15,384 --> 02:00:16,418 THINKING ABOUT THERAPEUTIC 3220 02:00:16,418 --> 02:00:18,220 DEVELOPMENT, WHAT WAS DISCUSSED 3221 02:00:18,220 --> 02:00:21,356 IN THIS WORKSHOP, I THINK, 3222 02:00:21,356 --> 02:00:23,492 REALLY HELPED TO HIGHLIGHT WHAT 3223 02:00:23,492 --> 02:00:25,194 THE KEY FACTORS ARE THAT NEED 3224 02:00:25,194 --> 02:00:27,663 TO GO INTO DEVELOPING THE 3225 02:00:27,663 --> 02:00:29,665 NATURAL HISTORY STUDY REGISTRY. 3226 02:00:29,665 --> 02:00:32,768 AT THE CONFERENCE THERE WERE 3227 02:00:32,768 --> 02:00:35,204 ABOUT 230 INDIVIDUALS 3228 02:00:35,204 --> 02:00:37,573 REGISTERED IN PERSON AND ABOUT 3229 02:00:37,573 --> 02:00:38,540 3,000 VIRTUAL REGISTRANTS. 3230 02:00:38,540 --> 02:00:39,708 THIS IS QUITE A BIT OF NEED AND 3231 02:00:39,708 --> 02:00:41,043 INTEREST. 3232 02:00:41,043 --> 02:00:42,878 I WILL CLOSE OUT WITH TALKING 3233 02:00:42,878 --> 02:00:44,980 ABOUT OUR RARE DISEASE DAY. 3234 02:00:44,980 --> 02:00:46,582 BECAUSE THIS IS ONE OF MY 3235 02:00:46,582 --> 02:00:51,119 FAVORITE DAYS. 3236 02:00:51,119 --> 02:00:52,588 BEFORE I WAS IN MY ROLE BEFORE 3237 02:00:52,588 --> 02:00:55,123 I STARTED IN SEPTEMBER. 3238 02:00:55,123 --> 02:00:58,760 I USED TO ATTEND ON THE OTHER 3239 02:00:58,760 --> 02:00:59,928 SIDE, PATIENT ADVOCATE SIDE, 3240 02:00:59,928 --> 02:01:02,397 I'M A MOTHER OF AN INDIVIDUAL 3241 02:01:02,397 --> 02:01:04,299 WHO LIVES WITH A RARE DISEASE. 3242 02:01:04,299 --> 02:01:06,435 WHAT I LOVE ABOUT OUR RARE 3243 02:01:06,435 --> 02:01:07,269 DISEASE DAY IS COMMUNITY IT 3244 02:01:07,269 --> 02:01:09,905 BRINGSES TOGETHER. 3245 02:01:09,905 --> 02:01:12,274 IT IS PALPABLE, YOU ARE IN THE 3246 02:01:12,274 --> 02:01:13,875 ROOM AND SURROUNDED BY PEOPLE 3247 02:01:13,875 --> 02:01:15,711 THAT WANT TO BE THERE AND WANT 3248 02:01:15,711 --> 02:01:17,546 TO BE PART OF A COMMUNITY AND 3249 02:01:17,546 --> 02:01:24,219 WANT TO BE PART OF THE SOLUTION. 3250 02:01:24,219 --> 02:01:27,956 THESE PHOTOS, WHILE JUST STILL 3251 02:01:27,956 --> 02:01:29,391 SHOTS CAN'T CAPTURE THE 3252 02:01:29,391 --> 02:01:29,992 ENTHUSIASM AND EXCITEMENT IN 3253 02:01:29,992 --> 02:01:31,393 THERE. 3254 02:01:31,393 --> 02:01:32,327 IT HIGHLIGHTS HOW ENGAGED THIS 3255 02:01:32,327 --> 02:01:36,064 COMMUNITY IS. 3256 02:01:36,064 --> 02:01:38,200 WE HAVE ABOUT 600 INDIVIDUALS, 3257 02:01:38,200 --> 02:01:44,539 IN-PERSON ATTENDANTS AND I 3258 02:01:44,539 --> 02:01:46,675 THINK ABOUT 1300 VIRTUALLY. 3259 02:01:46,675 --> 02:01:49,678 WE KNOW NOT EVERYONE CAN TRAVEL 3260 02:01:49,678 --> 02:01:50,512 IN, ESPECIALLY WITH MEDICAL 3261 02:01:50,512 --> 02:01:52,414 DISEASES THEY MAY NOT BE ABLE 3262 02:01:52,414 --> 02:01:55,284 TO, OR A CAREGIVER OF A CHILD 3263 02:01:55,284 --> 02:01:58,487 WHO CAN'T LEAVE. 3264 02:01:58,487 --> 02:02:00,055 THROUGH OUR HYBRID VIRTUAL 3265 02:02:00,055 --> 02:02:02,457 PLATFORM IT ALLOWS INTERACTION. 3266 02:02:02,457 --> 02:02:03,425 COMMUNITY MEMBERS CAN INTERACT 3267 02:02:03,425 --> 02:02:05,661 WITH EACH OTHER, AND CONNECT, 3268 02:02:05,661 --> 02:02:07,462 SO THEY DON'T MISS OUT ENTIRELY 3269 02:02:07,462 --> 02:02:09,498 IF THEY AREN'T THERE IN PERSON, 3270 02:02:09,498 --> 02:02:10,632 THOUGH WE LOVE IT WHEN THEY ARE 3271 02:02:10,632 --> 02:02:12,200 IN PERSON. 3272 02:02:12,200 --> 02:02:14,936 WE HAD OVER 100 EXHIBITORS 3273 02:02:14,936 --> 02:02:16,004 WHICH HIGHLIGHT THERE'S IS SO 3274 02:02:16,004 --> 02:02:17,873 MUCH GOING ON IN THE RARE 3275 02:02:17,873 --> 02:02:19,675 DISEASE SPACE AND PEOPLE ARE 3276 02:02:19,675 --> 02:02:20,842 EAGER TO SHARE THEIR LEARNING, 3277 02:02:20,842 --> 02:02:22,444 TO CONNECT WITH OTHERS. 3278 02:02:22,444 --> 02:02:26,848 AND REALLY WHAT THEY WANT IS TO 3279 02:02:26,848 --> 02:02:29,384 NOT HAVE THAT FIRST SLIDE OF 3280 02:02:29,384 --> 02:02:30,585 LESS THAN 5% OF RARE DISEASES 3281 02:02:30,585 --> 02:02:36,491 HAVE TREATMENT. 3282 02:02:36,491 --> 02:02:38,660 SO THESE PEOPLE ARE THE BRAINS 3283 02:02:38,660 --> 02:02:40,662 AND HEART BEHIND THIS, BUT IT'S 3284 02:02:40,662 --> 02:02:42,698 A PROGRAM THAT WE ENGAGED OTHER 3285 02:02:42,698 --> 02:02:45,534 INDIVIDUALS FROM THE NIH, AS 3286 02:02:45,534 --> 02:02:47,436 WELL AS OUTSIDE TO HELP TO PLAN 3287 02:02:47,436 --> 02:02:49,671 IT. 3288 02:02:49,671 --> 02:02:51,773 THESE ARE JUST, YOU KNOW, A FEW 3289 02:02:51,773 --> 02:02:53,342 MORE SLIDES HIGHLIGHTING SOME 3290 02:02:53,342 --> 02:02:54,810 OF THE UNIQUE ASPECTS OF THIS 3291 02:02:54,810 --> 02:02:57,179 CONFERENCE. 3292 02:02:57,179 --> 02:03:00,148 YOU SEE THERE ON THE TOP LEFT, 3293 02:03:00,148 --> 02:03:01,683 WE HAD INDIVIDUALS REACH OUT TO 3294 02:03:01,683 --> 02:03:03,952 US AND SAY WE HAVE RARE DISEASE 3295 02:03:03,952 --> 02:03:06,788 ART WE WANT TO SHARE WITH THIS 3296 02:03:06,788 --> 02:03:07,055 COMMUNITY. 3297 02:03:07,055 --> 02:03:08,990 THERE WERE DIFFERENT ART 3298 02:03:08,990 --> 02:03:11,326 EXHIBITS ABOUT RARE DISEASE, 3299 02:03:11,326 --> 02:03:12,728 PEOPLE THAT ARE THRIVING OR 3300 02:03:12,728 --> 02:03:13,962 LIVING WITH RARE DISEASES THAT 3301 02:03:13,962 --> 02:03:18,200 WANT TO SHARE THEIR STORY. 3302 02:03:18,200 --> 02:03:20,001 DOCTOR EARLIER TALKED ABOUT THE 3303 02:03:20,001 --> 02:03:22,938 COUNCIL WHICH IS REALLY AN 3304 02:03:22,938 --> 02:03:25,006 INCREDIBLE MOMENT TO SEE THEM 3305 02:03:25,006 --> 02:03:30,612 SHARE THAT PROCLAMATION. 3306 02:03:30,612 --> 02:03:32,147 DR. MONICA BERTAGNOLLI. 3307 02:03:32,147 --> 02:03:34,015 WE WERE HONORED TO HAVE HER 3308 02:03:34,015 --> 02:03:35,150 COME AND PRESENT. 3309 02:03:35,150 --> 02:03:36,585 AND I HAD THE OPPORTUNITY TO 3310 02:03:36,585 --> 02:03:40,288 SHARE A LITTLE BIT ABOUT MY 3311 02:03:40,288 --> 02:03:41,723 JOURNEY, AS I MENTIONED, I'M A 3312 02:03:41,723 --> 02:03:43,825 MOTHER TO A -- SHE IS NO 3313 02:03:43,825 --> 02:03:44,926 LONGER THAT LITTLE, SHE IS 17 3314 02:03:44,926 --> 02:03:46,795 YEARS OLD. 3315 02:03:46,795 --> 02:03:48,630 A YOUNG LADY WITH A RARE 3316 02:03:48,630 --> 02:03:50,198 DISEASE AND HOW IT REALLY 3317 02:03:50,198 --> 02:03:51,733 LAUNCHED ME INTO A DIFFERENT 3318 02:03:51,733 --> 02:03:54,870 CAREER PATH THAN I THOUGHT I 3319 02:03:54,870 --> 02:03:58,473 WAS GO. 3320 02:03:58,473 --> 02:04:01,009 SCHOOL GRADLATION. 3321 02:04:01,009 --> 02:04:02,244 -- GRADUATION. 3322 02:04:02,244 --> 02:04:04,546 THIS SOMETHING WE HAVE THE 3323 02:04:04,546 --> 02:04:05,213 SUPPORT OF THE BROADER NIH 3324 02:04:05,213 --> 02:04:07,716 COMMUNITY. 3325 02:04:07,716 --> 02:04:10,318 THE BUILDS LIT UP FOR RARE 3326 02:04:10,318 --> 02:04:11,920 DISEASE DAY ARE SYMBOLIC FOR 3327 02:04:11,920 --> 02:04:14,790 THE CROSS NIH SUPPORT WE HAVE 3328 02:04:14,790 --> 02:04:16,091 FOR IT RARE DISEASE DAY. 3329 02:04:16,091 --> 02:04:18,827 I'M GOING TO LAND ON THE FINAL 3330 02:04:18,827 --> 02:04:20,529 SLIDE THAT HIGHLIGHTS SOME 3331 02:04:20,529 --> 02:04:22,964 PROGRAMS AND INITIATIVES THAT 3332 02:04:22,964 --> 02:04:24,566 WE HAVE AT DRDRI. 3333 02:04:24,566 --> 02:04:26,201 I WAS ONLY ABLE TO TOUCH ON A 3334 02:04:26,201 --> 02:04:28,036 FEW OF THEM. 3335 02:04:28,036 --> 02:04:29,404 BUT I'M HAPPY TO OPEN IT UP FOR 3336 02:04:29,404 --> 02:04:35,010 QUESTIONS. 3337 02:04:35,010 --> 02:04:36,278 >> Joni Rutter: FANTASTIC. 3338 02:04:36,278 --> 02:04:37,746 THANK YOU, DOMINIQUE. 3339 02:04:37,746 --> 02:04:40,682 WE DO HAVE TIME FOR QUESTIONS. 3340 02:04:40,682 --> 02:04:42,784 SO ANY QUESTIONS FROM 3341 02:04:42,784 --> 02:04:49,958 COUNCILMEMBERS? 3342 02:04:49,958 --> 02:04:51,693 YOU SAID IT ALL. 3343 02:04:51,693 --> 02:04:54,529 I SEE ANNIE LOOKING AT ME. 3344 02:04:54,529 --> 02:04:57,732 >> I TRY NOT TO MONOPOLIZE. 3345 02:04:57,732 --> 02:04:58,934 FIRST, JUST REALLY THANK YOU. 3346 02:04:58,934 --> 02:05:00,769 MAYBE NOT A QUESTION, AS MUCH 3347 02:05:00,769 --> 02:05:04,906 AS YOU HAVE ONE SLIDE THAT HAD 3348 02:05:04,906 --> 02:05:07,042 A LOT DIFFERENT INFOGRAPHICS OF 3349 02:05:07,042 --> 02:05:10,245 IT, I SENT A PICTURE OF IT AND 3350 02:05:10,245 --> 02:05:12,380 SENT IT TO MY TEAM. 3351 02:05:12,380 --> 02:05:15,517 THERE ARE SOME IMAGES THAT 3352 02:05:15,517 --> 02:05:17,052 SHOULD BE WRAPPED AROUND 3353 02:05:17,052 --> 02:05:17,619 METROBUSES AROUND TOWN AND 3354 02:05:17,619 --> 02:05:19,554 BILLBOARDS. 3355 02:05:19,554 --> 02:05:22,190 BUT THAT IMAGE ITSELF THAT HAD 3356 02:05:22,190 --> 02:05:26,661 ALL THE INFOGRAPHICS STARTED 3357 02:05:26,661 --> 02:05:28,029 WITH THE NUMBER OF GCRN SLIDE 3358 02:05:28,029 --> 02:05:33,935 THAT TALKED ABOUT THE NUMBER OF 3359 02:05:33,935 --> 02:05:39,074 DISEASES, PROJECTS, PARTNERS 3360 02:05:39,074 --> 02:05:41,009 AND CLINICAL SITES AND 11 AND 3361 02:05:41,009 --> 02:05:42,410 12 PATIENT COMMUNITIES. 3362 02:05:42,410 --> 02:05:44,913 I THINK THE MORE THOSE MESSAGES 3363 02:05:44,913 --> 02:05:45,914 CAN BE AMPLIFIED AND SHARED, 3364 02:05:45,914 --> 02:05:48,483 THE BETTER. 3365 02:05:48,483 --> 02:05:50,385 BUT THERE IS NO MORE PROOF IN 3366 02:05:50,385 --> 02:05:52,153 THE PUDDING OF THE WORK THAT IS 3367 02:05:52,153 --> 02:05:53,622 BEING DONE HERE. 3368 02:05:53,622 --> 02:05:56,224 NOT JUST HERE BUT THROUGHOUT 3369 02:05:56,224 --> 02:06:03,098 THE NATION OF FUNDING. 3370 02:06:03,098 --> 02:06:04,232 IT WAS ARTICULATED BEAUTIFULLY 3371 02:06:04,232 --> 02:06:05,534 IN THAT SLIDE. 3372 02:06:05,534 --> 02:06:07,168 I WANT TO APPLAUD THE MANY 3373 02:06:07,168 --> 02:06:08,904 PEOPLE WHO HELPED TO PUT THAT 3374 02:06:08,904 --> 02:06:09,738 TOGETHER AND TO SAY MORE, MORE 3375 02:06:09,738 --> 02:06:13,842 OF THAT. 3376 02:06:13,842 --> 02:06:16,545 I REALLY LIKE THAT SLIDE TOO. 3377 02:06:16,545 --> 02:06:18,380 IF WE CAN GET IT ON THE 3378 02:06:18,380 --> 02:06:19,214 METROBUS WE WILL TRY TO FIGURE 3379 02:06:19,214 --> 02:06:21,917 IT OUT. 3380 02:06:21,917 --> 02:06:24,619 >> Joni Rutter: EMILY? 3381 02:06:24,619 --> 02:06:26,254 EMILY IS OUR COMMUNICATIONS 3382 02:06:26,254 --> 02:06:28,523 DIRECTOR AND IS AMAZING AT WHAT 3383 02:06:28,523 --> 02:06:30,792 SHE DOES. 3384 02:06:30,792 --> 02:06:32,294 THANK YOU FOR THAT COMMENT. 3385 02:06:32,294 --> 02:06:33,094 ANY OTHER COMMENTS FROM THE 3386 02:06:33,094 --> 02:06:40,669 COUNCIL? 3387 02:06:40,669 --> 02:06:41,903 >> GREAT QUESTION, GREAT TALK. 3388 02:06:41,903 --> 02:06:43,204 GOING BACK TO THE SLIDE ABOUT 3389 02:06:43,204 --> 02:06:45,140 THE DRUG APPROVAL. 3390 02:06:45,140 --> 02:06:49,077 IS THERE SOME WAY TO TRACE IS 3391 02:06:49,077 --> 02:06:52,314 BACK TO THE RDCRN AND SEE IF 3392 02:06:52,314 --> 02:06:53,281 THERE WAS SOMETHING SPECIAL OR 3393 02:06:53,281 --> 02:06:56,985 IF IT WAS LUCK? 3394 02:06:56,985 --> 02:06:58,720 >> GREAT QUESTION. 3395 02:06:58,720 --> 02:07:01,222 IS THERE SOMETHING ABOUT THOSE 3396 02:07:01,222 --> 02:07:02,824 THAT ALLOWED THEM TO BE MORE 3397 02:07:02,824 --> 02:07:05,493 DRUG-READY I WILL SAY? 3398 02:07:05,493 --> 02:07:06,628 THAT HASN'T BEEN LOOKED AT, TO 3399 02:07:06,628 --> 02:07:08,530 MY KNOWLEDGE. 3400 02:07:08,530 --> 02:07:10,699 CERTAINLY SOMETHING WE CAN LOOK 3401 02:07:10,699 --> 02:07:13,468 AT. 3402 02:07:13,468 --> 02:07:23,979 I WON'T EVEN TELL YOU MY GUT. 3403 02:07:38,893 --> 02:07:40,462 THERE ARE SOME CONSORTIA THAT 3404 02:07:40,462 --> 02:07:42,163 MAY NOT HAVE APPROVAL. 3405 02:07:42,163 --> 02:07:43,999 THERE ARE PROBABLY OTHER WAYS 3406 02:07:43,999 --> 02:07:46,601 TO MEASURE SUCCESS BEYOND THAT. 3407 02:07:46,601 --> 02:07:47,402 IT WOULD PROBABLY BE 3408 02:07:47,402 --> 02:07:49,004 INTERESTING IF THEY ARE ALREADY 3409 02:07:49,004 --> 02:07:53,408 DOING IT TO GO BACK AND LOOK AT 3410 02:07:53,408 --> 02:07:55,276 THE FIRST EARLY CONSORTIA STILL 3411 02:07:55,276 --> 02:07:57,312 BEING FUNDED AND LOOK TO SEE IF 3412 02:07:57,312 --> 02:07:59,547 THERE ARE OTHER MEASURES OF 3413 02:07:59,547 --> 02:08:01,182 SUCCESS THAT WE COULD ALSO BE 3414 02:08:01,182 --> 02:08:02,250 AMPLIFYING. 3415 02:08:02,250 --> 02:08:05,253 AND THEN WHAT IS THAT SECRET 3416 02:08:05,253 --> 02:08:06,187 SAUZ. 3417 02:08:06,187 --> 02:08:07,722 -SAUCE. 3418 02:08:07,722 --> 02:08:09,224 AND IF THERE ARE UNDER 3419 02:08:09,224 --> 02:08:10,759 PERFORMERS AND WHAT COULD BE 3420 02:08:10,759 --> 02:08:13,061 DONE TO BRING THEM ALONG AS 3421 02:08:13,061 --> 02:08:13,261 WELL. 3422 02:08:13,261 --> 02:08:14,596 >> THOSE ARE GREAT SUGGESTIONS, 3423 02:08:14,596 --> 02:08:17,899 THANK, ANNIE. 3424 02:08:17,899 --> 02:08:19,067 AND BALKI, THANK YOU FOR THE 3425 02:08:19,067 --> 02:08:19,968 QUESTION AS WELL. 3426 02:08:19,968 --> 02:08:20,635 >> Joni Rutter: ANY OTHER 3427 02:08:20,635 --> 02:08:21,536 QUESTIONS? 3428 02:08:21,536 --> 02:08:23,571 I'M LOOKING ONLINE. 3429 02:08:23,571 --> 02:08:26,107 I DON'T SEE ANY HANDS. 3430 02:08:26,107 --> 02:08:27,609 THANK YOU SO MUCH, DOMINIQUE, 3431 02:08:27,609 --> 02:08:28,109 REALLY APPRECIATE YOUR 3432 02:08:28,109 --> 02:08:36,384 PRESENTATION. 3433 02:08:36,384 --> 02:08:39,154 NEXT UP I'M PLEASED TO PRESENT 3434 02:08:39,154 --> 02:08:40,321 MATT HALL. 3435 02:08:40,321 --> 02:08:40,855 SO TAKE IT AWAY. 3436 02:08:40,855 --> 02:08:50,965 MATT. 3437 02:08:53,768 --> 02:08:56,905 >> MATT HALL: THANK YOU, JONI. 3438 02:08:56,905 --> 02:08:59,107 I WAS LUCKY ENOUGH TO PRESENT 3439 02:08:59,107 --> 02:09:00,508 TO COUNCIL ONCE, BUT IT WAS 3440 02:09:00,508 --> 02:09:01,643 REMOTE. 3441 02:09:01,643 --> 02:09:03,578 IT'S NICE TO SEE PEOPLE HERE IN 3442 02:09:03,578 --> 02:09:05,780 PERSON AND SHARE A LITTLE BIT 3443 02:09:05,780 --> 02:09:06,915 ABOUT MYSELF SO THE 3444 02:09:06,915 --> 02:09:08,817 INTRODUCTION I'M PLANNING TO 3445 02:09:08,817 --> 02:09:12,554 USE IS AN INTRODUCTION TO ME. 3446 02:09:12,554 --> 02:09:13,488 THIS WAS A REQUEST, NOT THAT I 3447 02:09:13,488 --> 02:09:14,289 WANT THAT. 3448 02:09:14,289 --> 02:09:24,833 I WILL TALK ABOUT THE OFFICE OF 3449 02:09:25,066 --> 02:09:27,502 PRECLINICAL INNOVATION AND OUR 3450 02:09:27,502 --> 02:09:31,039 ROLE WITH PARTNERS OUTSIDE NIH 3451 02:09:31,039 --> 02:09:34,109 AND NCATS AS WELL. 3452 02:09:34,109 --> 02:09:35,710 TALK ABOUT OUR APPROACH AND 3453 02:09:35,710 --> 02:09:37,712 SOME THINGS I'M LOOKING FORWARD 3454 02:09:37,712 --> 02:09:39,447 TO WORKING WITH MY COLLEAGUES 3455 02:09:39,447 --> 02:09:42,984 ON DPI IN THE FUTURE, SUCH AS 3456 02:09:42,984 --> 02:09:44,085 BUILDING RESEARCH PLATFORMS FOR 3457 02:09:44,085 --> 02:09:46,788 RARE DISEASES AND FILLING IN 3458 02:09:46,788 --> 02:09:49,324 SOME OF THOSE GAPS. 3459 02:09:49,324 --> 02:09:52,393 MYSELF, YOU MAY HAVE DETECTED A 3460 02:09:52,393 --> 02:09:54,596 SLIGHT ACCENT, AUSTRALIAN BY 3461 02:09:54,596 --> 02:09:56,598 BIRTH AND STUDIED AT THE 3462 02:09:56,598 --> 02:10:02,470 UNIVERSITY OF SYDNEY, I HAVE 3463 02:10:02,470 --> 02:10:03,071 THE OBLIGATORY KANGAROO PHOTO 3464 02:10:03,071 --> 02:10:04,305 HERE. 3465 02:10:04,305 --> 02:10:06,107 DURING MY Ph.D. I WAS LUCKY 3466 02:10:06,107 --> 02:10:10,845 ENOUGH TO LIVE IN THIS REALLY 3467 02:10:10,845 --> 02:10:11,946 HAPPY INTERSECTION BETWEEN 3468 02:10:11,946 --> 02:10:12,547 MOLECULAR PHARMACOLOGY, 3469 02:10:12,547 --> 02:10:17,819 UNDERSTANDING HOW DRUGS WORK 3470 02:10:17,819 --> 02:10:26,094 AND INORGANIC CHEMISTRY, 3471 02:10:26,094 --> 02:10:29,264 CISPLATIN, WHICH IS ONE OF THE 3472 02:10:29,264 --> 02:10:30,598 MOST COMMONLY USED DRUG IN 3473 02:10:30,598 --> 02:10:31,866 CHEMOTHERAPY. 3474 02:10:31,866 --> 02:10:33,001 I DECIDED THIS IS WHERE I 3475 02:10:33,001 --> 02:10:36,504 WANTED TO BE. 3476 02:10:36,504 --> 02:10:38,139 SO I CAME HERE. 3477 02:10:38,139 --> 02:10:39,741 I CAME FROM THE NATIONAL 3478 02:10:39,741 --> 02:10:47,248 INSTITUTES OF HEALTH WHERE I 3479 02:10:47,248 --> 02:10:50,819 WORKED WITH MIKE GOTTESMAN. 3480 02:10:50,819 --> 02:10:52,453 A PROTEIN, IT TAKES DRUGS AND 3481 02:10:52,453 --> 02:10:53,822 PUMPS THEM OUT OF CELLS SO THEY 3482 02:10:53,822 --> 02:10:56,491 CAN'T GET IN. 3483 02:10:56,491 --> 02:10:59,160 ONE CHALLENGE WITH 3484 02:10:59,160 --> 02:11:00,361 CHEMOTHERAPY, CELLS MAY 3485 02:11:00,361 --> 02:11:06,201 INITIALLY BE KILLED BY 3486 02:11:06,201 --> 02:11:07,101 CHEMOTHERAPY BUT THEY BECOME 3487 02:11:07,101 --> 02:11:08,837 UNRESPONSIVE OVER TIME. 3488 02:11:08,837 --> 02:11:10,872 I SPENT A LOT OF TIME WORKING 3489 02:11:10,872 --> 02:11:14,275 ON DEVELOPING THERAPEUTICS. 3490 02:11:14,275 --> 02:11:17,145 THESE PUMPS PLAY A CRITICAL 3491 02:11:17,145 --> 02:11:18,513 ROLE IN THE BLOOD-BRAIN 3492 02:11:18,513 --> 02:11:20,782 BARRIER, KEEPING DRUGS OUT OF 3493 02:11:20,782 --> 02:11:28,189 THE BRAIN. 3494 02:11:28,189 --> 02:11:33,428 A COLLEAGUE WITH ME AT NCATS. 3495 02:11:33,428 --> 02:11:37,065 KYLE BRIMACOMBE. 3496 02:11:37,065 --> 02:11:41,336 A FEW OTHER ENTHUSIASTIC AND 3497 02:11:41,336 --> 02:11:42,537 BRIGHT-EYED YOUNG PEOPLE 3498 02:11:42,537 --> 02:11:43,137 BUILDING THIS DRUG DISCOVERY 3499 02:11:43,137 --> 02:11:47,375 CENTER. 3500 02:11:47,375 --> 02:11:49,811 WE DESIGNED AN ASSAY. 3501 02:11:49,811 --> 02:11:52,647 I WAS A COLLABORATOR. 3502 02:11:52,647 --> 02:11:55,984 BEING A DIFFERENT KIND, ON 3503 02:11:55,984 --> 02:11:58,186 DIFFERENT SIDE OF THE FENCE. 3504 02:11:58,186 --> 02:12:01,723 WE WERE MIXING CELLS, GREEN 3505 02:12:01,723 --> 02:12:03,625 ONES THAT WERE VERY RESISTANT 3506 02:12:03,625 --> 02:12:04,392 AND RED ONES THAT WERE 3507 02:12:04,392 --> 02:12:06,261 SENSITIVE. 3508 02:12:06,261 --> 02:12:09,697 IT WAS A VERY SUCCESSFUL 3509 02:12:09,697 --> 02:12:11,933 RESEARCH PROJECT AND RESULTED 3510 02:12:11,933 --> 02:12:12,967 IN A NICE DESCRIPTION AND 3511 02:12:12,967 --> 02:12:14,469 BETTER UNDERSTANDING. 3512 02:12:14,469 --> 02:12:17,272 BUT IT MADE ME WANT TO BE AT 3513 02:12:17,272 --> 02:12:21,109 NCATS AND CONTINUE WORKING, BE 3514 02:12:21,109 --> 02:12:22,844 PART OF WHAT THEY WERE DOING 3515 02:12:22,844 --> 02:12:23,978 AND I COULDN'T BE HAPPIER. 3516 02:12:23,978 --> 02:12:26,581 THAT'S AMAZING. 3517 02:12:26,581 --> 02:12:28,383 I'M REALLY HAPPY. 3518 02:12:28,383 --> 02:12:29,951 SO I WORK WITH THIS TEAM HERE 3519 02:12:29,951 --> 02:12:31,319 AT DPI. 3520 02:12:31,319 --> 02:12:33,321 THIS IS MY DAY JOB AS A 3521 02:12:33,321 --> 02:12:35,757 RESEARCH LEAD AS PART OF A TEAM. 3522 02:12:35,757 --> 02:12:37,258 THIS LOOKS LIKE ONE GROUP, 3523 02:12:37,258 --> 02:12:38,993 THAT'S HOW IT IS SUPPOSED TO 3524 02:12:38,993 --> 02:12:39,627 LOOK BECAUSE THAT'S HOW WE 3525 02:12:39,627 --> 02:12:41,763 OPERATE. 3526 02:12:41,763 --> 02:12:46,567 THERE'S THREE GROUP, MEDICINAL 3527 02:12:46,567 --> 02:12:49,370 CHEMISTRY, MIN CHEN WHO LEADS 3528 02:12:49,370 --> 02:12:50,672 THE DATA SCIENCE. 3529 02:12:50,672 --> 02:12:53,141 AND MYSELF AS WELL. 3530 02:12:53,141 --> 02:12:55,276 SOME OF MY BIOLOGY GROUP TEAM 3531 02:12:55,276 --> 02:12:57,779 LEADS IN THE PHOTO, ON THE 3532 02:12:57,779 --> 02:12:57,979 RIGHT. 3533 02:12:57,979 --> 02:13:00,848 WE WORK TOGETHER PARTNERING 3534 02:13:00,848 --> 02:13:04,419 WITH OTHERS OUTSIDE NCATS TO 3535 02:13:04,419 --> 02:13:06,487 DEVELOP ASSAYS, SCREENINGS AND 3536 02:13:06,487 --> 02:13:08,389 DEVELOP MOLECULES FOR A RANGE 3537 02:13:08,389 --> 02:13:11,726 OF TARGETS AND RANGE OF 3538 02:13:11,726 --> 02:13:12,660 DISORDERS, MANY OF WHICH ARE 3539 02:13:12,660 --> 02:13:15,263 RARE DISEASES. 3540 02:13:15,263 --> 02:13:18,266 BY THE TIME COVID CAME, WE WERE 3541 02:13:18,266 --> 02:13:20,201 REALLY LUCKY TO TAKE EVERYTHING 3542 02:13:20,201 --> 02:13:22,937 WE WERE DOING AT DPI, KIND OF A 3543 02:13:22,937 --> 02:13:24,906 PLATFORM PLAYBOOK AND DIRECT IT 3544 02:13:24,906 --> 02:13:29,010 TOWARDS COVID. 3545 02:13:29,010 --> 02:13:31,245 REALLY GRATIFYING IN THIS PAPER 3546 02:13:31,245 --> 02:13:32,647 PUBLISHED LAST YEAR WITH 3547 02:13:32,647 --> 02:13:33,648 FRANCIS COLINS AND OTHERS. 3548 02:13:33,648 --> 02:13:36,284 I WAS INCLUDED IN. 3549 02:13:36,284 --> 02:13:37,986 TWO OTHER KEY HIGHLIGHTS DR. 3550 02:13:37,986 --> 02:13:39,420 COLINS AND OTHERS POINTED OUT 3551 02:13:39,420 --> 02:13:41,522 FROM THE EARLY DAYS OF OUR 3552 02:13:41,522 --> 02:13:43,458 RESPONSE, THE OPEN DATA PORTAL 3553 02:13:43,458 --> 02:13:46,661 I SPOKE ABOUT 3R50E6 YUSLY, 3554 02:13:46,661 --> 02:13:48,830 WHICH WAS REALLY INTENTIONALLY 3555 02:13:48,830 --> 02:13:49,597 GENERATING TRANSLATIONAL 3556 02:13:49,597 --> 02:13:51,132 SCIENCE DATA AND SHARING WITH 3557 02:13:51,132 --> 02:13:53,001 THE COMMUNITY OPENLY. 3558 02:13:53,001 --> 02:14:01,776 OPEN DATA SHARING. 3559 02:14:01,776 --> 02:14:05,179 AND ACTIV TRACE PROGRAM, OPEN 3560 02:14:05,179 --> 02:14:07,015 PUBLIC PRIVATE PARTNERSHIP. 3561 02:14:07,015 --> 02:14:09,017 IT MADE A LOT OF DIFFERENCE 3562 02:14:09,017 --> 02:14:11,719 FROM A COVID RESPONSE. 3563 02:14:11,719 --> 02:14:14,255 SO AS COVID WAS WINDING UP, I 3564 02:14:14,255 --> 02:14:16,891 FIND MYSELF HERE AS THE 3565 02:14:16,891 --> 02:14:18,292 SCIENTIFIC DIRECTOR AND 3566 02:14:18,292 --> 02:14:19,594 OPPORTUNITY TO ACKNOWLEDGE 3567 02:14:19,594 --> 02:14:21,829 ANTON, NOT ONLY MY PREDECESSOR 3568 02:14:21,829 --> 02:14:23,765 BUT LUCKY ENOUGH TO HAVE AS A 3569 02:14:23,765 --> 02:14:25,400 COLLEAGUE GOING FORWARD. 3570 02:14:25,400 --> 02:14:28,002 I WILL HAVE THE WISDOM AND 3571 02:14:28,002 --> 02:14:31,739 EXPERTISE TO RELY ON, PROBABLY 3572 02:14:31,739 --> 02:14:34,542 DIFFERENT TO MANY. 3573 02:14:34,542 --> 02:14:36,177 THANK YOU, ANTON FOR EVERYTHING 3574 02:14:36,177 --> 02:14:37,879 YOU HAVE DONE AND WILL DO, EVEN 3575 02:14:37,879 --> 02:14:38,946 THOUGH YOU DON'T KNOW WILL BE 3576 02:14:38,946 --> 02:14:39,414 DOING IT. 3577 02:14:39,414 --> 02:14:42,116 [LAUGHTER] 3578 02:14:42,116 --> 02:14:50,224 A LITTLE PIVOT TALKING ABOUT 3579 02:14:50,224 --> 02:14:51,726 RARE DISEASES AND MARRYING UP 3580 02:14:51,726 --> 02:14:53,861 WITH DOMINIQUE'S PRESENTATION. 3581 02:14:53,861 --> 02:14:57,999 I TOOK MY DAUGHTERS TO A MUSEUM. 3582 02:14:57,999 --> 02:14:59,333 HAD ALL THESE PILLS AND 3583 02:14:59,333 --> 02:15:02,136 MEDICINE. 3584 02:15:02,136 --> 02:15:04,172 I KNOW MY I.T. FRIENDS ARE KEY 3585 02:15:04,172 --> 02:15:05,873 TO PRESSING PLAY ON THIS. 3586 02:15:05,873 --> 02:15:07,742 WHAT YOU WILL SEE, I'M WALKING 3587 02:15:07,742 --> 02:15:10,511 ALONG AND JUST TAKING A VIDEO 3588 02:15:10,511 --> 02:15:15,383 OF THIS INCREDIBLY LONG 60 FOOT 3589 02:15:15,383 --> 02:15:17,285 DISPLAY OF PILLS AND MEDICINES 3590 02:15:17,285 --> 02:15:19,353 SOMEONE TAKES IN A LIFETIME. 3591 02:15:19,353 --> 02:15:20,555 THE A REPRESENTATIVE DISPLAY OF 3592 02:15:20,555 --> 02:15:23,391 RECORDS OF INDIVIDUAL PEOPLE. 3593 02:15:23,391 --> 02:15:25,126 IT'S THE AVERAGE PERSON, 3594 02:15:25,126 --> 02:15:26,828 THERE'S NO SOUND JUST MY 3595 02:15:26,828 --> 02:15:27,995 DAUGHTER TELLING ME SHE IS 3596 02:15:27,995 --> 02:15:31,599 HUNGRY IN THE BACKGROUND. 3597 02:15:31,599 --> 02:15:32,934 IT'S AN INCREDIBLY COMPELLING 3598 02:15:32,934 --> 02:15:36,204 DISPLAY, SEE THE VACCINES. 3599 02:15:36,204 --> 02:15:36,971 WORKING WITH RARE DISEASE 3600 02:15:36,971 --> 02:15:38,773 PATIENTS ALL THE TIME. 3601 02:15:38,773 --> 02:15:40,908 IT CERTAINLY DOESN'T LOOK LIKE 3602 02:15:40,908 --> 02:15:42,910 THIS, BUT IT'S WHAT WE WANT 3603 02:15:42,910 --> 02:15:44,512 RARE DISEASE PATIENTS TO HAVE. 3604 02:15:44,512 --> 02:15:45,847 WI WANT THEM TO HAVE THOSE 3605 02:15:45,847 --> 02:15:47,281 MEDICINES. 3606 02:15:47,281 --> 02:15:49,717 I THINK IT STRUCK ME IN MY OWN 3607 02:15:49,717 --> 02:15:55,256 LIFE I HAVE TWO FAMILY MEMBERS 3608 02:15:55,256 --> 02:15:56,757 WITH, TWO NEPHEWS, LIVING VERY 3609 02:15:56,757 --> 02:15:59,994 DIFFERENT RARE DISEASE LIVES. 3610 02:15:59,994 --> 02:16:02,663 COHEN WHO HAS CYSTIC FIBROSIS 3611 02:16:02,663 --> 02:16:05,333 AND BENEFITS ALREADY FROM A 3612 02:16:05,333 --> 02:16:09,303 YOUNG AGE. 3613 02:16:09,303 --> 02:16:10,938 A TRANSPORTER LIKE -- PROTEIN. 3614 02:16:10,938 --> 02:16:12,740 IT DOESN'T GET TO THE SURFACE 3615 02:16:12,740 --> 02:16:14,108 TO PUMP THINGS THE WAY IT IS 3616 02:16:14,108 --> 02:16:15,076 SUPPOSED TO. 3617 02:16:15,076 --> 02:16:20,581 ON THE OTHER HAND I HAVE A 3618 02:16:20,581 --> 02:16:22,183 YOUNG NEPHEW ARCHER. 3619 02:16:22,183 --> 02:16:28,322 AFTER A LITTLE BIT OF 3620 02:16:28,322 --> 02:16:33,461 DIAGNOSTIC ODYSSEY, HE WAS 3621 02:16:33,461 --> 02:16:35,496 DIAGNOSED WITH DIGEORGE 3622 02:16:35,496 --> 02:16:37,131 SYNDROME, CAUSED BY LOSSES OF 3623 02:16:37,131 --> 02:16:38,699 30-40 GENES. 3624 02:16:38,699 --> 02:16:42,203 A COMPLEX RARE DISEASE. 3625 02:16:42,203 --> 02:16:46,874 THERE AREN'T TREATMENTS, IT'S 3626 02:16:46,874 --> 02:16:47,808 THE 95% DOMINIQUE WAS TALKING 3627 02:16:47,808 --> 02:16:49,844 ABOUT. 3628 02:16:49,844 --> 02:16:51,245 THINKING BACK TO THAT DISPLAY, 3629 02:16:51,245 --> 02:16:53,080 IT'S EASY TO UNDERSTAND HOW WE 3630 02:16:53,080 --> 02:16:54,482 ARE ALSO DEDICATED TO THE 3631 02:16:54,482 --> 02:16:56,717 MISSION OF TRYING TO BRING 3632 02:16:56,717 --> 02:16:57,385 TREATMENTS AND UNDERSTANDING TO 3633 02:16:57,385 --> 02:17:01,455 RARE DISEASES. 3634 02:17:01,455 --> 02:17:02,957 DIVISION OF PRECLINICAL 3635 02:17:02,957 --> 02:17:06,460 INNOVATION, I'M NOW THE 3636 02:17:06,460 --> 02:17:09,030 CLINICAL DIRECTOR UNDERSTANDING 3637 02:17:09,030 --> 02:17:10,131 TARGETS, DEVELOPING ASSAYS, 3638 02:17:10,131 --> 02:17:12,466 EXECUTING STREENINGS AND THE 3639 02:17:12,466 --> 02:17:14,435 CHEMISTRY NEEDED TO CREATE DRUG 3640 02:17:14,435 --> 02:17:18,105 LEADS AND EXPERTISE. 3641 02:17:18,105 --> 02:17:19,440 IT'S REALLY INCREDIBLE COMPLEX 3642 02:17:19,440 --> 02:17:21,442 SET OF STUDIES REQUIRED TO GO 3643 02:17:21,442 --> 02:17:25,379 TO THE FDA AND ASK APPROVAL FOR 3644 02:17:25,379 --> 02:17:29,250 CLINICAL TRIALS TO BE INITIATED. 3645 02:17:29,250 --> 02:17:30,218 THESE SCIENTISTS, THERE IS 3646 02:17:30,218 --> 02:17:31,352 ORGANIZATION BUT THEY WORK 3647 02:17:31,352 --> 02:17:31,819 TOGETHER ACROSS THIS 3648 02:17:31,819 --> 02:17:34,288 ORGANIZATION. 3649 02:17:34,288 --> 02:17:37,325 IN DEDICATED TEAMS AND AN ON AD 3650 02:17:37,325 --> 02:17:39,527 HOC WAY TO SOLVE PROBLEMS. 3651 02:17:39,527 --> 02:17:42,463 GENUINELY DIFFERENT ENVIRONMENT. 3652 02:17:42,463 --> 02:17:45,499 MY PERSPECTIVE I'M BRINGING IN 3653 02:17:45,499 --> 02:17:48,703 IS TO EMBRACE THIS, VERY 3654 02:17:48,703 --> 02:17:49,136 INTENTIONALLY BUILT. 3655 02:17:49,136 --> 02:17:53,774 WHEN I THINK OF THE DIVISION OF 3656 02:17:53,774 --> 02:17:55,209 PRECLINICAL INNOVATION, MY JOB 3657 02:17:55,209 --> 02:17:57,712 IS TO RECOGNIZE THE UNIQUE 3658 02:17:57,712 --> 02:18:03,184 NATURE OF DIVISION OF 3659 02:18:03,184 --> 02:18:07,021 PRECLINICAL INNOVATION, MURAL 3660 02:18:07,021 --> 02:18:07,788 ENVIRONMENT, NCATS INTRA MURAL 3661 02:18:07,788 --> 02:18:10,458 ENVIRONMENT, IT'S UNIQUE. 3662 02:18:10,458 --> 02:18:14,295 WE CONTINUE TO BUILD OUR 3663 02:18:14,295 --> 02:18:15,796 REPUTATION AS WORLD CLASS 3664 02:18:15,796 --> 02:18:18,799 TRANSLATIONAL SCIENCE INSTITUTE. 3665 02:18:18,799 --> 02:18:21,369 MY GOAL OVER THE COURSE OF MY 3666 02:18:21,369 --> 02:18:22,903 WORK TOO, WHEN PEOPLE THINK 3667 02:18:22,903 --> 02:18:24,972 ABOUT MEDICINE, THEY THINK 3668 02:18:24,972 --> 02:18:26,107 ABOUT NCATS. 3669 02:18:26,107 --> 02:18:28,142 THAT'S WHAT I WANT PEOPLE TO 3670 02:18:28,142 --> 02:18:29,877 THINK OF, AND WHEN PEOPLE THINK 3671 02:18:29,877 --> 02:18:31,846 OF RARE DISEASES, I WANT THEM 3672 02:18:31,846 --> 02:18:32,780 TO THINK OF NCATS. 3673 02:18:32,780 --> 02:18:36,751 SO THAT'S KIND OF THE LENS I 3674 02:18:36,751 --> 02:18:39,253 COME TO THIS THROUGH. 3675 02:18:39,253 --> 02:18:40,655 IT'S QUITE A UNIQUE ENVIRONMENT 3676 02:18:40,655 --> 02:18:42,189 BUT ALSO GIVES US A GREAT DEAL 3677 02:18:42,189 --> 02:18:44,892 OF RESPONSEABILITID. 3678 02:18:44,892 --> 02:18:46,594 A RELATIVELY STABLE ENVIRONMENT. 3679 02:18:46,594 --> 02:18:51,032 BUT IT ALSO MEANS WE HAVE THE 3680 02:18:51,032 --> 02:18:51,832 CONFIDENCE TO CHANGE WHAT WE 3681 02:18:51,832 --> 02:18:53,167 ARE DOING. 3682 02:18:53,167 --> 02:18:55,503 WE NEED TO EMBRACE THAT, AND WE 3683 02:18:55,503 --> 02:18:57,938 ALSO HAVE THE OBLIGATION TO 3684 02:18:57,938 --> 02:19:00,341 TAKE ON VERY HIGH RISK SCIENCE 3685 02:19:00,341 --> 02:19:01,776 AND LONG-TERM PROJECTS. 3686 02:19:01,776 --> 02:19:02,943 THERE'S NO REASON WE SHOULDN'T, 3687 02:19:02,943 --> 02:19:05,212 WE HAVE THE STABILITY TO 3688 02:19:05,212 --> 02:19:07,481 UNDERTAKE THOSE WITHOUT FEAR OF 3689 02:19:07,481 --> 02:19:08,816 THE CONSEQUENCES OF FAILURE. 3690 02:19:08,816 --> 02:19:11,786 THOSE ARE THE KIND OF PROJECTS 3691 02:19:11,786 --> 02:19:14,488 THAT MAY NOT FIT INTO A 3692 02:19:14,488 --> 02:19:15,189 TRADITIONAL ACADEMIC FUNDING 3693 02:19:15,189 --> 02:19:16,824 SPACE OR MECHANISM. 3694 02:19:16,824 --> 02:19:20,761 COURSE WE CAN WORK WITH OUR 3695 02:19:20,761 --> 02:19:24,398 LEADERSHIP TO DEFINE WI CAN 3696 02:19:24,398 --> 02:19:30,171 WORK TOGETHER, NOT JUST WITHIN 3697 02:19:30,171 --> 02:19:32,973 DRDRI. 3698 02:19:32,973 --> 02:19:35,509 THE OPERATIONAL MODEL WHICH IS 3699 02:19:35,509 --> 02:19:36,143 UNIQUE FROM OTHER PROGRAMS AT 3700 02:19:36,143 --> 02:19:37,445 NIH. 3701 02:19:37,445 --> 02:19:39,280 THE LABS AND DEDICATION TO 3702 02:19:39,280 --> 02:19:39,914 BUILDING TECHNOLOGIES ANLD 3703 02:19:39,914 --> 02:19:41,682 TRYING TO UNDERSTAND THOSE. 3704 02:19:41,682 --> 02:19:43,884 BUT ALSO I WISH HI MORE TIME TO 3705 02:19:43,884 --> 02:19:46,053 TALK ABOUT IT TODAY, I HOPE WE 3706 02:19:46,053 --> 02:19:48,589 HAVE A TALK SOMETIME ABOUT 3707 02:19:48,589 --> 02:19:49,123 INTRAMURAL AND EXTRAMURAL 3708 02:19:49,123 --> 02:19:49,824 PARTNERSHIPS. 3709 02:19:49,824 --> 02:19:52,560 THE WAY WE WORK WITH COLLEAGUES 3710 02:19:52,560 --> 02:19:53,761 AROUND THE TABLE HERE, 3711 02:19:53,761 --> 02:19:54,662 COUNCILMEMBERS, BUILDING 3712 02:19:54,662 --> 02:19:56,664 PROGRAMS WITH THE DIVISION OF 3713 02:19:56,664 --> 02:19:57,198 RARE DISEASE RESEARCH AND 3714 02:19:57,198 --> 02:20:03,971 INNOVATION. 3715 02:20:03,971 --> 02:20:05,473 EXTRAMURAL, INTRAMURAL, OFFICE 3716 02:20:05,473 --> 02:20:06,073 OF STRATEGIC INITIATIVES AND 3717 02:20:06,073 --> 02:20:09,610 OTHERS. 3718 02:20:09,610 --> 02:20:12,446 SO BEING A RESEARCH IN A 3719 02:20:12,446 --> 02:20:13,347 RESEARCH LAB ORGANIZATION, ONE 3720 02:20:13,347 --> 02:20:14,648 THING I'M THINKING ABOUT IS 3721 02:20:14,648 --> 02:20:16,817 MAKING SURE WE HAVE BALANCE. 3722 02:20:16,817 --> 02:20:19,653 WHEN WE ARE CONDUCTING SCIENCE, 3723 02:20:19,653 --> 02:20:21,455 MUCH IS COLLABORATIVE, OUR 3724 02:20:21,455 --> 02:20:23,457 PARTNERS ARE COLLABORATORS WHO 3725 02:20:23,457 --> 02:20:27,294 COME TO US, BE IT ACADEMIC OR 3726 02:20:27,294 --> 02:20:28,929 PARENT. 3727 02:20:28,929 --> 02:20:31,932 THEY COME TO US WITH A 3728 02:20:31,932 --> 02:20:32,867 THERAPEUTIC IDEA, CANDIDATE 3729 02:20:32,867 --> 02:20:35,569 PRODUCT OR JUST LOOKING FOR 3730 02:20:35,569 --> 02:20:36,170 ADVICE IN THIS TRANSLATIONAL 3731 02:20:36,170 --> 02:20:37,104 SPACE. 3732 02:20:37,104 --> 02:20:41,442 WHAT WE BRING IS OUR EXPERTISE 3733 02:20:41,442 --> 02:20:42,610 IN DRUG FORMING DEVELOPMENT TO 3734 02:20:42,610 --> 02:20:44,378 PARTNER WITH THEM. 3735 02:20:44,378 --> 02:20:47,314 AND WE HAVE AN INTEREST FOR 3736 02:20:47,314 --> 02:20:48,816 IMPROVING THE DRUG DISCOVERY 3737 02:20:48,816 --> 02:20:50,251 PROCESS TO REDUCE THE FAILURE 3738 02:20:50,251 --> 02:20:52,753 RATE OF THE PROCESS. 3739 02:20:52,753 --> 02:20:56,090 REALLY OUR COLLABORATORS COME 3740 02:20:56,090 --> 02:20:57,992 TO US, SPEAKING EXPERTISE. 3741 02:20:57,992 --> 02:21:02,263 WE USE THAT EXPERTISE THAT WE 3742 02:21:02,263 --> 02:21:04,899 MAINTAIN TO INFORM THE RESEARCH 3743 02:21:04,899 --> 02:21:08,502 DECISIONS WE MAKE. 3744 02:21:08,502 --> 02:21:09,170 ADVANCING TRANSLATIONAL SCIENCE 3745 02:21:09,170 --> 02:21:11,238 COMPONENT OF WHAT WE DO. 3746 02:21:11,238 --> 02:21:13,574 MY GOAL IS MAKE SURE WE HAVE 3747 02:21:13,574 --> 02:21:17,011 THE SPACE FOR SCIENTISTS TO 3748 02:21:17,011 --> 02:21:17,511 THRIVE, COLLABORATE AND 3749 02:21:17,511 --> 02:21:20,014 INNOVATE TO MAKE SURE WE ARE 3750 02:21:20,014 --> 02:21:20,548 BRINGING THERAPEUTICS TO 3751 02:21:20,548 --> 02:21:21,715 PATIENT. 3752 02:21:21,715 --> 02:21:23,017 AND THEY ARE MANAGED AS A 3753 02:21:23,017 --> 02:21:26,720 PORTFOLIO AS A WHOLE. 3754 02:21:26,720 --> 02:21:27,721 I CAN SHARE IN THE FUTURE WITH 3755 02:21:27,721 --> 02:21:30,124 YOU. 3756 02:21:30,124 --> 02:21:31,392 THERE WILL BE INTERNATIONAL 3757 02:21:31,392 --> 02:21:39,633 REPUTATION OF OUR PROGRAM. 3758 02:21:39,633 --> 02:21:40,234 WE ALREADY HAVE INTERNATIONAL 3759 02:21:40,234 --> 02:21:49,877 REPUTATION. 3760 02:21:49,877 --> 02:21:51,412 I WON'T GO TOO DEEPLY BUT GIVEN 3761 02:21:51,412 --> 02:21:54,849 WHAT I TOLD YOU ABOUT THE 3762 02:21:54,849 --> 02:21:57,451 UNIQUE NATURE OF OUR RESEARCH 3763 02:21:57,451 --> 02:21:58,285 PROGRAM AND HIGHLY 3764 02:21:58,285 --> 02:21:59,386 COLLABORATIVE NATURE, WE ARE 3765 02:21:59,386 --> 02:22:03,624 WELL PLACED AND I WANT TO WORK 3766 02:22:03,624 --> 02:22:05,025 WITH MY DPI COLLEAGUES, EMBRACE 3767 02:22:05,025 --> 02:22:06,527 THE ENVIRONMENT BEING BUILT AND 3768 02:22:06,527 --> 02:22:08,262 EMBRACE THE CHALLENGES THAT THE 3769 02:22:08,262 --> 02:22:10,598 RARE DISEASE COMMUNITY FACES TO 3770 02:22:10,598 --> 02:22:13,634 WORK TOGETHER TO WORK ON NOT 3771 02:22:13,634 --> 02:22:15,035 JUST THERAPEUTICS BUT THE 3772 02:22:15,035 --> 02:22:16,804 RESOURCES WE CAN MAKE AVAILABLE 3773 02:22:16,804 --> 02:22:18,806 TO THE RARE DISEASE COMMUNITY. 3774 02:22:18,806 --> 02:22:20,407 AND PLATFORMS WE CAN BUILD FROM 3775 02:22:20,407 --> 02:22:23,677 A RESEARCH POINT OF VIEW TO 3776 02:22:23,677 --> 02:22:25,679 ENABLE RESEARCH COMMUNITY TO 3777 02:22:25,679 --> 02:22:28,315 BRING MORE UNDERSTANDING AND 3778 02:22:28,315 --> 02:22:28,883 THERAPEUTICS FOR MORE RARE 3779 02:22:28,883 --> 02:22:30,851 DISEASES. 3780 02:22:30,851 --> 02:22:34,255 I THINK IT'S IMPORTANT TO PAUSE 3781 02:22:34,255 --> 02:22:37,024 AND SAY OF COURSE, DPI HAS A 3782 02:22:37,024 --> 02:22:37,825 WONDERFUL RECORD OF CLINICAL 3783 02:22:37,825 --> 02:22:43,163 SUCCESS AND ONE THAT IS GROWING. 3784 02:22:43,163 --> 02:22:48,869 WE FILED NOW ACROSS ALL THE 3785 02:22:48,869 --> 02:22:49,670 SCIENTIFIC GROUPS, OVER 50 IND 3786 02:22:49,670 --> 02:22:51,338 APPLICATIONS. 3787 02:22:51,338 --> 02:22:56,510 I SAY OVER 50, WE ARE DOING 3788 02:22:56,510 --> 02:22:59,680 CENSUS TAKING TO CAPTURE. 3789 02:22:59,680 --> 02:23:02,249 SOME ARE MOLECULES, AND SOME 3790 02:23:02,249 --> 02:23:02,783 THERAPEUTIC CANDIDATES WE 3791 02:23:02,783 --> 02:23:03,183 ENABLED. 3792 02:23:03,183 --> 02:23:05,419 I WILL GIVE YOU SOME EXAMPLES, 3793 02:23:05,419 --> 02:23:07,087 WE ARE ALREADY UP TO THREE DRUG 3794 02:23:07,087 --> 02:23:08,055 APPROVALS. 3795 02:23:08,055 --> 02:23:11,559 WHICH IS AMAZING. 3796 02:23:11,559 --> 02:23:13,661 NCATS HASN'T EXISTED OVER THE 3797 02:23:13,661 --> 02:23:14,595 LIFETIME OF A SINGLE DRUG 3798 02:23:14,595 --> 02:23:21,135 DEVELOPMENT LIFETIME. 3799 02:23:21,135 --> 02:23:24,271 ONE CHRONIC YEAST INFECTIONS, 3800 02:23:24,271 --> 02:23:34,715 ONE AADC DEFICIENCY, AND 3801 02:23:37,785 --> 02:23:42,056 DUCHENNE MUSCULAR DYSTROPHY. 3802 02:23:42,056 --> 02:23:44,091 I KNOW THAT WILL BE THE CASE 3803 02:23:44,091 --> 02:23:46,026 FROM THE LISTENING SESSIONS. 3804 02:23:46,026 --> 02:23:48,062 ONE OF MY EARLY PRIORITIES IS 3805 02:23:48,062 --> 02:23:49,597 REALLY MAKING SURE WE CAPTURE 3806 02:23:49,597 --> 02:23:51,198 AND COMMUNICATE THE SUCCESSES 3807 02:23:51,198 --> 02:23:52,299 WITH THE SCIENTIFIC COMMUNITY 3808 02:23:52,299 --> 02:23:54,301 WITH PEOPLE WHO CARE ABOUT 3809 02:23:54,301 --> 02:23:56,837 NCATS WHO WANT TO TELL THE 3810 02:23:56,837 --> 02:23:57,338 STORY INCLUDING OUR OWN 3811 02:23:57,338 --> 02:23:58,138 SCIENTISTS. 3812 02:23:58,138 --> 02:24:00,174 THIS IS A MOCK UP OF A WEB PAGE 3813 02:24:00,174 --> 02:24:05,946 WE ARE IN THE PROCESS OF 3814 02:24:05,946 --> 02:24:07,748 PUTTING TOGETHER WITH WONDERFUL 3815 02:24:07,748 --> 02:24:09,550 NCATS COMMUNICATION PAGE WHERE 3816 02:24:09,550 --> 02:24:12,686 PEOPLE WILL SEE THOSE THINGS 3817 02:24:12,686 --> 02:24:14,188 LISTED OUT CONTRIBUTED TO THE 3818 02:24:14,188 --> 02:24:15,823 FILING OR APPROVAL FOR. 3819 02:24:15,823 --> 02:24:17,925 WILL BE ABLE TO CLICK ON THAT 3820 02:24:17,925 --> 02:24:20,694 AND GET INFORMATION ABOUT THE 3821 02:24:20,694 --> 02:24:21,996 PRODUCT, WHAT PATIENTS ARE 3822 02:24:21,996 --> 02:24:22,963 APPROVED THROUGH TREATMENT OF 3823 02:24:22,963 --> 02:24:23,864 THIS MEDICATION. 3824 02:24:23,864 --> 02:24:27,134 WE ARE GOING TO HAVE A STRONG 3825 02:24:27,134 --> 02:24:29,770 FOCUS EARLY ON, COMMUNICATING 3826 02:24:29,770 --> 02:24:35,409 THE AMAZING CONTRIBUTION, NOT 3827 02:24:35,409 --> 02:24:36,276 JUST ALONG SIZE BUT 3828 02:24:36,276 --> 02:24:38,445 THERAPEUTICS. 3829 02:24:38,445 --> 02:24:40,147 ONE PROGRAM THAT EXISTED IN DPI 3830 02:24:40,147 --> 02:24:41,982 I KNOW YOU WOULD HAVE HAD 3831 02:24:41,982 --> 02:24:47,921 PRESENTATIONS ON PREVIOUSLY. 3832 02:24:47,921 --> 02:24:49,289 ESTABLISHED FORMALLY IN 2009 3833 02:24:49,289 --> 02:24:51,558 AND RUNNING BY 2010. 3834 02:24:51,558 --> 02:24:53,360 IT'S REALLY HAD AN AMAZING 3835 02:24:53,360 --> 02:24:57,131 PIPELINE OF THERAPEUTICS FOR 3836 02:24:57,131 --> 02:24:58,832 RARE DISEASES. 3837 02:24:58,832 --> 02:24:59,933 I MENTIONED THE THREE APPROVALS 3838 02:24:59,933 --> 02:25:04,038 AND A SIGNIFICANT NUMBER OF 3839 02:25:04,038 --> 02:25:07,107 IND'S, SORT OF IND FILING LINE. 3840 02:25:07,107 --> 02:25:10,411 YOU CAN SEE WHERE SOME OF THE 3841 02:25:10,411 --> 02:25:11,111 PRODUCTS ARE, CONTINUING 3842 02:25:11,111 --> 02:25:14,281 THROUGH CLINICAL TRIALS. 3843 02:25:14,281 --> 02:25:16,850 IT'S AN INCREDIBLY EXCITING 3844 02:25:16,850 --> 02:25:18,419 PROGRAM, PROFESSIONAL PROGRAM. 3845 02:25:18,419 --> 02:25:20,354 AROUND THE PROJECT MANAGERS 3846 02:25:20,354 --> 02:25:21,855 MANY OF WHOM HAVE PRIVATE 3847 02:25:21,855 --> 02:25:23,991 SECTOR EXPERIENCE. 3848 02:25:23,991 --> 02:25:25,826 STEER THE SCIENCE, PARTNERSHIP 3849 02:25:25,826 --> 02:25:26,393 WITH THE COLLABORATOR AND 3850 02:25:26,393 --> 02:25:28,429 SCIENCES WITHIN. 3851 02:25:28,429 --> 02:25:31,231 I CAN'T GIVE YOU DEEP DETAILS 3852 02:25:31,231 --> 02:25:32,900 ABOUT THEM, THE NEW PROJECTS 3853 02:25:32,900 --> 02:25:35,602 THAT HAVE BEEN ACCEPTED FOR 3854 02:25:35,602 --> 02:25:36,870 2024 HAVE BEEN SENT THEIR 3855 02:25:36,870 --> 02:25:39,840 ACCEPTANCE LETTERS. 3856 02:25:39,840 --> 02:25:40,874 THE AGREEMENTS AREN'T SIGNED 3857 02:25:40,874 --> 02:25:41,975 YET, SO I CAN'T LIST THEM OUT 3858 02:25:41,975 --> 02:25:43,343 FOR YOU. 3859 02:25:43,343 --> 02:25:46,080 I WOULD SAY THERE ARE TEN 3860 02:25:46,080 --> 02:25:47,114 ACCEPTED, AND NINE ARE FOR RARE 3861 02:25:47,114 --> 02:25:48,215 DISEASES. 3862 02:25:48,215 --> 02:25:50,217 YOU WANT TO SHARE WITH YOU, AND 3863 02:25:50,217 --> 02:25:59,693 REALLY CALL THAT OUT. 3864 02:25:59,693 --> 02:26:04,364 PARTNERS COME FROM ACROSS THE 3865 02:26:04,364 --> 02:26:08,102 SECTOR, ACADEMIA, BIOTECH, 3866 02:26:08,102 --> 02:26:10,137 CONSORTIUM, EIGHT ARE NEW 3867 02:26:10,137 --> 02:26:10,804 MOLECULAR ENTITY, ONE IS 3868 02:26:10,804 --> 02:26:11,739 REPOSITIONING PROJECT. 3869 02:26:11,739 --> 02:26:15,909 YOU CAN SEE THERE ARE A NUMBER 3870 02:26:15,909 --> 02:26:18,512 OF INDICATIONS THAT THESE NEW 3871 02:26:18,512 --> 02:26:19,546 PROJECTS COULD BE BUCKETED 3872 02:26:19,546 --> 02:26:20,314 INTO, THEY ARE ARRANGED BY 3873 02:26:20,314 --> 02:26:22,382 SUCCESS. 3874 02:26:22,382 --> 02:26:23,884 YOU CAN SEE REALLY DIVERSE IN 3875 02:26:23,884 --> 02:26:25,719 TERMS OF THE DISEASE AREA. 3876 02:26:25,719 --> 02:26:27,721 SOME PROJECTS MAY TAKE A YEAR 3877 02:26:27,721 --> 02:26:28,956 OR TWO, SOME MAY TAKE FIVE OR 3878 02:26:28,956 --> 02:26:30,257 MORE YEARS. 3879 02:26:30,257 --> 02:26:34,695 BUT THE COMMITMENT IS THERE IN 3880 02:26:34,695 --> 02:26:34,962 EACH CASE. 3881 02:26:34,962 --> 02:26:36,263 TO MOVE THESE THROUGH THE 3882 02:26:36,263 --> 02:26:37,131 PIPELINE AS APPROPRIATE AND 3883 02:26:37,131 --> 02:26:39,833 DEVELOP THEM AND GET THEM TO 3884 02:26:39,833 --> 02:26:41,535 THE FDA FOR IND EVALUATION AND 3885 02:26:41,535 --> 02:26:49,476 PATIENTS IN CLINICAL TRIALS. 3886 02:26:49,476 --> 02:26:50,077 DOMINIQUE TOUCHED BRIEFLY ON 3887 02:26:50,077 --> 02:26:53,680 PAVE-GT. 3888 02:26:53,680 --> 02:26:55,716 INCREDIBLY VALUABLE FROM A 3889 02:26:55,716 --> 02:26:59,119 SCIENTIFIC POINT OF VIEW, THE 3890 02:26:59,119 --> 02:27:02,089 HYPOTHESIS THAT CAME FROM DRI. 3891 02:27:02,089 --> 02:27:04,625 THIS IS A COLLABORATION FROM 3892 02:27:04,625 --> 02:27:09,863 DRDRI AND DPI. 3893 02:27:09,863 --> 02:27:10,430 TO TAKE A PLATFORM VECTOR 3894 02:27:10,430 --> 02:27:12,499 PROECH. 3895 02:27:12,499 --> 02:27:19,473 -- APPROACH. 3896 02:27:19,473 --> 02:27:21,775 TO INCREASE EFFICIENCY IN 3897 02:27:21,775 --> 02:27:22,309 CLINICAL TRIALS FOR GENE 3898 02:27:22,309 --> 02:27:26,213 THERAPIES. 3899 02:27:26,213 --> 02:27:26,980 WITH DPI'S EXPERTISES IN 3900 02:27:26,980 --> 02:27:28,148 PRECLINICAL DEVELOPMENT. 3901 02:27:28,148 --> 02:27:29,850 AND OF COURSE OUR LABORATORY 3902 02:27:29,850 --> 02:27:32,486 CAPABILITIES. 3903 02:27:32,486 --> 02:27:35,823 THE WAY THIS IS BEING PUT 3904 02:27:35,823 --> 02:27:37,224 TOGETHER UNDER THE CONCEPT 3905 02:27:37,224 --> 02:27:39,159 THESE FOUR, THERE ARE TWO 3906 02:27:39,159 --> 02:27:41,195 DIFFERENT DISEASES. 3907 02:27:41,195 --> 02:27:42,296 GENES IN TWO DIFFERENT RARE 3908 02:27:42,296 --> 02:27:44,531 DISEASE FAMILIES. 3909 02:27:44,531 --> 02:27:47,835 THE FOUR GENE THERAPY PROJECTS 3910 02:27:47,835 --> 02:27:53,740 ARE DEVELOPED IN PARALLEL, 3911 02:27:53,740 --> 02:27:57,945 NCATS PRE-CLINICAL SCIENTISTS. 3912 02:27:57,945 --> 02:27:59,947 THIS IS A TRANSNIH PARTNERSHIP 3913 02:27:59,947 --> 02:28:02,983 THAT BRINGS TOGETHER THE 3914 02:28:02,983 --> 02:28:04,117 CLINICAL CENTER TO CONDUCT 3915 02:28:04,117 --> 02:28:06,520 THOSE CLINICAL TRIALS. 3916 02:28:06,520 --> 02:28:07,654 THE COMMONALITIES WILL BE 3917 02:28:07,654 --> 02:28:12,159 LEVERAGED RIGHT AWAY THROUGH 3918 02:28:12,159 --> 02:28:13,660 THE PRE-CLINICAL PHASE AND 3919 02:28:13,660 --> 02:28:15,596 CLINICAL PROTOCOL AS WELL. 3920 02:28:15,596 --> 02:28:17,564 BEYOND THAT THOUGH, I SHOULD 3921 02:28:17,564 --> 02:28:19,967 SAY THIS PROGRAM, ALL THE GENE 3922 02:28:19,967 --> 02:28:21,001 THERAPY PRODUCTS ARE ADVANCING 3923 02:28:21,001 --> 02:28:22,169 THROUGH THE PIPELINES. 3924 02:28:22,169 --> 02:28:23,303 YOU COULD SEE THE CHEVRONS 3925 02:28:23,303 --> 02:28:26,673 HIGHLIGHTED HERE. 3926 02:28:26,673 --> 02:28:27,274 FDA INTERACTIONS HAVE ALREADY 3927 02:28:27,274 --> 02:28:28,876 DONE. 3928 02:28:28,876 --> 02:28:29,810 ALL WORKING THROUGH THE 3929 02:28:29,810 --> 02:28:31,178 DEVELOPMENT TO MAKE SURE IT'S 3930 02:28:31,178 --> 02:28:34,948 KNOWN THEY COULD BE 3931 02:28:34,948 --> 02:28:35,549 MANUFACTURED WELL AND DEFINED 3932 02:28:35,549 --> 02:28:38,719 DISCRETELY. 3933 02:28:38,719 --> 02:28:39,386 I WILL RETURN TO PAVE-GT 3934 02:28:39,386 --> 02:28:41,121 SHORTLY. 3935 02:28:41,121 --> 02:28:42,623 BUT ONE THING TO HIGHLIGHT, 3936 02:28:42,623 --> 02:28:48,428 IT'S NOT JUST ABOUT DEVELOPING 3937 02:28:48,428 --> 02:28:51,932 THE GENE THERAPIES FOR THOSE 3938 02:28:51,932 --> 02:28:52,499 PATIENTS BUT ACROSS INTYRE 3939 02:28:52,499 --> 02:28:55,702 COMMUNITY. 3940 02:28:55,702 --> 02:28:57,938 ENTIRE COMMUNITY. 3941 02:28:57,938 --> 02:29:00,240 THE COMMUNICATIONS WITH THE FDA 3942 02:29:00,240 --> 02:29:02,142 ALL THE DOCUMENTS BEING 3943 02:29:02,142 --> 02:29:03,443 CREATED, THE INTENTION IS TO 3944 02:29:03,443 --> 02:29:04,544 MAKE ALL OF THIS AS OPEN AS 3945 02:29:04,544 --> 02:29:07,180 POSSIBLE. 3946 02:29:07,180 --> 02:29:09,516 NOT JUST THE CLINICAL TRIAL 3947 02:29:09,516 --> 02:29:12,252 DATA BUT ASSOCIATED WITH 3948 02:29:12,252 --> 02:29:13,387 PREPARING THAT CLINICAL TRIAL. 3949 02:29:13,387 --> 02:29:14,821 ALL OF THAT IS MADE AVAILABLE 3950 02:29:14,821 --> 02:29:15,989 ON THE WEB. 3951 02:29:15,989 --> 02:29:19,626 YOU REQUEST CLICK ON THIS QR 3952 02:29:19,626 --> 02:29:21,962 CODE, YOU SHOULD DO LATER, NOT 3953 02:29:21,962 --> 02:29:23,964 NOW, BECAUSE I'M HERE AND YOU 3954 02:29:23,964 --> 02:29:25,165 ARE LISTENING TO ME. 3955 02:29:25,165 --> 02:29:29,236 BUT LATER YOU CAN SEE YOU CAN 3956 02:29:29,236 --> 02:29:32,773 SUBSCRIBE FOR UPDATES. 3957 02:29:32,773 --> 02:29:35,509 ALL OF THE DOCUMENTS AND 3958 02:29:35,509 --> 02:29:37,277 REQUESTS ARE THERE, CAN THINK 3959 02:29:37,277 --> 02:29:39,246 ABOUT THIS IN A WAY AS 3960 02:29:39,246 --> 02:29:41,515 REGULATORY REPURPOSING. 3961 02:29:41,515 --> 02:29:43,350 THE HOPE IS THIS DOCUMENTATION 3962 02:29:43,350 --> 02:29:45,285 AND SUCCESS IT IS LEADING TO 3963 02:29:45,285 --> 02:29:49,356 COULD BE LEARNED FROM BY OTHERS 3964 02:29:49,356 --> 02:29:52,926 TRYING TO WORK IN RARE DISEASE 3965 02:29:52,926 --> 02:29:55,028 FOUNDATIONS, BIOTECH. 3966 02:29:55,028 --> 02:29:56,763 SEE THE DOCUMENTATION AND WHAT 3967 02:29:56,763 --> 02:30:02,703 HAS WORKED AND WHAT COULD BE 3968 02:30:02,703 --> 02:30:03,437 REPURPOSED TO ACCELERATE AS 3969 02:30:03,437 --> 02:30:05,639 MANY AS POSSIBLE. 3970 02:30:05,639 --> 02:30:06,173 WONDERFUL EXAMPLE OF DATA 3971 02:30:06,173 --> 02:30:07,074 SHARING. 3972 02:30:07,074 --> 02:30:10,978 I WANT TO PUT A LITTLE VIGNETTE 3973 02:30:10,978 --> 02:30:13,680 ON OTHER I'M PARTICULARLY 3974 02:30:13,680 --> 02:30:18,785 EXCITED BY CURE ID. 3975 02:30:18,785 --> 02:30:23,991 DR. -- LEADS, PARTNERSHIP 3976 02:30:23,991 --> 02:30:25,792 WITH THE US FDA, CREATING A 3977 02:30:25,792 --> 02:30:27,995 DATA WAREHOUSE. 3978 02:30:27,995 --> 02:30:29,563 FOR INFECTIOUS DISEASES WITH 3979 02:30:29,563 --> 02:30:31,398 THE ORIGINAL GOAL BUT ALSO NOW 3980 02:30:31,398 --> 02:30:32,566 RARE DISEASES AS PART OF THAT 3981 02:30:32,566 --> 02:30:34,501 CONVERSATION. 3982 02:30:34,501 --> 02:30:35,535 THERE ARE NO APPROVED 3983 02:30:35,535 --> 02:30:38,305 TREATMENTS BUT THERE ARE PEOPLE 3984 02:30:38,305 --> 02:30:38,739 TREATED AND TREATED 3985 02:30:38,739 --> 02:30:40,907 SUCCESSFULLY. 3986 02:30:40,907 --> 02:30:42,075 WE WANT TO CAPTURE EACH CASE 3987 02:30:42,075 --> 02:30:47,481 STUDY. 3988 02:30:47,481 --> 02:30:49,149 CAPTURE TREATMENT EXPERIENCE 3989 02:30:49,149 --> 02:30:52,219 FROM CLINICIANS, EXPERIENCE. 3990 02:30:52,219 --> 02:30:53,920 THINKING ABOUT HEALTH RECORDS 3991 02:30:53,920 --> 02:30:55,989 AS WELL AND IDENTIFY SUCCESSES. 3992 02:30:55,989 --> 02:30:58,091 AND SHARE IT BACK WITH THE 3993 02:30:58,091 --> 02:30:58,825 SCIENTIFIC COMMUNITY SO OTHERS 3994 02:30:58,825 --> 02:31:08,201 CAN LEARN DPR IT. 3995 02:31:08,201 --> 02:31:09,202 IT'S AVAILABLE FOR iPHONE APP, 3996 02:31:09,202 --> 02:31:10,871 I DON'T WANT TO SAY A 3997 02:31:10,871 --> 02:31:14,474 PARTICULAR MANIER. 3998 02:31:14,474 --> 02:31:16,676 MANUFACTURER. 3999 02:31:16,676 --> 02:31:19,713 YOU CAN ACCESS THAT WEB PAGE, 4000 02:31:19,713 --> 02:31:20,180 BOTH HAVE EQUIVALENT 4001 02:31:20,180 --> 02:31:21,448 FUNCTIONALITY. 4002 02:31:21,448 --> 02:31:23,683 IT CAME OUT AT A PERFECT TIME, 4003 02:31:23,683 --> 02:31:27,087 THERE WAS AN UPDATE TO COUNCIL 4004 02:31:27,087 --> 02:31:30,624 AROUND 2019 AND THEN COVID CAME. 4005 02:31:30,624 --> 02:31:32,225 WE HAD A SIGNIFICANT AMOUNT OF 4006 02:31:32,225 --> 02:31:34,461 USES. 4007 02:31:34,461 --> 02:31:36,897 WE HAVE OVER 2,000 REGISTERED 4008 02:31:36,897 --> 02:31:37,998 USERS AND THE CLINICIAN REPORTS 4009 02:31:37,998 --> 02:31:39,199 ARE COMING IN. 4010 02:31:39,199 --> 02:31:42,803 WE HAVE BEEN ABLE TO TURN IN 4011 02:31:42,803 --> 02:31:43,870 ELECTRONIC HEALTH RECORDS. 4012 02:31:43,870 --> 02:31:46,273 EVEN THOUGH WE ARE THE U.S. AND 4013 02:31:46,273 --> 02:31:49,810 CARE ABOUT THE U.S. TAXPAYER, 4014 02:31:49,810 --> 02:31:51,945 NOT JUST U.S. ACTIVITY. 4015 02:31:51,945 --> 02:31:57,717 ALL OF THIS IS AVAILABLE TO THE 4016 02:31:57,717 --> 02:31:59,119 SCIENTIFIC COMMUNITY. 4017 02:31:59,119 --> 02:32:01,354 IT COULD BE KICK STARTING NEW 4018 02:32:01,354 --> 02:32:02,789 DRUG REPURPOSING PROGRAMS AS 4019 02:32:02,789 --> 02:32:02,989 WELL. 4020 02:32:02,989 --> 02:32:05,725 A WOND FULL EXAMPLE OF CROWD 4021 02:32:05,725 --> 02:32:06,893 SOURCING AND PROVEN TO BE VERY 4022 02:32:06,893 --> 02:32:08,028 SUCCESSFUL. 4023 02:32:08,028 --> 02:32:10,964 I THINK THE LAST THING I WANTED 4024 02:32:10,964 --> 02:32:13,567 TO SHARE WITH YOU TODAY, WAS AN 4025 02:32:13,567 --> 02:32:18,205 EXAMPLE OF THE KIND OF SCIENCE 4026 02:32:18,205 --> 02:32:19,639 AT DPI THAT REALLY EXCITES ME 4027 02:32:19,639 --> 02:32:21,141 BECAUSE I DIDN'T HAVE ANYTHING 4028 02:32:21,141 --> 02:32:22,175 TO DO WITH IT GETTING STARTED 4029 02:32:22,175 --> 02:32:23,777 AT ALL. 4030 02:32:23,777 --> 02:32:25,412 IT DIDN'T COME FROM LEADERSHIP, 4031 02:32:25,412 --> 02:32:26,646 IT CAME FROM THE SCIENTISTS 4032 02:32:26,646 --> 02:32:29,149 WITHIN DPI. 4033 02:32:29,149 --> 02:32:31,651 I SHOWED YOU OUR ORG OR 4034 02:32:31,651 --> 02:32:36,123 STRUCTURAL KHAIRT LATER ON. 4035 02:32:36,123 --> 02:32:39,226 I HAVE HIGHLIGHTED SOME OF THEM 4036 02:32:39,226 --> 02:32:49,169 HERE, WE ALL FOUND A FUNCTIONAL 4037 02:32:49,169 --> 02:32:49,803 LAB, STEM CELL, PHARMACOLOGICS 4038 02:32:49,803 --> 02:32:54,407 PROGRAM. 4039 02:32:54,407 --> 02:32:55,408 SMALL MOLECULE DISCOVERY, 4040 02:32:55,408 --> 02:32:57,711 INFORMATICS AND AUTOMATION, ALL 4041 02:32:57,711 --> 02:33:00,080 OF THE UNDERLYING TECHNOLOGIES 4042 02:33:00,080 --> 02:33:02,782 NEEDED TO MAKE NCATS SPECIAL. 4043 02:33:02,782 --> 02:33:04,084 THEY HAVE FOUND EACH OTHER AND 4044 02:33:04,084 --> 02:33:05,919 THEY ARE WORKING TOGETHER TO 4045 02:33:05,919 --> 02:33:08,355 TRY TO BUILD THIS PROGRAM 4046 02:33:08,355 --> 02:33:09,089 CALLED I3D-RARE. 4047 02:33:09,089 --> 02:33:11,892 WHAT IS IT? 4048 02:33:11,892 --> 02:33:14,194 WE KNOW THE PROBLEM. 4049 02:33:14,194 --> 02:33:16,396 DOMINIQUE DESCRIBED THE PROBLEM. 4050 02:33:16,396 --> 02:33:18,331 THE PROBLEM IS NOT ONLY THEY 4051 02:33:18,331 --> 02:33:20,333 DON'T HAVE TREATMENT, BUT THEY 4052 02:33:20,333 --> 02:33:22,068 DON'T HAVE A PIPELINE AVAILABLE. 4053 02:33:22,068 --> 02:33:23,803 WE DON'T HAVE THE UNDERSTANDING 4054 02:33:23,803 --> 02:33:25,939 AND MODELS NEEDED FROM A 4055 02:33:25,939 --> 02:33:28,642 PRE-CLINICAL DEVELOPMENT POINT 4056 02:33:28,642 --> 02:33:30,143 OF VIEW. 4057 02:33:30,143 --> 02:33:32,179 SO TACKLE THIS LACK OF 4058 02:33:32,179 --> 02:33:34,881 DISEASE-RELEVANT MODELS. 4059 02:33:34,881 --> 02:33:37,017 RECOGNIZE THAT NON ANIMAL MODS 4060 02:33:37,017 --> 02:33:39,753 NOT ONLY DON'T EXIST, SORRY, 4061 02:33:39,753 --> 02:33:42,055 ANIMAL MODELS DON'T EXIST FOR 4062 02:33:42,055 --> 02:33:44,357 RARE DISEASES BUT THE FDA 4063 02:33:44,357 --> 02:33:48,228 MODERNIZATION ACT 2.0, I DON'T 4064 02:33:48,228 --> 02:33:50,630 THINK CAME UP THIS MORNING, 4065 02:33:50,630 --> 02:33:55,101 WHEN DR. MARKS WAS SPEAKING. 4066 02:33:55,101 --> 02:33:56,303 CELL-BASED ASSAYS TO 4067 02:33:56,303 --> 02:33:56,836 INVESTIGATE SAFETY AND 4068 02:33:56,836 --> 02:33:59,873 EFFECTIVENESS OF A DRUG. 4069 02:33:59,873 --> 02:34:03,577 IF WE CAN CREATE COMPLEX 4070 02:34:03,577 --> 02:34:04,878 CELLULAR MODELS RARE DISEASE, 4071 02:34:04,878 --> 02:34:11,651 DO IT WITH A PLATFORM APPROACH 4072 02:34:11,651 --> 02:34:13,486 WE HAVE THE ABILITY TO 4073 02:34:13,486 --> 02:34:14,487 DEMONSTRATE AS PART OF THE 4074 02:34:14,487 --> 02:34:16,122 REGULATORY WORK. 4075 02:34:16,122 --> 02:34:18,625 BRINGING TOGETHER THE RESEARCH 4076 02:34:18,625 --> 02:34:20,527 ENVIRONMENT AND DRUG DISCOVERY 4077 02:34:20,527 --> 02:34:21,761 ENVIRONMENT WE HAVE MAXIMIZING 4078 02:34:21,761 --> 02:34:25,098 THE EFFICIENCY OF THOSE. 4079 02:34:25,098 --> 02:34:30,370 THESE PERSONALIZED OR 4080 02:34:30,370 --> 02:34:31,004 PREDICTIVE CLINICAL ASSAYS IS 4081 02:34:31,004 --> 02:34:34,107 PART OF THE GOAL. 4082 02:34:34,107 --> 02:34:35,342 STEM CELL DIFFERENTIATION IN 4083 02:34:35,342 --> 02:34:37,143 THE CELL PLEX. 4084 02:34:37,143 --> 02:34:38,311 WE HAVE A PROGRAM DESCRIBED TO 4085 02:34:38,311 --> 02:34:40,247 COUNCIL BEFORE. 4086 02:34:40,247 --> 02:34:46,886 THESE CELLS COULD BE BOUGHT TO 4087 02:34:46,886 --> 02:34:50,523 CREATE 3D CELLULAR MODEL. 4088 02:34:50,523 --> 02:34:52,559 BIO PRINTED. 4089 02:34:52,559 --> 02:34:57,731 RIGHT TO TISSUES ON A CHIP, WE 4090 02:34:57,731 --> 02:35:00,433 HAVE A WONDERFUL PROGRAM AT 4091 02:35:00,433 --> 02:35:02,769 NCATS THROUGH EXTRAMURAL. 4092 02:35:02,769 --> 02:35:04,738 USE THESE MOD HES TO DEVELOP 4093 02:35:04,738 --> 02:35:08,108 ASSAYS. 4094 02:35:08,108 --> 02:35:12,779 ASSESS SAFETY. 4095 02:35:12,779 --> 02:35:13,780 ARTIFICIAL INTELLIGENCE AND 4096 02:35:13,780 --> 02:35:14,781 OTHER OMICS MODELS AND OTHER 4097 02:35:14,781 --> 02:35:16,583 THINGS TO BEAR. 4098 02:35:16,583 --> 02:35:20,220 SO THEY ARE AVAILABLE FOR THE 4099 02:35:20,220 --> 02:35:20,720 SCIENTIFIC COMMUNITY TO 4100 02:35:20,720 --> 02:35:22,255 REPRODUCE. 4101 02:35:22,255 --> 02:35:25,892 ONE NICE ADVANTAGE OF AN 4102 02:35:25,892 --> 02:35:27,027 APPROACH LIKE THIS, A, IT'S NOT 4103 02:35:27,027 --> 02:35:29,663 MICE. 4104 02:35:29,663 --> 02:35:31,031 B, IT'S NOT JUST WUNL MOUSE 4105 02:35:31,031 --> 02:35:35,001 STRAIN. 4106 02:35:35,001 --> 02:35:37,337 YOU COULD BRING STRAINS FROM 4107 02:35:37,337 --> 02:35:38,838 DIFFERENT DONORS TO STUDY 4108 02:35:38,838 --> 02:35:39,973 REPRESENTATIVE CELL LINES 4109 02:35:39,973 --> 02:35:42,342 ACROSS A SINGLE DISEASE AND 4110 02:35:42,342 --> 02:35:43,209 REALLY EMPOWER OUR 4111 02:35:43,209 --> 02:35:44,678 UNDERSTANDING OF THE IMPACT OF 4112 02:35:44,678 --> 02:35:45,478 DIVERSITY IN THE RESEARCH WE 4113 02:35:45,478 --> 02:35:46,613 ARE DOING. 4114 02:35:46,613 --> 02:35:49,983 MOST OF US KNOW WE ARE ONLY 4115 02:35:49,983 --> 02:35:54,387 USING ONE CELL LIERN, IT'S 4116 02:35:54,387 --> 02:35:58,858 POSSIBLE THE SAME CELL LINE 4117 02:35:58,858 --> 02:36:00,560 PILOT STUDIES. 4118 02:36:00,560 --> 02:36:01,194 PAVE-GT, MODELS TO DEMONSTRATE 4119 02:36:01,194 --> 02:36:06,599 THE WORK. 4120 02:36:06,599 --> 02:36:09,669 ALSO ALAGILLE SYNDROME. 4121 02:36:09,669 --> 02:36:11,271 DISEASE MODELING, BUILDING 4122 02:36:11,271 --> 02:36:13,807 MODELS FOR THEM, DR. CATHERINE 4123 02:36:13,807 --> 02:36:15,809 CHEN HERE WHO WILL SPEAK LATER 4124 02:36:15,809 --> 02:36:18,945 ABOUT PROPOSAL IN THIS WORK. 4125 02:36:18,945 --> 02:36:21,715 AND ATAXIA AS WELL. 4126 02:36:21,715 --> 02:36:22,882 BRINGING ALL THESE SCIENTISTS 4127 02:36:22,882 --> 02:36:24,718 TOGETHER, WE DIDN'T BRING THEM 4128 02:36:24,718 --> 02:36:27,053 TOGETHER, THEY BROUGHT EACH 4129 02:36:27,053 --> 02:36:30,990 OTHER TOGETHER, THEY EMBRACED 4130 02:36:30,990 --> 02:36:32,892 THAT TEAM SCIENCE APPROACH WE 4131 02:36:32,892 --> 02:36:35,395 LOVE AT NCATS AND HOW TO BUILD 4132 02:36:35,395 --> 02:36:38,231 ON WHAT THEY STARTED AND 4133 02:36:38,231 --> 02:36:38,765 MAXIMIZE THE BENEFITS TO 4134 02:36:38,765 --> 02:36:42,902 PATIENTS. 4135 02:36:42,902 --> 02:36:45,739 THEY ORGANIZED WORKSHOP TO 4136 02:36:45,739 --> 02:36:47,741 BRING BACK FROM COMMUNITY, THIS 4137 02:36:47,741 --> 02:36:49,809 LINKS TO A VIDEO, DON'T GO TO 4138 02:36:49,809 --> 02:36:52,278 YET, YOU ARE WATCHING THIS 4139 02:36:52,278 --> 02:36:53,513 VIDEO, DO IT LATER. 4140 02:36:53,513 --> 02:36:57,584 YOU SEE A LOT OF INTERACTION OF 4141 02:36:57,584 --> 02:36:59,452 PEOPLE FROM INDUSTRY, NONPROFIT 4142 02:36:59,452 --> 02:37:00,787 SECTORS, GOVERNMENT AND 4143 02:37:00,787 --> 02:37:05,091 ACADEMIA, PROVIDING ADVICE AND 4144 02:37:05,091 --> 02:37:06,326 IMPACT ON THE I3D. 4145 02:37:06,326 --> 02:37:09,028 THERE ARE A SIGNIFICANT NUMBER 4146 02:37:09,028 --> 02:37:10,563 OF ATTENDEES, VERY EXCITING, 4147 02:37:10,563 --> 02:37:11,931 INCLUDING AN INTERNATIONAL 4148 02:37:11,931 --> 02:37:15,001 AUDIENCE AND HAVING A ZOOM 4149 02:37:15,001 --> 02:37:16,236 INSTANCE OR VIDEOCAST ALWAYS 4150 02:37:16,236 --> 02:37:17,737 MAXIMIZES THE NUMBER OF PEOPLE 4151 02:37:17,737 --> 02:37:23,109 WHO CAN LEARN FROM WHAT WE ARE 4152 02:37:23,109 --> 02:37:27,247 DOING AND PROVIDE. 4153 02:37:27,247 --> 02:37:28,181 WITH THAT, 28 MINUTES, I TRIED 4154 02:37:28,181 --> 02:37:30,150 TO GET THERE. 4155 02:37:30,150 --> 02:37:32,685 I JUST WANT TO REINFORCE, WE 4156 02:37:32,685 --> 02:37:34,921 HAVE A DEEP COMMITMENT TO THE 4157 02:37:34,921 --> 02:37:40,326 RARE DISEASE COMMUNITY AND TRY 4158 02:37:40,326 --> 02:37:42,061 TO GET. 4159 02:37:42,061 --> 02:37:44,898 WE WANT TO KEEP PATIENTS AT THE 4160 02:37:44,898 --> 02:37:47,434 CENTER OF EVERYTHING WE DO, DPI 4161 02:37:47,434 --> 02:37:49,369 SCIENCE IS AT THE ENTER AS WELL. 4162 02:37:49,369 --> 02:37:51,604 I WANT TO THANK THEM AND YOUR 4163 02:37:51,604 --> 02:37:52,472 ATTENTION AND LEAVE SOME IMAGES 4164 02:37:52,472 --> 02:37:54,107 OF THE PEOPLE DOING THE WORK 4165 02:37:54,107 --> 02:37:54,908 I'VE BEEN DESCRIBING TODAY. 4166 02:37:54,908 --> 02:38:03,249 THANK YOU VERY MUCH. 4167 02:38:03,249 --> 02:38:05,018 [ APPLAUSE ] 4168 02:38:05,018 --> 02:38:06,386 >> Joni Rutter: THANK YOU, MATT 4169 02:38:06,386 --> 02:38:07,520 THAT WAS TERRIFIC. 4170 02:38:07,520 --> 02:38:09,322 WE HAVE TIME FOR QUESTIONS. 4171 02:38:09,322 --> 02:38:11,057 I WANT TO MAKE A CLARIFICATION, 4172 02:38:11,057 --> 02:38:18,031 WHEN I SPOKE THIS MORNING ABOUT 4173 02:38:18,031 --> 02:38:24,304 THE IMAGING THERAPY, IT'S A 4174 02:38:24,304 --> 02:38:25,805 METHYLMALONIC ACIDEMIA, MATT IS 4175 02:38:25,805 --> 02:38:27,507 WORKING ON ACIDEMIAS AS WELL. 4176 02:38:27,507 --> 02:38:32,278 SO NOW WE ARE ACTUALLY TALKING 4177 02:38:32,278 --> 02:38:33,980 ABOUT THREE DIFFERENT ORGANIC 4178 02:38:33,980 --> 02:38:34,948 ACIDEMIA GENES WE ARE TRYING TO 4179 02:38:34,948 --> 02:38:37,016 PUSH THROUGH. 4180 02:38:37,016 --> 02:38:38,952 BUT THE MMA WON'T GO THROUGH, 4181 02:38:38,952 --> 02:38:40,887 IT'S ACTUALLY AHEAD OF THE GAME. 4182 02:38:40,887 --> 02:38:42,455 WE ARE GOING TO CAPITALIZE ON 4183 02:38:42,455 --> 02:38:44,791 THE FACT WE HAVE EVERYTHING IN 4184 02:38:44,791 --> 02:38:46,426 PLACE BECAUSE OF THE WORK THAT 4185 02:38:46,426 --> 02:38:48,962 WE HAVE BEEN DOING IT THE 4186 02:38:48,962 --> 02:38:50,463 INTRAMURAL PROGRAM AND BECAUSE 4187 02:38:50,463 --> 02:38:51,798 OF DOMINIQUE'S DIVISION AS WELL. 4188 02:38:51,798 --> 02:38:53,299 I THINK THAT'S JUST ONE OF THE 4189 02:38:53,299 --> 02:38:55,268 THINGS I WANTED TO MAKE SURE IT 4190 02:38:55,268 --> 02:39:04,410 WAS QUITE CLEAR. 4191 02:39:04,410 --> 02:39:09,782 >> YES, THANK YOU. 4192 02:39:09,782 --> 02:39:12,519 WE REALLY DEVELOPED AS THE 4193 02:39:12,519 --> 02:39:16,923 LEADER OF GENE THERAPIES AT NIH 4194 02:39:16,923 --> 02:39:19,359 OR FOR NIH, BUT FROM AN 4195 02:39:19,359 --> 02:39:21,060 INTELLECTUAL POINT OF VIEW, 4196 02:39:21,060 --> 02:39:22,462 UNDERSTANDING THE CLINICAL 4197 02:39:22,462 --> 02:39:24,097 CHALLENGES BUT ALSO 4198 02:39:24,097 --> 02:39:27,200 UNDERSTANDING THE COMPLEX 4199 02:39:27,200 --> 02:39:28,801 PRE-CLINICAL DEVELOPMENT 4200 02:39:28,801 --> 02:39:29,068 PIPELINE. 4201 02:39:29,068 --> 02:39:31,871 IT'S VERY EXPENSIVE SCIENCE IS. 4202 02:39:31,871 --> 02:39:36,910 BUT WORKING WITH OTHERS WE ARE 4203 02:39:36,910 --> 02:39:38,411 EXCITED FOR NEW GENE THERAPIES 4204 02:39:38,411 --> 02:39:39,412 AND GETTING THEM TO PATIENTS. 4205 02:39:39,412 --> 02:39:40,947 >> Joni Rutter: I COULDN'T 4206 02:39:40,947 --> 02:39:41,748 AGREE MORE. 4207 02:39:41,748 --> 02:39:43,716 ONE THING IT BRINGS IS THE 4208 02:39:43,716 --> 02:39:45,184 POWER OF THE PROGRAM MANAGERS 4209 02:39:45,184 --> 02:39:48,655 HELPING US TO DO THAT SO WELL. 4210 02:39:48,655 --> 02:39:50,256 COORDINATING ACTIVITIES NOT 4211 02:39:50,256 --> 02:39:52,025 JUST THROUGH NCATS BUT THE 4212 02:39:52,025 --> 02:39:57,363 GROUPS ACROSS NIH AND THEY ARE 4213 02:39:57,363 --> 02:40:03,269 INCREDIBLY EFFECTIVE. 4214 02:40:03,269 --> 02:40:06,105 I SEE YOUR HAND UP, GO AHEAD. 4215 02:40:06,105 --> 02:40:08,408 >> PAUL: ALL OF THE PROGRAMS 4216 02:40:08,408 --> 02:40:10,743 YOU INHERITED AS WELL AS ONES 4217 02:40:10,743 --> 02:40:12,078 YOU ARE PUSHING FORWARD. 4218 02:40:12,078 --> 02:40:17,050 YOU DID A GREAT JOB TELLING US 4219 02:40:17,050 --> 02:40:20,353 HOW THE SCIENCE, YOU HAVE GREAT 4220 02:40:20,353 --> 02:40:21,220 MECHANISMS TO LISTEN TO 4221 02:40:21,220 --> 02:40:22,989 SCIENTISTS AND THEY ARE 4222 02:40:22,989 --> 02:40:23,790 EMPOWERED TO CHIRP THEIR VOICE 4223 02:40:23,790 --> 02:40:25,291 AND THAT'S ONE OF THE REASONS 4224 02:40:25,291 --> 02:40:27,660 THIS IS COMING TOGETHER. 4225 02:40:27,660 --> 02:40:29,729 YOU ALSO HAVE NCATS GREAT 4226 02:40:29,729 --> 02:40:33,132 RESOURCE IN YOUR CONNECTION TO 4227 02:40:33,132 --> 02:40:34,500 ADVOCACY, AND COMMUNITY 4228 02:40:34,500 --> 02:40:34,801 ENGAGEMENT. 4229 02:40:34,801 --> 02:40:36,502 CAN YOU TALK A LITTLE HOW YOU 4230 02:40:36,502 --> 02:40:40,039 ARE USING THAT INPUT TO SUPPORT 4231 02:40:40,039 --> 02:40:40,640 THE DECISION IN THE PROGRAM 4232 02:40:40,640 --> 02:40:43,276 DIRECTION? 4233 02:40:43,276 --> 02:40:43,910 >> YEAH, CERTAINLY, 4234 02:40:43,910 --> 02:40:44,777 COLLABORATION PROPOSALS HAVE 4235 02:40:44,777 --> 02:40:47,413 COME TO US FROM ACADEMICS. 4236 02:40:47,413 --> 02:40:49,749 SOME, TAKE THE PRIVATE SECTOR, 4237 02:40:49,749 --> 02:40:52,118 SOME COME DIRECTLY FROM RARE 4238 02:40:52,118 --> 02:40:54,887 DISEASE FOUNDATION PARENTS. 4239 02:40:54,887 --> 02:40:55,421 OFTEN THROUGH CONNECTIONS 4240 02:40:55,421 --> 02:40:58,558 THROUGH DRDRI. 4241 02:40:58,558 --> 02:41:00,960 SOME WE PROVIDE ADVICE AND 4242 02:41:00,960 --> 02:41:02,495 GUIDANCE, OTHERS WE FORM 4243 02:41:02,495 --> 02:41:03,997 COLLABORATION TO HELP THEM WITH 4244 02:41:03,997 --> 02:41:08,935 THAT PROCESS AND MATCH MAKE. 4245 02:41:08,935 --> 02:41:10,770 I WOULD SAY THAT FROM A 4246 02:41:10,770 --> 02:41:12,271 COLLABORATION POINT OF VIEW 4247 02:41:12,271 --> 02:41:13,473 THAT OVER CONCENTRATED WE DO 4248 02:41:13,473 --> 02:41:15,174 THE BEST WE CAN, BUT LIMITED BY 4249 02:41:15,174 --> 02:41:16,409 THE BUDGET WE HAVE. 4250 02:41:16,409 --> 02:41:18,378 BUT WE DO A LOT OF MATCHMAKING 4251 02:41:18,378 --> 02:41:22,081 TO TRY TO BE AS HELPFUL AS 4252 02:41:22,081 --> 02:41:22,682 POSSIBLE IN PARTNERSHIP WITH 4253 02:41:22,682 --> 02:41:23,783 DRDRI. 4254 02:41:23,783 --> 02:41:25,618 IN TERMS OF COMMUNITY INPUT IN 4255 02:41:25,618 --> 02:41:27,420 THE PROJECTS WE TAKE ON, SOME 4256 02:41:27,420 --> 02:41:31,391 OF THE LATER STAGE PROJECTS I 4257 02:41:31,391 --> 02:41:35,428 WAS DESCRIBING, RARE DISEASES 4258 02:41:35,428 --> 02:41:36,929 PROGRAM THEY NEED TO SEE THE 4259 02:41:36,929 --> 02:41:39,432 PATHWAY AND HAS TO UNDERSTAND 4260 02:41:39,432 --> 02:41:40,900 THE LANDSCAPE OF OTHER 4261 02:41:40,900 --> 02:41:42,602 THERAPEUTICS AND WHAT IS THE 4262 02:41:42,602 --> 02:41:44,303 ENGAGEMENT IS WITH RARE DISEASE 4263 02:41:44,303 --> 02:41:45,104 COMMUNITY AND RARE DISEASE 4264 02:41:45,104 --> 02:41:46,439 FOUNDATIONS. 4265 02:41:46,439 --> 02:41:48,975 ONE OF THE THINGS JONI AND I 4266 02:41:48,975 --> 02:41:51,277 HAVEN'T HAD A LONG CONVERSATION 4267 02:41:51,277 --> 02:41:53,913 ABOUT YET, BUT ON MY LIST WHEN 4268 02:41:53,913 --> 02:41:56,516 BEING INTERVIEWED, IS HOW TO 4269 02:41:56,516 --> 02:41:57,950 BUILD A SCIENTIFIC ADVISORY, I 4270 02:41:57,950 --> 02:41:59,585 WAS GOING TO SAY BOARD, BUT 4271 02:41:59,585 --> 02:42:01,954 SOME TYPE OF GROUP WITH THE 4272 02:42:01,954 --> 02:42:03,923 RARE DISEASE COMMUNITY, RATHER 4273 02:42:03,923 --> 02:42:05,825 THAN FROM SCIENTISTS THEMSELVES. 4274 02:42:05,825 --> 02:42:09,195 AND TRY TO GET FEEDBACK FROM 4275 02:42:09,195 --> 02:42:10,663 THEM AND ALSO LET THEM HEAR 4276 02:42:10,663 --> 02:42:15,435 FROM US ABOUT WHAT WE ARE DOING. 4277 02:42:15,435 --> 02:42:17,804 COUNCIL IS A GREAT FORMAL WAY 4278 02:42:17,804 --> 02:42:20,173 TO BUILD ENGAGEMENT THERE. 4279 02:42:20,173 --> 02:42:21,307 RARE DISEASE DAY, MY FAVORITE 4280 02:42:21,307 --> 02:42:22,809 DAY OF THE YEAR, LIKE 4281 02:42:22,809 --> 02:42:24,310 EVERYBODY, WE GET TO GO, 4282 02:42:24,310 --> 02:42:26,846 DOMINIQUE YOU SAID BEFORE, BUT 4283 02:42:26,846 --> 02:42:29,682 THE IDEA THAT EVERYBODY 4284 02:42:29,682 --> 02:42:32,418 ACTUALLY WANTS TO BE THERE, 4285 02:42:32,418 --> 02:42:34,520 UNLIKE MOST THINGS I GO TO. 4286 02:42:34,520 --> 02:42:36,222 IT GENUINELY FEELS THAT WAY. 4287 02:42:36,222 --> 02:42:36,923 IT'S THE MOST MAGICAL DAY OF 4288 02:42:36,923 --> 02:42:38,691 THE YEAR. 4289 02:42:38,691 --> 02:42:40,827 TRYING TO NOT MAKE THAT A 4290 02:42:40,827 --> 02:42:42,462 ONE-DAY A YEAR THING IS VERY 4291 02:42:42,462 --> 02:42:51,304 IMPORTANT TO ME. 4292 02:42:51,304 --> 02:42:53,973 >> Joni Rutter: ALL RIGHT. 4293 02:42:53,973 --> 02:42:54,674 ANY OTHER QUESTIONS FOR DR. 4294 02:42:54,674 --> 02:42:56,609 HALL? 4295 02:42:56,609 --> 02:42:58,211 OKAY, SO MAYBE IN ANOTHER YEAR 4296 02:42:58,211 --> 02:42:59,278 WE WILL HAVE ANOTHER TOUR. 4297 02:42:59,278 --> 02:43:00,880 >> I WAS ABOUT TO SAY, PLEASE 4298 02:43:00,880 --> 02:43:02,682 COME AND VISIT ANY TIME. 4299 02:43:02,682 --> 02:43:04,083 AT LEAST TWO PEOPLE WHO WILL 4300 02:43:04,083 --> 02:43:05,518 NOT LIKE ME SAYING THAT. 4301 02:43:05,518 --> 02:43:07,520 PLEASE COME AND VISIT ANY TIME. 4302 02:43:07,520 --> 02:43:09,856 I'M SORRY I WASN'T HERE WHEN WE 4303 02:43:09,856 --> 02:43:12,959 DID THE LUNCH TOUR BUT ALWAYS 4304 02:43:12,959 --> 02:43:13,559 WELCOME. 4305 02:43:13,559 --> 02:43:14,393 THANK YOU VERY MUCH. 4306 02:43:14,393 --> 02:43:15,061 >> Joni Rutter: THANK YOU VERY 4307 02:43:15,061 --> 02:43:16,295 MUCH. 4308 02:43:16,295 --> 02:43:19,031 OKAY, WE ARE ABOUT, I WOULD SAY 4309 02:43:19,031 --> 02:43:20,266 ABOUT MAYBE FIVE MINUTES AHEAD 4310 02:43:20,266 --> 02:43:22,235 OF SCHEDULE. 4311 02:43:22,235 --> 02:43:24,704 SO LET'S TAKE A 20-MINUTE BREAK. 4312 02:43:24,704 --> 02:43:29,642 AND WE WILL RECONVENE AT 2:20, 4313 02:43:29,642 --> 02:43:31,344 WHERE WE WILL GO THROUGH OUR 4314 02:43:31,344 --> 02:43:32,245 CONCEPT CLEARANCES. 4315 02:43:32,245 --> 02:43:34,013 AND RIGHT AFTER THAT, WE WILL 4316 02:43:34,013 --> 02:43:34,647 GO INTO OUR STRATEGIC PLANNING 4317 02:43:34,647 --> 02:43:37,250 DISCUSSION. 4318 02:43:37,250 --> 02:43:39,452 OH. 4319 02:43:39,452 --> 02:43:41,154 AND THERE ARE SNACKS BACK HERE. 4320 02:43:41,154 --> 02:43:41,888 SO PLEASE, HELP YOURSELVES. 4321 02:43:41,888 --> 02:43:44,048 THANK YOU. 4322 02:43:46,775 --> 02:43:52,781 CLEARANCE OF CONCEPTS OF 4323 02:43:52,781 --> 02:43:55,383 SPECIAL INITIATIVES. 4324 02:43:55,383 --> 02:43:57,619 TAN TAGLE, ARE YOU THERE? 4325 02:43:57,619 --> 02:43:58,820 >> DAN: I AM. 4326 02:43:58,820 --> 02:44:02,257 >> I THINK HE IS IN JAPAN AND 4327 02:44:02,257 --> 02:44:05,126 IT'S LIKE 3:00 IN THE MORNING. 4328 02:44:05,126 --> 02:44:07,929 >> DAN: THANK YOU, JONI. 4329 02:44:07,929 --> 02:44:12,767 I'M DAN TAGLE, DIRECTOR FOR THE 4330 02:44:12,767 --> 02:44:14,703 OFFICE OF SPECIAL INITIATIVES 4331 02:44:14,703 --> 02:44:15,603 HERE AT NCATS. 4332 02:44:15,603 --> 02:44:18,840 IF YOU GO TO THE NEXT SLIDE, 4333 02:44:18,840 --> 02:44:24,179 PLEASE, OUR MISSION IN THE 4334 02:44:24,179 --> 02:44:27,015 OFFICE IS TO DEVELOP INNOVATIVE 4335 02:44:27,015 --> 02:44:28,750 SOLUTIONS THROUGH DISRUPTIVE 4336 02:44:28,750 --> 02:44:30,819 TECHNOLOGIES IN ORDER TO 4337 02:44:30,819 --> 02:44:32,420 ADDRESS MAJOR TRANSLATIONAL 4338 02:44:32,420 --> 02:44:32,687 PROBLEMS. 4339 02:44:32,687 --> 02:44:34,289 WITH THE END IN MIND OF 4340 02:44:34,289 --> 02:44:34,990 CREATING A PARADIGM SHIFT IN 4341 02:44:34,990 --> 02:44:37,726 THE FIELD. 4342 02:44:37,726 --> 02:44:39,728 SO THE NEXT SLIDE SHOULD GIVE 4343 02:44:39,728 --> 02:44:41,963 YOU, SORT OF LIKE A BIRD'S EYE 4344 02:44:41,963 --> 02:44:46,901 VIEW OF WHAT'S GOING ON RIGHT 4345 02:44:46,901 --> 02:44:48,203 NOW IN THE OFFICE. 4346 02:44:48,203 --> 02:44:53,174 WE CERTAINLY HAVE A NUMBER OF 4347 02:44:53,174 --> 02:44:58,013 DIFFERENT PROGRAMS THAT SPANS 4348 02:44:58,013 --> 02:45:03,284 FROM FUNDAMENTAL RESEARCH TO 4349 02:45:03,284 --> 02:45:10,158 REGULATORY ACCEPTANCE AND ALL 4350 02:45:10,158 --> 02:45:12,394 ADHERE TO PRINCIPLE OF 4351 02:45:12,394 --> 02:45:13,294 DEVELOPING, DEMONSTRATING AND 4352 02:45:13,294 --> 02:45:15,597 DISSEMINATING THE TECHNOLOGY. 4353 02:45:15,597 --> 02:45:18,700 FOR THIS CONCEPT WE HAVE A 4354 02:45:18,700 --> 02:45:21,703 PARTICULAR CONCEPT ON QUANTUM 4355 02:45:21,703 --> 02:45:24,806 TECHNOLOGIES THAT WILL BE 4356 02:45:24,806 --> 02:45:26,841 INTRODUCED BY DR. GEETHA 4357 02:45:26,841 --> 02:45:29,244 SENTHIL. 4358 02:45:29,244 --> 02:45:33,882 SHE HOLDS A DOCTORATE IN 4359 02:45:33,882 --> 02:45:40,722 MOLECULAR GENETICS FROM 4360 02:45:40,722 --> 02:45:41,256 UNIVERSITY OF GANDHI AND 4361 02:45:41,256 --> 02:45:42,857 SCOTLAND. 4362 02:45:42,857 --> 02:45:46,327 BECOMING ONE OF THE LEADING 4363 02:45:46,327 --> 02:45:50,598 EXPERTS NOT ONLY WITHIN NCATS 4364 02:45:50,598 --> 02:45:54,002 BUT WITH NIH IN QUANTUM 4365 02:45:54,002 --> 02:45:55,403 TECHNOLOGIES AND HELP 4366 02:45:55,403 --> 02:45:56,304 COORDINATE EFFORTS ACROSS 4367 02:45:56,304 --> 02:45:57,105 AGENCIES AND AS WELL AS 4368 02:45:57,105 --> 02:45:57,939 GLOBALLY. 4369 02:45:57,939 --> 02:45:59,374 WITH THAT I WILL TURN IT OVER 4370 02:45:59,374 --> 02:46:03,812 TO GEETHA. 4371 02:46:03,812 --> 02:46:06,014 >> GEETHA: THANK YOU, DAN FOR 4372 02:46:06,014 --> 02:46:09,350 THE INTRODUCTION. 4373 02:46:09,350 --> 02:46:12,687 I'M DELIGHTED TO PRESENT THIS 4374 02:46:12,687 --> 02:46:14,456 QUANTUM ENABLED TECHNOLOGIES 4375 02:46:14,456 --> 02:46:15,190 FOR BIOMEDICAL APPLICATIONS FOR 4376 02:46:15,190 --> 02:46:16,558 YOUR CONSIDERATION. 4377 02:46:16,558 --> 02:46:18,126 ONE OF THE CHALLENGES WE 4378 02:46:18,126 --> 02:46:19,160 DISCUSSED TODAY EARLIER IS ALSO 4379 02:46:19,160 --> 02:46:24,132 WHAT WE ARE GOOING TO TALK 4380 02:46:24,132 --> 02:46:31,706 ABOUT AGAIN, THE DETECTION OF 4381 02:46:31,706 --> 02:46:37,445 DISEASES EARLY ON. 4382 02:46:37,445 --> 02:46:39,981 WE ARE UNABLE TO DETECT MANY 4383 02:46:39,981 --> 02:46:44,586 DISEASES EARLY ON AND CAN'T 4384 02:46:44,586 --> 02:46:49,257 ACCURATELY DIAGNOSE THEM. 4385 02:46:49,257 --> 02:46:50,058 BECAUSE OF THE HIGH BACKGROUND 4386 02:46:50,058 --> 02:46:51,493 NOISE. 4387 02:46:51,493 --> 02:46:53,561 WE ARE UNABLE TO MONITOR THE 4388 02:46:53,561 --> 02:46:55,763 DISEASE OVER TIME BECAUSE THE 4389 02:46:55,763 --> 02:46:57,398 SIGNALS FROM THESE METHODS ARE 4390 02:46:57,398 --> 02:47:03,738 NOT STABLE, SO WE CAN'T JUST 4391 02:47:03,738 --> 02:47:04,873 TRACK THE CHANGES IN DISEASE 4392 02:47:04,873 --> 02:47:07,475 MARKERS. 4393 02:47:07,475 --> 02:47:15,049 THE OTHER ISSUE WE HAVE 4394 02:47:15,049 --> 02:47:15,650 COMPUTATIONAL LIMITATIONS IN 4395 02:47:15,650 --> 02:47:17,986 ANALYZING COMPLEX DATA. 4396 02:47:17,986 --> 02:47:19,387 THE CURRENT MACHINE LEARNING 4397 02:47:19,387 --> 02:47:22,223 METHODS DON'T REALLY WORK WELL 4398 02:47:22,223 --> 02:47:23,758 WITH SMALL DATASETS THAT ARE 4399 02:47:23,758 --> 02:47:26,161 NOISY, SUCH AS IN THE CASE OF 4400 02:47:26,161 --> 02:47:28,696 RARE DISEASES, WE HEARD FROM 4401 02:47:28,696 --> 02:47:30,632 DOMINIQUE WE HAVE SPARSE 4402 02:47:30,632 --> 02:47:34,169 INFORMATION ON THESE PATIENTS. 4403 02:47:34,169 --> 02:47:36,871 AND DIAGNOSING IS A CHALLENGE, 4404 02:47:36,871 --> 02:47:38,072 ACCURATE DIAGNOSIS IN RARE 4405 02:47:38,072 --> 02:47:38,806 DISEASES. 4406 02:47:38,806 --> 02:47:43,745 THE OTHER PROBLEM IS THE 4407 02:47:43,745 --> 02:47:47,081 METRICS WE HAVE CAN'T DETECT 4408 02:47:47,081 --> 02:47:48,783 SUCH DIFFERENCES TO DETECT 4409 02:47:48,783 --> 02:47:49,317 EARLY CHANGES RELATED TO 4410 02:47:49,317 --> 02:47:51,619 DISEASE. 4411 02:47:51,619 --> 02:47:54,756 SO THESE STRUGGLES WE HAVE IN 4412 02:47:54,756 --> 02:47:55,790 EARLY DETECTION AND ACTUAL 4413 02:47:55,790 --> 02:47:57,492 DIAGNOSIS. 4414 02:47:57,492 --> 02:47:59,794 AND THERE ARE NOW NEXT 4415 02:47:59,794 --> 02:48:00,828 GENERATION QUANTUM TECHNOLOGIES 4416 02:48:00,828 --> 02:48:01,763 THAT CAN HELP US SOLVE THIS 4417 02:48:01,763 --> 02:48:03,131 PROBLEM. 4418 02:48:03,131 --> 02:48:09,437 AND WHAT WE ARE PROPOSING IS TO 4419 02:48:09,437 --> 02:48:11,072 CATALYZE THE APPLICATIONAL 4420 02:48:11,072 --> 02:48:12,373 QUANTUM TECHNOLOGY TO PROVIDE 4421 02:48:12,373 --> 02:48:13,575 INNOVATIVE SOLUTIONS AND 4422 02:48:13,575 --> 02:48:18,213 BROADEN OUR CAPABILITIES IN 4423 02:48:18,213 --> 02:48:20,715 EARLY DETECTION, DIAGNOSIS AS 4424 02:48:20,715 --> 02:48:22,483 WELL AS THERAPEUTIC DEVELOPMENT. 4425 02:48:22,483 --> 02:48:28,823 WHY ARE WE EXCITED ABOUT THE 4426 02:48:28,823 --> 02:48:29,757 NEXT GENERATION QUANTUM 4427 02:48:29,757 --> 02:48:31,392 TECHNOLOGIES AND WHY DO WE 4428 02:48:31,392 --> 02:48:32,026 THINK THEY CAN SOLVE THIS PROB 4429 02:48:32,026 --> 02:48:42,103 HEM? 4430 02:48:48,810 --> 02:48:52,480 -PROBLEM. 4431 02:48:52,480 --> 02:49:02,690 [ NO AUDIO ] 4432 02:49:15,570 --> 02:49:18,506 >> JONI, I'M SORRY TO 4433 02:49:18,506 --> 02:49:19,641 INTERRUPT, BUT WE CANNOT HEAR. 4434 02:49:19,641 --> 02:49:29,884 WE LOST AUDIO. 4435 02:49:35,143 --> 02:49:37,078 >> Joni Rutter: OKAY, I SEE THUMB'S UP. 4436 02:49:37,078 --> 02:49:38,646 THANK YOU, SOMEHOW WE GOT 4437 02:49:38,646 --> 02:49:41,316 DISCONNECTED UP THERE. 4438 02:49:41,316 --> 02:49:43,551 >> GEETHA: I CAN GO BACK TO ONE 4439 02:49:43,551 --> 02:49:48,957 MINUTE BACK TO TALK ABOUT THE 4440 02:49:48,957 --> 02:49:51,693 QUANTUM SENSING TECHNOLOGY. 4441 02:49:51,693 --> 02:49:56,364 WE USE ENGINEERED ATOMS WE CAN 4442 02:49:56,364 --> 02:49:57,198 DETECT SINGLE MARKER WITH GREAT 4443 02:49:57,198 --> 02:49:59,367 SENSITIVITY. 4444 02:49:59,367 --> 02:50:02,036 LIKE THE CURRENT METHOD, THEY 4445 02:50:02,036 --> 02:50:04,038 ARE NOT SENSITIVE, THEY NEED 4446 02:50:04,038 --> 02:50:05,140 HUNDREDS AND THOUSANDS OF 4447 02:50:05,140 --> 02:50:06,141 MOLECULES TO BE PRESENT BEFORE 4448 02:50:06,141 --> 02:50:08,643 THEY WERE ABLE TO PICK UP THE 4449 02:50:08,643 --> 02:50:10,512 DISEASE. 4450 02:50:10,512 --> 02:50:14,349 IN THIS CASE THE CURRENT 4451 02:50:14,349 --> 02:50:16,284 METHODS DEPEND ON AVERAGE OF 4452 02:50:16,284 --> 02:50:20,688 SIGNALS FROM THOUSANDS OF 4453 02:50:20,688 --> 02:50:22,857 MOLECULES SO THEY ARE NOT 4454 02:50:22,857 --> 02:50:25,059 PRECISE OR SENSITIVE. 4455 02:50:25,059 --> 02:50:27,162 IN THE QUANTUM SENSORS SINCE WE 4456 02:50:27,162 --> 02:50:29,197 ARE MEASURING IT IN AN ATOMIC 4457 02:50:29,197 --> 02:50:33,334 SCALE WE ARE ABLE TO LOOK AT 4458 02:50:33,334 --> 02:50:34,469 INDIVIDUAL MARKERS SUGGESTED 4459 02:50:34,469 --> 02:50:36,971 CELLS, WE CAN MONITOR THEM OVER 4460 02:50:36,971 --> 02:50:37,906 TIME INSTEAD OF AVERAGING THE 4461 02:50:37,906 --> 02:50:40,275 SIGNALS. 4462 02:50:40,275 --> 02:50:42,343 WE CAN BE MORE PRECISE, 4463 02:50:42,343 --> 02:50:43,478 ACCURATE AND BETTER RESOLUTION. 4464 02:50:43,478 --> 02:50:47,749 IN THE CASE OF QUANTUM 4465 02:50:47,749 --> 02:50:49,417 COMPUTING, LET'S SEE, THE SLIDE 4466 02:50:49,417 --> 02:50:52,587 IS NOT ADVANCING. 4467 02:50:52,587 --> 02:50:58,726 OKAY. 4468 02:50:58,726 --> 02:51:00,762 THE CASE OF QUANTUM COMPUTING, 4469 02:51:00,762 --> 02:51:03,631 THE ENGINEERED ATOMS COULD BE 4470 02:51:03,631 --> 02:51:07,268 USED TO PERFORM COMPUTATIONAL 4471 02:51:07,268 --> 02:51:14,742 TASKS WITH ATOMS CALLED KUBITS. 4472 02:51:14,742 --> 02:51:19,981 -- QUBIT. 4473 02:51:19,981 --> 02:51:27,856 WE CAN COMPUTE ON COMPLEX 4474 02:51:27,856 --> 02:51:28,489 BIOMEDICAL DATA AT MUCH HIGHER 4475 02:51:28,489 --> 02:51:31,359 SPEED. 4476 02:51:31,359 --> 02:51:33,461 AND THEY CAN PROVIDE IMPROVED 4477 02:51:33,461 --> 02:51:36,331 PREDICTION. 4478 02:51:36,331 --> 02:51:38,666 SMALLER TRAINING DATASETS WHICH 4479 02:51:38,666 --> 02:51:39,767 IS PARTICULARLY INTERESTING IN 4480 02:51:39,767 --> 02:51:43,905 THE CASE OF RARE DISEASES. 4481 02:51:43,905 --> 02:51:45,406 WHERE ARE WE WITH THESE TWO 4482 02:51:45,406 --> 02:51:46,441 TECHNOLOGIES? 4483 02:51:46,441 --> 02:51:48,176 I WILL GIVE YOU TWO EXAMPLES TO 4484 02:51:48,176 --> 02:51:49,477 TALK ABOUT THE STAGE OF THESE 4485 02:51:49,477 --> 02:51:50,511 TECHNOLOGIES. 4486 02:51:50,511 --> 02:52:00,955 THE FIRST ONE IS QUANTUM 4487 02:52:04,893 --> 02:52:05,727 SPECIFIC TECHNOLOGIES, MORE 4488 02:52:05,727 --> 02:52:07,729 MATURE IT'S READY FOR YOUR OWN 4489 02:52:07,729 --> 02:52:13,501 APPLICATION AND EXAMPLE OF 4490 02:52:13,501 --> 02:52:15,670 QUANTUM ATOMIC MAGNETOMETER. 4491 02:52:15,670 --> 02:52:26,214 STUDIES ARE BEING DONE THROUGH 4492 02:52:28,783 --> 02:52:32,820 CLINICAL DEVICES CALLED SQUID 4493 02:52:32,820 --> 02:52:39,460 -- WHICH ARE BULKY AND THEY 4494 02:52:39,460 --> 02:52:39,994 NEED CRYOGENICS, THEY ARE 4495 02:52:39,994 --> 02:52:44,933 EXPENSIVE,. 4496 02:52:44,933 --> 02:52:47,168 THE MODERN ARE WEARABLE, 4497 02:52:47,168 --> 02:52:47,669 PORTABLE AND DON'T NEED 4498 02:52:47,669 --> 02:52:52,407 CRYOGENICKS. 4499 02:52:52,407 --> 02:52:55,877 WE CAN GET MUCH BETTER SIGNAL 4500 02:52:55,877 --> 02:52:58,379 QUALITY IN DETECTING REALLY 4501 02:52:58,379 --> 02:53:00,682 SUBTLE DIFFERENCES IN CARDIAC 4502 02:53:00,682 --> 02:53:02,617 FUNCTION DEFECTS AS WELL AS IN 4503 02:53:02,617 --> 02:53:05,753 THE BRAIN ACTIVITY. 4504 02:53:05,753 --> 02:53:13,594 THEY ARE EASY TO USE ON 4505 02:53:13,594 --> 02:53:18,366 CHILDREN TO DETECT FOR EXAMPLE, 4506 02:53:18,366 --> 02:53:20,501 IN EPILEPSY AND RARE DISEASES. 4507 02:53:20,501 --> 02:53:23,538 IF YOU HAVE HANDHELD DEVICE OF 4508 02:53:23,538 --> 02:53:27,675 THIS KIND TO USE ON A PREGNANT 4509 02:53:27,675 --> 02:53:33,014 WOMAN TO DETECT RARE GENETIC 4510 02:53:33,014 --> 02:53:34,248 CONDITION, FETAL CARDIAC 4511 02:53:34,248 --> 02:53:36,117 ARRHYTHMIA. 4512 02:53:36,117 --> 02:53:40,288 THEY ARE COST EFFECTIVE, THEY 4513 02:53:40,288 --> 02:53:41,756 CAN BE SCALABLE AND DEPLOYED IN 4514 02:53:41,756 --> 02:53:42,790 MORE SITUATIONS. 4515 02:53:42,790 --> 02:53:45,626 THEY ARE THE ADVANTAGES. 4516 02:53:45,626 --> 02:53:48,363 THE TYPE OF QUANTUM COMPUTING, 4517 02:53:48,363 --> 02:53:51,199 UNLIKE QUANTUM SENSING THIS IS 4518 02:53:51,199 --> 02:53:52,166 EARLY STAGE, IT'S EMERGING 4519 02:53:52,166 --> 02:53:55,503 THOUGH RAPIDLY. 4520 02:53:55,503 --> 02:53:58,072 THIS IS ONE EXAMPLE WHERE 4521 02:53:58,072 --> 02:54:00,108 QUANTUM COMPUTING COULD BE 4522 02:54:00,108 --> 02:54:00,675 USEFUL IN ACCELERATING DRUG 4523 02:54:00,675 --> 02:54:02,777 DISCOVERY. 4524 02:54:02,777 --> 02:54:08,583 THE CURRENT INDUSTRY STANDARD 4525 02:54:08,583 --> 02:54:10,184 COMPUTATIONAL METHODS ARE 4526 02:54:10,184 --> 02:54:11,085 TEDIOUS, LENGTHY, INVOLVES 4527 02:54:11,085 --> 02:54:13,521 MULTIPLE STEPS AND TAKES YEARS 4528 02:54:13,521 --> 02:54:14,622 AND MILLIONS OF DOLLARS AND 4529 02:54:14,622 --> 02:54:17,759 THEY ARE NOT ALL THAT ACCURATE. 4530 02:54:17,759 --> 02:54:18,559 WITH QUANTUM COMPUTING, THE 4531 02:54:18,559 --> 02:54:22,230 HOPE IS THEY CAN DO THIS MUCH 4532 02:54:22,230 --> 02:54:28,069 FASTER AND DO DRUG TARGET 4533 02:54:28,069 --> 02:54:29,570 INTERACTIONS SIMULATIONS MORE 4534 02:54:29,570 --> 02:54:32,273 ACCURATELY AND TO DESIGN MORE 4535 02:54:32,273 --> 02:54:36,277 SAFER EFFECTIVE DRUGS. 4536 02:54:36,277 --> 02:54:37,045 SO THE OPPORTUNITY WE HAVE, 4537 02:54:37,045 --> 02:54:39,714 WHAT IS THE OPPORTUNITY? 4538 02:54:39,714 --> 02:54:45,253 THERE ARE CURRENTLY SEVERAL 4539 02:54:45,253 --> 02:54:48,089 FUNDAMENTAL TECHNOLOGY 4540 02:54:48,089 --> 02:54:48,790 DEVELOPMENTS OCCURRING ACROSS 4541 02:54:48,790 --> 02:54:49,891 TRANSFEDERAL ACTIVITIES, THIS 4542 02:54:49,891 --> 02:54:53,428 IS A NATIONAL PRIORITY AT THE 4543 02:54:53,428 --> 02:54:56,164 WHITE HOUSE TO DOWNLOAD THE 4544 02:54:56,164 --> 02:55:01,602 TECHNOLOGY AS WELL AS ACCESS A 4545 02:55:01,602 --> 02:55:03,438 WAY OF ADOPTION OF THIS 4546 02:55:03,438 --> 02:55:03,905 TECHNOLOGY IN GLOBAL 4547 02:55:03,905 --> 02:55:07,442 APPLICATION. 4548 02:55:07,442 --> 02:55:09,911 SO WE DID TWO WORKSHOPS. 4549 02:55:09,911 --> 02:55:13,014 PROVIDING QUANTUM EXPERTS AND 4550 02:55:13,014 --> 02:55:19,954 BY MEDICAL EXPERTS, HAD THEIR 4551 02:55:19,954 --> 02:55:20,488 SESSIONS TO IDENTIFY SOME 4552 02:55:20,488 --> 02:55:22,824 OPPORTUNITIES. 4553 02:55:22,824 --> 02:55:29,964 WE HAVE BEEN COLLABORATING WITH 4554 02:55:29,964 --> 02:55:32,200 DOE. 4555 02:55:32,200 --> 02:55:37,772 WHAT WE LEARNED IS THERE ARE 4556 02:55:37,772 --> 02:55:39,373 SEVERAL AVAILABLE CORE QUANTUM 4557 02:55:39,373 --> 02:55:41,109 CORE TECHNOLOGIES, THEY HAVE 4558 02:55:41,109 --> 02:55:42,710 GREAT POTENTIAL BUT NOT BEING 4559 02:55:42,710 --> 02:55:43,611 DIRECTED TO BUY YO MEDICAL 4560 02:55:43,611 --> 02:55:46,848 APPLICATIONS. 4561 02:55:46,848 --> 02:55:55,056 THERE'S NO FOCUS INVESTMENT. 4562 02:55:55,056 --> 02:55:58,659 BIOMEDICAL EXPERTS ARE NOT 4563 02:55:58,659 --> 02:55:59,127 FAMILIAR WITH QUANTUM 4564 02:55:59,127 --> 02:56:01,395 TECHNOLOGY OPPORTUNITIES. 4565 02:56:01,395 --> 02:56:05,032 THE OTHER IS COST OF GENERATION. 4566 02:56:05,032 --> 02:56:12,507 THE OPPORTUNITY IS TO DERISK 4567 02:56:12,507 --> 02:56:14,842 THIS TECHNOLOGY TOWARD SOLVING 4568 02:56:14,842 --> 02:56:16,677 TRANSLATIONAL PROBLEMS IN EARLY 4569 02:56:16,677 --> 02:56:19,413 DETECTION SHUN AND DIAGNOSE I 4570 02:56:19,413 --> 02:56:22,517 DISCUSSED EARLIER AND ADVANCING 4571 02:56:22,517 --> 02:56:24,619 THE PROTOTYPE TECHNOLOGIES TO A 4572 02:56:24,619 --> 02:56:27,155 REAL WORLD APPLICATION. 4573 02:56:27,155 --> 02:56:29,857 WE ARE PROPOSING TO LAUNCH A 4574 02:56:29,857 --> 02:56:31,692 PRIZE CHALLENGE COMPETITION, 4575 02:56:31,692 --> 02:56:37,565 TWO OF THEM, TWO TARGET DATA 4576 02:56:37,565 --> 02:56:38,533 SENSING AND COMPETING TO 4577 02:56:38,533 --> 02:56:42,503 CATALYZE THE APPLICATION OF 4578 02:56:42,503 --> 02:56:42,937 THIS TECHNOLOGY TO 4579 02:56:42,937 --> 02:56:45,406 MULTI-DISCIPLINARY EFFORTS. 4580 02:56:45,406 --> 02:56:47,575 AND SPECIFICALLY AND QUANTUM 4581 02:56:47,575 --> 02:56:51,078 SENSING AREA CHALLENGE TO FOCUS 4582 02:56:51,078 --> 02:56:56,717 ON DEVELOPING NOVEL SCALABLE 4583 02:56:56,717 --> 02:56:58,152 ENHANCING PRE-CLINICAL DRUG 4584 02:56:58,152 --> 02:57:02,290 DISCOVERY. 4585 02:57:02,290 --> 02:57:03,658 DEVELOPING NON INVASIVE 4586 02:57:03,658 --> 02:57:04,825 SENSITIVE APPROACHES FOR 4587 02:57:04,825 --> 02:57:06,127 ENABLING EARLY DETECTION AND 4588 02:57:06,127 --> 02:57:10,298 IMPROVING ACTIVITY OF DIAGNOSE. 4589 02:57:10,298 --> 02:57:11,699 BUT PORTABLE AVAILABLE DEVICES 4590 02:57:11,699 --> 02:57:13,434 FOR INCLUDING PATIENT CARE AND 4591 02:57:13,434 --> 02:57:15,870 HEALTH MONITORING IN CASE OF 4592 02:57:15,870 --> 02:57:18,940 QUANTUM COMPUTING WHILE WE ARE 4593 02:57:18,940 --> 02:57:22,210 EXPECTING TO DEVELOP 4594 02:57:22,210 --> 02:57:23,578 ALGORITHMS, QUANTUM ALGORITHMS 4595 02:57:23,578 --> 02:57:27,415 FOR ACCELERATING DISCOVERY AND 4596 02:57:27,415 --> 02:57:29,417 IMPROVING MOLECULAR SIMULATION 4597 02:57:29,417 --> 02:57:30,151 AND DIAGNOSE RECEIVE DIAGNOSIS, 4598 02:57:30,151 --> 02:57:31,052 PARTICULARLY IN THE CASE OF 4599 02:57:31,052 --> 02:57:33,287 RARE DISEASES. 4600 02:57:33,287 --> 02:57:39,961 THE PRIZE CHALLENGE IS A 4601 02:57:39,961 --> 02:57:40,962 CRITICAL MECHANISM TO DERISK 4602 02:57:40,962 --> 02:57:43,431 THIS TECHNOLOGY TO US. 4603 02:57:43,431 --> 02:57:44,999 WE CAN RAPIDLY IDENTIFY BEST 4604 02:57:44,999 --> 02:57:46,000 SOLUTIONS AND MOVE THEM FORWARD 4605 02:57:46,000 --> 02:57:50,871 MORE QUICKLY. 4606 02:57:50,871 --> 02:57:54,475 THE REWARD THE TEAM OF QUANTUM 4607 02:57:54,475 --> 02:57:56,911 EXPERTS AND ENVIRONMENTAL 4608 02:57:56,911 --> 02:57:58,012 EXPERTS TO COME UP WITH THE 4609 02:57:58,012 --> 02:58:00,214 BEST SOLUTIONS. 4610 02:58:00,214 --> 02:58:02,149 WE ARE PARTNERING WITH NIH 4611 02:58:02,149 --> 02:58:04,485 AGENCIES WHO SHARE INTEREST IN 4612 02:58:04,485 --> 02:58:07,989 THE PART I SEE WHO ARE JOINING 4613 02:58:07,989 --> 02:58:12,159 ARE LISTED BELOW, NATIONAL 4614 02:58:12,159 --> 02:58:16,931 INSTITUTE OF BIOMEDICAL 4615 02:58:16,931 --> 02:58:19,734 ENGINEERING AND BIO 4616 02:58:19,734 --> 02:58:22,870 ENVIRONMENTAL ENGINEERING, 4617 02:58:22,870 --> 02:58:24,639 IBID, DATA SCIENCE STRATEGY, 4618 02:58:24,639 --> 02:58:25,139 CENTER FOR INFORMATION 4619 02:58:25,139 --> 02:58:26,574 TECHNOLOGY. 4620 02:58:26,574 --> 02:58:29,844 HOW WE PLAN TO LAUNCH THIS 4621 02:58:29,844 --> 02:58:31,646 INITIATIVE IS IN TWO STAGES, 4622 02:58:31,646 --> 02:58:35,583 STAGE ONE WE DO IDEATION. 4623 02:58:35,583 --> 02:58:39,854 INVITE INNOVATIVE SOLUTIONS 4624 02:58:39,854 --> 02:58:43,658 FROM A DIVERSE RANGE OF 4625 02:58:43,658 --> 02:58:45,092 AUDIENCE INCLUDING INDUSTRIES, 4626 02:58:45,092 --> 02:58:46,727 ACADEMIA AND QUANTUM EXPERTS 4627 02:58:46,727 --> 02:58:48,296 WHO ARE NOT NEUTRAL, SO IT'S A 4628 02:58:48,296 --> 02:58:50,331 GREAT WAY TO HAVE THEM COME 4629 02:58:50,331 --> 02:58:51,899 FORWARD TO BRING THEIR 4630 02:58:51,899 --> 02:58:52,767 SOLUTIONS. 4631 02:58:52,767 --> 02:58:55,670 IN STAGE TWO WE WILL IMPLEMENT 4632 02:58:55,670 --> 02:58:57,705 THE BEST SOLUTION TO REACTION 4633 02:58:57,705 --> 02:59:02,343 TO FACTOR CHALLENGE THROUGH 4634 02:59:02,343 --> 02:59:04,245 OTHER FUNDING MECHANISM TO 4635 02:59:04,245 --> 02:59:05,446 ADVANCES IN TECHNOLOGY TO 4636 02:59:05,446 --> 02:59:08,249 USEFUL AND VISIBLE APPLICATION. 4637 02:59:08,249 --> 02:59:08,883 THE BILATERAL AND TRANSLATIONAL 4638 02:59:08,883 --> 02:59:11,552 FIELD, THE SUCCESS OF THIS 4639 02:59:11,552 --> 02:59:12,953 PROGRAM, THEY ARE MORE 4640 02:59:12,953 --> 02:59:14,689 SENSITIVE AND ACCURATE THAN 4641 02:59:14,689 --> 02:59:25,199 WHAT WE HAVE CURRENTLY, THIS 4642 02:59:28,269 --> 02:59:28,803 INCLUDES QUANTUM ENHANCEMENT 4643 02:59:28,803 --> 02:59:30,037 MICROSCOPY,. 4644 02:59:30,037 --> 02:59:33,074 IT COULD ENHANCE THE CURRENT 4645 02:59:33,074 --> 02:59:34,542 COMPUTATIONAL LANDSCAPE WE WORK 4646 02:59:34,542 --> 02:59:36,344 WITH FOR DRUG DEVELOPMENT AS 4647 02:59:36,344 --> 02:59:42,450 WELL AS DIAGNOSIS. 4648 02:59:42,450 --> 02:59:43,784 THIS TECHNOLOGICAL, HAVE PUBLIC 4649 02:59:43,784 --> 02:59:47,121 HEALTH IMPACT, TO LEAD TO 4650 02:59:47,121 --> 02:59:52,760 BETTER TOOLS FOR THE DETECTION, 4651 02:59:52,760 --> 02:59:53,294 DIAGNOSIS AND THERAPEUTIC 4652 02:59:53,294 --> 02:59:56,097 DEVELOPMENT. 4653 02:59:56,097 --> 02:59:58,399 THE TEAM WE WILL BUILD WILL 4654 02:59:58,399 --> 03:00:02,470 HAVE A POSITIVE IMPACT ON 4655 03:00:02,470 --> 03:00:03,938 NATIONAL QUANTUM ECONOMY 4656 03:00:03,938 --> 03:00:06,307 ECOSYSTEM. 4657 03:00:06,307 --> 03:00:10,144 WE WILL CATALYZE THE NOVEL AREA 4658 03:00:10,144 --> 03:00:11,846 OF QUANTUM TECHNOLOGY 4659 03:00:11,846 --> 03:00:12,947 APPROACHES TOWARDS APPLICATIONS 4660 03:00:12,947 --> 03:00:14,081 IN DEVELOPING HUMAN HEALTH 4661 03:00:14,081 --> 03:00:17,118 CONDITIONS AND WE ARE EXCITED 4662 03:00:17,118 --> 03:00:18,552 TO LEVERAGE THIS UNPRECEDENTED 4663 03:00:18,552 --> 03:00:20,955 AND TIMELY OPPORTUNITY THAT 4664 03:00:20,955 --> 03:00:22,757 QUANTUM TECHNOLOGIES OFFER IN 4665 03:00:22,757 --> 03:00:23,257 ADVANCING DETECTION AND 4666 03:00:23,257 --> 03:00:24,058 DIAGNOSIS. 4667 03:00:24,058 --> 03:00:29,730 WITH THESE WE WILL BE ABLE TO 4668 03:00:29,730 --> 03:00:31,766 DETECT DISEASES EARLY ON AND 4669 03:00:31,766 --> 03:00:32,867 MORE ACCURATELY AND PROVIDE 4670 03:00:32,867 --> 03:00:34,668 BETTER PATIENT CARE. 4671 03:00:34,668 --> 03:00:36,704 AS WELL AS CONTRIBUTE TO THE 4672 03:00:36,704 --> 03:00:38,005 WORLD MISSION OF DEVELOPING 4673 03:00:38,005 --> 03:00:39,407 MORE TREATMENTS MORE QUICKLY 4674 03:00:39,407 --> 03:00:40,107 AND MAKE THEM MORE ACCESSIBLE 4675 03:00:40,107 --> 03:00:41,041 TO ALL. 4676 03:00:41,041 --> 03:00:42,143 THANK YOU, AND WITH THAT I 4677 03:00:42,143 --> 03:00:44,578 WOULD LOVE TO HEAR FROM YOU, 4678 03:00:44,578 --> 03:00:46,814 WHAT YOU ARE THINKING. 4679 03:00:46,814 --> 03:00:48,549 YOUR TALKS ON THIS INITIATIVE 4680 03:00:48,549 --> 03:00:50,251 AS WELL AS ANY AREAS WE SHOULD 4681 03:00:50,251 --> 03:00:51,118 CONSIDER AS PART OF THIS 4682 03:00:51,118 --> 03:00:52,052 INITIATIVE. 4683 03:00:52,052 --> 03:00:53,988 >> Joni Rutter: OKAY, THANK YOU 4684 03:00:53,988 --> 03:00:56,424 SO MUCH, GEETHA FOR THAT 4685 03:00:56,424 --> 03:00:57,925 OVERVIEW FOR THIS CONCEPT. 4686 03:00:57,925 --> 03:00:59,026 WE HAVE TWO DISCUSSANTS. 4687 03:00:59,026 --> 03:01:04,565 I WILL TURN IT OVER TO THEM 4688 03:01:04,565 --> 03:01:05,132 FIRST, STARTING WITH SERGIO 4689 03:01:05,132 --> 03:01:05,499 AGUILAR-GAXIOLA. 4690 03:01:05,499 --> 03:01:08,436 SERGIO? 4691 03:01:08,436 --> 03:01:11,972 >> SERGIO: THANK YOU. 4692 03:01:11,972 --> 03:01:15,409 THANK YOU FOR VERY, I MEAN AN 4693 03:01:15,409 --> 03:01:15,976 EXCELLENT OVERVIEW OF THIS 4694 03:01:15,976 --> 03:01:20,548 CONCEPT. 4695 03:01:20,548 --> 03:01:23,050 IT IS A LITTLE BIT OUTSIDE OF 4696 03:01:23,050 --> 03:01:28,255 THE KIND OF THINGS THAT I DO, 4697 03:01:28,255 --> 03:01:30,558 BUT IT IS, I THINK THERE IS A 4698 03:01:30,558 --> 03:01:37,731 NEED FOR THIS KIND OF 4699 03:01:37,731 --> 03:01:38,732 TECHNOLOGY AND YOU IDENTIFIED 4700 03:01:38,732 --> 03:01:40,367 WHAT IS THE PROBLEM THAT NEEDS 4701 03:01:40,367 --> 03:01:43,904 TO BE SOLVED IN THE PROPOSED 4702 03:01:43,904 --> 03:01:50,244 SOLUTION AS WELL. 4703 03:01:50,244 --> 03:01:53,380 I'M MORE ON THE SIDE, HOW DO 4704 03:01:53,380 --> 03:01:55,916 YOU ACTIVELY LISTEN TO THOSE 4705 03:01:55,916 --> 03:01:58,452 WHO STAND TO BENEFIT FROM THIS 4706 03:01:58,452 --> 03:01:59,854 TECHNOLOGY FOR EXAMPLE. 4707 03:01:59,854 --> 03:02:01,789 HOW DO YOU ENGAGE WITH THEM IN 4708 03:02:01,789 --> 03:02:02,656 A MEANINGFUL MANNER? 4709 03:02:02,656 --> 03:02:07,294 I WOULD LOVE TO HAVE YOUR 4710 03:02:07,294 --> 03:02:10,097 THOUGHTS ON, YOU KNOW, HOW DO 4711 03:02:10,097 --> 03:02:11,565 YOU GO ABOUT ENGAGING, 4712 03:02:11,565 --> 03:02:15,903 ESPECIALLY THOSE WHO STAND TO 4713 03:02:15,903 --> 03:02:19,740 BENEFIT FROM THIS TECHNOLOGY. 4714 03:02:19,740 --> 03:02:24,278 >> GEETHA: THANK YOU, DR. 4715 03:02:24,278 --> 03:02:25,479 AGUILAR-GAXIOLA. 4716 03:02:25,479 --> 03:02:31,986 WE HAVE THOUGHT OF RAISING 4717 03:02:31,986 --> 03:02:33,988 AWARENESS OF BIOMEDICAL EXPERTS 4718 03:02:33,988 --> 03:02:35,723 OR QUANTUM EXPERTS BRINGING THE 4719 03:02:35,723 --> 03:02:38,292 COMMUNITIES TOGETHER TO BUILD A 4720 03:02:38,292 --> 03:02:38,726 MULTI-DISCIPLINARY 4721 03:02:38,726 --> 03:02:39,960 TEAMS,ACTUALLY. 4722 03:02:39,960 --> 03:02:41,228 WE HAVE BEEN DOING THIS THE 4723 03:02:41,228 --> 03:02:43,430 PAST COUPLE YEARS. 4724 03:02:43,430 --> 03:02:45,299 THE WORKSHOPS WERE A WAY TO 4725 03:02:45,299 --> 03:02:46,634 BUILD THESE COMMUNITIES AND NOW 4726 03:02:46,634 --> 03:02:48,235 WE ARE IN TOUCH WITH BOTH. 4727 03:02:48,235 --> 03:02:53,874 WE ARE PLANNING FOR THE NEXT 4728 03:02:53,874 --> 03:02:54,608 WORKSHOP WITH INDUSTRY 4729 03:02:54,608 --> 03:02:56,710 PARTNERS, AND WE HAVE BEEN IN 4730 03:02:56,710 --> 03:02:59,079 REGULAR COMMUNICATION WITH THE 4731 03:02:59,079 --> 03:03:02,483 FEDERAL AGENCIES WHO ARE 4732 03:03:02,483 --> 03:03:03,284 SUPPORTING THIS TECHNOLOGY AND 4733 03:03:03,284 --> 03:03:05,185 TRANSLATIONAL TECHNOLOGIES. 4734 03:03:05,185 --> 03:03:07,955 AND WE HAVE SCIENTIFIC INTEREST 4735 03:03:07,955 --> 03:03:10,891 GROUP AT NIH, THE A 4736 03:03:10,891 --> 03:03:13,460 PUBLIC-FACING GROUP, WHERE WE 4737 03:03:13,460 --> 03:03:14,495 CONDUCT MONTHLY SEMINARS 4738 03:03:14,495 --> 03:03:16,196 INVITING TECHNOLOGY DEVELOPERS, 4739 03:03:16,196 --> 03:03:17,698 AS WELL AS BIOMEDICAL 4740 03:03:17,698 --> 03:03:20,634 SCIENTISTS TO CONTINUE THIS 4741 03:03:20,634 --> 03:03:23,370 DIALOGUE AND EDUCATE BOTH 4742 03:03:23,370 --> 03:03:24,872 FIELDS TO EXCHANGE KNOWLEDGE 4743 03:03:24,872 --> 03:03:28,943 AND IDEAS, SO THERE IS THIS 4744 03:03:28,943 --> 03:03:31,779 ONGOING EFFORT WHERE WE SEE 4745 03:03:31,779 --> 03:03:32,479 CONTINUING FURTHER. 4746 03:03:32,479 --> 03:03:34,381 >> Joni Rutter: AND JUST TO ADD 4747 03:03:34,381 --> 03:03:38,652 ONTO THAT, YOU KNOW, I THINK TO 4748 03:03:38,652 --> 03:03:40,321 SERGIO'S POINT AS WELL IS, YOU 4749 03:03:40,321 --> 03:03:42,289 KNOW, THINKING ABOUT WHO IS 4750 03:03:42,289 --> 03:03:44,658 GOING TO BENEFIT FROM THE 4751 03:03:44,658 --> 03:03:46,627 TECHNOLOGY THAT GETS GENERATED. 4752 03:03:46,627 --> 03:03:52,066 YOU SHOWED THAT REALLY NICE 4753 03:03:52,066 --> 03:03:54,602 PHOTO OF THE MEG WITH BIG 4754 03:03:54,602 --> 03:03:55,903 MAGNET AND PERHAPS GETTING THAT 4755 03:03:55,903 --> 03:03:58,339 TO A POINT WHERE IT'S ACTUALLY 4756 03:03:58,339 --> 03:03:59,940 SOMETHING VERY SMALL THAT CAN 4757 03:03:59,940 --> 03:04:02,042 FIT ON SOMEONE'S HEAD AND TAKE 4758 03:04:02,042 --> 03:04:03,777 IMAGES OF THE BRAIN FOR 4759 03:04:03,777 --> 03:04:04,445 EXAMPLE, OR DETECT WAVES IN THE 4760 03:04:04,445 --> 03:04:05,412 BRAIN. 4761 03:04:05,412 --> 03:04:09,850 SO I THINK RIGHT NOW IT'S ABOUT 4762 03:04:09,850 --> 03:04:11,051 UNDERSTANDING WHERE OUR 4763 03:04:11,051 --> 03:04:12,486 OPPORTUNITIES ARE WITH 4764 03:04:12,486 --> 03:04:18,826 TECHNOLOGY AND WHERE THEY MAY 4765 03:04:18,826 --> 03:04:19,460 BENEFIT MOST FOR THE 4766 03:04:19,460 --> 03:04:20,628 COMMUNITIES WE SERVE. 4767 03:04:20,628 --> 03:04:22,830 I DON'T KNOW THAT WE CAN 4768 03:04:22,830 --> 03:04:23,731 PINPOINT THAT YET, EXACTLY. 4769 03:04:23,731 --> 03:04:25,733 I WILL SAY ONE OF THE 4770 03:04:25,733 --> 03:04:27,935 OPPORTUNITIES I DO SEE IS 4771 03:04:27,935 --> 03:04:29,036 CERTAINLY IN THE COMPUTING 4772 03:04:29,036 --> 03:04:31,672 SPACE IS THINKING ABOUT THE 4773 03:04:31,672 --> 03:04:33,807 DIAGNOSTIC ODYSSEY AND PERHAPS 4774 03:04:33,807 --> 03:04:36,644 USING ALGORITHM DEVELOPMENT TO 4775 03:04:36,644 --> 03:04:37,311 IDENTIFY WAYS TO APPROACH THOSE 4776 03:04:37,311 --> 03:04:37,945 MORE. 4777 03:04:37,945 --> 03:04:40,447 YOU THINK WE HAVE A LOT TO 4778 03:04:40,447 --> 03:04:42,182 LEARN BEFORE WE START TO ENGAGE 4779 03:04:42,182 --> 03:04:44,018 THE COMMUNITY SO WE CAN GO AND 4780 03:04:44,018 --> 03:04:45,786 HAVE A DEEPER UNDERSTANDING OF 4781 03:04:45,786 --> 03:04:48,622 HOW TO SPEAK ABOUT THE BENEFITS 4782 03:04:48,622 --> 03:04:50,224 THAT QUANTUM SENSING AND 4783 03:04:50,224 --> 03:04:52,059 QUANTUM COMPUTING CAN HAVE. 4784 03:04:52,059 --> 03:04:54,495 BUT I THINK YOUR POINT IS WELL 4785 03:04:54,495 --> 03:04:56,830 TAKEN AS WELL, WE NEED TO BE 4786 03:04:56,830 --> 03:04:57,998 THINKING ABOUT THOSE 4787 03:04:57,998 --> 03:04:58,799 COMMUNITIES TOO AND BEING 4788 03:04:58,799 --> 03:05:00,634 ENGAGED EARLIER ON. 4789 03:05:00,634 --> 03:05:03,203 I THINK THAT WILL ALSO HELP US 4790 03:05:03,203 --> 03:05:06,840 BE AT THE FOREFRONT OF DRIVE 4791 03:05:06,840 --> 03:05:09,243 ING HOW IMPORTANT IT IS TO 4792 03:05:09,243 --> 03:05:11,612 BRING QUANTUM SENSING AND 4793 03:05:11,612 --> 03:05:12,713 QUANTUM COMPUTING INTO THE 4794 03:05:12,713 --> 03:05:14,081 BIOMEDICAL SPACE. 4795 03:05:14,081 --> 03:05:16,016 ONE OF THE THINGS WE ARE TRYING 4796 03:05:16,016 --> 03:05:19,153 TO DO NOW IS ENSURE NIH AND THE 4797 03:05:19,153 --> 03:05:21,689 FOLKS AT THE NIH WORKING ON 4798 03:05:21,689 --> 03:05:23,824 THIS, LIKE GEETHA WHO IS 4799 03:05:23,824 --> 03:05:28,529 LEADING A LOT OF THESE EFFORTS 4800 03:05:28,529 --> 03:05:30,764 IS ENSURING THAT WE HAVE THE 4801 03:05:30,764 --> 03:05:32,399 ABILITY TO START LEADING THE 4802 03:05:32,399 --> 03:05:34,301 USE CASES FOR WHAT THESE TECH 4803 03:05:34,301 --> 03:05:36,136 NOLS ARE FOR AND THEN DRIVING 4804 03:05:36,136 --> 03:05:40,174 THAT TO HELP STRENGTHEN THE USE 4805 03:05:40,174 --> 03:05:42,576 OF THEM IN MORE WORLD KINDS OF 4806 03:05:42,576 --> 03:05:44,912 APPLICATION AND BRING IN THOSE 4807 03:05:44,912 --> 03:05:45,512 COMMUNITIES THAT WILL BENEFIT 4808 03:05:45,512 --> 03:05:46,714 THE MOST. 4809 03:05:46,714 --> 03:05:47,981 WE AREN'T QUITE SURE YET HOW TO 4810 03:05:47,981 --> 03:05:49,183 ANSWER YOUR QUESTION. 4811 03:05:49,183 --> 03:05:50,451 BUT I THINK IT'S AN IMPORTANT 4812 03:05:50,451 --> 03:05:51,952 ONE AND WE ARE CONTINUING TO 4813 03:05:51,952 --> 03:05:55,289 MONITOR IT AS WELL. 4814 03:05:55,289 --> 03:05:58,425 >> SERGIO: THAT'S A WONDERFUL 4815 03:05:58,425 --> 03:05:59,159 COMMENTS, JONI. 4816 03:05:59,159 --> 03:06:02,563 YOU REALLY APPRECIATE THAT. 4817 03:06:02,563 --> 03:06:03,997 BECAUSE AS I HAVE SEEN SINCE 4818 03:06:03,997 --> 03:06:09,970 THE TIME I HAVE BEEN IN THE 4819 03:06:09,970 --> 03:06:12,406 COUNCIL, YOU ARE LEADING, ALONG 4820 03:06:12,406 --> 03:06:19,046 WITH THE TEAM, EFFORTS TO 4821 03:06:19,046 --> 03:06:20,681 REALLY GROUND WHATEVER IS BEING 4822 03:06:20,681 --> 03:06:23,684 DONE WITH THE INPUT OF 4823 03:06:23,684 --> 03:06:25,085 LISTENING TO OTHERS. 4824 03:06:25,085 --> 03:06:28,756 AND ONE SUGGESTION I MIGHT 4825 03:06:28,756 --> 03:06:30,390 HAVE, DR. SENTHIL IS AS THIS 4826 03:06:30,390 --> 03:06:39,133 IS, YOU KNOW, AS YOU GET THE, 4827 03:06:39,133 --> 03:06:43,704 AS THIS GETS CLEARANCE, THAT 4828 03:06:43,704 --> 03:06:45,739 YOU ENDEAVOR TO, YOU KNOW, 4829 03:06:45,739 --> 03:06:52,412 THERE ARE SEVERAL METHODS TO 4830 03:06:52,412 --> 03:06:54,414 REALLY GATHER COMMENTS DIRECTLY 4831 03:06:54,414 --> 03:06:55,249 FROM COMMUNITIES, ESPECIALLY 4832 03:06:55,249 --> 03:06:59,253 THOSE THAT STAND TO BENEFIT. 4833 03:06:59,253 --> 03:07:01,255 THERE IS SUCH NOW CALLED 4834 03:07:01,255 --> 03:07:03,223 COMMUNITY ENGAGEMENT STUDENTS. 4835 03:07:03,223 --> 03:07:06,426 IT USE TO BE COMMUNITY REVIEW 4836 03:07:06,426 --> 03:07:10,764 BOARDS THAT REALLY GROUND THE 4837 03:07:10,764 --> 03:07:12,199 RESEARCHERS BY LISTENING TO 4838 03:07:12,199 --> 03:07:14,468 COMMUNITIES ON WHAT MATTERS TO 4839 03:07:14,468 --> 03:07:16,036 THEM AND THE INPUT. 4840 03:07:16,036 --> 03:07:17,838 AND WHAT I HAVE SEEN, 4841 03:07:17,838 --> 03:07:19,873 PERSONALLY, IS THAT IT HAS BEEN 4842 03:07:19,873 --> 03:07:21,875 OF TREMENDOUS HELP FOR THE 4843 03:07:21,875 --> 03:07:28,048 RESEARCHERS THEMSELVES. 4844 03:07:28,048 --> 03:07:29,850 BECAUSE THEY BRING ANGLES THAT 4845 03:07:29,850 --> 03:07:31,118 THEY WERE NOT CONTEMPLATING. 4846 03:07:31,118 --> 03:07:32,519 >> Joni Rutter: I THINK THAT'S 4847 03:07:32,519 --> 03:07:36,356 A BRILLIANT SUGGESTION. 4848 03:07:36,356 --> 03:07:37,991 AND WE WILL CERTAINLY FIGURE 4849 03:07:37,991 --> 03:07:40,594 OUT THE BEST TIMING FOR OUR 4850 03:07:40,594 --> 03:07:44,498 APPROACHES TO DOING THAT. 4851 03:07:44,498 --> 03:07:47,901 MAYBE THAT'S STARTING NOW, IT'S 4852 03:07:47,901 --> 03:07:49,937 NOT TOO EARLY, THINKING OF THE 4853 03:07:49,937 --> 03:07:51,438 PRIZE COMPETITION AS A MEANS TO 4854 03:07:51,438 --> 03:07:52,973 ENGAGE HOW WE CAN GET STARTED 4855 03:07:52,973 --> 03:07:54,708 IN THE SPACE WOULD BE GREAT. 4856 03:07:54,708 --> 03:07:56,877 I SEE DAN HAS HIS HAND UP. 4857 03:07:56,877 --> 03:07:58,145 DAN, DO YOU HAVE AN EXTRA 4858 03:07:58,145 --> 03:07:59,980 COMMENT TOO? 4859 03:07:59,980 --> 03:08:01,114 >> DAN: YOU ACTUALLY JUST 4860 03:08:01,114 --> 03:08:02,216 STATED IT, JONI. 4861 03:08:02,216 --> 03:08:05,352 I WAS JUST GOING TO STATE TO 4862 03:08:05,352 --> 03:08:08,088 SERGIO, THE USE OF THE PRIZE 4863 03:08:08,088 --> 03:08:10,090 COMPETITION IS TO CROWD SOURCE 4864 03:08:10,090 --> 03:08:11,692 POTENTIAL SOLUTIONS AND IN SOME 4865 03:08:11,692 --> 03:08:13,293 WAYS BROADEN THE INPUT WE ARE 4866 03:08:13,293 --> 03:08:17,030 TRYING TO GET, NOT ONLY FROM 4867 03:08:17,030 --> 03:08:18,832 THE TECHNOLOGY EXPERT, BUT ALSO 4868 03:08:18,832 --> 03:08:21,602 TO GET THE IDEAS FROM THE 4869 03:08:21,602 --> 03:08:22,803 PEOPLE WHO WILL BENEFIT FROM 4870 03:08:22,803 --> 03:08:24,037 THIS TECHNOLOGY. 4871 03:08:24,037 --> 03:08:25,639 SO THANK YOU FOR THOSE 4872 03:08:25,639 --> 03:08:27,474 THOUGHTFUL SUGGESTIONS AS WELL. 4873 03:08:27,474 --> 03:08:28,876 >> Joni Rutter: YEAH, AND MAYBE 4874 03:08:28,876 --> 03:08:30,777 THAT'S SOMETHING WE NEED TO 4875 03:08:30,777 --> 03:08:32,412 STATE IN THE COMPETITION 4876 03:08:32,412 --> 03:08:37,351 ITSELF, WE WOULD LIKE THE 4877 03:08:37,351 --> 03:08:39,286 SUBMITTERS TO INCLUDE 4878 03:08:39,286 --> 03:08:43,190 APPROACHES FOR ENGAGEMENT OF 4879 03:08:43,190 --> 03:08:45,225 THE COMMUNITY, LAY INDIVIDUALS, 4880 03:08:45,225 --> 03:08:46,293 FOR EXAMPLE, WHO MAY BENEFIT 4881 03:08:46,293 --> 03:08:49,162 FROM THIS TYPE OF WORK. 4882 03:08:49,162 --> 03:08:50,264 THAT'S SOMETHING WE CAN ASK 4883 03:08:50,264 --> 03:09:00,374 THEM TO WEIGH IN ON AS WELL. 4884 03:09:00,374 --> 03:09:02,709 >> SERGIO: WE WOULD LOVE THAT, 4885 03:09:02,709 --> 03:09:04,011 JONI, ONE MORE QUESTION, SORRY 4886 03:09:04,011 --> 03:09:05,412 TO BE TAKING TOO MUCH TIME. 4887 03:09:05,412 --> 03:09:06,613 THIS IS ALSO WHAT ALL OF YOU 4888 03:09:06,613 --> 03:09:07,848 STARTED. 4889 03:09:07,848 --> 03:09:11,385 THE LISTENING SESSIONS. 4890 03:09:11,385 --> 03:09:15,822 AND REALLY CONNECT WITH, IN A 4891 03:09:15,822 --> 03:09:17,557 MUCH MORE PURPOSEFULLY MANNER 4892 03:09:17,557 --> 03:09:18,525 WITH THOSE THAT STAND TO 4893 03:09:18,525 --> 03:09:26,133 BENEFIT THE MOST. 4894 03:09:26,133 --> 03:09:26,867 >> Joni Rutter: WONDERFUL, 4895 03:09:26,867 --> 03:09:28,769 THANK YOU SO MUCH. 4896 03:09:28,769 --> 03:09:29,736 WE HAVE ANOTHER DISCUSSANT 4897 03:09:29,736 --> 03:09:31,772 BEFORE WE OPEN IT UP TO 4898 03:09:31,772 --> 03:09:34,808 COMMENTS OR QUESTIONS. 4899 03:09:34,808 --> 03:09:38,879 ANNIE KENNEDY? 4900 03:09:38,879 --> 03:09:42,282 >> ANNIE KENNEDY: I THINK MY 4901 03:09:42,282 --> 03:09:42,816 COMMENTS ARE ALIGNED WITH 4902 03:09:42,816 --> 03:09:48,155 SERGIO. 4903 03:09:48,155 --> 03:09:50,657 I'M NOT THE EXPERT WHOSE GOING 4904 03:09:50,657 --> 03:09:53,694 TO COMMENT ON QUANTUM ENABLED 4905 03:09:53,694 --> 03:09:57,364 TECHNOLOGY FOR BIOMEDICAL 4906 03:09:57,364 --> 03:09:59,399 APPLICATION BUT I DO COMMENT 4907 03:09:59,399 --> 03:10:01,001 NCATS ON SEEING THE OPPORTUNITY 4908 03:10:01,001 --> 03:10:02,102 FOR THIS INNOVATION TO SOLVE 4909 03:10:02,102 --> 03:10:04,338 FOR SOME OF THE REAL BARRIERS. 4910 03:10:04,338 --> 03:10:06,640 AND I COMMEND FOR THE PRIZE 4911 03:10:06,640 --> 03:10:10,043 CHALLENGE TO BRING IN MAYBE NEW 4912 03:10:10,043 --> 03:10:11,979 STAKEHOLDERS WHO AREN'T ALREADY 4913 03:10:11,979 --> 03:10:13,880 ENGAGING WITH THE SOON TO BE 4914 03:10:13,880 --> 03:10:14,915 INSTITUTE. 4915 03:10:14,915 --> 03:10:18,085 BUT THE ONE THING I WILL MAYBE 4916 03:10:18,085 --> 03:10:19,353 UNDERSCORE THAT SERGIO ALREADY 4917 03:10:19,353 --> 03:10:21,288 RAISED IS THAT, YOU KNOW, AND I 4918 03:10:21,288 --> 03:10:23,390 THINK IT'S SOMETHING MATT SAID 4919 03:10:23,390 --> 03:10:24,925 IN HIS PRESENTATION EARLIER, I 4920 03:10:24,925 --> 03:10:27,327 DO ENCOURAGE WE THINK WITH THE 4921 03:10:27,327 --> 03:10:28,662 END-USER IN MIND AT THE 4922 03:10:28,662 --> 03:10:33,800 BEGINNING AS MUCH AS POSSIBLE. 4923 03:10:33,800 --> 03:10:35,435 WE CAN'T ALWAYS DO THAT. 4924 03:10:35,435 --> 03:10:36,169 BUT AS MUCH AS POSSIBLE WE 4925 03:10:36,169 --> 03:10:37,671 SHOULD. 4926 03:10:37,671 --> 03:10:39,573 WE SHOULD START HIGHER AND THEN 4927 03:10:39,573 --> 03:10:41,608 GO MORE GRANULAR, BUT MAYBE A 4928 03:10:41,608 --> 03:10:44,811 WAY OF GOING ABOUT THAT, HAVE 4929 03:10:44,811 --> 03:10:46,246 THE LIST OF THE TRANSNIH 4930 03:10:46,246 --> 03:10:50,484 INSTITUTE YOU ARE WORKING WITH. 4931 03:10:50,484 --> 03:10:52,219 AND MAYBE THERE'S AN 4932 03:10:52,219 --> 03:10:53,754 OPPORTUNITY AS PART OF THE 4933 03:10:53,754 --> 03:10:54,421 PRIZE SELECTION COMMITTEE, 4934 03:10:54,421 --> 03:10:56,256 WHETHER OR NOT THERE ARE 4935 03:10:56,256 --> 03:10:58,358 PATIENT REPRESENTATIVES ON THE 4936 03:10:58,358 --> 03:10:59,659 COUNCIL OF THOSE NIH 4937 03:10:59,659 --> 03:11:01,094 INSTITUTES, AND INCLUDING 4938 03:11:01,094 --> 03:11:03,997 SOMEBODY HERE FROM THIS 4939 03:11:03,997 --> 03:11:08,502 COUNCIL, MAYBE HAVE 4940 03:11:08,502 --> 03:11:09,569 REPRESENTATION FROM THOSE 4941 03:11:09,569 --> 03:11:10,437 PATIENT GROUPS AS PART OF THE 4942 03:11:10,437 --> 03:11:11,405 SELECTION. 4943 03:11:11,405 --> 03:11:16,343 SO AT LEAST YOU START WITH SOME 4944 03:11:16,343 --> 03:11:17,044 SEMBLANCE OF PATIENT 4945 03:11:17,044 --> 03:11:19,579 REPRESENTATION, AND THINK ABOUT 4946 03:11:19,579 --> 03:11:22,049 WHO IS THE PART OF VETTING SOME 4947 03:11:22,049 --> 03:11:23,483 OF THE APPLICANTS AND THEN 4948 03:11:23,483 --> 03:11:24,918 MAYBE GET MORE SPECIFIC WHEN 4949 03:11:24,918 --> 03:11:26,520 YOU THINK ABOUT THE TECHNOLOGY, 4950 03:11:26,520 --> 03:11:29,122 HAVING PEOPLE WHO ARE MAYBE A 4951 03:11:29,122 --> 03:11:30,690 LITTLE MORE SPECIFIC TO THOSE 4952 03:11:30,690 --> 03:11:31,925 POPULATIONS THAT YOU ARE 4953 03:11:31,925 --> 03:11:33,193 WORKING ON TECHNOLOGY FOR. 4954 03:11:33,193 --> 03:11:36,196 AND THEN THE ONE THING I WILL 4955 03:11:36,196 --> 03:11:38,932 SAY, THE IMAGES IN THE 4956 03:11:38,932 --> 03:11:39,633 PRESENTATION YOU PROVIDED 4957 03:11:39,633 --> 03:11:42,269 REALLY CALLED TO MIND IS JUST 4958 03:11:42,269 --> 03:11:50,444 TO KEEP IN MIND THAT ALL 4959 03:11:50,444 --> 03:11:51,011 PATIENT -- AREN'T CREATED 4960 03:11:51,011 --> 03:11:56,349 EQUAL. 4961 03:11:56,349 --> 03:12:02,456 I REALLY APPRECIATE IMAGE OF 4962 03:12:02,456 --> 03:12:03,924 TECHNOLOGY BEING REFINED FOR 4963 03:12:03,924 --> 03:12:06,126 SOMETHING MORE DEFINED. 4964 03:12:06,126 --> 03:12:07,527 THINK WHO WE ARE DESIGNING THE 4965 03:12:07,527 --> 03:12:08,762 TECHNOLOGY FOR. 4966 03:12:08,762 --> 03:12:11,865 GETTING TO BE PART OF THE 4967 03:12:11,865 --> 03:12:13,500 PROJECTS IN WEARABLE AND 4968 03:12:13,500 --> 03:12:15,836 ROBOTICS AND WE SPENT MILLIONS 4969 03:12:15,836 --> 03:12:17,437 OF DOLLARS DEVELOPING 4970 03:12:17,437 --> 03:12:19,005 TECHNOLOGY AND HAVE WONDERFUL 4971 03:12:19,005 --> 03:12:19,906 PATIENT REPRESENTATIVES BE PART 4972 03:12:19,906 --> 03:12:22,576 OF THIS PROJECT. 4973 03:12:22,576 --> 03:12:23,510 OFTEN TIMES THEY WERE 4974 03:12:23,510 --> 03:12:24,344 CAREGIVERS WHO WERE PART OF 4975 03:12:24,344 --> 03:12:25,846 THIS PROJECT. 4976 03:12:25,846 --> 03:12:26,346 AND DEVELOPED WEARABLE 4977 03:12:26,346 --> 03:12:26,947 TECHNOLOGY. 4978 03:12:26,947 --> 03:12:29,182 AND AT THE END OF THE DAY YOU 4979 03:12:29,182 --> 03:12:31,084 HAD A TEENAGER WHO WAS SUPPOSED 4980 03:12:31,084 --> 03:12:33,587 TO WEAR IT, AND LOOK AT IT AND 4981 03:12:33,587 --> 03:12:38,258 SAY THAT LOOKS LIKE AN ANKLET 4982 03:12:38,258 --> 03:12:40,293 FOR A PRISONER AND I'M NOT 4983 03:12:40,293 --> 03:12:40,961 GOING TO WEAR THAT IN HIGH 4984 03:12:40,961 --> 03:12:44,798 SCHOOL. 4985 03:12:44,798 --> 03:12:46,566 OR DEVELOP A ROBOTIC WEARABLE 4986 03:12:46,566 --> 03:12:48,135 SUIT THAT WAS MODIFIED FROM 4987 03:12:48,135 --> 03:12:50,604 SOMETHING THAT HAD BEEN 4988 03:12:50,604 --> 03:12:53,206 DEVELOPED IN THE MILITARY AND 4989 03:12:53,206 --> 03:12:54,741 THE SENSORS WERE JUST TOO HEAVY 4990 03:12:54,741 --> 03:12:55,942 FOR THE INDIVIDUAL WITH THE 4991 03:12:55,942 --> 03:12:58,578 MUSCLE DISEASE. 4992 03:12:58,578 --> 03:13:00,881 SO REALLY THINKING ABOUT WHO IS 4993 03:13:00,881 --> 03:13:02,616 THE SUB POPULATION WE ARE 4994 03:13:02,616 --> 03:13:04,584 SPECIFICALLY LOOKING FOR AND OF 4995 03:13:04,584 --> 03:13:06,019 COURSE FURTHER DOWN, MAYBE 4996 03:13:06,019 --> 03:13:08,221 THINKING ABOUT YOUR PATIENT 4997 03:13:08,221 --> 03:13:10,123 REPRESENTATION MORE BROAD AND 4998 03:13:10,123 --> 03:13:11,391 THEN GETTING MORE SPECIFIC. 4999 03:13:11,391 --> 03:13:12,559 >> Joni Rutter: THESE ARE 5000 03:13:12,559 --> 03:13:13,960 FANTASTIC COMMENTS. 5001 03:13:13,960 --> 03:13:15,328 I THINK WE CAN CERTAINLY WORK 5002 03:13:15,328 --> 03:13:18,865 TOGETHER TO MAKE SURE WE 5003 03:13:18,865 --> 03:13:20,300 INCORPORATE THEM, IF THIS DOES 5004 03:13:20,300 --> 03:13:23,503 PROCEED FORWARD. 5005 03:13:23,503 --> 03:13:26,806 I THINK IT'S BY DESIGN WE HAVE 5006 03:13:26,806 --> 03:13:28,475 BOTH SERGIO AND ANNIE PROVIDING 5007 03:13:28,475 --> 03:13:30,577 THESE COMMENTS TO US ON 5008 03:13:30,577 --> 03:13:31,912 SOMETHING THAT IS SO DEEPLY, 5009 03:13:31,912 --> 03:13:33,213 HIGHLY TECHNICAL. 5010 03:13:33,213 --> 03:13:34,714 I THINK THAT'S REALLY THE ANGLE 5011 03:13:34,714 --> 03:13:37,284 WE NEED TO MAKE SURE WE ARE 5012 03:13:37,284 --> 03:13:38,885 DESIGNING FOR, FROM THE VERY 5013 03:13:38,885 --> 03:13:40,187 BEGINNING WHEN WE START THIS. 5014 03:13:40,187 --> 03:13:41,621 I THINK WE ARE PROBABLY NOT 5015 03:13:41,621 --> 03:13:44,758 GOING TO SEE THE FRUITS OF MUCH 5016 03:13:44,758 --> 03:13:46,960 OF THIS TECHNOLOGY FOR ANOTHER 5017 03:13:46,960 --> 03:13:48,161 5-10 YEARS BUT THINKING ABOUT 5018 03:13:48,161 --> 03:13:51,198 THAT NOW IS CRITICAL. 5019 03:13:51,198 --> 03:13:52,165 I'M TAKING NOTES ON YOUR 5020 03:13:52,165 --> 03:13:53,667 COMMENTS AND WE WILL BE SURE TO 5021 03:13:53,667 --> 03:13:54,668 INCORPORATE THOSE. 5022 03:13:54,668 --> 03:13:56,403 I WOULD LIKE TO OPEN IT UP FOR 5023 03:13:56,403 --> 03:13:57,504 ANY OTHER DISCUSSION FROM OUR 5024 03:13:57,504 --> 03:14:01,341 COUNCILMEMBERS. 5025 03:14:01,341 --> 03:14:03,310 I DON'T KNOW IF ANYBODY HAS 5026 03:14:03,310 --> 03:14:03,577 ANYTHING. 5027 03:14:03,577 --> 03:14:05,478 PAUL, THANK YOU. 5028 03:14:05,478 --> 03:14:06,279 >> PAUL: GREAT PRESENTATION, 5029 03:14:06,279 --> 03:14:07,314 THANK YOU SO MUCH. 5030 03:14:07,314 --> 03:14:09,950 CAN YOU TALK A LITTLE MORE 5031 03:14:09,950 --> 03:14:11,618 ABOUT YOUR EXPECTATIONS ON THE 5032 03:14:11,618 --> 03:14:13,453 MECHANICS OF THE CHALLENGE. 5033 03:14:13,453 --> 03:14:15,989 IS THERE GOING TO BE ONE, TWO. 5034 03:14:15,989 --> 03:14:18,291 >> THERE WILL BE TWO 5035 03:14:18,291 --> 03:14:20,360 CHALLENGES, ONE FOR COMPUTING 5036 03:14:20,360 --> 03:14:24,965 AND ONE FOR SENSING. 5037 03:14:24,965 --> 03:14:28,902 THEY WILL HAVE TWO STAGES. 5038 03:14:28,902 --> 03:14:33,206 IN THE IDEATION PHASE WE WILL 5039 03:14:33,206 --> 03:14:35,275 GRADUATE THE PROPOSAL. 5040 03:14:35,275 --> 03:14:37,611 ASKING THE TEAM THAT ALREADY 5041 03:14:37,611 --> 03:14:38,478 HAS THE PROTOTYPE TECHNOLOGY IN 5042 03:14:38,478 --> 03:14:40,347 HAND TO COME FORWARD. 5043 03:14:40,347 --> 03:14:42,415 IT SHOULD HAVE ALREADY SOME 5044 03:14:42,415 --> 03:14:44,384 TECHNICAL FEASIBILITY TO BE 5045 03:14:44,384 --> 03:14:47,487 APPLIED IN A BIOMEDICAL CONTEXT. 5046 03:14:47,487 --> 03:14:51,157 TO HOW IT WORKS IN A NOVEL 5047 03:14:51,157 --> 03:14:51,691 BIOMEDICAL TRANSLATIONAL 5048 03:14:51,691 --> 03:14:54,160 CONTEXT. 5049 03:14:54,160 --> 03:14:55,562 SO THE QUANTUM TECHNOLOGY 5050 03:14:55,562 --> 03:14:57,597 EXPERTS ARE EXPECTED TO 5051 03:14:57,597 --> 03:15:03,036 COLLABORATE WITH SOMEONE FROM 5052 03:15:03,036 --> 03:15:05,572 BIOMEDICAL OR CLINICAL SCIENCES. 5053 03:15:05,572 --> 03:15:08,708 AND TO ANNIE'S POINT, HAVING 5054 03:15:08,708 --> 03:15:16,583 THE END GOAL IN MIND WHEN ARE 5055 03:15:16,583 --> 03:15:17,284 OPTIMIZING ENGINEERING 5056 03:15:17,284 --> 03:15:18,518 TECHNOLOGY TOOL WHO WANT TO 5057 03:15:18,518 --> 03:15:23,456 HAVE THE AUDIENCE. 5058 03:15:23,456 --> 03:15:27,794 >> PAUL: THAT'S THE IDEATION. 5059 03:15:27,794 --> 03:15:35,669 >> GEETHA: WE WILL HAVE THESE 5060 03:15:35,669 --> 03:15:37,504 REVIEWERS AND THE SELECTED ONES 5061 03:15:37,504 --> 03:15:40,607 WILL BE ALLOWED TO GO FORWARD 5062 03:15:40,607 --> 03:15:44,277 TO IMPLEMENTATION. 5063 03:15:44,277 --> 03:15:46,446 MILESTONE DRIVEN, THEY HAVE TO 5064 03:15:46,446 --> 03:15:49,449 DEMONSTRATE IF THEY ARE MAKING 5065 03:15:49,449 --> 03:15:51,151 PROGRESS ON WHAT THEY PROPOSE 5066 03:15:51,151 --> 03:15:54,721 AND WILL GET A SMALL REWARD IF 5067 03:15:54,721 --> 03:15:57,424 THEY SHOW PROGRESS. 5068 03:15:57,424 --> 03:15:58,525 INITIAL DEMONSTRATION OF THE 5069 03:15:58,525 --> 03:16:02,162 APPROPRIATE TYPE TECHNOLOGY. 5070 03:16:02,162 --> 03:16:04,564 IF THEY COULD BE THESE 5071 03:16:04,564 --> 03:16:07,600 PROTOTYPE DEVICES COULD BE FROM 5072 03:16:07,600 --> 03:16:10,136 DISCIPLINES LIKE NASA FOR 5073 03:16:10,136 --> 03:16:12,572 EXAMPLE, THEY HAVE A PROTOTYPE 5074 03:16:12,572 --> 03:16:15,642 TECHNOLOGY, COULD BE OPTIMIZED 5075 03:16:15,642 --> 03:16:22,048 TO MAKE THEM BIO MECHANICAL. 5076 03:16:22,048 --> 03:16:24,451 >> SORRY, DO YOU HAVE TO WIN 5077 03:16:24,451 --> 03:16:26,553 IDEATION? 5078 03:16:26,553 --> 03:16:28,388 >> GEETHA: YES. 5079 03:16:28,388 --> 03:16:30,190 THE PUBLIC TOO WILL BE ALLOWED 5080 03:16:30,190 --> 03:16:32,525 TO GO FORWARD TO THE 5081 03:16:32,525 --> 03:16:34,327 IMPLEMENTATION PHASE AND AS 5082 03:16:34,327 --> 03:16:37,497 THEY ACHIEVE MORE MILESTONES 5083 03:16:37,497 --> 03:16:40,900 THEY GET REWARD. 5084 03:16:40,900 --> 03:16:42,702 ONCE THEY ACCOMPLISH THE 5085 03:16:42,702 --> 03:16:44,938 MILESTONE, AT THE END, WHOEVER 5086 03:16:44,938 --> 03:16:46,239 DELIVERS WORKING TECHNOLOGY 5087 03:16:46,239 --> 03:16:49,309 THEY WILL BE THE WINNER. 5088 03:16:49,309 --> 03:16:52,712 AND THERE WILL BE A RUNNER-UP. 5089 03:16:52,712 --> 03:16:54,748 >> I MAY HAVE MISSED IT BUT 5090 03:16:54,748 --> 03:16:56,149 WHAT IS THE FUNDING LEVEL, OR 5091 03:16:56,149 --> 03:16:57,250 COULD YOU SPEAK TO THE FUNDING 5092 03:16:57,250 --> 03:17:02,021 LEVEL? 5093 03:17:02,021 --> 03:17:04,424 >> GEETHA: WE NEED TO APPROVE 5094 03:17:04,424 --> 03:17:05,925 THE CONCEPT FIRST AND THEN WE 5095 03:17:05,925 --> 03:17:07,627 WILL FIGURE THAT OUT. 5096 03:17:07,627 --> 03:17:09,095 >> THE REASON I'M WONDERING 5097 03:17:09,095 --> 03:17:13,233 THAT, I WONDER IF THAT 5098 03:17:13,233 --> 03:17:17,036 IMPLEMENTATION IS A CHALLENGE 5099 03:17:17,036 --> 03:17:22,909 OR IT'S OVER TO THE SPI, SCPR. 5100 03:17:22,909 --> 03:17:25,245 >> GEETHA: WE ARE THINKING OF 5101 03:17:25,245 --> 03:17:26,780 REDUCTION TO PRACTICE AND OTHER 5102 03:17:26,780 --> 03:17:28,281 FUNDING OPPORTUNITY. 5103 03:17:28,281 --> 03:17:31,618 OTHER FUNDING MECHANISM. 5104 03:17:31,618 --> 03:17:33,920 THE CONCEPT IS FOR PRIZE 5105 03:17:33,920 --> 03:17:35,355 CHALLENGES AND DEPENDING ON HOW 5106 03:17:35,355 --> 03:17:37,056 THE SOLUTION IS COMING AND 5107 03:17:37,056 --> 03:17:39,359 WHAT'S A SUITABLE WAY OF 5108 03:17:39,359 --> 03:17:41,694 IMPLEMENTING FORWARD AND WITH 5109 03:17:41,694 --> 03:17:42,996 PERMISSION FROM OUR DEA, WE 5110 03:17:42,996 --> 03:17:45,532 WILL EXPLORE THOSE. 5111 03:17:45,532 --> 03:17:46,332 >> Joni Rutter: THANK YOU VERY 5112 03:17:46,332 --> 03:17:47,133 MUCH. 5113 03:17:47,133 --> 03:17:49,803 ANY OTHER QUESTIONS? 5114 03:17:49,803 --> 03:17:50,703 AND KELLY, I SEE YOUR COMMENT 5115 03:17:50,703 --> 03:17:51,905 ONLINE. 5116 03:17:51,905 --> 03:17:53,273 THAT WOULD BE GREAT TO MAKE 5117 03:17:53,273 --> 03:17:56,743 CONNECTIONS FOR SURE. 5118 03:17:56,743 --> 03:17:59,112 IF HAVE ANY OTHER COMMENTS I'M 5119 03:17:59,112 --> 03:18:01,514 HAPPY TO TAKE THOSE TOO. 5120 03:18:01,514 --> 03:18:02,649 >> KELLY: THIS IS GREAT ARE 5121 03:18:02,649 --> 03:18:03,950 TACKLING THIS. 5122 03:18:03,950 --> 03:18:06,553 I DON'T REALLY HAVE ANY 5123 03:18:06,553 --> 03:18:08,988 QUESTIONS, I DON'T HAVE ENOUGH 5124 03:18:08,988 --> 03:18:10,590 DEPTH WITH QUANTUM COMPUTING. 5125 03:18:10,590 --> 03:18:12,625 I GUESS I HAD QUESTIONS ABOUT, 5126 03:18:12,625 --> 03:18:14,828 IT SOUNDS LIKE YOU ARE NOT, ONE 5127 03:18:14,828 --> 03:18:17,096 QUESTION IS WERE YOU BUYING A 5128 03:18:17,096 --> 03:18:18,631 QUANTUM COMPUTER? 5129 03:18:18,631 --> 03:18:21,167 BUT IT SOUNDS LIKE YOU ARE 5130 03:18:21,167 --> 03:18:21,701 COLLABORATING WITH OTHER 5131 03:18:21,701 --> 03:18:22,902 INSTITUTES. 5132 03:18:22,902 --> 03:18:25,472 >> Joni Rutter: THAT'S RIGHT. 5133 03:18:25,472 --> 03:18:27,173 >> KELLY: THERE'S ONE COMMENT I 5134 03:18:27,173 --> 03:18:29,476 DON'T KNOW IF THIS WOULD SHAPE 5135 03:18:29,476 --> 03:18:31,511 IN ANY WAY THE COMPETITION. 5136 03:18:31,511 --> 03:18:33,413 AGAIN, HAVING NOT DONE THIS 5137 03:18:33,413 --> 03:18:35,048 RESEARCH OR USE THESE 5138 03:18:35,048 --> 03:18:36,249 TECHNOLOGIES PERSONALLY, BUT 5139 03:18:36,249 --> 03:18:37,083 HAVING KIND OF COLLABORATED 5140 03:18:37,083 --> 03:18:38,551 WITH THOSE WHO HAVE BEEN VERY 5141 03:18:38,551 --> 03:18:40,286 EXCITED ABOUT IT. 5142 03:18:40,286 --> 03:18:42,822 ONE THING THAT WAS REALLY 5143 03:18:42,822 --> 03:18:46,059 STRIKING TO ME, IS THAT THE 5144 03:18:46,059 --> 03:18:47,994 QUANTUM COMPUTERS ARE JUST NOT 5145 03:18:47,994 --> 03:18:49,295 CREATED EQUALLY. 5146 03:18:49,295 --> 03:18:54,234 THERE WAS A GROUP PART OF THIS 5147 03:18:54,234 --> 03:18:56,469 NATIONAL SCIENCE FOUNDATION 5148 03:18:56,469 --> 03:18:57,637 CONSORTIUM FOR ACCELERATED 5149 03:18:57,637 --> 03:19:00,073 COMPUTING HAD THESE TEAMS OF 5150 03:19:00,073 --> 03:19:02,909 PEOPLE WORKING ON ALGORITHMS AN 5151 03:19:02,909 --> 03:19:04,911 STARTED DOING BASIC TESTING ON 5152 03:19:04,911 --> 03:19:06,446 DIFFERENT QUANTUM PARADIGMS. 5153 03:19:06,446 --> 03:19:11,618 SO I THINK LIKE THE NAMES I 5154 03:19:11,618 --> 03:19:13,786 REMEMBER ARE D-WAVE OR REGETTI 5155 03:19:13,786 --> 03:19:15,221 QUANTUM COMPUTING. 5156 03:19:15,221 --> 03:19:16,456 BUT IT WAS INTERESTING, THERE 5157 03:19:16,456 --> 03:19:18,958 WASN'T A LOT OF -- THEY WERE 5158 03:19:18,958 --> 03:19:21,261 HAVING PROBLEMS WITH THE 5159 03:19:21,261 --> 03:19:24,197 ALGORITHMS TRANSFERRING FROM 5160 03:19:24,197 --> 03:19:26,266 ONE QUANTUM COMPUTING 5161 03:19:26,266 --> 03:19:27,233 ENVIRONMENT AND TECH NOOLG 5162 03:19:27,233 --> 03:19:28,868 STACK TOGETHER, I DON'T KNOW IF 5163 03:19:28,868 --> 03:19:31,771 THAT IS IMPORTANT OR RELEVANT 5164 03:19:31,771 --> 03:19:32,805 TO YOUR CHALLENGE. 5165 03:19:32,805 --> 03:19:35,742 BUT IT WAS MAKING THE 5166 03:19:35,742 --> 03:19:37,010 SCIENTISTS LEADING REALLY 5167 03:19:37,010 --> 03:19:40,079 SCRATCHING THEIR HEADS. 5168 03:19:40,079 --> 03:19:40,813 >> GEETHA: I'M HAPPY TO TAKE 5169 03:19:40,813 --> 03:19:45,118 THAT QUESTION. 5170 03:19:45,118 --> 03:19:46,853 AS ITS QUANTUM COMPUTING 5171 03:19:46,853 --> 03:19:49,188 HARDWARE IS EVOLVE, AND THERE 5172 03:19:49,188 --> 03:19:49,756 ARE MULTIPLE HARDWARES OUT 5173 03:19:49,756 --> 03:19:53,593 THERE. 5174 03:19:53,593 --> 03:19:54,060 AND SEVERAL DIFFERENT 5175 03:19:54,060 --> 03:19:54,827 ALGORITHMIC COMPANIES. 5176 03:19:54,827 --> 03:19:57,463 WHAT WE ARE ASKING IN THE PRIZE 5177 03:19:57,463 --> 03:19:58,164 CHALLENGE IS THINKING OF A 5178 03:19:58,164 --> 03:20:01,301 PROBLEM. 5179 03:20:01,301 --> 03:20:02,936 CHOOSING THE RIGHT PROBLEM IS 5180 03:20:02,936 --> 03:20:05,338 AMUSING. 5181 03:20:05,338 --> 03:20:10,476 THAT IS QUANTUM AMENABLE. 5182 03:20:10,476 --> 03:20:15,949 THE RIGHT HARDWARE THAT WOULD 5183 03:20:15,949 --> 03:20:17,550 BEAL GROW RHYTHM DESIGN TO 5184 03:20:17,550 --> 03:20:20,620 SOLVE THAT PROBLEM. 5185 03:20:20,620 --> 03:20:23,289 AND SURE, HOW YOU CAN SIMULATE 5186 03:20:23,289 --> 03:20:25,625 IF THAT WORKS ON ITS SIMULATOR 5187 03:20:25,625 --> 03:20:29,262 AND TAKE IT TO HARDWARE. 5188 03:20:29,262 --> 03:20:30,330 THEY CAN TEST IT ON DIFFERENT 5189 03:20:30,330 --> 03:20:35,969 HARDWARE. 5190 03:20:35,969 --> 03:20:38,671 MOST ALGORITHM DEVELOPERS THEY 5191 03:20:38,671 --> 03:20:40,506 ARE FAMILIAR WITH DIFFERENT 5192 03:20:40,506 --> 03:20:42,275 HARDWARE, WHAT I LEARNED FROM 5193 03:20:42,275 --> 03:20:44,477 COMMUNITIES THEY CAN ADAPT THE 5194 03:20:44,477 --> 03:20:46,245 ALGORITHMS TO DIFFERENT 5195 03:20:46,245 --> 03:20:46,746 HARDWARE. 5196 03:20:46,746 --> 03:20:51,918 BUT THE MORE MATURE ONES ARE 5197 03:20:51,918 --> 03:20:54,354 SUPER CONDUCTING QUBITS. 5198 03:20:54,354 --> 03:20:55,154 THE DEVELOPERS ARE VERY 5199 03:20:55,154 --> 03:20:58,825 FAMILIAR WITH THE PROBLEM. 5200 03:20:58,825 --> 03:21:02,528 I MUST SAY I HAVE TO REITERATE 5201 03:21:02,528 --> 03:21:06,299 THIS EARLY STAGE FOR QUANTUM 5202 03:21:06,299 --> 03:21:08,401 COMPUTING, WE WANT BIOMEDICAL 5203 03:21:08,401 --> 03:21:09,836 SCIENTISTS TO GET ENGAGED WITH 5204 03:21:09,836 --> 03:21:13,873 THINKING ABOUT HOW TO SOLVE A 5205 03:21:13,873 --> 03:21:16,743 PROBLEM IN QUANTUM ALGORITHM 5206 03:21:16,743 --> 03:21:18,511 LANGUAGE RIGHT, CODE, SOLVE AND 5207 03:21:18,511 --> 03:21:20,313 APPLY THAT YOU CAN ENHANCE THE 5208 03:21:20,313 --> 03:21:23,149 CURRENT LANDSCAPE. 5209 03:21:23,149 --> 03:21:30,690 THERE ARE CERTAIN ADVANTAGES 5210 03:21:30,690 --> 03:21:32,125 WITHIN NOISY INTERMEDIATE 5211 03:21:32,125 --> 03:21:37,764 SCALE, QUANTUM COMPUTERS. 5212 03:21:37,764 --> 03:21:38,898 CERTAIN PROBLEMS BEING TESTED. 5213 03:21:38,898 --> 03:21:39,565 >> Joni Rutter: THANK YOU VERY 5214 03:21:39,565 --> 03:21:41,801 MUCH. 5215 03:21:41,801 --> 03:21:45,938 IF THERE AREN'T ANY OTHER 5216 03:21:45,938 --> 03:21:47,940 COMMENTS, ANNE? 5217 03:21:47,940 --> 03:21:49,709 >> OKAY, COULD I HAVE A MOTION 5218 03:21:49,709 --> 03:21:50,643 TO APPROVE THE CONCEPT? 5219 03:21:50,643 --> 03:21:52,211 SECOND? 5220 03:21:52,211 --> 03:21:56,149 ALL IN FAVOR? 5221 03:21:56,149 --> 03:21:58,484 ANY OPPOSED? 5222 03:21:58,484 --> 03:22:00,887 ANY ABSTENTIONS? 5223 03:22:00,887 --> 03:22:07,060 THANK YOU. 5224 03:22:07,060 --> 03:22:08,061 THE CONCEPT IS APPROVED. 5225 03:22:08,061 --> 03:22:09,996 >> Joni Rutter: NEXT WE HAVE 5226 03:22:09,996 --> 03:22:12,098 ANOTHER CONCEPT FROM OFFICE OF 5227 03:22:12,098 --> 03:22:12,665 POLICY, COMMUNICATIONS AND 5228 03:22:12,665 --> 03:22:16,903 EDUCATION. 5229 03:22:16,903 --> 03:22:19,172 PENNY BURGOON WILL KICK US OFF 5230 03:22:19,172 --> 03:22:23,142 INTRODUCING. 5231 03:22:23,142 --> 03:22:26,679 >> PENNY: GOOD AFTERNOON. 5232 03:22:26,679 --> 03:22:29,015 I'M HERE TO GIVE A BACKGROUND 5233 03:22:29,015 --> 03:22:30,183 AND BRIEF INTRODUCTION ON THE 5234 03:22:30,183 --> 03:22:31,951 OFFICE OF THIS CONCEPT FROM THE 5235 03:22:31,951 --> 03:22:32,785 OFFICE OF POLICY COMMUNICATIONS 5236 03:22:32,785 --> 03:22:33,653 AND EDUCATION. 5237 03:22:33,653 --> 03:22:34,654 NEXT SLIDE, PLEASE. 5238 03:22:34,654 --> 03:22:36,089 THIS IS A CONCEPT FROM THE 5239 03:22:36,089 --> 03:22:37,790 EDUCATION BRANCH. 5240 03:22:37,790 --> 03:22:40,093 THIS BRANCH IS REALLY WORKING 5241 03:22:40,093 --> 03:22:45,665 TO DEVELOP A VISION FOR A 5242 03:22:45,665 --> 03:22:46,599 HIGHLY-SKILLED LARGE DIVERSE 5243 03:22:46,599 --> 03:22:49,702 TRANSLATIONAL SCIENCE WORKFORCE. 5244 03:22:49,702 --> 03:22:53,039 ALONG WITH THE COMPASS NEEDED 5245 03:22:53,039 --> 03:22:55,208 TO ACCELERATE PROGRESS ALONG 5246 03:22:55,208 --> 03:22:57,710 THE TRANSLATIONAL PIPELINE WITH 5247 03:22:57,710 --> 03:22:58,444 MORE HEALTH SOLUTIONS FOR ALL 5248 03:22:58,444 --> 03:23:03,483 PEOPLE. 5249 03:23:03,483 --> 03:23:10,323 BY DR. AMANDA VOGEL. 5250 03:23:10,323 --> 03:23:17,964 DR. BELEN HURLE, DR. HODGES AND 5251 03:23:17,964 --> 03:23:20,933 DR. JUAREZ. 5252 03:23:20,933 --> 03:23:23,236 THE WORK IS EXTENSIVE FOR 5253 03:23:23,236 --> 03:23:28,508 PEOPLE INCLUDING COLLABORATING 5254 03:23:28,508 --> 03:23:32,345 WITH THOSE ACROSS OUR 5255 03:23:32,345 --> 03:23:32,879 INTERMURAL ACTIVITIES TO 5256 03:23:32,879 --> 03:23:36,249 ADVANCE UNDERSTANDING. 5257 03:23:36,249 --> 03:23:36,816 THEY ALSO PRODUCE ORIGINAL 5258 03:23:36,816 --> 03:23:38,785 SCHOLARSHIP. 5259 03:23:38,785 --> 03:23:40,953 SO WITH THAT, I'M GOING TO -- 5260 03:23:40,953 --> 03:23:42,155 NEXT SLIDE, PLEASE. 5261 03:23:42,155 --> 03:23:44,957 THESE ARE JUST SOME OF THE 5262 03:23:44,957 --> 03:23:45,992 EDUCATIONAL BRANCH GOALS, BUT 5263 03:23:45,992 --> 03:23:52,131 IN THE INTEREST OF TIME, I'M 5264 03:23:52,131 --> 03:23:53,966 GOING TO LET AMANDA VOGEL SO 5265 03:23:53,966 --> 03:23:57,970 SHE CAN TELL YOU ABOUT THE 5266 03:23:57,970 --> 03:23:58,437 CONCEPT TODAY FOR 5267 03:23:58,437 --> 03:23:59,071 TRANSFORMATIONAL EDUCATION AND 5268 03:23:59,071 --> 03:24:00,706 TRAINING. 5269 03:24:00,706 --> 03:24:04,143 >> AMANDA: THANK YOU, I'M 5270 03:24:04,143 --> 03:24:08,447 AMANDA VOGEL, ACTING DIRECTOR 5271 03:24:08,447 --> 03:24:10,216 FOR THE EDUCATION BRANCH. 5272 03:24:10,216 --> 03:24:15,988 ONE OF THE CORE GOALS IS TO 5273 03:24:15,988 --> 03:24:16,622 COLLABORATE, DISSEMINATE 5274 03:24:16,622 --> 03:24:17,523 KNOWLEDGE AND AMPLIFY THAT 5275 03:24:17,523 --> 03:24:18,858 KNOWLEDGE THAT COMES THROUGH 5276 03:24:18,858 --> 03:24:20,626 THE SCIENTIFIC COMMUNITY. 5277 03:24:20,626 --> 03:24:22,962 THAT CONCEPT FOR A CHALLENGE 5278 03:24:22,962 --> 03:24:24,764 PRIZE IS ALIGNED WITH THAT GOAL. 5279 03:24:24,764 --> 03:24:27,733 NEXT SLIDE, PLEASE. 5280 03:24:27,733 --> 03:24:28,568 SO IT SEEMS LIKE CHALLENGE 5281 03:24:28,568 --> 03:24:31,537 PRIZES ARE THE THEME OF THE DAY. 5282 03:24:31,537 --> 03:24:33,573 AND THIS PRIZE COMPETITION THAT 5283 03:24:33,573 --> 03:24:36,075 I'M SHARING WITH YOU TODAY, AS 5284 03:24:36,075 --> 03:24:37,710 A CONCEPT IS FOR TRANSLATIONAL 5285 03:24:37,710 --> 03:24:40,646 SCIENCE EDUCATION AND TRAINING. 5286 03:24:40,646 --> 03:24:43,983 THE GOAL OF THIS CONCEPT IS TO 5287 03:24:43,983 --> 03:24:46,485 USE THIS MECHANISM AS AN AVENUE 5288 03:24:46,485 --> 03:24:51,257 TO IDENTIFY, AMPLIFY AND 5289 03:24:51,257 --> 03:24:53,726 DISSEMINATE TRAINING THAT HAVE 5290 03:24:53,726 --> 03:24:56,062 BEEN GENERATED BY THE COMMUNITY. 5291 03:24:56,062 --> 03:24:57,730 NEXT SLIDE, PLEASE. 5292 03:24:57,730 --> 03:25:00,299 I WANT TO START BY GIVING YOU A 5293 03:25:00,299 --> 03:25:01,133 LITTLE BIT BACKGROUND TO THIS 5294 03:25:01,133 --> 03:25:04,570 CONCEPT. 5295 03:25:04,570 --> 03:25:05,571 SO NCATS HAS ARTICULATED A 5296 03:25:05,571 --> 03:25:07,974 VISION FOR THE FIELD OF TS 5297 03:25:07,974 --> 03:25:09,408 EDUCATION WAND TRAINING TO 5298 03:25:09,408 --> 03:25:10,409 EQUIP THE WORKFORCE WITH 5299 03:25:10,409 --> 03:25:14,747 KNOWLEDGE AND SKILLS THAT ARE 5300 03:25:14,747 --> 03:25:16,749 SPECIFIC TO IMPROVING AND 5301 03:25:16,749 --> 03:25:17,650 ACCELERATING TRANSLATIONAL 5302 03:25:17,650 --> 03:25:18,217 RESEARCH AND TRANSLATIONAL 5303 03:25:18,217 --> 03:25:19,318 PROGRESS. 5304 03:25:19,318 --> 03:25:25,491 AND THIS IS IN ORDER TO ENHANCE 5305 03:25:25,491 --> 03:25:26,325 BOTH THE SPEED AND IMPACT OF 5306 03:25:26,325 --> 03:25:28,327 OUR WORK. 5307 03:25:28,327 --> 03:25:32,131 THIS VISION IS REFLECTED IN THE 5308 03:25:32,131 --> 03:25:33,065 TRANSLATIONAL SCIENCE 5309 03:25:33,065 --> 03:25:35,801 PRINCIPLES SHOWN ON THE RIGHT 5310 03:25:35,801 --> 03:25:40,539 SIDE OF THESE SLIDE, THESE 5311 03:25:40,539 --> 03:25:42,041 PRINCIPLES EXEMPLIFY EFFECTIVE 5312 03:25:42,041 --> 03:25:45,111 SCIENTIFIC AND OPERATIONAL 5313 03:25:45,111 --> 03:25:45,578 APPROACHES TO ADVANCE 5314 03:25:45,578 --> 03:25:49,048 TRANSLATIONAL PROGRESS. 5315 03:25:49,048 --> 03:25:50,316 SOME EXAMPLES OF PRINCIPLES AS 5316 03:25:50,316 --> 03:25:53,085 SHOWN ON THE RIGHT ARE 5317 03:25:53,085 --> 03:25:53,653 EMPHASIZING CREATIVITY AND 5318 03:25:53,653 --> 03:26:01,928 INNOVATION. 5319 03:26:01,928 --> 03:26:03,796 FOCUSING ON UNMET NEEDS, 5320 03:26:03,796 --> 03:26:07,166 ENHANCING EFFICIENCY AND SPEED 5321 03:26:07,166 --> 03:26:08,301 AND LEVERAGING CROSS 5322 03:26:08,301 --> 03:26:10,169 DISCIPLINARY TEAM-BASED SCIENCE 5323 03:26:10,169 --> 03:26:13,873 AND BOUNDARY CROSSING 5324 03:26:13,873 --> 03:26:14,874 PARTNERSHIPS INCLUDING 5325 03:26:14,874 --> 03:26:16,409 PARTNERSHIPS ACROSS GOVERNMENT 5326 03:26:16,409 --> 03:26:18,511 UNIVERSITIES AND INDUSTRY AND 5327 03:26:18,511 --> 03:26:19,345 WITH COMMUNITIES AND PATIENT 5328 03:26:19,345 --> 03:26:20,846 PARTNERS AND RESEARCH. 5329 03:26:20,846 --> 03:26:23,182 ANOTHER KEY PART OF OUR VISION 5330 03:26:23,182 --> 03:26:23,983 FOR TRANSLATIONAL SCIENCE 5331 03:26:23,983 --> 03:26:26,719 EDUCATION AND TRAINING IS TO 5332 03:26:26,719 --> 03:26:29,922 EXPAND ACCESS TO TRANSLATIONAL 5333 03:26:29,922 --> 03:26:31,624 SCIENCE KNOWLEDGE FOR LEARNING 5334 03:26:31,624 --> 03:26:32,191 ACROSS TRAINING AND CAREER 5335 03:26:32,191 --> 03:26:34,293 STAGES. 5336 03:26:34,293 --> 03:26:37,396 IN A VARIETY OF ROLES, IT 5337 03:26:37,396 --> 03:26:38,431 INCLUDES COMMUNITY AND PATIENT 5338 03:26:38,431 --> 03:26:41,233 PARTNERS AS I MENTIONED. 5339 03:26:41,233 --> 03:26:42,335 WE SHARED SOME RELATED 5340 03:26:42,335 --> 03:26:45,004 MATERIALS TODAY IN A FOLDER 5341 03:26:45,004 --> 03:26:45,905 THAT WAS DISTRIBUTED TO 5342 03:26:45,905 --> 03:26:46,772 COUNCILMEMBERS WHO ARE HERE IN 5343 03:26:46,772 --> 03:26:49,041 PERSON. 5344 03:26:49,041 --> 03:26:50,343 AND THESE INCLUDE AN ARTICLE 5345 03:26:50,343 --> 03:26:53,045 THAT SHARES OUR VISION FOR 5346 03:26:53,045 --> 03:26:53,779 TRANSLATIONAL SCIENCE, 5347 03:26:53,779 --> 03:26:56,115 EDUCATION AND TRAINING AND SOME 5348 03:26:56,115 --> 03:26:58,117 FUN STICKERS THAT FEATURE THE 5349 03:26:58,117 --> 03:26:58,584 TRANSLATIONAL SCIENCE 5350 03:26:58,584 --> 03:26:59,418 PRINCIPLES. 5351 03:26:59,418 --> 03:27:01,354 FOR THOSE OF US JOINING ONLINE, 5352 03:27:01,354 --> 03:27:03,656 YOU CAN FIND THE SAME MATERIALS 5353 03:27:03,656 --> 03:27:07,293 AS YOU CAN GO TO THE NCATS WEB 5354 03:27:07,293 --> 03:27:08,828 PAGE AND SEARCH FOR 5355 03:27:08,828 --> 03:27:09,295 TRANSLATIONAL SCIENCE 5356 03:27:09,295 --> 03:27:10,162 PRINCIPLES. 5357 03:27:10,162 --> 03:27:12,064 AT THE BOTTOM OF THE PAGE YOU 5358 03:27:12,064 --> 03:27:17,136 WILL FIND A LINK TO OUR ARTICLE 5359 03:27:17,136 --> 03:27:19,338 THAT IS INCLUDED IN THE FOLDER 5360 03:27:19,338 --> 03:27:22,541 FOR THOSE HERE IN PERSON. 5361 03:27:22,541 --> 03:27:24,176 SO THE SECOND POINT THAT I 5362 03:27:24,176 --> 03:27:26,112 WOULD LIKE TO MAKE ON THIS 5363 03:27:26,112 --> 03:27:28,314 SLIDE IS AS A FIELD 5364 03:27:28,314 --> 03:27:29,048 TRANSLATIONAL SCIENCE, 5365 03:27:29,048 --> 03:27:30,549 EDUCATION AND TRAINING IS STILL 5366 03:27:30,549 --> 03:27:33,085 VERY MUCH IN DEVELOPMENT. 5367 03:27:33,085 --> 03:27:35,788 AND THERE ARE TRAIL BLAZERS IN 5368 03:27:35,788 --> 03:27:37,123 THE COMMUNITY GENERATING NOVEL 5369 03:27:37,123 --> 03:27:37,823 EDUCATION AND TRAINING 5370 03:27:37,823 --> 03:27:39,558 OPPORTUNITIES WHERE THEY ARE 5371 03:27:39,558 --> 03:27:42,595 LAYING OUT CORE CONTENT IN 5372 03:27:42,595 --> 03:27:45,398 TRANSLATIONAL SCIENCE AND 5373 03:27:45,398 --> 03:27:46,832 EDUCATION AND TRAINING AND 5374 03:27:46,832 --> 03:27:48,567 DEVELOPING METHODS TO CONVEY 5375 03:27:48,567 --> 03:27:49,068 THAT CONTENT TO VARIED 5376 03:27:49,068 --> 03:27:50,669 AUDIENCES. 5377 03:27:50,669 --> 03:27:52,905 TIES ARE TRAIL BLAZERS OF 5378 03:27:52,905 --> 03:27:55,541 COURSE IN ACADEMIA, FOR 5379 03:27:55,541 --> 03:27:57,843 EXAMPLE, OUR CTSA SUPPORTED 5380 03:27:57,843 --> 03:27:59,345 INSTITUTIONS AND ALSO TRAIL 5381 03:27:59,345 --> 03:28:01,280 BLAZERS IN OTHER SETTINGS, FOR 5382 03:28:01,280 --> 03:28:02,314 EX ESPECIALLY, INDUSTRY AND 5383 03:28:02,314 --> 03:28:03,616 PROFESSIONAL SOCIETIES. 5384 03:28:03,616 --> 03:28:05,284 WHAT THEY ARE DEVELOPING IN 5385 03:28:05,284 --> 03:28:06,519 THESE SETTINGS MAY BE RELEVANT 5386 03:28:06,519 --> 03:28:09,655 TO OTHERS IN THE SAME SETTINGS 5387 03:28:09,655 --> 03:28:10,523 BUT ALSO BROADLY RELEVANT 5388 03:28:10,523 --> 03:28:13,092 ACROSS SETTINGS. 5389 03:28:13,092 --> 03:28:14,293 BUT THOSE APPROACHES TO 5390 03:28:14,293 --> 03:28:15,561 EDUCATION AND TRAINING MAY NOT 5391 03:28:15,561 --> 03:28:17,630 HAVE BEEN SHARED BROADLY. 5392 03:28:17,630 --> 03:28:20,032 SO AS EVIDENCE OF THIS THE 5393 03:28:20,032 --> 03:28:21,067 EDUCATION BRANCH CONDUCTED A 5394 03:28:21,067 --> 03:28:24,503 SCHOLARSHIPING REVIEW OF THE 5395 03:28:24,503 --> 03:28:26,405 PEER REVIEW LITERATURE ON 5396 03:28:26,405 --> 03:28:27,907 TRANSLATIONAL SCIENCE EDUCATION 5397 03:28:27,907 --> 03:28:29,542 AND TRAINING. 5398 03:28:29,542 --> 03:28:31,477 WHILE LOOKING AT A 15-YEAR 5399 03:28:31,477 --> 03:28:33,579 PERIOD WE FOUND ONLY 29 5400 03:28:33,579 --> 03:28:34,914 ARTICLES THAT DESCRIBE 5401 03:28:34,914 --> 03:28:39,785 EDUCATIONAL AND TRAINING 5402 03:28:39,785 --> 03:28:41,887 OPPORTUNITIES THAT REFLECT THE 5403 03:28:41,887 --> 03:28:42,388 NCATS UNDERSTANDING OF 5404 03:28:42,388 --> 03:28:43,289 TRANSLATIONAL SCIENCE. 5405 03:28:43,289 --> 03:28:44,623 WE KNOW THERE THERE IS MORE OUT 5406 03:28:44,623 --> 03:28:48,160 THERE. 5407 03:28:48,160 --> 03:28:51,464 TO SUM UP THIS SLIDE WE FEEL 5408 03:28:51,464 --> 03:28:56,302 THERE'S A NEED TO IDENTIFY, 5409 03:28:56,302 --> 03:28:57,236 AMPLIFY AND DISSEMINATE 5410 03:28:57,236 --> 03:28:58,938 EXEMPLARY MODELS FROM THE 5411 03:28:58,938 --> 03:29:01,207 SCIENTIFIC COMMUNITY AND PLAN 5412 03:29:01,207 --> 03:29:04,376 TO USE OUR ROLE AT NCATS TO DO 5413 03:29:04,376 --> 03:29:05,511 THAT WITH THIS CHALLENGE. 5414 03:29:05,511 --> 03:29:08,647 NEXT SLIDE, PLEASE. 5415 03:29:08,647 --> 03:29:12,284 YOU SEE IN A VERSION THIS SLIDE 5416 03:29:12,284 --> 03:29:12,918 AND DOMINIQUE'S PRESENTATION 5417 03:29:12,918 --> 03:29:20,860 THIS MORNING, I THINK THAT 5418 03:29:20,860 --> 03:29:26,732 UNDERSCORES ACCENT RATE AREAS. 5419 03:29:26,732 --> 03:29:31,837 ACCELERATE AREAS. 5420 03:29:31,837 --> 03:29:33,939 THEY OVERCOME LONG STANDING 5421 03:29:33,939 --> 03:29:35,241 CHALLENGES ALONG THE 5422 03:29:35,241 --> 03:29:36,976 STRANSLATIONAL RESEARCH 5423 03:29:36,976 --> 03:29:38,711 PIPELINE AND THOSE INNOVATIONS 5424 03:29:38,711 --> 03:29:41,313 AND ADVANCED PROGRESS BY BOTH 5425 03:29:41,313 --> 03:29:43,649 ACCELERATING THE SPEED AND OUR 5426 03:29:43,649 --> 03:29:45,751 RESEARCH AND ENHANCING ITS 5427 03:29:45,751 --> 03:29:48,821 IMPACT AND THIS SLIDE HERE ARE 5428 03:29:48,821 --> 03:29:50,189 SOME EXAMPLES OF TRANSLATIONAL 5429 03:29:50,189 --> 03:29:52,224 RESEARCH KHAL LINGS AND RELATED 5430 03:29:52,224 --> 03:29:52,892 TRANSLATIONAL SCIENCE 5431 03:29:52,892 --> 03:29:54,059 SOLUTIONS, THESE ARE EXAMPLES 5432 03:29:54,059 --> 03:29:57,363 THAT WE HOPE TO EQUIP OUR 5433 03:29:57,363 --> 03:29:58,697 WORKFORCE WITH AND THE FIELD 5434 03:29:58,697 --> 03:30:00,599 WILL BIN FIT FROM. 5435 03:30:00,599 --> 03:30:03,435 SO THE FIRST BULLET POINT UNDER 5436 03:30:03,435 --> 03:30:06,472 BOTTLENECKS TO ADDRESS THE 5437 03:30:06,472 --> 03:30:08,507 CHALLENGE OF INCOMPATIBLE 5438 03:30:08,507 --> 03:30:11,410 DATABASES, WE INVESTED IN DATA 5439 03:30:11,410 --> 03:30:13,145 INTEROPERABILITY AND 5440 03:30:13,145 --> 03:30:14,346 INTEGRATION AND EXAMPLE 5441 03:30:14,346 --> 03:30:19,118 PROVIDED HERE TO ADDRESS THE 5442 03:30:19,118 --> 03:30:19,985 CHALLENGE OF ADMINISTRATIVE 5443 03:30:19,985 --> 03:30:22,655 BURDEN FOR STUDY START UP. 5444 03:30:22,655 --> 03:30:24,089 WE FOCUS ON STREAMLINING 5445 03:30:24,089 --> 03:30:26,859 BUSINESS PROCESSES SUCH AS THE 5446 03:30:26,859 --> 03:30:28,727 SMART IRP AND. 5447 03:30:28,727 --> 03:30:30,329 WE FOCUS ON DEVELOPMENT OF 5448 03:30:30,329 --> 03:30:32,464 MODEL THAT'S MIMIC THE 5449 03:30:32,464 --> 03:30:35,467 STRUCTURE AND FUNCTION OF HUMAN 5450 03:30:35,467 --> 03:30:37,136 TISSUE AS THROUGH THE TISSUE 5451 03:30:37,136 --> 03:30:39,538 CHIP INITIATIVE. 5452 03:30:39,538 --> 03:30:40,639 SO TRANSLATIONAL SCIENCE, 5453 03:30:40,639 --> 03:30:43,576 EDUCATION AND TRAINING AIMS TO 5454 03:30:43,576 --> 03:30:44,743 EQUIP OUR WORKFORCE FOR THESE 5455 03:30:44,743 --> 03:30:45,477 INITIATIVES. 5456 03:30:45,477 --> 03:30:50,716 NEXT SLIDE, PLEASE. 5457 03:30:50,716 --> 03:30:52,651 WE ARE PROPOSING THIS 5458 03:30:52,651 --> 03:30:54,353 TRANSLATIONAL SLIDE TO RAISE 5459 03:30:54,353 --> 03:30:57,122 AWARENESS WHAT IT CAN DO AND 5460 03:30:57,122 --> 03:31:02,828 THE VALUE IT COULD ADD TO OUR 5461 03:31:02,828 --> 03:31:05,064 WORKFORCE PREPARATION AND 5462 03:31:05,064 --> 03:31:06,198 ACCELERATE DISSEMINATION OF 5463 03:31:06,198 --> 03:31:08,067 EXEMPLARY MODELS INCLUDING CORE 5464 03:31:08,067 --> 03:31:11,003 CONTENT FOR EDUCATION TRAINING. 5465 03:31:11,003 --> 03:31:11,937 INNOVATIVE TEACHING APPROACHES 5466 03:31:11,937 --> 03:31:14,340 AND MODELS OF WAYS OF REACHING 5467 03:31:14,340 --> 03:31:15,975 DIVERSE LEARNER DOLLARS. 5468 03:31:15,975 --> 03:31:19,411 NEXT SLIDE, PLEASE. 5469 03:31:19,411 --> 03:31:24,984 -- LEARNERS. 5470 03:31:24,984 --> 03:31:28,320 THIS SLIDE WILL RISE, REWARD 5471 03:31:28,320 --> 03:31:29,922 AND DISSEMINATE TRANSLATIONAL 5472 03:31:29,922 --> 03:31:31,890 SCIENCE EDUCATION AND TRAINING 5473 03:31:31,890 --> 03:31:34,994 PROGRAMS THAT PROVIDE CONTENT 5474 03:31:34,994 --> 03:31:36,028 THAT ALIGNS WITH THE NCATS 5475 03:31:36,028 --> 03:31:37,329 UNDERSTANDING OF THE FIELD OF 5476 03:31:37,329 --> 03:31:39,932 TRANSLATIONAL SCIENCE. 5477 03:31:39,932 --> 03:31:42,001 EQUIP LEARNERS, KNOWLEDGE AND 5478 03:31:42,001 --> 03:31:44,303 SKILLS TO OVERCOME BOTTLENECKS 5479 03:31:44,303 --> 03:31:45,838 AND ROADBLOCK THAT'S ARE 5480 03:31:45,838 --> 03:31:46,972 COMMONLY FOUND IN RESEARCH 5481 03:31:46,972 --> 03:31:49,775 ACROSS DISEASES AND CONDITIONS. 5482 03:31:49,775 --> 03:31:51,377 AND LEVERAGE INNOVATIVE 5483 03:31:51,377 --> 03:31:53,912 EDUCATION AND TRAINING MODALITY 5484 03:31:53,912 --> 03:31:59,752 TEACHING APPROACHES AND 5485 03:31:59,752 --> 03:32:01,287 FORMATS, THAT HELP REACH BROAD 5486 03:32:01,287 --> 03:32:02,554 AND DIVERSE AUDIENCES. 5487 03:32:02,554 --> 03:32:05,591 NOW I WANT TO TALK ABOUT WHY WE 5488 03:32:05,591 --> 03:32:07,493 ARE PROPOSING A CHALLENGE PRIZE 5489 03:32:07,493 --> 03:32:09,561 VERSUS A GRANT. 5490 03:32:09,561 --> 03:32:11,030 THERE ARE TWO ADVANTAGES OF A 5491 03:32:11,030 --> 03:32:13,132 CHALLENGE PRIZE. 5492 03:32:13,132 --> 03:32:14,533 FIRST OF ALL, IT RECOGNIZES 5493 03:32:14,533 --> 03:32:17,002 WORK THAT HAS ALREADY BEEN DONE. 5494 03:32:17,002 --> 03:32:20,506 THIS CHALLENGE WILL REWARD AND 5495 03:32:20,506 --> 03:32:22,474 AMPLIFY ADDITIONAL 5496 03:32:22,474 --> 03:32:22,808 OPPORTUNITIES. 5497 03:32:22,808 --> 03:32:26,578 IT ALLOWS US TO BEAT THE BUSHES 5498 03:32:26,578 --> 03:32:28,480 FOR WHAT IS ELEVATED AND 5499 03:32:28,480 --> 03:32:30,716 DISSEMINATED. 5500 03:32:30,716 --> 03:32:33,085 THE PRIZE WILL BE BROADLY 5501 03:32:33,085 --> 03:32:35,387 INCLUSIVE A WIDE RANGE OF 5502 03:32:35,387 --> 03:32:37,890 MODALITIES, IN DICTION TO 5503 03:32:37,890 --> 03:32:39,024 COURSES, CERTIFICATES DEGREE 5504 03:32:39,024 --> 03:32:41,760 PROGRAMS WE ARE THINKING MORE 5505 03:32:41,760 --> 03:32:43,162 BROADLY TO CAPTURE MODALITIES 5506 03:32:43,162 --> 03:32:45,464 THAT CAN GET TO PEOPLE ACROSS 5507 03:32:45,464 --> 03:32:50,135 TRAINING AND CAREER STAGES, SO 5508 03:32:50,135 --> 03:32:52,771 FOR EXAMPLE, WORKSHOPS, 5509 03:32:52,771 --> 03:32:55,808 CONSULTING SEMINAR SERIES ET 5510 03:32:55,808 --> 03:32:56,041 CETERA. 5511 03:32:56,041 --> 03:32:58,877 IT EXPANDS THE APPLICANT POOL 5512 03:32:58,877 --> 03:33:01,347 TO CAPTURE DIVERSE APPROACHES. 5513 03:33:01,347 --> 03:33:02,848 THE IDEA BEHIND THE CHALLENGES 5514 03:33:02,848 --> 03:33:05,884 IS THAT THEY ARE AN OPEN 5515 03:33:05,884 --> 03:33:07,920 INNOVATION INITIATIVE. 5516 03:33:07,920 --> 03:33:11,523 THE IDEA IS THAT YOU LEVERAGE 5517 03:33:11,523 --> 03:33:12,024 THE PUBLIC TO SIMULATE 5518 03:33:12,024 --> 03:33:16,795 INNOVATION. 5519 03:33:16,795 --> 03:33:18,630 THAT YOU INCLUDES ACADEMIA, 5520 03:33:18,630 --> 03:33:19,131 INDUSTRY, PROFESSIONAL 5521 03:33:19,131 --> 03:33:20,265 SOCIETIES, ET CETERA. 5522 03:33:20,265 --> 03:33:23,535 WE THINK DOING THIS WE WILL GET 5523 03:33:23,535 --> 03:33:26,338 SOME CROSS FERTILIZATION OF 5524 03:33:26,338 --> 03:33:28,474 IDEAS AND WE WILL GENERATE, 5525 03:33:28,474 --> 03:33:30,442 IDENTIFY IDEAS THAT HAVEN'T 5526 03:33:30,442 --> 03:33:32,277 BEEN PUBLISHED FOR EXAMPLE, IN 5527 03:33:32,277 --> 03:33:36,081 THE PEER REVIEW LITERATURE. 5528 03:33:36,081 --> 03:33:37,082 INCLUDING UNDERGRAD AND 5529 03:33:37,082 --> 03:33:38,384 GRADUATE EDUCATION AND EARLY, 5530 03:33:38,384 --> 03:33:40,686 MID AND SENIOR CAREER. 5531 03:33:40,686 --> 03:33:51,230 OUR INTENTION IS WE WILL BE -- 5532 03:33:53,665 --> 03:33:56,268 I WANT TO TALK ABOUT HOW THIS 5533 03:33:56,268 --> 03:33:58,070 CHALLENGE CONCEPT FITS INTO OUR 5534 03:33:58,070 --> 03:34:01,240 OTHER EFFORTS AND AS WE EXPECT 5535 03:34:01,240 --> 03:34:03,041 TO SEE AS THE IMPACT. 5536 03:34:03,041 --> 03:34:04,543 WE BELIEVE THIS WILL CONTRIBUTE 5537 03:34:04,543 --> 03:34:08,714 TO OUR WORK IN DEVELOPING 5538 03:34:08,714 --> 03:34:09,415 TRANSLATIONAL SCIENCES OF FIELD 5539 03:34:09,415 --> 03:34:10,816 OF STUDY. 5540 03:34:10,816 --> 03:34:14,353 IT WILL DO THIS BY 5541 03:34:14,353 --> 03:34:17,356 COMPLEMENTING EXISTING 5542 03:34:17,356 --> 03:34:17,923 ACTIVITIES AND RESOURCES AT 5543 03:34:17,923 --> 03:34:22,895 NCATS. 5544 03:34:22,895 --> 03:34:24,430 INCLUDES EXTRAMURAL FUNDING FOR 5545 03:34:24,430 --> 03:34:25,063 TRANSLATIONAL SCIENCE EDUCATION 5546 03:34:25,063 --> 03:34:26,331 AND TRAINING. 5547 03:34:26,331 --> 03:34:29,301 AS WELL AS ONLINE COURSES THAT 5548 03:34:29,301 --> 03:34:30,903 WE HAVE DEVELOPED THROUGH THE 5549 03:34:30,903 --> 03:34:32,805 EDUCATION BRANCH. 5550 03:34:32,805 --> 03:34:34,039 THAT WE ARE MAKING AVAILABLE TO 5551 03:34:34,039 --> 03:34:35,941 THE PUBLIC IN THE FUTURE. 5552 03:34:35,941 --> 03:34:38,177 AND OUR ORIGINAL SCHOLARSHIP 5553 03:34:38,177 --> 03:34:39,711 FROM THE GRANT THAT'S 5554 03:34:39,711 --> 03:34:42,114 CONTRIBUTING TO THE NATIONAL 5555 03:34:42,114 --> 03:34:46,485 CONVERSATION ON DIRECTIONS FOR 5556 03:34:46,485 --> 03:34:47,219 ADVANCING TRANSLATIONAL SCIENCE 5557 03:34:47,219 --> 03:34:48,887 EDUCATION AND TRAINING. 5558 03:34:48,887 --> 03:34:52,391 ENHANCING ACCESSIBILITY. 5559 03:34:52,391 --> 03:34:55,661 FINALLY OUR INTEND IN THIS 5560 03:34:55,661 --> 03:35:04,770 PRIZE WILL IDENTIFY, AMPLIFY 5561 03:35:04,770 --> 03:35:05,604 EXEMPLARS OF TRANSLATIONAL 5562 03:35:05,604 --> 03:35:07,439 SCIENCE EDUCATION THAT MAY NOT 5563 03:35:07,439 --> 03:35:08,407 HAVE BEEN SHARED BROADLY. 5564 03:35:08,407 --> 03:35:11,343 NEXT SLIDE, PLEASE. 5565 03:35:11,343 --> 03:35:13,479 THE CONCEPT AIMS TO RAISE 5566 03:35:13,479 --> 03:35:16,782 AWARENESS OF THE VALUE ADD OF 5567 03:35:16,782 --> 03:35:17,883 THE TRANSLATIONAL SCIENCE 5568 03:35:17,883 --> 03:35:19,184 EDUCATION AND TRAINING THAT 5569 03:35:19,184 --> 03:35:21,420 ALIGNS WITH THE NCATS DIVISION. 5570 03:35:21,420 --> 03:35:24,022 AND ULTIMATELY WE HOPE IT WILL 5571 03:35:24,022 --> 03:35:29,294 CONTRIBUTE TO ENHANCING THE 5572 03:35:29,294 --> 03:35:31,063 QUALITY OF TRANSLATIONAL 5573 03:35:31,063 --> 03:35:33,131 SCIENCE AND TO INCREASING 5574 03:35:33,131 --> 03:35:35,801 ACCESS TO THOSE OPPORTUNITIES. 5575 03:35:35,801 --> 03:35:38,837 THIS WILL HELP EQUIP MORE 5576 03:35:38,837 --> 03:35:40,305 MEMBERS OF THE COMMUNITY WITH 5577 03:35:40,305 --> 03:35:46,612 THE SKILLS AND KNOWLEDGE NEEDED 5578 03:35:46,612 --> 03:35:48,580 TO HELP ACCELERATE PROGRESS 5579 03:35:48,580 --> 03:35:49,081 ALONG THE TRANSLATIONAL 5580 03:35:49,081 --> 03:35:49,348 PIPELINE. 5581 03:35:49,348 --> 03:35:50,682 NEXT SLIDE, PLEASE. 5582 03:35:50,682 --> 03:35:52,251 WITH THAT I WOULD LIKE TO OPEN 5583 03:35:52,251 --> 03:35:53,986 IT UP TO YOUR COMMENTS. 5584 03:35:53,986 --> 03:35:56,388 WE ARE VERY INTERESTED TO HEAR 5585 03:35:56,388 --> 03:35:57,923 YOUR GENERAL COMMENTS ON 5586 03:35:57,923 --> 03:35:59,525 POTENTIAL WAYS TO IMPROVE THE 5587 03:35:59,525 --> 03:36:00,759 CONCEPT AND OTHER KEY POINTS TO 5588 03:36:00,759 --> 03:36:02,861 CONSIDER. 5589 03:36:02,861 --> 03:36:04,363 AND WE'RE SPECIFICALLY 5590 03:36:04,363 --> 03:36:06,498 INTERESTED IN HOW YOUR IDEAS 5591 03:36:06,498 --> 03:36:10,135 FOR HOW WE CAN EFFECTIVELY 5592 03:36:10,135 --> 03:36:12,504 OUTREACH COLLEAGUES ACROSS 5593 03:36:12,504 --> 03:36:13,138 SECTORS TO SOLICIT APPLICATION. 5594 03:36:13,138 --> 03:36:13,839 >> Joni Rutter: THANK YOU VERY 5595 03:36:13,839 --> 03:36:16,742 MUCH. 5596 03:36:16,742 --> 03:36:20,479 WE HAVE TWO DISCUSSANTS, SERGIO 5597 03:36:20,479 --> 03:36:21,280 AGUILAR-GAXIOLA, PLEASE GO 5598 03:36:21,280 --> 03:36:24,850 AHEAD, YOU ARE FIRST AGAIN. 5599 03:36:24,850 --> 03:36:28,020 >> SERGIO: THANK YOU, JONI AND 5600 03:36:28,020 --> 03:36:29,454 THANK YOU, MS. VOGEL FOR THIS 5601 03:36:29,454 --> 03:36:37,029 EXCELLENT PRESENTATION. 5602 03:36:37,029 --> 03:36:39,765 YOU KNOW, YOU HAVE SO MUCH 5603 03:36:39,765 --> 03:36:40,699 INFORMATION THAT RESONATES WITH 5604 03:36:40,699 --> 03:36:47,906 ME, IT'S ATTRACTIVE. 5605 03:36:47,906 --> 03:36:49,441 THAT I WISH TO HAVE TIME TO 5606 03:36:49,441 --> 03:36:50,609 REALLY LOOK AT YOUR SLIDES MORE 5607 03:36:50,609 --> 03:36:51,643 CAREFULLY. 5608 03:36:51,643 --> 03:36:58,150 BUT I WILL COMMENT ON SOMETHING 5609 03:36:58,150 --> 03:37:00,185 THAT, THERE ARE THREE SLIDES I 5610 03:37:00,185 --> 03:37:02,521 WAS LOOK AT VERY CAREFULLY OF 5611 03:37:02,521 --> 03:37:09,828 WHAT YOU PRESENTED THAT TRIGGER 5612 03:37:09,828 --> 03:37:10,596 MY COMMENT, MY MOST IMPORTANT 5613 03:37:10,596 --> 03:37:11,797 COMMENT. 5614 03:37:11,797 --> 03:37:16,702 AND THAT IS THAT IN ONE OF YOUR 5615 03:37:16,702 --> 03:37:20,906 SLIDES, THE ONE OF THE GOALS OF 5616 03:37:20,906 --> 03:37:24,109 THE EDUCATION BRANCH, YOU HAVE 5617 03:37:24,109 --> 03:37:29,381 THE LAST OF SEVERAL STAGES IN A 5618 03:37:29,381 --> 03:37:31,550 PROCESS, CONVENE, COLLABORATE, 5619 03:37:31,550 --> 03:37:32,618 DISSEMINATE AND AMPLIFY 5620 03:37:32,618 --> 03:37:36,788 COMMUNITY EXPERTISE. 5621 03:37:36,788 --> 03:37:39,491 AND THEN, YOU ALSO HAVE ON THE 5622 03:37:39,491 --> 03:37:41,493 OBJECTIVES AND AREAS OF 5623 03:37:41,493 --> 03:37:45,063 EMPHASIS ON THE CONCEPT THAT 5624 03:37:45,063 --> 03:37:55,073 YOU ARE SHARING WITH US, WITH 5625 03:37:55,073 --> 03:37:56,875 SEVERAL OBJECTIVES FOR RELATED 5626 03:37:56,875 --> 03:37:57,376 TO RECOGNIZE REWARD AND 5627 03:37:57,376 --> 03:38:03,348 DISSEMINATE. 5628 03:38:03,348 --> 03:38:06,385 AND THEN FINALLY, YOU HAVE IN 5629 03:38:06,385 --> 03:38:07,019 THE IMPLEMENTATION AND EXPECTED 5630 03:38:07,019 --> 03:38:08,620 IMPACT. 5631 03:38:08,620 --> 03:38:12,157 LET ME TELL YOU THAT, WHAT I'M 5632 03:38:12,157 --> 03:38:14,059 RESPONDING TO IS THAT THERE IS 5633 03:38:14,059 --> 03:38:17,062 A STRONG SENSE ON WHAT YOU ARE 5634 03:38:17,062 --> 03:38:18,597 PRESENTED THAT EDUCATION IS 5635 03:38:18,597 --> 03:38:20,432 UNIDIRECTIONAL. 5636 03:38:20,432 --> 03:38:21,433 THAT YOU GO AND ALLOCATE 5637 03:38:21,433 --> 03:38:23,635 COMMUNITIES. 5638 03:38:23,635 --> 03:38:24,903 WHEN IN FACT, COMMUNITIES CAN 5639 03:38:24,903 --> 03:38:30,609 EDUCATE US AS WELL. 5640 03:38:30,609 --> 03:38:33,412 AND MAYBE THAT IS NOT WHAT YOU 5641 03:38:33,412 --> 03:38:36,882 WERE INTENDING TO PRESENT. 5642 03:38:36,882 --> 03:38:38,717 BUT I GOT THAT IMPRESSION. 5643 03:38:38,717 --> 03:38:40,218 MAYBE I'M MISTAKEN. 5644 03:38:40,218 --> 03:38:44,089 AND I WOULD LOVE FOR YOU TO 5645 03:38:44,089 --> 03:38:46,291 POINT, IF I'M IN ERROR. 5646 03:38:46,291 --> 03:38:48,193 BUT YOU KNOW, JUST TO GIVE YOU 5647 03:38:48,193 --> 03:38:57,402 A SENSE. 5648 03:38:57,402 --> 03:38:59,805 THE AAMC THREE YEARS AGO HAD 5649 03:38:59,805 --> 03:39:03,241 BEEN DEVELOPING AND PERFECTING 5650 03:39:03,241 --> 03:39:05,677 THED TEN PRINCIPLES OF 5651 03:39:05,677 --> 03:39:07,079 COMMUNITY ENGAGEMENT, EXCUSE 5652 03:39:07,079 --> 03:39:07,946 ME, TEN PRINCIPLES OF 5653 03:39:07,946 --> 03:39:08,914 TRUSTWORTHINESS. 5654 03:39:08,914 --> 03:39:12,918 THE FIRST ONE IS THE 5655 03:39:12,918 --> 03:39:13,852 COMMUNITIES ARE ALREADY 5656 03:39:13,852 --> 03:39:15,020 EDUCATE, THAT'S WHY THEY DON'T 5657 03:39:15,020 --> 03:39:18,323 TRUST YOU, OKAY. 5658 03:39:18,323 --> 03:39:20,826 AND WE STILL, EVEN WITH THIS 5659 03:39:20,826 --> 03:39:24,162 INCREDIBLE PROGRESS THAT WE 5660 03:39:24,162 --> 03:39:30,535 HAVE DONE ON TRANSLATIONAL 5661 03:39:30,535 --> 03:39:31,369 SCIENCE, AND TRANSLATIONAL 5662 03:39:31,369 --> 03:39:35,874 RESEARCH, WE ARE STILL, FROM MY 5663 03:39:35,874 --> 03:39:43,849 PERSPECTIVE, NOT MADE ENOUGH 5664 03:39:43,849 --> 03:39:45,050 PROGRESS TO REALLY CONSIDER, 5665 03:39:45,050 --> 03:39:47,652 THAT WHEN WE GO AND ENGAGE 5666 03:39:47,652 --> 03:39:49,054 COMMUNITIES, EMPHASIZING THE 5667 03:39:49,054 --> 03:39:51,523 POINT THAT I MADE AT THE 5668 03:39:51,523 --> 03:39:53,558 BEGINNING IN ONE OF YOUR 5669 03:39:53,558 --> 03:39:57,796 SLIDES, AND THAT IS THE SLIDE 5670 03:39:57,796 --> 03:40:00,132 ON CONVENE, COLLABORATE, 5671 03:40:00,132 --> 03:40:00,899 DISSEMINATE AND AMPLIFY 5672 03:40:00,899 --> 03:40:03,201 COMMUNITY EXPERTISE. 5673 03:40:03,201 --> 03:40:06,471 IS THAT WE NEED TO BE, FROM MY 5674 03:40:06,471 --> 03:40:10,909 OPINION, MORE HUMBLE. 5675 03:40:10,909 --> 03:40:15,113 AND REALLY, AND MAKE IT 5676 03:40:15,113 --> 03:40:15,514 BIDIRECTIONAL OR 5677 03:40:15,514 --> 03:40:23,755 MULTI-DIRECTIONAL COMMUNICATION. 5678 03:40:23,755 --> 03:40:26,491 I'M GOING TO STOP THERE. 5679 03:40:26,491 --> 03:40:33,265 YOU HAVE DONE IT ALREADY, NCATS. 5680 03:40:33,265 --> 03:40:34,866 YOU LEAD THE FOR THE ABOUT 5681 03:40:34,866 --> 03:40:36,701 LISTENING SESSIONS AND I WAS 5682 03:40:36,701 --> 03:40:38,103 VERY IMPRESSED WITH THE 5683 03:40:38,103 --> 03:40:39,671 INFORMATION THAT WAS COLLECTED 5684 03:40:39,671 --> 03:40:40,172 THROUGH THOSE LISTENING 5685 03:40:40,172 --> 03:40:41,039 SESSIONS. 5686 03:40:41,039 --> 03:40:49,948 I THINK THAT IN THIS CONCEPT 5687 03:40:49,948 --> 03:40:50,448 LISTENING ACTIVELY AND 5688 03:40:50,448 --> 03:40:51,082 ATTENTIVELY IS IMPORTANT TO BE 5689 03:40:51,082 --> 03:40:52,450 INCLUDED. 5690 03:40:52,450 --> 03:40:58,123 I'M GOING TO STOP HERE. 5691 03:40:58,123 --> 03:41:01,526 >> THANK YOU, FIRST IT WASN'T 5692 03:41:01,526 --> 03:41:03,662 MY INTENTION TO SUGGEST A 5693 03:41:03,662 --> 03:41:05,263 LINEAR PROCESS WITH THAT SLIDE 5694 03:41:05,263 --> 03:41:13,038 WITH THE ARROWS. 5695 03:41:13,038 --> 03:41:15,473 AND ALSO I REALIZED THAT IN USE 5696 03:41:15,473 --> 03:41:16,675 OF THE WORD COMMUNITY I WASN'T 5697 03:41:16,675 --> 03:41:18,009 CLEAR. 5698 03:41:18,009 --> 03:41:20,412 WE ARE THINKING OF COMMUNITY 5699 03:41:20,412 --> 03:41:22,013 BROADLY TO INCLUDE ANYONE 5700 03:41:22,013 --> 03:41:23,548 OUTSIDE OF GOVERNMENT WHOSE 5701 03:41:23,548 --> 03:41:25,884 DEVELOPED AN EDUCATION OR 5702 03:41:25,884 --> 03:41:26,384 TRAINING OPPORTUNITY IN 5703 03:41:26,384 --> 03:41:31,556 TRANSLATIONAL SCIENCE. 5704 03:41:31,556 --> 03:41:33,925 AND IN OPENING UP COLLEGE, 5705 03:41:33,925 --> 03:41:35,560 CREATING A CHALLENGE RATHER 5706 03:41:35,560 --> 03:41:38,096 THAN A GRANT, WE OPEN UP THE 5707 03:41:38,096 --> 03:41:43,335 OPPORTUNITY FOR THOSE OUTSIDE 5708 03:41:43,335 --> 03:41:44,502 ACADEMIA TO SUBMIT AN 5709 03:41:44,502 --> 03:41:46,204 APPLICATION TO BE RECOGNIZED 5710 03:41:46,204 --> 03:41:46,872 FOR THEIR TRAINING OR EDUCATION 5711 03:41:46,872 --> 03:41:47,706 OPPORTUNITY. 5712 03:41:47,706 --> 03:41:51,142 SO IN FACT, ONE OF THE IDEAS WE 5713 03:41:51,142 --> 03:41:54,679 HAD IN MIND IN DOING THAT, IT 5714 03:41:54,679 --> 03:41:57,048 WOULD OPEN IT UP TO EXPERTISE 5715 03:41:57,048 --> 03:41:59,017 OUTSIDE OF ACADEMIA. 5716 03:41:59,017 --> 03:42:00,619 I WOULD IMAGINE FOR EXAMPLE, 5717 03:42:00,619 --> 03:42:02,654 ALSO GOING ALONG WITH OUR THEME 5718 03:42:02,654 --> 03:42:05,457 OF EXPANDING ACCESS, I COULD 5719 03:42:05,457 --> 03:42:06,825 IMAGINE, FOR EXAMPLE, SOMEONE 5720 03:42:06,825 --> 03:42:17,369 APPLYING WITH AN OPPORTUNITY TO 5721 03:42:26,144 --> 03:42:27,212 ENGAGES COMMUNITY MEMBERS 5722 03:42:27,212 --> 03:42:29,614 PARTNERS IN RESEARCH. 5723 03:42:29,614 --> 03:42:31,850 PERHAPS YOU ARE POINTING TO A 5724 03:42:31,850 --> 03:42:33,151 LACK CLARITY IN COMMUNICATION, 5725 03:42:33,151 --> 03:42:34,185 WHICH WILL BE REALLY VALUABLE 5726 03:42:34,185 --> 03:42:35,186 TO US AS WE DEVELOP THIS 5727 03:42:35,186 --> 03:42:38,323 FURTHER. 5728 03:42:38,323 --> 03:42:42,460 I WOULD ALSO BE VERY INTERESTED 5729 03:42:42,460 --> 03:42:43,862 IN YOUR FEEDBACK AND 5730 03:42:43,862 --> 03:42:45,263 RECOMMENDATIONS AROUND HOW TO 5731 03:42:45,263 --> 03:42:47,565 ENGAGE WITH A BROADER RANGE OF 5732 03:42:47,565 --> 03:42:49,200 STAKEHOLDERS SO WE ARE MAKING 5733 03:42:49,200 --> 03:42:51,670 THEM AWARE OF THIS OPPORTUNITY. 5734 03:42:51,670 --> 03:42:52,837 BECAUSE IN FACT, YOUR 5735 03:42:52,837 --> 03:42:54,072 PRIORITIES THAT YOU HAVE 5736 03:42:54,072 --> 03:42:56,207 REFLECTED IN YOUR COMMENTS, I 5737 03:42:56,207 --> 03:42:58,843 THINK ARE 100% ALIGNED WITH 5738 03:42:58,843 --> 03:43:00,946 OURS, IN TERMS OF BROADENING 5739 03:43:00,946 --> 03:43:03,081 ENGAGEMENT AND USING THIS 5740 03:43:03,081 --> 03:43:05,517 MECHANISM TO BROADEN ENGAGEMENT 5741 03:43:05,517 --> 03:43:07,719 WITH PARTNERS IN RESEARCH WHO 5742 03:43:07,719 --> 03:43:09,220 HAVE UNIQUE EXPERTISE, THAT IS 5743 03:43:09,220 --> 03:43:11,089 NOT REFLECTED FOR EXAMPLE IN 5744 03:43:11,089 --> 03:43:12,257 THAT LITERATURE REVIEW, RIGHT? 5745 03:43:12,257 --> 03:43:14,392 SO THE POINT HERE IS TO 5746 03:43:14,392 --> 03:43:15,827 COMPLIMENT THAT SORT OF REVIEW 5747 03:43:15,827 --> 03:43:18,663 THAT SUMMARIZES WHAT IS IN THE 5748 03:43:18,663 --> 03:43:20,231 LITERATURE WITH OTHER 5749 03:43:20,231 --> 03:43:23,034 MECHANISMS THAT IDENTIFY 5750 03:43:23,034 --> 03:43:23,535 COMMUNITY EXPERTISE AND 5751 03:43:23,535 --> 03:43:25,236 DISSEMINATE IT. 5752 03:43:25,236 --> 03:43:27,305 >> SERGIO: THANK YOU. 5753 03:43:27,305 --> 03:43:32,811 CAN I CALL YOU AMANDA? 5754 03:43:32,811 --> 03:43:34,846 >> AMANDA VOGEL: YES. 5755 03:43:34,846 --> 03:43:37,782 >> SERGIO: THANK YOU. 5756 03:43:37,782 --> 03:43:38,650 I APPRECIATE YOUR COMMENTS 5757 03:43:38,650 --> 03:43:40,352 TRULY, AND I WOULD BE MORE THAN 5758 03:43:40,352 --> 03:43:41,953 HAPPY TO SPEAK WITH YOU, 5759 03:43:41,953 --> 03:43:43,588 BECAUSE I HAVE SEVERAL IDEAS ON 5760 03:43:43,588 --> 03:43:49,227 HOW YOU CAN GO ABOUT DOING WHAT 5761 03:43:49,227 --> 03:43:54,366 YOU JUST SHARED WITH US THE 5762 03:43:54,366 --> 03:43:57,135 THAT ARE MAJOR DEVELOPMENTS ON 5763 03:43:57,135 --> 03:43:59,304 MEANINGFUL COMMUNITY ENGAGEMENT. 5764 03:43:59,304 --> 03:44:00,839 LANDMARK WORK THAT HAVE, YOU 5765 03:44:00,839 --> 03:44:04,275 KNOW, THE METHODOLOGY HOW WE 5766 03:44:04,275 --> 03:44:05,210 CAN GO ABOUT DOING THAT 5767 03:44:05,210 --> 03:44:08,213 PRECISELY. 5768 03:44:08,213 --> 03:44:11,916 AND NOT ONLY THAT, TO MEASURE 5769 03:44:11,916 --> 03:44:16,221 THE PROCESS OF ENGAGING 5770 03:44:16,221 --> 03:44:18,523 COMMUNITIES IN MEANINGFUL WAYS. 5771 03:44:18,523 --> 03:44:20,325 AMANDA, PLEASE, REACH OUT, OR I 5772 03:44:20,325 --> 03:44:22,093 CAN REACH OUT. 5773 03:44:22,093 --> 03:44:24,596 JONI, I WOULD LOVE TO HAVE THAT 5774 03:44:24,596 --> 03:44:26,931 OPPORTUNITY WITH AMANDA AS WELL. 5775 03:44:26,931 --> 03:44:27,632 >> Joni Rutter: THANK YOU, SO 5776 03:44:27,632 --> 03:44:29,367 MUCH. 5777 03:44:29,367 --> 03:44:30,535 THAT SOUNDS TERRIFIC AND A 5778 03:44:30,535 --> 03:44:31,970 GREAT OPPORTUNITY TO ALSO HAVE 5779 03:44:31,970 --> 03:44:34,973 YOU KIND OF HELP BE AN 5780 03:44:34,973 --> 03:44:36,674 AMBASSADOR AND GET THE WORD OUT 5781 03:44:36,674 --> 03:44:38,143 AS WELL IF THIS PROJECT 5782 03:44:38,143 --> 03:44:39,444 INITIATIVE MOVES FORWARD. 5783 03:44:39,444 --> 03:44:43,982 WE HAVE ONE MORE DISCUSSANT, 5784 03:44:43,982 --> 03:44:48,119 PAUL HARRIS, GO AHEAD. 5785 03:44:48,119 --> 03:44:49,354 >> GREAT PRESENTATION AND A 5786 03:44:49,354 --> 03:44:51,956 THOUGHTFUL APPROACH. 5787 03:44:51,956 --> 03:44:53,992 AS I WAS READ THIS, AND 5788 03:44:53,992 --> 03:44:55,894 LISTENING TO YOU, I THINK IT 5789 03:44:55,894 --> 03:44:57,695 WOULD BE WISE TO FOCUS ON THE 5790 03:44:57,695 --> 03:44:58,797 DISSEMINATION PIECE OF THIS. 5791 03:44:58,797 --> 03:45:00,565 YOU HAVE IT THERE IN YOUR LAST 5792 03:45:00,565 --> 03:45:02,367 BULLET. 5793 03:45:02,367 --> 03:45:04,602 I WOULD FRIP THAT QUESTION 5794 03:45:04,602 --> 03:45:05,703 AROUND, MAYBE THE CHALLENGE, 5795 03:45:05,703 --> 03:45:08,840 SINCE YOU ARE LOOKING FOR 5796 03:45:08,840 --> 03:45:13,078 THINGS ALREADY DEVELOPED, MAYBE 5797 03:45:13,078 --> 03:45:14,879 YOU TELL THE REVIEWERS WHERE 5798 03:45:14,879 --> 03:45:17,615 THIS FILLS A GAP THAT IS NOT, 5799 03:45:17,615 --> 03:45:18,650 WHERE THIS FILLS A GAP AT THIS 5800 03:45:18,650 --> 03:45:20,351 POINT. 5801 03:45:20,351 --> 03:45:22,687 AND THE CHALLENGE IS HOW DO WE 5802 03:45:22,687 --> 03:45:25,490 TAKE WHAT, HOW DO YOU TAKE WHAT 5803 03:45:25,490 --> 03:45:26,224 YOU HAVE, AND DISSEMINATE IT 5804 03:45:26,224 --> 03:45:27,592 WIDELY? 5805 03:45:27,592 --> 03:45:31,963 WAND YOU KNOW, IF IT'S A 5806 03:45:31,963 --> 03:45:36,901 TRADITIONAL-TYPE WORKSHOP OR 5807 03:45:36,901 --> 03:45:38,002 COURSE, MAYBE THAT'S A COURSE 5808 03:45:38,002 --> 03:45:41,372 ERROR OF COURSE. 5809 03:45:41,372 --> 03:45:42,507 IF IT'S AN APPLICATION THAT'S 5810 03:45:42,507 --> 03:45:44,275 SOMETHING ELTS. 5811 03:45:44,275 --> 03:45:49,914 I WOULD PUT THE ONUS ON THE 5812 03:45:49,914 --> 03:45:56,821 GROUP TO USE THE MONEY TO HELP 5813 03:45:56,821 --> 03:45:58,123 WITH DISSEMINATION RATHER THAN 5814 03:45:58,123 --> 03:45:59,557 NCATS INVESTING IN THE MIDDLE 5815 03:45:59,557 --> 03:46:00,625 GROUND AND THEN THINKING THEY 5816 03:46:00,625 --> 03:46:02,327 ARE GOING TO DO THE 5817 03:46:02,327 --> 03:46:03,394 DISSEMINATION PIECE. 5818 03:46:03,394 --> 03:46:07,632 DOES THAT MAKE SENSE? 5819 03:46:07,632 --> 03:46:08,566 >> ANDREA VOGEL: YEAH, THANK, 5820 03:46:08,566 --> 03:46:14,172 YOU ARE RIGHT. 5821 03:46:14,172 --> 03:46:16,040 IDENTIFYING EXEMPLARS IS JUST 5822 03:46:16,040 --> 03:46:19,878 THE BEGINNING AND SEN 5823 03:46:19,878 --> 03:46:20,478 DISSEMINATION IS THE ULTIMATE 5824 03:46:20,478 --> 03:46:21,146 GOAL. 5825 03:46:21,146 --> 03:46:26,017 >> IF I GO OUT AND WIN A 5826 03:46:26,017 --> 03:46:28,520 CONCEPT CHALLENGE CONTEST AND I 5827 03:46:28,520 --> 03:46:29,654 SPEND MONEY ON INSTITUTIONAL 5828 03:46:29,654 --> 03:46:31,956 THINGS, IS IT EASY TO DO THAT, 5829 03:46:31,956 --> 03:46:33,658 VERSUS TAKING THE PRIZE MONEY 5830 03:46:33,658 --> 03:46:34,425 AS AN INDIVIDUAL OR OUTSIDE 5831 03:46:34,425 --> 03:46:35,527 GROUP. 5832 03:46:35,527 --> 03:46:37,695 I JUST DON'T KNOW THE ANSWER. 5833 03:46:37,695 --> 03:46:40,064 BUT IF IT'S THE LATTER, IF IT'S 5834 03:46:40,064 --> 03:46:42,467 HARD TO BRING IT IN OUTSIDE OF 5835 03:46:42,467 --> 03:46:52,944 BEING, AND SPEND IT LIKE A 5836 03:46:53,511 --> 03:46:55,480 GRANT, IT MAY BE PROHIBITIVE TO 5837 03:46:55,480 --> 03:46:56,915 ME TO ACTUALLY DO THE WORK. 5838 03:46:56,915 --> 03:46:58,316 >> I WILL TAKE THAT. 5839 03:46:58,316 --> 03:47:00,218 SO THE FIRST THING YOU HAVE TO 5840 03:47:00,218 --> 03:47:04,489 DO IS CHECK WITH YOUR ACTUAL 5841 03:47:04,489 --> 03:47:07,125 INSTITUTIONAL OFFICIALS. 5842 03:47:07,125 --> 03:47:09,894 ANYBODY CAN DONATE, IT WOULD BE 5843 03:47:09,894 --> 03:47:15,967 SPENT AS YOU PRESCRIBE. 5844 03:47:15,967 --> 03:47:22,040 I WOULD IMAGINE. 5845 03:47:22,040 --> 03:47:24,576 >> THIS IS GOING TO GET VERY 5846 03:47:24,576 --> 03:47:25,176 COMPETITIVE ALREADY, I DON'T 5847 03:47:25,176 --> 03:47:25,810 KNOW. 5848 03:47:25,810 --> 03:47:26,778 [LAUGHTER] 5849 03:47:26,778 --> 03:47:29,247 >> Joni Rutter: ARE THERE ANY 5850 03:47:29,247 --> 03:47:29,747 OTHER COMMENTS FROM OUR 5851 03:47:29,747 --> 03:47:33,685 COUNCILMEMBERS? 5852 03:47:33,685 --> 03:47:36,688 YES, MERMELSTEIN? 5853 03:47:36,688 --> 03:47:37,422 >> THANK YOU, GREAT 5854 03:47:37,422 --> 03:47:39,324 PRESENTATION AND I LOVE THE 5855 03:47:39,324 --> 03:47:44,896 CONCEPT AND FOCUS ON EDUCATION. 5856 03:47:44,896 --> 03:47:47,131 WITHIN THE PTSA ORGANIZATION 5857 03:47:47,131 --> 03:47:49,834 THERE ARE MANY INNOVATIONS AND 5858 03:47:49,834 --> 03:47:50,435 ACCOMPLISHMENTS AS YOU SAID 5859 03:47:50,435 --> 03:47:52,770 WITH EDUCATION. 5860 03:47:52,770 --> 03:47:54,973 MAYBE IN YOUR COMPETITION THINK 5861 03:47:54,973 --> 03:48:01,145 ABOUT BUILDING DEMAND, SO THE 5862 03:48:01,145 --> 03:48:02,080 CTSA PROGRAM CERTAINLY BUILT 5863 03:48:02,080 --> 03:48:03,081 PROGRAMS AND THEY ARE 5864 03:48:03,081 --> 03:48:04,582 STRUGGLING WITH THE FACT THAT 5865 03:48:04,582 --> 03:48:05,350 THINK BUILD THEM AND NOBODY 5866 03:48:05,350 --> 03:48:07,218 COMES. 5867 03:48:07,218 --> 03:48:11,055 SO MAYBE WHAT YOU NEED TO BUILD 5868 03:48:11,055 --> 03:48:13,258 INTO THIS COMPETITION IS HOW DO 5869 03:48:13,258 --> 03:48:15,193 YOU INCREASE THE DEMAND. 5870 03:48:15,193 --> 03:48:18,863 FOR THIS KIND OF EDUCATION. 5871 03:48:18,863 --> 03:48:20,665 THERE'S BEEN VERY MANY 5872 03:48:20,665 --> 03:48:22,467 INNOVATIONS BUT THERE'S VERY 5873 03:48:22,467 --> 03:48:24,302 LITTLE MOTIVATION AND DEMAND 5874 03:48:24,302 --> 03:48:26,704 WITHIN ACADEMIA RIGHT NOW FOR 5875 03:48:26,704 --> 03:48:26,904 THEM. 5876 03:48:26,904 --> 03:48:28,840 THAT SHOULD BE FACTORED IN 5877 03:48:28,840 --> 03:48:31,876 SOMEHOW SO IT TRULY HAS AN 5878 03:48:31,876 --> 03:48:35,913 AUDIENCE TO DISSEMINATE TO 5879 03:48:35,913 --> 03:48:40,785 THOSE WHO ARE ALREADY PART. 5880 03:48:40,785 --> 03:48:41,386 >> ANDREA VOGEL: THANK YOU SO 5881 03:48:41,386 --> 03:48:41,753 MUCH. 5882 03:48:41,753 --> 03:48:44,389 I WOULD SAY ONE OF THE MESSAGES 5883 03:48:44,389 --> 03:48:45,723 WE HEARD REPEATEDLY IS WHERE IS 5884 03:48:45,723 --> 03:48:48,159 THE SPACE IN THE CURRICULUM TO 5885 03:48:48,159 --> 03:48:49,227 INTEGRATE NEW CONTENT. 5886 03:48:49,227 --> 03:48:51,129 SO NOW YOU ARE MAKING ME THINK 5887 03:48:51,129 --> 03:48:53,298 ABOUT WHETHER THAT'S A THEME WE 5888 03:48:53,298 --> 03:48:57,735 CAN HIGHLIGHT IS, YOU KNOW, 5889 03:48:57,735 --> 03:49:04,275 APPROACHES THAT ARE EASY TO 5890 03:49:04,275 --> 03:49:06,811 UPTAKE, EASY TO IMPLEMENT,, 5891 03:49:06,811 --> 03:49:09,047 INTEGRATE WITH CURRICULUM OR 5892 03:49:09,047 --> 03:49:09,914 FOR SELF STUDY OR PROFESSIONAL 5893 03:49:09,914 --> 03:49:11,549 DEVELOPMENT. 5894 03:49:11,549 --> 03:49:14,485 I WOULD BE VERY INTERESTED IN 5895 03:49:14,485 --> 03:49:16,921 ADDITIONAL THOUGHTS RELATED TO 5896 03:49:16,921 --> 03:49:19,457 THINKING ABOUT HOW WE QUO 5897 03:49:19,457 --> 03:49:22,994 SIMULATE SHARING OF MODELS THAT 5898 03:49:22,994 --> 03:49:24,195 OVERCOME THAT CHALLENGE. 5899 03:49:24,195 --> 03:49:26,097 >> I THINK THE OTHER PART I 5900 03:49:26,097 --> 03:49:27,665 REALLY LIKES WITH YOUR 5901 03:49:27,665 --> 03:49:29,867 PRESENTATION IS FOCUS ON NOT 5902 03:49:29,867 --> 03:49:34,005 ACADEMIA, AND I THINK PERHAPS 5903 03:49:34,005 --> 03:49:34,806 THINK THROUGH ANOTHER AUDIENCE 5904 03:49:34,806 --> 03:49:38,409 FOR THIS, WHO ARE THE TRANSLATE 5905 03:49:38,409 --> 03:49:40,845 YOORS, AMONG THE USE MEDIA AND 5906 03:49:40,845 --> 03:49:42,447 REPORTERS AND HOW THESE 5907 03:49:42,447 --> 03:49:43,481 TRANSLATIONAL FINDS GET 5908 03:49:43,481 --> 03:49:46,317 COMMUNICATED TO THE PUBLIC TO 5909 03:49:46,317 --> 03:49:48,653 POLICY MAKERS TO BUILD THAT. 5910 03:49:48,653 --> 03:49:50,088 CAN YOU EDUCATE THEM? 5911 03:49:50,088 --> 03:49:50,922 >> Joni Rutter: THANK YOU. 5912 03:49:50,922 --> 03:49:51,689 GREAT IDEA. 5913 03:49:51,689 --> 03:49:53,291 THAT'S IMPORTANT. 5914 03:49:53,291 --> 03:49:54,792 ANY OTHER COMMENTS FROM OUR 5915 03:49:54,792 --> 03:49:55,026 COUNCIL? 5916 03:49:55,026 --> 03:49:56,327 ALL RIGHT. 5917 03:49:56,327 --> 03:49:58,596 ANNA, I THINK OVER TO YOU, IF 5918 03:49:58,596 --> 03:50:01,466 THERE'S NO FURTHER DISCUSSION. 5919 03:50:01,466 --> 03:50:03,501 >> ANNA: INDEED, CAN I HAVE A 5920 03:50:03,501 --> 03:50:05,503 MOTION TO APPROVE THE CONCEPT? 5921 03:50:05,503 --> 03:50:08,339 >> SERGIO: SO MOVED. 5922 03:50:08,339 --> 03:50:09,374 >> ANNA: SECOND? 5923 03:50:09,374 --> 03:50:10,875 ALL IN FAVOR? 5924 03:50:10,875 --> 03:50:12,977 OPPOSED? 5925 03:50:12,977 --> 03:50:16,013 ANY ABSTENTIONS? 5926 03:50:16,013 --> 03:50:17,115 WITH THAT, THE CONCEPT IS 5927 03:50:17,115 --> 03:50:17,382 APPROVED. 5928 03:50:17,382 --> 03:50:25,223 THANK YOU. 5929 03:50:25,223 --> 03:50:27,125 >> Joni Rutter: MAKING NOTE. 5930 03:50:27,125 --> 03:50:34,599 WE WILL MOVE FORWARD WITH OUR 5931 03:50:34,599 --> 03:50:42,240 LAST CONCEPT, IT'S COMING OUT 5932 03:50:42,240 --> 03:50:46,511 OF OUR SMALL STEPS NCATS. 5933 03:50:46,511 --> 03:50:48,179 WE HOPE TO MOVE THROUGH 5934 03:50:48,179 --> 03:50:49,280 RELATIVELY BRIEFLY. 5935 03:50:49,280 --> 03:50:59,357 GO AHEAD, MATT. 5936 03:50:59,357 --> 03:51:03,161 >> MATT: I ONLY HAVE THREE 5937 03:51:03,161 --> 03:51:03,394 SLIDES. 5938 03:51:03,394 --> 03:51:04,128 YOU ALREADY HAD HEARD ME SPEAK 5939 03:51:04,128 --> 03:51:06,230 TODAY. 5940 03:51:06,230 --> 03:51:08,132 YOU KNOW ABOUT THE API AND YOU 5941 03:51:08,132 --> 03:51:10,535 ARE GOING TO HEAR FROM TWO 5942 03:51:10,535 --> 03:51:12,270 PEOPLE, DR. CATHERINE CHEN IS 5943 03:51:12,270 --> 03:51:15,306 GOING TO SPEAK ABOUT AND DR. 5944 03:51:15,306 --> 03:51:16,908 SAM MICHAEL WILL JOIN REMOTELY 5945 03:51:16,908 --> 03:51:19,043 TO DESCRIBE A CONCEPT OUT OF 5946 03:51:19,043 --> 03:51:21,245 THE ASPIRE PROGRAM TO REMIND 5947 03:51:21,245 --> 03:51:24,282 YOU, YOU HAVE SEEN 5948 03:51:24,282 --> 03:51:28,820 PRESENTATIONS ON THIS, THE 5949 03:51:28,820 --> 03:51:29,387 AUTOMATION OF REALLY CLOSE 5950 03:51:29,387 --> 03:51:31,389 LABORATORY. 5951 03:51:31,389 --> 03:51:33,024 THESE COME OUT OF CLOSE 5952 03:51:33,024 --> 03:51:35,259 CONTRACTS PROJECT. 5953 03:51:35,259 --> 03:51:39,297 IT'S A LITTLE BIT DIFFERENT, IT 5954 03:51:39,297 --> 03:51:40,431 COMES FROM MY COLLEAGUE FROM 5955 03:51:40,431 --> 03:51:41,732 DPI. 5956 03:51:41,732 --> 03:51:43,067 BOTH OF MY COLLEAGUES WILL 5957 03:51:43,067 --> 03:51:44,669 PRESENT THE CONCEPTS TO YOU ONE 5958 03:51:44,669 --> 03:51:46,471 AT A TIME, AS AN OPPORTUNITY 5959 03:51:46,471 --> 03:51:48,806 FOR FEEDBACK AND THEN MOVE TO 5960 03:51:48,806 --> 03:51:51,342 THE NEXT, I'M COGNIZANT OF 5961 03:51:51,342 --> 03:51:54,145 TIME, BUT WE PRACTICED AND THEY 5962 03:51:54,145 --> 03:51:54,645 HAVE VERY EFFICIENT 5963 03:51:54,645 --> 03:51:57,081 PRESENTATIONS FOR YOU. 5964 03:51:57,081 --> 03:51:58,216 CATHERINE, DO YOU WANT TO COME 5965 03:51:58,216 --> 03:51:58,416 OVER? 5966 03:51:58,416 --> 03:52:08,493 YEP. 5967 03:52:10,928 --> 03:52:12,129 >> CATHERINE: THANK YOU FOR 5968 03:52:12,129 --> 03:52:14,065 HAVING ME HERE, THIS IS A 5969 03:52:14,065 --> 03:52:16,400 PRESENTATION ON BEHALF OF 5970 03:52:16,400 --> 03:52:19,203 MYSELF AND MY COLLEAGUE DR. 5971 03:52:19,203 --> 03:52:22,173 WESHAM. 5972 03:52:22,173 --> 03:52:25,109 IT'S SCALABLE GENERATION OF 5973 03:52:25,109 --> 03:52:27,211 LIVER AND BRAIN ORGANOIDS 5974 03:52:27,211 --> 03:52:36,721 DERIVED FROM HUMAN IPS CELLS. 5975 03:52:36,721 --> 03:52:40,658 SO CURRENTLY THERE'S INCREASING 5976 03:52:40,658 --> 03:52:46,264 USAGE OF HUMAN IPS CELLS 5977 03:52:46,264 --> 03:52:49,534 DERIVED ORGANOIDS AS A DISEASE 5978 03:52:49,534 --> 03:52:50,201 MODEL SYSTEM FOR DRUG 5979 03:52:50,201 --> 03:52:52,970 DEVELOPMENT AND RESEARCH. 5980 03:52:52,970 --> 03:52:56,707 IT COULD BE OBTAINED FROM SKIN 5981 03:52:56,707 --> 03:53:00,845 FIBROBLASTS AND BLOOD CELLS. 5982 03:53:00,845 --> 03:53:03,214 IPS CELLS HAVE UNLIMITED 5983 03:53:03,214 --> 03:53:05,416 EXPANSION CAPABILITIES AND THEY 5984 03:53:05,416 --> 03:53:10,488 CAN BE DIFFERENTIATED INTO 5985 03:53:10,488 --> 03:53:12,423 VARIOUS DISEASE RELEVANT 2D 5986 03:53:12,423 --> 03:53:18,796 CELLS AND ORGAN NOID TO STUDY 5987 03:53:18,796 --> 03:53:21,332 DISEASE IN VITRO AND TEST 5988 03:53:21,332 --> 03:53:22,300 EFFICACY AND TOXICITY OF DRUG 5989 03:53:22,300 --> 03:53:24,168 CANDIDATES. 5990 03:53:24,168 --> 03:53:26,170 SO CURRENTLY THERE'S INCREASED 5991 03:53:26,170 --> 03:53:27,672 DEMAND FOR THESE ORGANOIDS, 5992 03:53:27,672 --> 03:53:32,610 HOWEVER ONE OF THE BOTTLENECKS 5993 03:53:32,610 --> 03:53:34,512 IS GENERATION OF THE ORGANOID 5994 03:53:34,512 --> 03:53:37,081 IS VERY LABOR INTENSIVE. 5995 03:53:37,081 --> 03:53:39,216 ALSO THEY LACK SCALABILITY, AS 5996 03:53:39,216 --> 03:53:40,484 WELL AS BATCH TO BATCH 5997 03:53:40,484 --> 03:53:44,355 REPRODUCABILITY. 5998 03:53:44,355 --> 03:53:46,057 THAT'S WHY DPI IS PROPOSING 5999 03:53:46,057 --> 03:53:48,559 THIS CONCEPT TO IMPROVE THE 6000 03:53:48,559 --> 03:53:50,928 EFFICIENCY OF THE METHODS AND 6001 03:53:50,928 --> 03:53:57,001 REDUCE COSTS FOR GENERATION OF 6002 03:53:57,001 --> 03:53:58,069 IPS SCALES DERIVED ORGANOIDS 6003 03:53:58,069 --> 03:54:00,037 NOR DISEASE MODELING. 6004 03:54:00,037 --> 03:54:03,541 THE SO THE OBJECTIVES OF THIS 6005 03:54:03,541 --> 03:54:05,476 CONTRACT SOLICITATION IS FOR 6006 03:54:05,476 --> 03:54:09,513 SCALABLE PRODUCTION FOR LIVER 6007 03:54:09,513 --> 03:54:10,681 AND BRAIN ORGANOID WITH SOME 6008 03:54:10,681 --> 03:54:13,017 LEVEL OF AUTOMATION. 6009 03:54:13,017 --> 03:54:14,852 BASED ON NEEDS OF CPI 6010 03:54:14,852 --> 03:54:18,589 SCIENTISTS FOR RESEARCH, WE ARE 6011 03:54:18,589 --> 03:54:21,892 LIMITING THIS TO BRAIN AND 6012 03:54:21,892 --> 03:54:26,697 LIVER ORGANOIDS. 6013 03:54:26,697 --> 03:54:27,698 EVEN PARTIALLY AUTOMATED WOULD 6014 03:54:27,698 --> 03:54:30,001 REDUCE THE COST OF THE 6015 03:54:30,001 --> 03:54:32,336 ORGANOIDS AND ALSO IMPROVE THE 6016 03:54:32,336 --> 03:54:33,938 BATCH TO BATCH. 6017 03:54:33,938 --> 03:54:36,907 SOME OF THE OTHER KEY CRITERIA 6018 03:54:36,907 --> 03:54:39,343 IS THAT ORGANOIDS SHOULD SHOW 6019 03:54:39,343 --> 03:54:42,146 THE PROPER IDENTITY MARKERS FOR 6020 03:54:42,146 --> 03:54:44,849 EACH TYPE OF ORGANOID AND 6021 03:54:44,849 --> 03:54:46,584 SHOULD BE OPTIONS TO INTEGRATE 6022 03:54:46,584 --> 03:54:52,623 AS THEY READ OUT SUCH AS 6023 03:54:52,623 --> 03:54:55,159 FLUORESCENT BIO SENSORS TO BE 6024 03:54:55,159 --> 03:54:58,696 ABLE TO DETECT CELSIUS CHANGES 6025 03:54:58,696 --> 03:55:01,932 IN THE IMPACT LIVE ORGANOID. 6026 03:55:01,932 --> 03:55:03,701 AND IN TERMS OF IMPLEMENTATION 6027 03:55:03,701 --> 03:55:07,104 AND EXPECTED IMPACT AS I 6028 03:55:07,104 --> 03:55:08,973 MENTIONED DISEASE MODELING 6029 03:55:08,973 --> 03:55:11,509 USING IPSL DERIVED ORGAN NOID 6030 03:55:11,509 --> 03:55:15,579 ORIGINALLY THE FAST GROWING 6031 03:55:15,579 --> 03:55:17,381 RESOIX AREA, AND BOTTLENECK 6032 03:55:17,381 --> 03:55:22,153 THAT WE'RE HOPING TO ALLEVIATE 6033 03:55:22,153 --> 03:55:25,589 BY SCALABLE PRODUCTION OF HIGH 6034 03:55:25,589 --> 03:55:31,629 QUALITY ORGANOIDS. 6035 03:55:31,629 --> 03:55:34,632 AND COMMERCIAL AVAILABILITY OF 6036 03:55:34,632 --> 03:55:37,001 THESE ORGANOIDS. 6037 03:55:37,001 --> 03:55:39,003 ALSO THIS EFFORT WILL BENEFIT 6038 03:55:39,003 --> 03:55:41,372 THE PILOT PROJECT OF THE I3D 6039 03:55:41,372 --> 03:55:43,841 PROGRAM. 6040 03:55:43,841 --> 03:55:45,976 MATT ALREADY TOLD YOU ABOUT, 6041 03:55:45,976 --> 03:55:52,850 THE STATUS IS SEVERAL GROUPS 6042 03:55:52,850 --> 03:55:56,887 WITHIN THE I3D WORKING ON PILOT 6043 03:55:56,887 --> 03:56:03,694 PROJECT THAT'S FALL UNDER THE 6044 03:56:03,694 --> 03:56:05,863 I3D WARE UMBRELLA. 6045 03:56:05,863 --> 03:56:10,134 THE CELL LINE FOR ORGANOID 6046 03:56:10,134 --> 03:56:20,644 GENERATION CAN EITHER BE MADE 6047 03:56:20,911 --> 03:56:22,747 AVAILABLE FROM NCATS. 6048 03:56:22,747 --> 03:56:26,584 IN TERMS OF THE START IPS CELL 6049 03:56:26,584 --> 03:56:29,520 LINE WE CAN SELECT CELL LINES 6050 03:56:29,520 --> 03:56:31,922 WITH DIVERSITY IN AGE, GENDER 6051 03:56:31,922 --> 03:56:32,690 AND RACE FOR THE ORGANOID 6052 03:56:32,690 --> 03:56:34,792 GENERATION. 6053 03:56:34,792 --> 03:56:37,294 AND IN SUMMARY THIS CONCEPT 6054 03:56:37,294 --> 03:56:39,530 AIMS TO IMPROVE THE EFFICIENCY 6055 03:56:39,530 --> 03:56:43,234 OF THE METHODS AND REDUCE COSTS 6056 03:56:43,234 --> 03:56:46,704 IN GENERATION OF HUMAN IPS CELL 6057 03:56:46,704 --> 03:56:49,507 DERIVED LIVER AND BRAIN 6058 03:56:49,507 --> 03:56:51,008 ORGANOIDS FOR DISEASE MODELING. 6059 03:56:51,008 --> 03:56:55,479 OUR HOPE IS THAT BY PROVIDING 6060 03:56:55,479 --> 03:56:58,082 HIGH QUALITY ORGANOIDS AT A 6061 03:56:58,082 --> 03:56:59,917 MORE AFFORDABLE PRICE, WE WOULD 6062 03:56:59,917 --> 03:57:02,686 ENABLE BROAD USE OF THIS 6063 03:57:02,686 --> 03:57:04,255 PLATFORM FOR DISEASE MODELING 6064 03:57:04,255 --> 03:57:06,290 AND DRUG DISCOVERIES. 6065 03:57:06,290 --> 03:57:09,593 AND THE PRIOR PRESERVATION OF 6066 03:57:09,593 --> 03:57:12,763 THE ORGANOIDS WILL FACILITATE 6067 03:57:12,763 --> 03:57:13,764 COMMERCIALIZATION OF THE 6068 03:57:13,764 --> 03:57:15,599 ORGANOIDS AS AN OFF THE SHELF 6069 03:57:15,599 --> 03:57:17,001 CATALOG PRODUCT. 6070 03:57:17,001 --> 03:57:21,906 SO CURRENTLY IF WE WANT TO OUZ 6071 03:57:21,906 --> 03:57:22,840 ORGANOIDS FOR RESEARCHING OUR 6072 03:57:22,840 --> 03:57:24,942 LAB WE EITHER HAVE TO GENERATE 6073 03:57:24,942 --> 03:57:26,243 THEM OURSELVES OR PUT TOGETHER 6074 03:57:26,243 --> 03:57:28,179 A STATEMENT OF WORK IN A 6075 03:57:28,179 --> 03:57:30,614 CONTRACT TO HAVE A BATCH 6076 03:57:30,614 --> 03:57:35,119 GENERATED AT A CONTRACT 6077 03:57:35,119 --> 03:57:36,787 RESEARCH ORGANIZATION. 6078 03:57:36,787 --> 03:57:42,259 SO WITH THAT IT'S COSTLY AND WE 6079 03:57:42,259 --> 03:57:45,262 SEE A LOT OF BATCH TO BATCH 6080 03:57:45,262 --> 03:57:47,531 VARIABILITY. 6081 03:57:47,531 --> 03:57:49,834 WITH THAT WE SEE IT COULD BE 6082 03:57:49,834 --> 03:57:50,901 OFFERED AS AN OFF THE SHELF 6083 03:57:50,901 --> 03:57:54,271 PRODUCT. 6084 03:57:54,271 --> 03:57:55,773 IN ADDITION INTEGRATION OF BIO 6085 03:57:55,773 --> 03:57:59,510 SENSE SORES WILL FACILITATE 6086 03:57:59,510 --> 03:58:00,544 DOWNSTREAM ASSETS. 6087 03:58:00,544 --> 03:58:02,546 AND WITH THAT I THANK YOU FOR 6088 03:58:02,546 --> 03:58:03,480 YOUR TIME AND WELCOME FEEDBACK. 6089 03:58:03,480 --> 03:58:04,081 >> Joni Rutter: THANK YOU SO 6090 03:58:04,081 --> 03:58:06,183 MUCH. 6091 03:58:06,183 --> 03:58:16,727 WE HAVE TWO DISCUSSANTS, ONE IS 6092 03:59:04,541 --> 03:59:06,377 ROBIN. 6093 03:59:06,377 --> 03:59:09,513 >> THANK YOU. 6094 03:59:09,513 --> 03:59:10,381 IT DOESN'T JUST GET 6095 03:59:10,381 --> 03:59:12,650 CONCENTRATED AT ONE POINT. 6096 03:59:12,650 --> 03:59:19,390 SO A BROAD REACH THAT WAY. 6097 03:59:19,390 --> 03:59:21,025 >> OKAY, THANK YOU. 6098 03:59:21,025 --> 03:59:22,326 >> Joni Rutter: FANTASTIC. 6099 03:59:22,326 --> 03:59:25,162 AGREE COMPLETELY. 6100 03:59:25,162 --> 03:59:27,464 WE NEED TO FIGURE OUT AND MAKE 6101 03:59:27,464 --> 03:59:28,799 SURE THESE GET ADOPTED IF THEY 6102 03:59:28,799 --> 03:59:30,935 ARE VERY USEFUL. 6103 03:59:30,935 --> 03:59:33,337 THANK YOU FOR THOSE COMMENTS. 6104 03:59:33,337 --> 03:59:35,673 KELLY McVEARRY? 6105 03:59:35,673 --> 03:59:39,109 >> DR. CHEN, THIS IS SO EXCITE, 6106 03:59:39,109 --> 03:59:40,210 I'M REALLY THRILLED THIS IS 6107 03:59:40,210 --> 03:59:43,714 GOING TO BE PUT OUT THERE TO 6108 03:59:43,714 --> 03:59:45,349 COMMERCIALIZE. 6109 03:59:45,349 --> 03:59:47,451 YOU ASKED FOR FEEDBACK ON WHO 6110 03:59:47,451 --> 03:59:50,020 WOULD BE EARLY ADOPTERS. 6111 03:59:50,020 --> 03:59:52,222 IT SEEMS TO ME THAT THERE'S AN 6112 03:59:52,222 --> 03:59:54,525 INTERESTING ROLE THAT THE 6113 03:59:54,525 --> 03:59:55,960 PATIENT ADVOCACY GROUPS COULD 6114 03:59:55,960 --> 03:59:59,029 PLAY IN MAKING SURE THAT SOME 6115 03:59:59,029 --> 04:00:01,098 OF THE BIOTECH COMPANIES AND ET 6116 04:00:01,098 --> 04:00:03,567 CETERA SORT OF PRIORITIZE THIS. 6117 04:00:03,567 --> 04:00:08,572 BUT I'M NOT SURE, I MEAN I 6118 04:00:08,572 --> 04:00:10,307 CAN'T IMAGINE THAT YOU DON'T 6119 04:00:10,307 --> 04:00:11,942 HAVE THE RIGHT ECOSYSTEM OF 6120 04:00:11,942 --> 04:00:13,310 EARLY ADOPTERS. 6121 04:00:13,310 --> 04:00:14,445 IF THERE'S A SPECIFIC PROBLEM I 6122 04:00:14,445 --> 04:00:16,146 WOULD LOVE TO KNOW WHY. 6123 04:00:16,146 --> 04:00:17,881 MY QUESTION, I WAS SORT OF 6124 04:00:17,881 --> 04:00:18,482 SURPRISE TODAY SEE THIS 6125 04:00:18,482 --> 04:00:19,817 QUESTION, WHO WOULD BE THE 6126 04:00:19,817 --> 04:00:21,618 EARLY ADOPTERS? 6127 04:00:21,618 --> 04:00:22,853 BECAUSE IT SEEMS LIKE THIS WILL 6128 04:00:22,853 --> 04:00:24,588 BE EMBRACED. 6129 04:00:24,588 --> 04:00:26,156 SO I'M CURIOUS ABOUT THAT AS A 6130 04:00:26,156 --> 04:00:27,257 BUSINESS PROBLEM TO SOLVE AND 6131 04:00:27,257 --> 04:00:31,128 HOW WE CAN HELP. 6132 04:00:31,128 --> 04:00:32,930 FOR THE WHICH DISEASES WOULD 6133 04:00:32,930 --> 04:00:35,666 BENEFIT MOST FROM THIS, I THINK 6134 04:00:35,666 --> 04:00:38,235 IT'S SO SENSIBLE TO GO AFTER 6135 04:00:38,235 --> 04:00:39,570 BRAIN AND LIVER. 6136 04:00:39,570 --> 04:00:40,838 I WAS KIND OF HOPING TO SEE 6137 04:00:40,838 --> 04:00:42,306 KIDNEY THERE. 6138 04:00:42,306 --> 04:00:44,074 I WAS THINKING BECAUSE WHEN YOU 6139 04:00:44,074 --> 04:00:45,776 ASKED WHICH DISEASES I WAS 6140 04:00:45,776 --> 04:00:52,216 THINKING WOULDN'T THIS BE GREAT 6141 04:00:52,216 --> 04:00:53,884 TO BRING INTO THE LUPUS 6142 04:00:53,884 --> 04:00:59,823 POPULATION. 6143 04:00:59,823 --> 04:01:01,025 SO I COULD ELABORATE MORE. 6144 04:01:01,025 --> 04:01:03,260 I WOULD LOVE FOR YOU TO ADDRESS 6145 04:01:03,260 --> 04:01:07,398 THOSE QUESTIONS AND GET SOME 6146 04:01:07,398 --> 04:01:08,499 CLARITY ABOUT WHY YOU ASKED THE 6147 04:01:08,499 --> 04:01:09,933 QUESTION WHO WOULD BE THE EARLY 6148 04:01:09,933 --> 04:01:11,101 ADOPTERS. 6149 04:01:11,101 --> 04:01:14,038 AND THEN I THINK I HAVE A 6150 04:01:14,038 --> 04:01:16,740 PRACTICAL QUESTION, BY 6151 04:01:16,740 --> 04:01:20,611 RELEASING THIS ONTO AN SBR AND 6152 04:01:20,611 --> 04:01:21,512 STTR MECHANISM, MY 6153 04:01:21,512 --> 04:01:23,247 UNDERSTANDING OF THAT PROCESS 6154 04:01:23,247 --> 04:01:24,915 THERE ARE REAL CONSTRAINTS OF A 6155 04:01:24,915 --> 04:01:27,885 STAGE OR PHASE ONE IS A PRETTY 6156 04:01:27,885 --> 04:01:29,186 SMALL BUCKET OF MONEY, AND 6157 04:01:29,186 --> 04:01:31,221 PHASE TWO IS A MUCH LARGER 6158 04:01:31,221 --> 04:01:32,856 BUCKET OF MONEY WHEN THERE'S 6159 04:01:32,856 --> 04:01:35,259 BEEN SOME EARLY PROOF. 6160 04:01:35,259 --> 04:01:37,327 BUT THAT STILL SEEMS TO BE 6161 04:01:37,327 --> 04:01:40,330 SMALL FOR SOME OF THE GOALS 6162 04:01:40,330 --> 04:01:47,004 HAVE TO PO TO* ACHIEVE BATCH TO 6163 04:01:47,004 --> 04:01:47,704 BATCH REPRODUCABILITY AND 6164 04:01:47,704 --> 04:01:48,539 ULTIMATELY FIELD OFF THE SHELF 6165 04:01:48,539 --> 04:01:49,807 PRODUCT. 6166 04:01:49,807 --> 04:01:52,042 SO I'M JUST WONDERING IF THE 6167 04:01:52,042 --> 04:01:53,877 SAME DOLLAR LIMITS APPLY FOR 6168 04:01:53,877 --> 04:01:54,978 THE PARTICULAR OPPORTUNITY YOU 6169 04:01:54,978 --> 04:01:56,547 ARE GOING TO RELEASE. 6170 04:01:56,547 --> 04:01:57,281 THOSE ARE MY THREE THOUGHTS TO 6171 04:01:57,281 --> 04:01:57,948 DISCUSS. 6172 04:01:57,948 --> 04:01:59,416 >> YEAH, THANK YOU. 6173 04:01:59,416 --> 04:02:03,854 SO THIS IS A PHASE ONE. 6174 04:02:03,854 --> 04:02:05,856 SO THEN THE CHOICE FOR LIVER 6175 04:02:05,856 --> 04:02:07,291 AND BRAIN IS MOSTLY BASED ON 6176 04:02:07,291 --> 04:02:08,625 THE RESEARCH THAT WE HAVE 6177 04:02:08,625 --> 04:02:10,294 CURRENTLY GOING ON. 6178 04:02:10,294 --> 04:02:13,330 AND THEN ALSO IT'S LOOKING AT 6179 04:02:13,330 --> 04:02:19,103 WHICH ORGANOID TECHNOLOGY IS 6180 04:02:19,103 --> 04:02:20,270 MORE MATURE TO BE ADOPTED IN 6181 04:02:20,270 --> 04:02:23,340 THIS FASHION. 6182 04:02:23,340 --> 04:02:25,742 YEAH, I DEFINITELY THINK, MAYBE 6183 04:02:25,742 --> 04:02:27,911 IF THIS WAS SUCCESSFUL THAN IN 6184 04:02:27,911 --> 04:02:30,013 LATER PHASES IT COULD BE 6185 04:02:30,013 --> 04:02:32,316 EXPANDED TO OTHER ORGANOIDS AS 6186 04:02:32,316 --> 04:02:36,553 WELL. 6187 04:02:36,553 --> 04:02:38,722 AND I THINK, I GUESS THE OTHER 6188 04:02:38,722 --> 04:02:39,456 QUESTION IS THE MONEY LIMIT ON 6189 04:02:39,456 --> 04:02:40,424 THIS? 6190 04:02:40,424 --> 04:02:42,226 >> YEAH, ARE YOU GOING TO BE 6191 04:02:42,226 --> 04:02:45,395 ABLE TO ACHIEVE YOUR GOALS WITH 6192 04:02:45,395 --> 04:02:49,266 THIS PROGRAM IF THE NORMAL 6193 04:02:49,266 --> 04:02:53,670 DOLLAR LIMITS ARE IN PLACE, 6194 04:02:53,670 --> 04:02:54,938 THAT'S MY UNDERSTAND, TYPICALLY 6195 04:02:54,938 --> 04:02:56,507 GOVERN THESE PROGRAMS? 6196 04:02:56,507 --> 04:03:05,015 >> YEAH, THAT'S A GREAT 6197 04:03:05,015 --> 04:03:14,158 QUESTION, DR. McVEARRY. 6198 04:03:14,158 --> 04:03:15,859 $225,000 ISN'T A LOT OF MONEY, 6199 04:03:15,859 --> 04:03:18,729 SO THE STATEMENT HAS BEEN 6200 04:03:18,729 --> 04:03:20,330 CAREFULLY CRAFTED SO THE AIMS 6201 04:03:20,330 --> 04:03:22,566 ARE ACHIEVABLE WITH THAT MONEY. 6202 04:03:22,566 --> 04:03:23,567 WE MIGHT FOCUS ON CERTAIN PLATT 6203 04:03:23,567 --> 04:03:25,769 FOORM BUILD. 6204 04:03:25,769 --> 04:03:26,236 CAPABILITIES SUCH AS 6205 04:03:26,236 --> 04:03:26,870 REPRODUCABILITY. 6206 04:03:26,870 --> 04:03:29,139 WE WILL BE ABLE TO WORK OUT 6207 04:03:29,139 --> 04:03:34,745 THOSE THINGS, BUT IF WE DO 6208 04:03:34,745 --> 04:03:35,879 SUCCESSFULLY DEVELOP PHASE TWO, 6209 04:03:35,879 --> 04:03:37,481 IT WILL BE A LARGER PART OF 6210 04:03:37,481 --> 04:03:40,517 MONEY, OR SOME OF THE MORE 6211 04:03:40,517 --> 04:03:49,092 COMPLICATED ASPECTS SUCH AS THE 6212 04:03:49,092 --> 04:03:52,863 BIO SENSOR, THE DIVERSITY OF 6213 04:03:52,863 --> 04:03:56,533 THE HIGH PSV POOL, BECAUSE ONCE 6214 04:03:56,533 --> 04:03:59,836 YOU START WIDENING THE LENGTH, 6215 04:03:59,836 --> 04:04:01,138 TERMS OF REQUIREMENTS, THE 6216 04:04:01,138 --> 04:04:05,209 AMOUNT OF MONEY YOU NEED GETS 6217 04:04:05,209 --> 04:04:08,512 EXPONENTIALLY START TO GREEN. 6218 04:04:08,512 --> 04:04:12,049 WE HAVE TO BE CAREFUL. 6219 04:04:12,049 --> 04:04:12,716 JUST 2-3 VERY IMPORTANT 6220 04:04:12,716 --> 04:04:13,250 QUESTIONS TO ASK. 6221 04:04:13,250 --> 04:04:15,586 >> RIGHT. 6222 04:04:15,586 --> 04:04:18,822 THIS WILL HAVE A HUGE TOTAL 6223 04:04:18,822 --> 04:04:20,357 ADDRESSABLE MARKET IN THE 6224 04:04:20,357 --> 04:04:22,025 UNFUNDED MAZE 3. 6225 04:04:22,025 --> 04:04:23,694 -- PHASE 3. 6226 04:04:23,694 --> 04:04:26,496 GETTING IT TO THAT POINT SEEMS 6227 04:04:26,496 --> 04:04:27,731 HARD WITH THE DOLLAR 6228 04:04:27,731 --> 04:04:29,366 CONTRAINTS, THAT'S ALL. 6229 04:04:29,366 --> 04:04:30,801 SO THANK YOU FOR YOUR VERY 6230 04:04:30,801 --> 04:04:32,035 THOUGHTFUL ANSWER. 6231 04:04:32,035 --> 04:04:34,204 >> Joni Rutter: AND JUST ONE 6232 04:04:34,204 --> 04:04:44,681 MORE SORT OF TANGENTIALL YE 6233 04:04:47,784 --> 04:04:51,922 RELATED ASPECT TO THIS AS YOU 6234 04:04:51,922 --> 04:04:53,824 RECALL, MANY MODELS WE HOPE 6235 04:04:53,824 --> 04:04:54,791 WILL BE INFUSED IN THAT SPACE 6236 04:04:54,791 --> 04:04:56,960 AS WELL. 6237 04:04:56,960 --> 04:04:58,762 SO THERE MAY BE SOME PARALLEL 6238 04:04:58,762 --> 04:05:00,931 EFFORTS. 6239 04:05:00,931 --> 04:05:02,766 THEY WON'T BE THE SPR COMMUNITY 6240 04:05:02,766 --> 04:05:04,568 BUT THIS, I THINK WILL WORK IN 6241 04:05:04,568 --> 04:05:09,606 PARALLEL WITH SOME OF THE 6242 04:05:09,606 --> 04:05:12,109 CONFUSION OF THE EXCITEMENT AND 6243 04:05:12,109 --> 04:05:13,243 TECHNOLOGIES AND GENERATED 6244 04:05:13,243 --> 04:05:15,946 THROUGH THERE AND PERHAPS THERE 6245 04:05:15,946 --> 04:05:20,083 WILL BE SOME CONVERGENCE TO 6246 04:05:20,083 --> 04:05:21,685 ULTIMATELY GET MORE TISSUES AND 6247 04:05:21,685 --> 04:05:24,521 ORGANS REPRESENTED AS WELL. 6248 04:05:24,521 --> 04:05:26,456 BUT STARTING HERE WILL 6249 04:05:26,456 --> 04:05:27,691 HOPEFULLY GIVE US A FOCAL POINT 6250 04:05:27,691 --> 04:05:32,029 TO MOVE THIS FORWARD. 6251 04:05:32,029 --> 04:05:35,966 >> ONE MORE POINT, MS. 6252 04:05:35,966 --> 04:05:37,668 McVEARRY, ONCE SOMEONE UNLOCKS 6253 04:05:37,668 --> 04:05:43,240 PROOF OF CONCEPT OR FEASIBILITY 6254 04:05:43,240 --> 04:05:44,775 PROBLEM THEN OTHER PRIVATE 6255 04:05:44,775 --> 04:05:46,877 FUNDING MIGHT EVEN FLOW IN. 6256 04:05:46,877 --> 04:05:49,313 BECAUSE WHAT HAPPENS IS SMALL 6257 04:05:49,313 --> 04:05:53,250 BUSINESS IS ABLE TO SHOW THIS 6258 04:05:53,250 --> 04:05:55,652 IS A SUSTAINABLE BUSINESS, FOR 6259 04:05:55,652 --> 04:05:58,889 WHICH THEY HAVE SOLVED ONE OF 6260 04:05:58,889 --> 04:06:01,358 THE REALLY IMPORTANT VARIABLES 6261 04:06:01,358 --> 04:06:01,692 AND PROBLEMS, 6262 04:06:01,692 --> 04:06:02,225 >> RIGHT. 6263 04:06:02,225 --> 04:06:05,128 THANK YOU. 6264 04:06:05,128 --> 04:06:07,464 >> Joni Rutter: ARE THERE ANY 6265 04:06:07,464 --> 04:06:11,401 OTHER COMMENTS FROM OUR COUNCIL? 6266 04:06:11,401 --> 04:06:17,074 OKAY, HEARING NONE. 6267 04:06:17,074 --> 04:06:17,741 ANNA, WE WILL TURN IT OVER TO 6268 04:06:17,741 --> 04:06:19,376 YOU. 6269 04:06:19,376 --> 04:06:21,111 >> ANNA: ALL RIGHT, MAY HAVE I 6270 04:06:21,111 --> 04:06:22,646 A MOTION TO APPROVE THE CONCEPT? 6271 04:06:22,646 --> 04:06:23,547 SECOND. 6272 04:06:23,547 --> 04:06:25,749 ALL IN FAVOR? 6273 04:06:25,749 --> 04:06:31,521 ANY OPPOSED? 6274 04:06:31,521 --> 04:06:37,794 ANY ABSTENTIONS? 6275 04:06:37,794 --> 04:06:39,196 WITH THAT, IT'S APPROVED. 6276 04:06:39,196 --> 04:06:40,497 >> Joni Rutter: THANK YOU, WITH 6277 04:06:40,497 --> 04:06:43,633 THAT WE HAVE ONE MORE TO GO. 6278 04:06:43,633 --> 04:06:49,406 I WILL KICK IT OVER TO MICHAEL 6279 04:06:49,406 --> 04:06:58,648 TO GET US STARTED. 6280 04:06:58,648 --> 04:07:01,118 THIS IS DEVELOPMENT OF 6281 04:07:01,118 --> 04:07:03,153 VERSATILE SMALL FOOTPRINT 6282 04:07:03,153 --> 04:07:03,987 BEFRNL TOP DEVICE TO PERFORM 6283 04:07:03,987 --> 04:07:10,093 BATCH EVAPORATION. 6284 04:07:10,093 --> 04:07:12,095 [READING RAPIDLY] 6285 04:07:12,095 --> 04:07:14,064 AS DAN TAGLE SAID AND MATT HALL 6286 04:07:14,064 --> 04:07:16,433 SAID AS PART OF THE ASPIRE 6287 04:07:16,433 --> 04:07:18,468 PROCESS WE ARE TRYING TO FOCUS 6288 04:07:18,468 --> 04:07:21,505 ON THE AUTOMATION OF CHEMISTRY. 6289 04:07:21,505 --> 04:07:24,040 AND FOR THE PERSPECTIVE, MOST 6290 04:07:24,040 --> 04:07:26,343 FOLKS ARE AWARE OF THE STRONG 6291 04:07:26,343 --> 04:07:28,812 CLOSE TO TWO DECADE PROCESS OF 6292 04:07:28,812 --> 04:07:30,981 AUTOMATION OF BIOLOGY AND THAT 6293 04:07:30,981 --> 04:07:34,651 COUPLES WITH 20 PLUS YEARS OF 6294 04:07:34,651 --> 04:07:35,952 BILLIONS OF INVESTMENT IN 6295 04:07:35,952 --> 04:07:37,521 INDUSTRY TO OVERCOMING SOME OF 6296 04:07:37,521 --> 04:07:38,789 THESE BOTTLENECKS. 6297 04:07:38,789 --> 04:07:46,430 THIS ISN'T THE MOST GLAMOROUS 6298 04:07:46,430 --> 04:07:47,998 COMPONENT. 6299 04:07:47,998 --> 04:07:49,299 BUT THAT SIMILAR INVESTMENT HAS 6300 04:07:49,299 --> 04:07:51,001 NOT BEEN MADE IN THE AUTOMATION 6301 04:07:51,001 --> 04:07:54,371 OF CHEMISTRY. 6302 04:07:54,371 --> 04:07:58,508 REALLY TOWARD THAT GOAL OF 6303 04:07:58,508 --> 04:08:01,411 AUTOMATE UGH CHEMISTRY. 6304 04:08:01,411 --> 04:08:03,046 NEXT SLIDE, PLEASE. 6305 04:08:03,046 --> 04:08:09,186 THEY SHOULD BE ABLE TO REACH 6306 04:08:09,186 --> 04:08:10,253 90% TOTAL EVAPORATION IN UNDER 6307 04:08:10,253 --> 04:08:12,989 TEN MINUTE DOLLARS. 6308 04:08:12,989 --> 04:08:15,192 THIS SAW KEY POINT, THEY WANT 6309 04:08:15,192 --> 04:08:16,860 TO GET DOWN TO 100%. 6310 04:08:16,860 --> 04:08:19,696 IN THIS CASE WE WANT TO DO IT 6311 04:08:19,696 --> 04:08:24,634 IN A BATCH FASHION TO GET US TO 6312 04:08:24,634 --> 04:08:26,770 90% COMPLETELY. 6313 04:08:26,770 --> 04:08:27,871 SO SOME KEY AREAS THAT WE WILL 6314 04:08:27,871 --> 04:08:30,273 HAVE TO BE ABLE TO USE, WE WILL 6315 04:08:30,273 --> 04:08:33,076 HAVE TO USE HIGH RECOVERY VIALS 6316 04:08:33,076 --> 04:08:35,245 SPECIFIED BY NCATS. 6317 04:08:35,245 --> 04:08:36,546 AGAIN, THIS ISN'T A GLAMOROUS 6318 04:08:36,546 --> 04:08:40,717 TOPIC, BUT PART OF THE REASON 6319 04:08:40,717 --> 04:08:43,119 BIOLOGICAL SCREENING HAS BEEN 6320 04:08:43,119 --> 04:08:48,091 SUCCESSFUL, THE SBS FOOTPRINT 6321 04:08:48,091 --> 04:08:51,328 WHICH SAY MICRO TITER PLATE. 6322 04:08:51,328 --> 04:08:53,330 WE ARE TRYING TO UTILIZE 6323 04:08:53,330 --> 04:08:56,266 EXISTING VIALS THAT ARE IN THE 6324 04:08:56,266 --> 04:08:58,101 CHEMICAL WORKFLOW, BUT STANDARD 6325 04:08:58,101 --> 04:08:59,870 VIAL SO WE CAN AUTOMATE EVERY 6326 04:08:59,870 --> 04:09:01,505 STEP THE PROCESS. 6327 04:09:01,505 --> 04:09:04,808 RELATED TO THAT HAS TO BE 6328 04:09:04,808 --> 04:09:08,111 SUITABLE FOR USE WITHIN 6329 04:09:08,111 --> 04:09:08,712 EXISTING AUTOMATED CHEMICAL 6330 04:09:08,712 --> 04:09:10,814 SENSE WORTH FLOW DOLLARS AND 6331 04:09:10,814 --> 04:09:13,149 FINALLY A DEVICE MUST BE 6332 04:09:13,149 --> 04:09:15,151 AUTOMATION FRIENDLY OR HAVE AN 6333 04:09:15,151 --> 04:09:16,286 API FOR THIS DEVICE. 6334 04:09:16,286 --> 04:09:19,222 WE HAVE THE DESIGN OF A 6335 04:09:19,222 --> 04:09:20,357 MOLECULE, COMPLETE WORKFLOW 6336 04:09:20,357 --> 04:09:21,858 FROM START TO FINISH, FROM 6337 04:09:21,858 --> 04:09:23,059 EVERYTHING FROM THE VIRTUAL 6338 04:09:23,059 --> 04:09:25,662 DESIGN TO ULTIMATELY HAVE THE 6339 04:09:25,662 --> 04:09:26,997 SYNTHESIS OF WHATEVER COMPOUND 6340 04:09:26,997 --> 04:09:28,798 WE ARE LOOKING TO MAKE IN AN 6341 04:09:28,798 --> 04:09:29,833 AUTOMATED FASHION. 6342 04:09:29,833 --> 04:09:32,235 NEXT SLIDE, PLEASE. 6343 04:09:32,235 --> 04:09:42,846 SO FROM THE IMPLEMENTATION 6344 04:09:42,846 --> 04:09:43,914 EXPECTED IMPACT, WE ALREADY -- 6345 04:09:43,914 --> 04:09:49,419 IF WE ARE DOING AN SBIR WE 6346 04:09:49,419 --> 04:09:53,156 HAVE A GOOD IDEA GET SOMETHING 6347 04:09:53,156 --> 04:09:55,392 TO WORK, BUT IN THIS CASE, WE 6348 04:09:55,392 --> 04:09:57,394 WOULD LIKE TO HAVE I COMMERCIAL 6349 04:09:57,394 --> 04:09:58,528 DEVICE WE CAN JUST BUY OFF THE 6350 04:09:58,528 --> 04:09:59,930 SHELF. 6351 04:09:59,930 --> 04:10:01,865 NOT JUST FOR US, BUT FOR OTHERS 6352 04:10:01,865 --> 04:10:04,568 IN THE RESEARCH COMMUNITY. 6353 04:10:04,568 --> 04:10:05,802 OTHER LABORATORIES WOULD LIKELY 6354 04:10:05,802 --> 04:10:08,505 USE THIS AS WELL SINCE MORE AND 6355 04:10:08,505 --> 04:10:11,174 MORE FOLKS ARE TRYING TO GET 6356 04:10:11,174 --> 04:10:11,675 INVOLVED WITH AUTOMATIC 6357 04:10:11,675 --> 04:10:16,580 CHEMISTRY. 6358 04:10:16,580 --> 04:10:17,814 SO FOR THE PROGRAMMATIC 6359 04:10:17,814 --> 04:10:21,117 SIGNIFICANCE OF THIS, HAVING 6360 04:10:21,117 --> 04:10:22,452 THE AUTOMATED BATCH EVAPORATED 6361 04:10:22,452 --> 04:10:25,288 WOULD BE A KEY COMPONENT. 6362 04:10:25,288 --> 04:10:26,990 THERE ARE OTHER MEANS OF 6363 04:10:26,990 --> 04:10:29,859 WORKFLOWS BUT THEY ARE SLOW AND 6364 04:10:29,859 --> 04:10:33,263 NOT SUITABLE FOR AUTOMATION OR 6365 04:10:33,263 --> 04:10:34,397 ONLY PERFORM FULL EVAPORATION 6366 04:10:34,397 --> 04:10:36,299 ON ONE VIAL AT A TIME. 6367 04:10:36,299 --> 04:10:38,902 IMAGINE YOU ARE TRYING TO CLOSE 6368 04:10:38,902 --> 04:10:44,808 AFTER ONE ARTICLE OF COLLEGING. 6369 04:10:44,808 --> 04:10:46,242 IT'S NOTE REALLY AN EXPEDITED 6370 04:10:46,242 --> 04:10:47,510 WAY. 6371 04:10:47,510 --> 04:10:48,945 GET OVER THIS GOAL TO CREATE 6372 04:10:48,945 --> 04:10:49,346 MORE COME PRINCE 6373 04:10:49,346 --> 04:10:50,447 GEORGE-VALEMOUNTS. 6374 04:10:50,447 --> 04:10:53,350 THIS IS A KEY DEVICE THAT NCATS 6375 04:10:53,350 --> 04:10:56,586 IS ALREADY USING, PROTOTYPE IN 6376 04:10:56,586 --> 04:10:58,722 OUR LABORATORY, THERE'S BEEN 6377 04:10:58,722 --> 04:11:00,557 STRONG INTEREST EXPRESSED BY 6378 04:11:00,557 --> 04:11:04,294 OTHER LABS, THIS WAS PRESENTED 6379 04:11:04,294 --> 04:11:04,995 AT SLAS CONFERENCE THIS PAST 6380 04:11:04,995 --> 04:11:06,596 WINTER. 6381 04:11:06,596 --> 04:11:08,999 AS PART OF A BROADER PORTFOLIO 6382 04:11:08,999 --> 04:11:10,734 NCATS WORKED ON. 6383 04:11:10,734 --> 04:11:13,136 THIS WAS THE DEVICE MANY 6384 04:11:13,136 --> 04:11:16,006 CHEMISTS FOLLOWED UP AND TALKED 6385 04:11:16,006 --> 04:11:17,140 TO ENGINEER ESSENTIALLY HOW DO 6386 04:11:17,140 --> 04:11:18,308 I GET ONE OF THESE. 6387 04:11:18,308 --> 04:11:23,380 NEXT SLIDE, PLEASE. 6388 04:11:23,380 --> 04:11:26,883 SOME EYE VAP RATION, THAT'S A 6389 04:11:26,883 --> 04:11:27,817 ROTOAPP. 6390 04:11:27,817 --> 04:11:31,021 THE VIALS IN THE LAB WARE IT'S 6391 04:11:31,021 --> 04:11:31,655 REALLY NOT AUTOMATION FRIENDLY 6392 04:11:31,655 --> 04:11:33,256 AT ALL. 6393 04:11:33,256 --> 04:11:34,057 THIS IS REALLY NOT SUITABLE FOR 6394 04:11:34,057 --> 04:11:35,692 US. 6395 04:11:35,692 --> 04:11:40,096 ON THE RIGHT THAT'S A BIOTAGE, 6396 04:11:40,096 --> 04:11:42,332 V 10. 6397 04:11:42,332 --> 04:11:44,601 THE SEMI AUTOMATED AND SERIAL 6398 04:11:44,601 --> 04:11:45,235 PROCESS, MEANING ONE VIAL AT A 6399 04:11:45,235 --> 04:11:46,302 TIME. 6400 04:11:46,302 --> 04:11:49,539 NEXT SLIDE, PLEASE. 6401 04:11:49,539 --> 04:11:52,375 SO THE BATCH, THIS IS A 6402 04:11:52,375 --> 04:11:53,977 RENDERING OF WHAT THIS LOOKS 6403 04:11:53,977 --> 04:11:57,881 LIKE, ON THE BOTTOM A HEATING 6404 04:11:57,881 --> 04:11:58,415 BLOCK WITH FOUR DIFFERENT 6405 04:11:58,415 --> 04:12:01,551 MODELS. 6406 04:12:01,551 --> 04:12:04,688 THEN WE PUT THIS UNDER PRESSURE 6407 04:12:04,688 --> 04:12:10,493 WITH NITROGEN AND HEAT UP TO 6408 04:12:10,493 --> 04:12:10,794 50% CELSIUS. 6409 04:12:10,794 --> 04:12:15,331 WE WILL IMPLEMENT THAT WITH A 6410 04:12:15,331 --> 04:12:15,565 BIOTAGE. 6411 04:12:15,565 --> 04:12:18,001 WHAT WE WANT TO SHOW IS FOR 6412 04:12:18,001 --> 04:12:22,072 COMMON SOLVENTS USED WE WANT A 6413 04:12:22,072 --> 04:12:24,441 WIDE VARIETY OF SOLVENTS,WE 6414 04:12:24,441 --> 04:12:30,914 HAVE THIS UNDER 2 PSI OF 6415 04:12:30,914 --> 04:12:31,314 NITROGEN PRESSURE. 6416 04:12:31,314 --> 04:12:32,415 WE WERE UNDER TEN MINUTES. 6417 04:12:32,415 --> 04:12:34,484 WE USE WATER AS A CONTROL JUST 6418 04:12:34,484 --> 04:12:38,054 TO GIVE AN EXAMPLE WHAT IT 6419 04:12:38,054 --> 04:12:40,690 TAKES FROM AN EVAPORATION 6420 04:12:40,690 --> 04:12:41,758 PERSPECTIVE. 6421 04:12:41,758 --> 04:12:44,994 WE CAN DO FOUR AT A TIME. 6422 04:12:44,994 --> 04:12:49,632 FINALLY FOR THE OPT MYCATION, 6423 04:12:49,632 --> 04:12:55,972 IF WE ONLY DID SERIES, IT TAKES 6424 04:12:55,972 --> 04:13:00,143 ABOUT 8 MILS. 6425 04:13:00,143 --> 04:13:03,480 IF WE IMPLEMENT, AND IF WE 6426 04:13:03,480 --> 04:13:06,416 LIFRNL THOSE TOGETHER THE 6427 04:13:06,416 --> 04:13:08,418 PROSAYS GOES FROM 60 MINUTES, 6428 04:13:08,418 --> 04:13:10,553 WE SAVE CLOSE TO 60% OF THE 6429 04:13:10,553 --> 04:13:12,789 TIME MAKING IT AN EFFICIENT 6430 04:13:12,789 --> 04:13:14,057 PROCESS BY LINKING THESE TWO 6431 04:13:14,057 --> 04:13:14,324 TOGETHER. 6432 04:13:14,324 --> 04:13:15,325 NEXT SLIDE, PLEASE. 6433 04:13:15,325 --> 04:13:19,429 IN SUM ARE YOU WE PROPOSE THIS 6434 04:13:19,429 --> 04:13:26,436 CONCEPT DEVELOP A BATCH DEVICE 6435 04:13:26,436 --> 04:13:26,936 MULTIPLE OF RECOVERING 6436 04:13:26,936 --> 04:13:27,837 MULTI-MENT. 6437 04:13:27,837 --> 04:13:30,140 THIS IS JUST A KEY BOTTLENECK 6438 04:13:30,140 --> 04:13:32,642 RIGHT NOW MANY GROUPS ARE 6439 04:13:32,642 --> 04:13:33,943 STRUGGLING WITH REGARDS TO 6440 04:13:33,943 --> 04:13:34,978 AUTOMATING CHEMICAL SYNTHESIS. 6441 04:13:34,978 --> 04:13:37,013 NEXT SLIDE, PLEASE. 6442 04:13:37,013 --> 04:13:38,314 AND SO IN THIS CASE, THIS IS TO 6443 04:13:38,314 --> 04:13:42,485 THE COUNCIL. 6444 04:13:42,485 --> 04:13:43,887 WHAT MIGHT IMPROVE THIS, WHAT 6445 04:13:43,887 --> 04:13:45,555 ARE KEY POINTS TO CONSIDER, 6446 04:13:45,555 --> 04:13:46,623 WHAT DOES SUCCESS LIKE. 6447 04:13:46,623 --> 04:13:51,861 ONE OF THE QUESTIONS WE HAVE 6448 04:13:51,861 --> 04:14:00,703 HAD IS WITH REGARD TO NCATS 6449 04:14:00,703 --> 04:14:03,373 PATENT. 6450 04:14:03,373 --> 04:14:05,575 WE WOULD DO A NON-EXCLUSIVE 6451 04:14:05,575 --> 04:14:06,776 LICENSE TO ANYONE WHO COMES UP 6452 04:14:06,776 --> 04:14:08,211 WITH A MODEL HERE. 6453 04:14:08,211 --> 04:14:09,946 WE HAVE THE IP BECAUSE WE DID 6454 04:14:09,946 --> 04:14:11,848 COME UP WITH THIS IDEA. 6455 04:14:11,848 --> 04:14:16,119 BUT WE IN NO MEANS WANT TO MAKE 6456 04:14:16,119 --> 04:14:17,220 THIS RESTRICTED, THE WHOLE 6457 04:14:17,220 --> 04:14:19,355 INTENTION OF ASPIRE IS TO HAVE 6458 04:14:19,355 --> 04:14:20,023 RESOURCES AVAILABLE TO THE 6459 04:14:20,023 --> 04:14:20,857 BROADER COMMUNITY. 6460 04:14:20,857 --> 04:14:21,858 >> Joni Rutter: GREAT, THANK 6461 04:14:21,858 --> 04:14:22,859 YOU SO MUCH, SAM. 6462 04:14:22,859 --> 04:14:23,359 WE WILL MOVE INTO THE 6463 04:14:23,359 --> 04:14:25,895 DISCUSSION. 6464 04:14:25,895 --> 04:14:27,564 KELLY McVEARRY, PLEASE GO AHEAD. 6465 04:14:27,564 --> 04:14:28,731 >> THAT WAS REALLY COOL, SAM, 6466 04:14:28,731 --> 04:14:33,703 THANK YOU SO MUCH. 6467 04:14:33,703 --> 04:14:38,508 IT STRIKES ME THIS HAS 6468 04:14:38,508 --> 04:14:41,077 POTENTIAL FOR BEING FUNDAMENTAL 6469 04:14:41,077 --> 04:14:42,879 LABORATORY TECHNOLOGY THAT'S 6470 04:14:42,879 --> 04:14:45,281 JUST IMPROVES PROCESSES BEYOND 6471 04:14:45,281 --> 04:14:46,683 BIOMEDICAL RESEARCH, CONSIDER 6472 04:14:46,683 --> 04:14:47,150 QUESTIONS TO SIMULATE 6473 04:14:47,150 --> 04:14:48,151 CONVERSATION. 6474 04:14:48,151 --> 04:14:51,187 I WAS GOING TO MARKET SIZING. 6475 04:14:51,187 --> 04:14:54,090 WOULD YOU BE ABLE TO EXPLAIN TO 6476 04:14:54,090 --> 04:15:00,063 US, OUR YOU SEE THE USE CASES 6477 04:15:00,063 --> 04:15:02,498 BEYOND BIOMEDICAL RESEARCH AS 6478 04:15:02,498 --> 04:15:04,701 THAT HELPS FRAME WHAT KIND UP 6479 04:15:04,701 --> 04:15:10,373 TAKE, OR DO YOU SEE IT AS A 6480 04:15:10,373 --> 04:15:11,674 MORE LIMITED MARKET OF USERS. 6481 04:15:11,674 --> 04:15:13,676 >> WE STARTED THINKING OF THIS 6482 04:15:13,676 --> 04:15:15,511 SPECIFIC TO THE NEEDS OF THE 6483 04:15:15,511 --> 04:15:18,214 LABORATORY, TAKING A STEP BACK 6484 04:15:18,214 --> 04:15:19,482 TO YOUR POINT. 6485 04:15:19,482 --> 04:15:21,551 THE GOAL, THERE'S A VARIETY OF 6486 04:15:21,551 --> 04:15:23,820 REASONS PEOPLE WANT TO 6487 04:15:23,820 --> 04:15:26,489 EVAPORATE SOLVENTS. 6488 04:15:26,489 --> 04:15:28,258 YOU COULD CONSIDER COOKING 6489 04:15:28,258 --> 04:15:31,628 APPLICATIONS AS A REDUCTION. 6490 04:15:31,628 --> 04:15:32,128 THEY REALLY AREN'T THAT 6491 04:15:32,128 --> 04:15:33,196 EXPENSIVE. 6492 04:15:33,196 --> 04:15:35,131 WE HAD A CUSTOM MADE HEATING 6493 04:15:35,131 --> 04:15:37,166 BLOCK, IT MIGHT BE A CHALLENGE 6494 04:15:37,166 --> 04:15:39,369 IN KITCHENS TO GET THE PRESSURE. 6495 04:15:39,369 --> 04:15:41,671 BUT TRUTH BE TOLD THAT JUST 6496 04:15:41,671 --> 04:15:44,407 MAKES IT GO A LITTLE BIT FASTER. 6497 04:15:44,407 --> 04:15:45,942 SO THERE'S POSSIBILITY THERE 6498 04:15:45,942 --> 04:15:47,644 COULD BE UTILITY BEYOND JUST 6499 04:15:47,644 --> 04:15:48,845 THE BENCH TOP DEVICE IN A 6500 04:15:48,845 --> 04:15:51,281 CHEMICAL HOOD. 6501 04:15:51,281 --> 04:15:52,081 BECAUSE THERE'S MANY 6502 04:15:52,081 --> 04:15:55,952 APPLICATIONS WHERE QUICK LE 6503 04:15:55,952 --> 04:15:57,887 EVAPORATING SOMETHING, ONE IS 6504 04:15:57,887 --> 04:15:58,354 FOOD PROCESSING, FOOD 6505 04:15:58,354 --> 04:15:59,956 TECHNOLOGIES. 6506 04:15:59,956 --> 04:16:02,292 IT'S NOT A SPACE WE ULTIMATELY 6507 04:16:02,292 --> 04:16:04,727 GET INVOLVED WITH BUT 6508 04:16:04,727 --> 04:16:06,029 POTENTIALLY COULD BE AN 6509 04:16:06,029 --> 04:16:06,629 ADDITIONAL MARKET THAT WOULD 6510 04:16:06,629 --> 04:16:08,364 HAVE INTEREST. 6511 04:16:08,364 --> 04:16:10,166 WE HAVE OUR NEED BUT I LIKE 6512 04:16:10,166 --> 04:16:12,302 PUTTING SOMETHING OUT THERE. 6513 04:16:12,302 --> 04:16:15,171 THE BROADER BUSINESS COMMUNITY. 6514 04:16:15,171 --> 04:16:17,740 MANY FOLKS READ THESE, THEY MAY 6515 04:16:17,740 --> 04:16:19,042 HAVE UTILIZATION FOR THIS 6516 04:16:19,042 --> 04:16:19,609 TECHNOLOGY WE HAVEN'T QUITE 6517 04:16:19,609 --> 04:16:20,677 CONSIDERED. 6518 04:16:20,677 --> 04:16:21,577 >> THAT'S A GREAT NOTE TO END 6519 04:16:21,577 --> 04:16:22,979 ON. 6520 04:16:22,979 --> 04:16:24,948 THAT WAS A TERRIFIC ANSWER. 6521 04:16:24,948 --> 04:16:26,649 SO MY FOLLOW-UP QUESTION IS YOU 6522 04:16:26,649 --> 04:16:28,451 MENTIONED THAT YOU HAVE THE IP, 6523 04:16:28,451 --> 04:16:31,487 IT'S GOING TO BE A 6524 04:16:31,487 --> 04:16:33,489 NON-EXCLUSIVE LICENSE THAT'S 6525 04:16:33,489 --> 04:16:35,058 AVAILABLE TO SBIR RECIPIENTS 6526 04:16:35,058 --> 04:16:36,926 THAT ARE SUCCESSFUL. 6527 04:16:36,926 --> 04:16:42,098 DO YOU SEE ANY RISK BY NOT 6528 04:16:42,098 --> 04:16:43,633 OFFERING AN EXCLUSIVE LICENSE, 6529 04:16:43,633 --> 04:16:44,233 IF SOMEBODY REALLY WANTS TO 6530 04:16:44,233 --> 04:16:46,135 JUMP IN. 6531 04:16:46,135 --> 04:16:48,137 BECAUSE IT POSES A LITTLE BIT A 6532 04:16:48,137 --> 04:16:51,007 RISK TO THE SMALL BUSINESS TO 6533 04:16:51,007 --> 04:16:53,710 THINK THEY CAN'T COMMERCIALIZE 6534 04:16:53,710 --> 04:16:57,146 AFTER MAKING A MULTI-YEAR 6535 04:16:57,146 --> 04:16:59,349 INVESTMENT TO KIND OF 6536 04:16:59,349 --> 04:16:59,849 PROTOTYPE, AND SCALE TO 6537 04:16:59,849 --> 04:17:00,583 PRODUCTION. 6538 04:17:00,583 --> 04:17:02,085 >> IT'S A GOOD QUESTION AND ONE 6539 04:17:02,085 --> 04:17:03,519 WE TALKED ABOUT. 6540 04:17:03,519 --> 04:17:09,325 ONE OF THE CHALLENGES WE SAW 6541 04:17:09,325 --> 04:17:11,594 WITH POTENTIAL FOR AN EXCUSIVE. 6542 04:17:11,594 --> 04:17:16,866 IS THE TIME IT TAKES TO EXECUTE 6543 04:17:16,866 --> 04:17:18,768 THEM. 6544 04:17:18,768 --> 04:17:20,570 I THINK PHASE ONE SOME OF THE 6545 04:17:20,570 --> 04:17:23,506 TECHNICAL SIDES GO UP TO 375 6546 04:17:23,506 --> 04:17:24,574 AND PHASE TWO WAS 2 MILLION 6547 04:17:24,574 --> 04:17:25,842 OVER TWO YEARS. 6548 04:17:25,842 --> 04:17:27,577 WE HAVE SEEN THIS IN THE PAST, 6549 04:17:27,577 --> 04:17:30,380 THE CHALLENGE IS THE DOLLAR 6550 04:17:30,380 --> 04:17:32,548 AMOUNTS ARE GOOD BUT REALITY TO 6551 04:17:32,548 --> 04:17:33,149 GET A COMMERCIAL PRODUCT NOT 6552 04:17:33,149 --> 04:17:34,183 ENOUGH. 6553 04:17:34,183 --> 04:17:36,786 I THINK THE POINT ABOUT THAT 6554 04:17:36,786 --> 04:17:38,287 INVESTMENT REQUIRED, IF SOMEONE 6555 04:17:38,287 --> 04:17:39,522 HAS A SUCCESSFUL PRODUCT I 6556 04:17:39,522 --> 04:17:44,827 THINK WE WOULD BE OPEN TO A 6557 04:17:44,827 --> 04:17:46,629 LICENSE. 6558 04:17:46,629 --> 04:17:47,997 PART OF THE REASON FOR PHASE 6559 04:17:47,997 --> 04:17:50,199 ONE IN PARTICULAR IS THE TIME 6560 04:17:50,199 --> 04:17:52,769 IT TAKES TO EXECUTE AN 6561 04:17:52,769 --> 04:17:53,970 EXCLUSIVE LICENSE MIGHT TAKE 6562 04:17:53,970 --> 04:17:55,505 TOO LONG BEFORE WE HAVE TIME TO 6563 04:17:55,505 --> 04:17:57,306 GET TO THE NEXT STEP. 6564 04:17:57,306 --> 04:18:00,343 IF THAT ANSWERS YOUR QUESTION. 6565 04:18:00,343 --> 04:18:01,744 IT'S A CONSIDERATION WE HAVE, 6566 04:18:01,744 --> 04:18:03,146 WE UNDERSTAND THE CONCERN OF 6567 04:18:03,146 --> 04:18:06,783 THE SMALL BUSINESS. 6568 04:18:06,783 --> 04:18:08,818 THE SBR'S THE DOLLARS GO QUICK, 6569 04:18:08,818 --> 04:18:14,357 THE TIME TOO, IT GOES VERY FAST. 6570 04:18:14,357 --> 04:18:15,892 >> THANK YOU, IT'S EXCITING. 6571 04:18:15,892 --> 04:18:20,329 >> IN TERMS OF EXCLUSIVE 6572 04:18:20,329 --> 04:18:23,066 LICENSE DEBATE, WHAT HAPPENS IN 6573 04:18:23,066 --> 04:18:23,699 THESE PRODUCT DEVELOPMENT 6574 04:18:23,699 --> 04:18:27,437 CYCLES THERE WILL BE A LOT OF 6575 04:18:27,437 --> 04:18:28,438 FOLLOW-ON PATENTS THAT 6576 04:18:28,438 --> 04:18:29,072 ENGINEERING COMPANIES WILL FILE 6577 04:18:29,072 --> 04:18:35,378 ON. 6578 04:18:35,378 --> 04:18:37,046 THEY WILL AUTOMATICALLY AGREE 6579 04:18:37,046 --> 04:18:44,887 ADDITIONAL FENCES, I DON'T 6580 04:18:44,887 --> 04:18:46,122 THINK HAS HAVING AN-LIKE SAM 6581 04:18:46,122 --> 04:18:48,124 SAID IT MAY BE TOO EXPENSIVE 6582 04:18:48,124 --> 04:18:50,259 AND OUT OF REACH AND TOO LONG 6583 04:18:50,259 --> 04:18:51,494 TO EXECUTE TO GET THIS PROJECT 6584 04:18:51,494 --> 04:18:52,862 STARTED. 6585 04:18:52,862 --> 04:18:54,931 SO I THINK THE NON-EXCLUSIVE 6586 04:18:54,931 --> 04:18:55,465 LICENSE WOULD GET THINGS 6587 04:18:55,465 --> 04:18:58,267 STARTED. 6588 04:18:58,267 --> 04:19:02,738 ONE THING START THERE WILL BE 6589 04:19:02,738 --> 04:19:04,841 FURTHER AUTOMATION PROGRESSION 6590 04:19:04,841 --> 04:19:06,876 OF TECHNOLOGY DEVELOPMENT AND 6591 04:19:06,876 --> 04:19:08,144 FURTHER PATENTING, I THINK IT 6592 04:19:08,144 --> 04:19:10,146 IS HARD TO PREDICT RIGHT NOW. 6593 04:19:10,146 --> 04:19:10,746 >> YEAH, THAT'S GREAT, THANK 6594 04:19:10,746 --> 04:19:11,080 YOU. 6595 04:19:11,080 --> 04:19:13,349 >> Joni Rutter: AND THEN WE 6596 04:19:13,349 --> 04:19:23,693 HAVE KEITH MUELLER. 6597 04:19:25,294 --> 04:19:26,229 >> KEITH MUELLER: GREAT 6598 04:19:26,229 --> 04:19:27,330 PRESENTATION, YOU ANSWERED ALL 6599 04:19:27,330 --> 04:19:28,664 THE QUESTIONS I WAS WRITING 6600 04:19:28,664 --> 04:19:29,465 DOWN, YOU ANSWERED DURING THE 6601 04:19:29,465 --> 04:19:29,866 PRESENTATION. 6602 04:19:29,866 --> 04:19:33,436 SO THAT'S GREAT. 6603 04:19:33,436 --> 04:19:35,104 MY FOCUS IS AROUND WHAT DOES 6604 04:19:35,104 --> 04:19:39,308 SUCCESS LOOK LIKE. 6605 04:19:39,308 --> 04:19:43,646 I'M HEARING TWO THINGS. 6606 04:19:43,646 --> 04:19:45,448 WITH UTILIZATION A PRODUCT 6607 04:19:45,448 --> 04:19:47,483 BEING MORE WIDESPREAD THAN JUST 6608 04:19:47,483 --> 04:19:49,919 IN THE LAB AT NCATS AND I THINK 6609 04:19:49,919 --> 04:19:51,320 THAT'S A LEGITIMATE QUESTION TO 6610 04:19:51,320 --> 04:19:52,288 ASK AND ANSWER IF THIS ROLLS 6611 04:19:52,288 --> 04:19:53,422 OUT. 6612 04:19:53,422 --> 04:20:03,966 THE OTHER ONE WE HAD, AND THIS 6613 04:20:07,537 --> 04:20:09,772 IS SORT OF NAIVETE IF YOU WILL 6614 04:20:09,772 --> 04:20:11,841 SOMEBODY WHOSE NOT A CHEMIST 6615 04:20:11,841 --> 04:20:14,443 FROM DOING CHEMICAL RESEARCH. 6616 04:20:14,443 --> 04:20:16,345 AND UNDERSTANDING THE 60 6617 04:20:16,345 --> 04:20:17,680 MINUTE, 24 MINUTE GAIN THAT 6618 04:20:17,680 --> 04:20:18,514 CAME THROUGH REALLY CLEAR IN 6619 04:20:18,514 --> 04:20:19,282 THE PRESENTATION. 6620 04:20:19,282 --> 04:20:20,516 I APPRECIATE THAT. 6621 04:20:20,516 --> 04:20:23,519 I WOULD LIKE TO HEAR THE FINE 6622 04:20:23,519 --> 04:20:25,154 AIL I GUESS, CONNECTION HOW 6623 04:20:25,154 --> 04:20:26,989 DOES THAT IN TURN INFLUENCE THE 6624 04:20:26,989 --> 04:20:28,591 FINAL PRODUCT OF THE RESEARCH, 6625 04:20:28,591 --> 04:20:30,593 WHAT DOES IT MEAN TO SPEED UP 6626 04:20:30,593 --> 04:20:32,328 THE PROCESS TO THE ULTIMATE 6627 04:20:32,328 --> 04:20:32,828 OUTCOME OF THE RESEARCH 6628 04:20:32,828 --> 04:20:33,563 ACTIVITY. 6629 04:20:33,563 --> 04:20:35,131 >> IT'S A GREAT QUESTION. 6630 04:20:35,131 --> 04:20:38,467 TO THE POINT FIRST POINT, YEAH, 6631 04:20:38,467 --> 04:20:41,204 THIS IS REALLY ON OUR SIDE, THE 6632 04:20:41,204 --> 04:20:43,039 MARKET RESEARCH IS JUST BEING 6633 04:20:43,039 --> 04:20:45,241 INVOLVED IN THE ASPIRE PROGRAM 6634 04:20:45,241 --> 04:20:45,841 AND OVERCOMING THESE 6635 04:20:45,841 --> 04:20:47,977 BOTTLENECKS WE HAVE BEEN IN 6636 04:20:47,977 --> 04:20:52,715 TOUCH WITH MANY LABS IN THE 6637 04:20:52,715 --> 04:20:53,616 PROGRAM FROM AROUND THE WORLD, 6638 04:20:53,616 --> 04:20:55,351 LITERALLY. 6639 04:20:55,351 --> 04:20:57,153 THIS IS A KEY BOTTLENECK, THE 6640 04:20:57,153 --> 04:20:58,955 OTHER IS PURIFICATION. 6641 04:20:58,955 --> 04:21:01,023 THERE'S REALLY TWO PROBLEMS WE 6642 04:21:01,023 --> 04:21:02,925 SEE AS BOTTLENECKS. 6643 04:21:02,925 --> 04:21:04,760 THIS LEADS INTO YOUR SECOND 6644 04:21:04,760 --> 04:21:06,062 QUESTION, REALLY THE MORE 6645 04:21:06,062 --> 04:21:08,664 IMPORTANT QUESTION, SAY WE CAN 6646 04:21:08,664 --> 04:21:09,265 OVERCOME THOSE BOTTLENECKS, 6647 04:21:09,265 --> 04:21:11,133 THIS COMES DOWN TO THE 6648 04:21:11,133 --> 04:21:13,236 PRINCIPLE BEHIND THE ASPIRE 6649 04:21:13,236 --> 04:21:15,705 PROGRAM IS THIS WHOLE DESIGN 6650 04:21:15,705 --> 04:21:16,772 MAKE, TEST, ANALYZE PARADIGM. 6651 04:21:16,772 --> 04:21:19,375 THE GOAL IS WE WANT TO REDUCE 6652 04:21:19,375 --> 04:21:22,111 THAT ITERATION TIME TO GO 6653 04:21:22,111 --> 04:21:24,347 FASTER AND FASTER AND HOPEFULLY 6654 04:21:24,347 --> 04:21:29,819 GET TO MORE MOLECULES, THAT'S 6655 04:21:29,819 --> 04:21:31,621 IF WE CAN PRODUCE MOLECULES 6656 04:21:31,621 --> 04:21:33,522 FASTER, THAT COULD LEAD TO 6657 04:21:33,522 --> 04:21:34,657 TESTING AND TESTING COULD LEAD 6658 04:21:34,657 --> 04:21:36,359 TO TREATMENTS. 6659 04:21:36,359 --> 04:21:39,195 THIS IS PART OF THE REDUCTION 6660 04:21:39,195 --> 04:21:41,330 OF THE OVERALL RATE LIMITING 6661 04:21:41,330 --> 04:21:43,666 AND WE HAVE SEEN FOLKS OUT 6662 04:21:43,666 --> 04:21:46,168 THERE THAT HAVE THESE AUTOMATED 6663 04:21:46,168 --> 04:21:48,604 SYSTEMS THEY CAN GO REALLY FAST. 6664 04:21:48,604 --> 04:21:50,940 FOR ANY PROCESS ULTIMATELY YOUR 6665 04:21:50,940 --> 04:21:52,742 RATE LIMITING STEP IS WHAT 6666 04:21:52,742 --> 04:21:54,377 DRIVES YOUR TOTAL TIME FOR THAT 6667 04:21:54,377 --> 04:21:56,212 ITERATION, WHICH IS JUST A RATE 6668 04:21:56,212 --> 04:21:56,746 LIMITING STEP WE HAVE TO 6669 04:21:56,746 --> 04:21:59,482 OVERCOME. 6670 04:21:59,482 --> 04:22:00,116 BROADER PROCESS YOU WERE 6671 04:22:00,116 --> 04:22:01,517 MENTIONING WHEN WE LOOK AT THE 6672 04:22:01,517 --> 04:22:04,253 INTYRE WORKFLOW. 6673 04:22:04,253 --> 04:22:05,154 TAKE THESE RATE LIMTING STEPS 6674 04:22:05,154 --> 04:22:06,489 ONE AT A TIME. 6675 04:22:06,489 --> 04:22:08,591 THAT'S PART OF THE REASON WE 6676 04:22:08,591 --> 04:22:12,228 STARTED WORKING ON THIS. 6677 04:22:12,228 --> 04:22:14,664 WE HAVE TO BE AMENABLE TO 6678 04:22:14,664 --> 04:22:14,964 AUTOMATION. 6679 04:22:14,964 --> 04:22:16,299 THE GOAL IS REDUCE THAT TOITAL 6680 04:22:16,299 --> 04:22:18,434 TIME, HERE IS THE DESIGN OF THE 6681 04:22:18,434 --> 04:22:20,770 MOLECULE, ALL THE WAY TO WE 6682 04:22:20,770 --> 04:22:22,672 MADE IT, WE PURIFIED IT, WE 6683 04:22:22,672 --> 04:22:24,373 VALIDATED IT, AND THIS IS A KEY 6684 04:22:24,373 --> 04:22:26,242 STEP IN THE WORKFLOW. 6685 04:22:26,242 --> 04:22:27,143 THE DREAM IS ULTIMATELY WE WILL 6686 04:22:27,143 --> 04:22:29,845 BE TO THE POINT WE HAVE THE 6687 04:22:29,845 --> 04:22:31,881 WORKFLOW MEASURED IN HOURS. 6688 04:22:31,881 --> 04:22:34,050 THE REALITY RIGHT NOW THAT WILL 6689 04:22:34,050 --> 04:22:35,418 BE WEEKS, DAYS. 6690 04:22:35,418 --> 04:22:36,752 WE ARE TALKING ABOUT HOURS FOR 6691 04:22:36,752 --> 04:22:39,789 THAT WITH A BATTERY OF TESTS. 6692 04:22:39,789 --> 04:22:41,891 SO JUST GREAT QUESTION, BUT 6693 04:22:41,891 --> 04:22:43,693 OVERALL TO REALLY OVERCOME A 6694 04:22:43,693 --> 04:22:48,164 RATE-LIMITING STEP. 6695 04:22:48,164 --> 04:22:48,931 >> Joni Rutter: GREAT, THANK 6696 04:22:48,931 --> 04:22:50,466 YOU VERY MUCH. 6697 04:22:50,466 --> 04:22:51,767 ARE THERE ANY OTHER QUESTIONS 6698 04:22:51,767 --> 04:22:59,175 FROM OUR COUNCILMEMBERS? 6699 04:22:59,175 --> 04:23:00,576 SEEING NONE, I WILL TURN IT 6700 04:23:00,576 --> 04:23:01,811 OVER TO ANNA FOR A VOTE. 6701 04:23:01,811 --> 04:23:03,512 >> MAY I HAVE A MOTION TO 6702 04:23:03,512 --> 04:23:04,113 APPROVE THE CONCEPT. 6703 04:23:04,113 --> 04:23:04,680 >> SO MOVED. 6704 04:23:04,680 --> 04:23:09,285 >> SECOND. 6705 04:23:09,285 --> 04:23:10,786 >> ALL IN FAVOR? 6706 04:23:10,786 --> 04:23:12,088 OPPOSED? 6707 04:23:12,088 --> 04:23:14,023 ANY ABSTENTIONS? 6708 04:23:14,023 --> 04:23:16,058 WITH THAT OUR FOURTH CONCEPT 6709 04:23:16,058 --> 04:23:16,559 FOR THE DAY IS APPROVED. 6710 04:23:16,559 --> 04:23:17,326 THANK YOU. 6711 04:23:17,326 --> 04:23:19,362 >> Joni Rutter: ALL RIGHT. 6712 04:23:19,362 --> 04:23:22,398 AND WE WILL NOW WITH OUR LAST 6713 04:23:22,398 --> 04:23:24,433 TOPIC OF THE DAY, SUPER EXCITED 6714 04:23:24,433 --> 04:23:26,135 ABOUT THIS DISCUSSION, I ARE 6715 04:23:26,135 --> 04:23:29,338 TURN IT OVER TO MERIDETH 6716 04:23:29,338 --> 04:23:30,806 TEMPLE-O'CONNOR WHO HAS BEEN 6717 04:23:30,806 --> 04:23:32,775 LEADING THE EFFORTS ON OUR 6718 04:23:32,775 --> 04:23:33,976 STRATEGIC PLANNING PROCESSES 6719 04:23:33,976 --> 04:23:38,247 WITH HER VERY CAPABLE TEAM AND 6720 04:23:38,247 --> 04:23:41,450 I WILL TURN IT OVER TO HER FOR 6721 04:23:41,450 --> 04:23:42,084 THE PRESENTATION AND DISCUSSION 6722 04:23:42,084 --> 04:23:42,551 AFTERWARDS. 6723 04:23:42,551 --> 04:23:44,019 >> THANK YOU VERY MUCH. 6724 04:23:44,019 --> 04:23:45,121 LET ME SURE I CAN ADVANCE THIS. 6725 04:23:45,121 --> 04:23:46,956 THANK YOU. 6726 04:23:46,956 --> 04:23:48,090 WE WANT TO FOCUS REALLY ON THE 6727 04:23:48,090 --> 04:23:50,593 DISCUSSION TODAY. 6728 04:23:50,593 --> 04:23:52,395 AND THE COUNCILMEMBERS HAVE HAD 6729 04:23:52,395 --> 04:23:53,763 THE OPPORTUNITY TO SEE THE 6730 04:23:53,763 --> 04:23:55,431 DRAFT PLAN IN ADVANCE. 6731 04:23:55,431 --> 04:23:57,967 BUT I DID WANT, FOR THE BENEFIT 6732 04:23:57,967 --> 04:24:03,939 OF COUNCIL AND FOR FOLKS 6733 04:24:03,939 --> 04:24:05,007 LISTENING ON THE VIDEOCAST TO 6734 04:24:05,007 --> 04:24:06,609 HEAR HOW WE GOT WHERE WE ARE. 6735 04:24:06,609 --> 04:24:08,043 WE ARE EXCITED TO BE HERE. 6736 04:24:08,043 --> 04:24:10,312 AS CAN YOU SEE WE ARE ALMOST AT 6737 04:24:10,312 --> 04:24:11,580 THE END OF OUR TIMELINE. 6738 04:24:11,580 --> 04:24:14,283 WHICH IS FANTASTIC TO SEE. 6739 04:24:14,283 --> 04:24:16,419 WE STARTED THIS NOVEMBER 2022 6740 04:24:16,419 --> 04:24:19,121 WHEN JONI WAS NAMED THE 6741 04:24:19,121 --> 04:24:23,192 PERMANENT DIRECTOR FOR NCATS. 6742 04:24:23,192 --> 04:24:25,127 SO A KEY THEME THROUGHOUT ALL 6743 04:24:25,127 --> 04:24:27,563 OF IT HAS BEEN OUR ENGAGEMENT. 6744 04:24:27,563 --> 04:24:30,800 ENGAGEMENT WITH ALL OF OUR 6745 04:24:30,800 --> 04:24:31,901 CONSTITUENTS, INTERNALLY AND 6746 04:24:31,901 --> 04:24:32,201 EXTERNALLY. 6747 04:24:32,201 --> 04:24:35,237 AS YOU SAW ON THE PRIOR SLIDE, 6748 04:24:35,237 --> 04:24:45,648 IT'S GOING CRAZY ON ME. 6749 04:24:57,126 --> 04:24:59,495 IT'S REALLY BEEN A TREMENDOUS 6750 04:24:59,495 --> 04:25:00,596 ASSET SO OUR STRATEGIC PLANNING 6751 04:25:00,596 --> 04:25:01,497 PROCESS OVERALL. 6752 04:25:01,497 --> 04:25:03,399 THIS IS REALLY MEANT TO JUST 6753 04:25:03,399 --> 04:25:05,134 REMIND FOLKS OF THE BREADTH AND 6754 04:25:05,134 --> 04:25:07,436 DEPTH OF CONVERSATIONS WE HAVE 6755 04:25:07,436 --> 04:25:08,003 HAD ACROSS OUR CONSTITUENT 6756 04:25:08,003 --> 04:25:09,371 COMMUNITIES. 6757 04:25:09,371 --> 04:25:12,208 AND IT REALLY DID, WE COULDN'T 6758 04:25:12,208 --> 04:25:13,542 CONTINUE ON OR ELSE WOULDN'T BE 6759 04:25:13,542 --> 04:25:15,978 ABLE TO SEE THINGS BUT IT 6760 04:25:15,978 --> 04:25:16,512 REALLY HAS CONTINUED PAST 6761 04:25:16,512 --> 04:25:18,681 AUGUST. 6762 04:25:18,681 --> 04:25:20,316 WE HAD INBOX GOING, THE RFI 6763 04:25:20,316 --> 04:25:21,717 THAT WAS IN THE FALL FOR THE 6764 04:25:21,717 --> 04:25:22,384 PUBLIC TO COMMENT ON OUR 6765 04:25:22,384 --> 04:25:24,253 FRAMEWORK. 6766 04:25:24,253 --> 04:25:25,955 AND WE HAVE CONTINUED TO ENGAGE 6767 04:25:25,955 --> 04:25:27,389 STAFF AT DIFFERENT LEVELS. 6768 04:25:27,389 --> 04:25:29,492 WE HAVE HAD TOWN HALLS. 6769 04:25:29,492 --> 04:25:37,466 WE MET WITH INDIVIDUAL GROUPS. 6770 04:25:37,466 --> 04:25:38,868 ACROSS THE ORGANIZATIONAL 6771 04:25:38,868 --> 04:25:39,702 STRUCTURE TO INFORM THE 6772 04:25:39,702 --> 04:25:45,040 FRAMEWORK AND THE DRAFT PLAN. 6773 04:25:45,040 --> 04:25:47,877 SOMETHING ELSE I WANT TO TALK 6774 04:25:47,877 --> 04:25:49,778 ABOUT BRIEFLY, NOT ONLY WE GOT 6775 04:25:49,778 --> 04:25:51,013 TRY MEND US AMOUNT FEEDBACK AS 6776 04:25:51,013 --> 04:25:52,948 YOU SAW OP THE FIRST SLIDE, 6777 04:25:52,948 --> 04:25:54,917 OVER 1700 COMMENTS. 6778 04:25:54,917 --> 04:25:56,118 WE GOT 50 PLUS COMMENTS TO THE 6779 04:25:56,118 --> 04:25:58,187 RFI. 6780 04:25:58,187 --> 04:26:00,589 BUT FROM ALL OF THOSE MEETINGS 6781 04:26:00,589 --> 04:26:02,892 ABOUT 1700 COMMENTS THAT WE 6782 04:26:02,892 --> 04:26:08,163 DIGESTED, TEAM REALLY DID AN 6783 04:26:08,163 --> 04:26:09,798 EXCELLENT JOB USING TOOLS THAT 6784 04:26:09,798 --> 04:26:11,300 NIH HAS FOR THIS PURPOSE TO 6785 04:26:11,300 --> 04:26:11,901 ANALYZE THE INPUT THAT WE 6786 04:26:11,901 --> 04:26:19,074 RECEIVED. 6787 04:26:19,074 --> 04:26:20,042 THESE WERE KEY TOPICS THAT 6788 04:26:20,042 --> 04:26:21,043 EMERGED. 6789 04:26:21,043 --> 04:26:22,011 THESE WERE SOME OF THE BIGGER 6790 04:26:22,011 --> 04:26:23,012 ONES. 6791 04:26:23,012 --> 04:26:25,648 WE WANTED TO SHOW AND ENDED UP 6792 04:26:25,648 --> 04:26:27,883 DOING AN ANALYSIS TO SHOW HOW 6793 04:26:27,883 --> 04:26:29,785 DIFFERENT GROUPS WE ENGAGE WITH 6794 04:26:29,785 --> 04:26:31,487 ON THAT PRIOR SLIDE HAD A LOT 6795 04:26:31,487 --> 04:26:37,092 COMMON GROUND. 6796 04:26:37,092 --> 04:26:39,194 SO YOU COULD SEE FROM LEFT SIDE 6797 04:26:39,194 --> 04:26:40,896 TO THE RIGHT HOW THE DIFFERENT 6798 04:26:40,896 --> 04:26:41,997 GROUPS MAPPED TO THE DIFFERENT 6799 04:26:41,997 --> 04:26:43,165 KEY TOPICS. 6800 04:26:43,165 --> 04:26:45,167 AND THERE WAS A LOT OF 6801 04:26:45,167 --> 04:26:45,968 CRISSCROSS, THAT WAS ACTUALLY 6802 04:26:45,968 --> 04:26:47,970 GREAT FOR US TO SEE, THAT SHOWS 6803 04:26:47,970 --> 04:26:50,506 THERE'S A LOT OF COMMON GROUND 6804 04:26:50,506 --> 04:26:51,106 ACROSS OUR DIFFERENT 6805 04:26:51,106 --> 04:26:52,841 CONSTITUENTS IN TERMS OF THE 6806 04:26:52,841 --> 04:26:58,781 INPUT THEY PROVIDED AND HOW 6807 04:26:58,781 --> 04:27:01,417 THAT HAS INFORMED PLAN 6789 6808 04:27:01,417 --> 04:27:02,418 THIS IS THE FRAMEWORK LAST FALL 6809 04:27:02,418 --> 04:27:04,153 AS A RESULT OF THE INPUT. 6810 04:27:04,153 --> 04:27:06,855 SO THAT WAS SORT OF BY DESIGN. 6811 04:27:06,855 --> 04:27:08,424 THE ENGAGEMENT WAS REALLY MEANT 6812 04:27:08,424 --> 04:27:09,024 TO INFORM HOW WE STRUCTURED 6813 04:27:09,024 --> 04:27:09,725 THIS. 6814 04:27:09,725 --> 04:27:12,461 BECAUSE OF THE WAY THE FEEDBACK 6815 04:27:12,461 --> 04:27:14,063 CAME IN AND BECAUSE JONI 6816 04:27:14,063 --> 04:27:17,099 ALREADY HAD A VERY CLEAR VISION 6817 04:27:17,099 --> 04:27:18,701 FOR HOW SHE WANTED NCATS TO 6818 04:27:18,701 --> 04:27:21,637 MOVE FORWARD, WE WERE ABLE TO 6819 04:27:21,637 --> 04:27:23,339 LEVERAGE THAT, BOTH IN OUR 6820 04:27:23,339 --> 04:27:25,574 ENGAGEMENT PROCESS AS WELL AS 6821 04:27:25,574 --> 04:27:26,909 IN BUILDING THE FRAMEWORK TO 6822 04:27:26,909 --> 04:27:28,410 REFLECT THAT FEEDBACK. 6823 04:27:28,410 --> 04:27:29,845 SO WE RESULTED IN FIVE GOALS, 6824 04:27:29,845 --> 04:27:39,488 AS YOU SEE HERE. 6825 04:27:39,488 --> 04:27:43,058 WE HAD A CROSS CUTTING ACTIVITY 6826 04:27:43,058 --> 04:27:52,635 AND EFFORTS UNDER GOAL FOUR AND 6827 04:27:52,635 --> 04:27:54,570 THEN WE DECIDED BASED ON THE 6828 04:27:54,570 --> 04:27:56,672 INPUT AND FEEDBACK FROM OUR 6829 04:27:56,672 --> 04:27:58,807 COMMUNITY AND THE IMPORTANT 6830 04:27:58,807 --> 04:27:59,808 INTERNALLY OF STEWARDSHIP TO 6831 04:27:59,808 --> 04:28:00,576 ELEVATE IT TO BEING A GOAL AS 6832 04:28:00,576 --> 04:28:10,686 WELL. 6833 04:28:11,120 --> 04:28:12,855 I WOULD BE REMISS TO NOT 6834 04:28:12,855 --> 04:28:13,756 ACKNOWLEDGE THIS HAS BEEN A 6835 04:28:13,756 --> 04:28:15,224 TEAM EFFORT. 6836 04:28:15,224 --> 04:28:25,768 I PARTICULARLY WANT TO CALL OUT 6837 04:28:31,106 --> 04:28:33,842 DRS.JESSICA WALRATH. 6838 04:28:33,842 --> 04:28:35,911 AND JEN. 6839 04:28:35,911 --> 04:28:37,513 MANY OTHER PEOPLE PLAYED A ROLE. 6840 04:28:37,513 --> 04:28:42,184 WE CALLED OUT THOSE WHO PLAYED 6841 04:28:42,184 --> 04:28:45,287 A SPECIFIC ROLE IN THE PROCESS. 6842 04:28:45,287 --> 04:28:47,089 ALL OUR CONSTITUENTS INTERNALLY 6843 04:28:47,089 --> 04:28:47,923 AND EXTERNALLY HAVE BEEN VERY 6844 04:28:47,923 --> 04:28:49,258 ENGAGED. 6845 04:28:49,258 --> 04:28:51,660 OUR STAFF AT EVERY LEVEL HAVE 6846 04:28:51,660 --> 04:28:52,695 BEEN SUPER ENGAGED THROUGHOUT 6847 04:28:52,695 --> 04:28:54,730 THIS TIME WHICH HAS BEEN 6848 04:28:54,730 --> 04:28:56,198 EXTREMELY REWARDING TO SEE. 6849 04:28:56,198 --> 04:28:57,800 THE LAST THING BEFORE WE SHIFT 6850 04:28:57,800 --> 04:28:59,401 TO DISCUSSION, I WANTED TO MAKE 6851 04:28:59,401 --> 04:29:00,936 A PLUG, THE DRAFT PLAN IS OUT 6852 04:29:00,936 --> 04:29:02,438 ON OUR WEBSITE. 6853 04:29:02,438 --> 04:29:04,273 AND YOU CAN EITHER GET TO IT 6854 04:29:04,273 --> 04:29:05,974 THROUGH THE QR CODE, THROUGH 6855 04:29:05,974 --> 04:29:08,210 OUR WEBSITE IF YOU GOOGLE NCATS 6856 04:29:08,210 --> 04:29:09,311 STRATEGIC PLAN, IT'S THE FIRST 6857 04:29:09,311 --> 04:29:10,646 PAGE THAT COMES UP. 6858 04:29:10,646 --> 04:29:13,348 AND IT WILL BE OUT UNTIL JUNE 6859 04:29:13,348 --> 04:29:13,916 14th FOR COMMENTS FROM THE 6860 04:29:13,916 --> 04:29:16,185 PUBLIC. 6861 04:29:16,185 --> 04:29:18,287 AND YOU CAN EMAIL YOUR COMMENTS 6862 04:29:18,287 --> 04:29:19,788 TO THE EMAIL ADDRESS HERE. 6863 04:29:19,788 --> 04:29:20,422 IT'S ALSO ON OUR WEBSITE AS 6864 04:29:20,422 --> 04:29:23,058 WELL. 6865 04:29:23,058 --> 04:29:25,994 WITH THAT, WHAT I WOULD LIKE TO 6866 04:29:25,994 --> 04:29:28,197 DO WITH DR. RUTTER IS HAVE A 6867 04:29:28,197 --> 04:29:29,098 COUPLE OF QUESTIONS, REALLY 6868 04:29:29,098 --> 04:29:31,033 JUST TO KIND OF BREAK THE ICE, 6869 04:29:31,033 --> 04:29:33,135 IF YOU HAVE A FAVORITE GOAL OR 6870 04:29:33,135 --> 04:29:35,871 OBJECTIVE, WE WOULD LOVE TO 6871 04:29:35,871 --> 04:29:36,305 HERE THAT FROM THE 6872 04:29:36,305 --> 04:29:37,106 COUNCILMEMBERS. 6873 04:29:37,106 --> 04:29:39,441 ALSO DO YOU FEEL THE GOALS AND 6874 04:29:39,441 --> 04:29:40,075 OBJECTIVES ALIGN WITH OUR 6875 04:29:40,075 --> 04:29:41,543 VISION AND MISSION? 6876 04:29:41,543 --> 04:29:43,112 IS ANYTHING MISSING THE MARK? 6877 04:29:43,112 --> 04:29:44,213 THOSE ARE SORT OF OUR FRAMING 6878 04:29:44,213 --> 04:29:45,781 QUESTIONS FOR THE DISCUSSION. 6879 04:29:45,781 --> 04:29:47,583 OTHERWISE WE WOULD JUST LIKE TO 6880 04:29:47,583 --> 04:29:48,884 HEAR ANY THOUGHTS THAT YOU 6881 04:29:48,884 --> 04:29:51,320 WOULD LIKE TO OFFER. 6882 04:29:51,320 --> 04:29:54,857 I DO HAVE EACH GOAL A SLIDE FOR 6883 04:29:54,857 --> 04:29:56,291 EACH GOAL WITH ITS OBJECTIVES 6884 04:29:56,291 --> 04:29:57,326 WE CAN JUMP AROUND IF THAT'S 6885 04:29:57,326 --> 04:29:58,927 HELPFUL. 6886 04:29:58,927 --> 04:30:01,263 BUT WE WANTED TO FOCUS MORE ON 6887 04:30:01,263 --> 04:30:01,930 CONVERSATION THAN JUST WALKING 6888 04:30:01,930 --> 04:30:03,165 THROUGH THAT TOGETHER. 6889 04:30:03,165 --> 04:30:03,999 SO WITH THAT -- 6890 04:30:03,999 --> 04:30:05,467 >> Joni Rutter: WITH THAT, 6891 04:30:05,467 --> 04:30:07,136 THANK YOU SO MUCH, MERIDETH, 6892 04:30:07,136 --> 04:30:09,705 THAT WAS TERRIFIC. 6893 04:30:09,705 --> 04:30:11,440 AND I THINK I WOULD LIKE TO 6894 04:30:11,440 --> 04:30:12,708 JUST START US OFF WITH THAT ICE 6895 04:30:12,708 --> 04:30:13,976 BREAKER. 6896 04:30:13,976 --> 04:30:16,178 I ASKED THIS QUESTION TO THE 6897 04:30:16,178 --> 04:30:18,714 I.T. DIRECTORS WHEN WE HAD THE 6898 04:30:18,714 --> 04:30:19,248 ENGAGEMENT WITH THE I.T. 6899 04:30:19,248 --> 04:30:20,415 DIRECTORS. 6900 04:30:20,415 --> 04:30:23,519 I WAS REALLY DELIGHTED TO HEAR 6901 04:30:23,519 --> 04:30:23,952 THEIR FAVORITE GOAL 6902 04:30:23,952 --> 04:30:25,154 COLLECTIVELY. 6903 04:30:25,154 --> 04:30:26,688 THEY ALL HAD DIFFERENT ONES BUT 6904 04:30:26,688 --> 04:30:28,090 ONES JUMPED OUT. 6905 04:30:28,090 --> 04:30:30,425 SO I'M KIND OF CURIOUS WITH YOU 6906 04:30:30,425 --> 04:30:31,827 WHAT YOUR FAVORITE GOAL IS. 6907 04:30:31,827 --> 04:30:33,162 AND THEN WOULD LOVE TO HEAR 6908 04:30:33,162 --> 04:30:35,097 YOUR THOUGHTS ON HOW THESE 6909 04:30:35,097 --> 04:30:36,899 ALIGN WITH THE VISION MISSION 6910 04:30:36,899 --> 04:30:38,400 AS YOU SEE IT AND ARE WE 6911 04:30:38,400 --> 04:30:40,602 MISSING THE MARK. 6912 04:30:40,602 --> 04:30:42,471 SO PLEASE WOULD LOVE TO HERE 6913 04:30:42,471 --> 04:30:44,039 YOUR COMMENTS ON THESE THINGS. 6914 04:30:44,039 --> 04:30:45,741 AND SERGIO, I SEE YOUR HAND UP, 6915 04:30:45,741 --> 04:30:46,775 SO YOU GET THE HONOR OF GOING 6916 04:30:46,775 --> 04:30:46,975 FIRST. 6917 04:30:46,975 --> 04:30:57,152 THANK YOU. 6918 04:30:58,954 --> 04:31:00,189 >> SERGIO: A LITTLE PRAISE OF 6919 04:31:00,189 --> 04:31:00,722 THE PROCESS YOU HAVE GONE 6920 04:31:00,722 --> 04:31:02,391 THROUGH. 6921 04:31:02,391 --> 04:31:05,127 FOR ALMOST AT LEAST A YEAR AND 6922 04:31:05,127 --> 04:31:06,762 A HALF. 6923 04:31:06,762 --> 04:31:08,063 AND ALL THE LISTENING YOU DID 6924 04:31:08,063 --> 04:31:16,872 FOR THIS DRAFT THAT YOU ARE 6925 04:31:16,872 --> 04:31:17,773 PROVIDING US WITH, IT'S A MAJOR 6926 04:31:17,773 --> 04:31:20,008 PIECE OF WORK. 6927 04:31:20,008 --> 04:31:23,412 VERY PROUD YOU HAVE DONE THIS 6928 04:31:23,412 --> 04:31:25,347 AND THAT NCATS HAS TAKEN THE 6929 04:31:25,347 --> 04:31:31,019 LEAD ON REALLY CONSULTING WITH 6930 04:31:31,019 --> 04:31:32,754 SO MANY PEOPLE FROM SO MANY 6931 04:31:32,754 --> 04:31:33,322 DIFFERENT DISCIPLINES. 6932 04:31:33,322 --> 04:31:36,325 THAT'S PRAISE. 6933 04:31:36,325 --> 04:31:43,866 I HAVE TWO FAVORITE GOALS. 6934 04:31:43,866 --> 04:31:46,702 NUMBER TWO AND IT'S NUMBER FIVE. 6935 04:31:46,702 --> 04:31:48,770 BUT NUMBER TWO, MY GOODNESS, I 6936 04:31:48,770 --> 04:31:50,839 THINK THAT IS CAPTURED IN SOME 6937 04:31:50,839 --> 04:31:52,441 OF THE INITIAL TAKE AWAYS YOU 6938 04:31:52,441 --> 04:31:55,544 WERE SHARING WITH US IN THE 6939 04:31:55,544 --> 04:32:00,549 FIRST MEETING THAT WE ATTACHED 6940 04:32:00,549 --> 04:32:03,252 ON THE THE STRATEGIC PLAN. 6941 04:32:03,252 --> 04:32:05,687 NUMBER TWO IS ENABLE ALL PEOPLE 6942 04:32:05,687 --> 04:32:07,389 TO CONTRIBUTE TO AND BENEFIT 6943 04:32:07,389 --> 04:32:09,124 FROM TRANSLATIONAL SCIENCE. 6944 04:32:09,124 --> 04:32:10,792 I HAVE A FAVORITE OBJECTIVE 6945 04:32:10,792 --> 04:32:12,928 WITHIN THAT. 6946 04:32:12,928 --> 04:32:14,763 WHICH IS RELATED TO 6947 04:32:14,763 --> 04:32:15,397 ESTABLISHING TRUST, OR BUILDING 6948 04:32:15,397 --> 04:32:16,698 TRUST. 6949 04:32:16,698 --> 04:32:19,635 I THINK THAT IS SO CRITICALLY 6950 04:32:19,635 --> 04:32:23,138 IMPORTANT THAT WE FOCUS ON THAT. 6951 04:32:23,138 --> 04:32:25,474 I ENDEAVOR TO LOOK FOR HOW MANY 6952 04:32:25,474 --> 04:32:27,743 TIMES TRUST IS MENTIONED IN 6953 04:32:27,743 --> 04:32:31,847 DOCUMENT, IT'S FIVE TIMES. 6954 04:32:31,847 --> 04:32:36,518 BUT SOME THEM ARE IN THE TITLES. 6955 04:32:36,518 --> 04:32:40,155 BUT I ALSO ENDEAVOR TO SEARCH 6956 04:32:40,155 --> 04:32:41,690 FOR TRUSTWORTHINESS. 6957 04:32:41,690 --> 04:32:43,625 AND IT'S MENTIONED NONE. 6958 04:32:43,625 --> 04:32:47,362 AND I THINK THAT IS A MAJOR, 6959 04:32:47,362 --> 04:32:49,331 MAJOR AREA. 6960 04:32:49,331 --> 04:32:49,998 BECAUSE IT'S NOT ONLY BUILDING 6961 04:32:49,998 --> 04:32:51,900 TRUST. 6962 04:32:51,900 --> 04:32:55,837 IT'S HOW DO WE AS 6963 04:32:55,837 --> 04:32:59,107 ORGANIZATIONS, INCLUDING NCATS, 6964 04:32:59,107 --> 04:33:00,509 OUR ACADEMIC HEALTH CENTERS, 6965 04:33:00,509 --> 04:33:02,177 HOW WE CAN BECOME A TRUSTWORTHY 6966 04:33:02,177 --> 04:33:03,312 ORGANIZATIONS. 6967 04:33:03,312 --> 04:33:05,013 THERE IS A LOT OF WORK BEING 6968 04:33:05,013 --> 04:33:06,815 DONE IN THAT AREA. 6969 04:33:06,815 --> 04:33:09,051 AND I THINK THAT IS MISSING. 6970 04:33:09,051 --> 04:33:13,221 AND I'M GOING TO STOP HERE. 6971 04:33:13,221 --> 04:33:14,823 >> Joni Rutter: FANTASTIC, 6972 04:33:14,823 --> 04:33:16,258 THANK YOU SO MUCH, SERGIO, 6973 04:33:16,258 --> 04:33:16,792 APPRECIATE YOUR THOROUGH 6974 04:33:16,792 --> 04:33:18,160 READING OF IT. 6975 04:33:18,160 --> 04:33:22,898 I HAVE TAKEN DOWN THOSE NOTES. 6976 04:33:22,898 --> 04:33:26,034 WE HAVE #2 AND #5 IS YOUR 6977 04:33:26,034 --> 04:33:29,972 FAVORITE SO FAR. 6978 04:33:29,972 --> 04:33:32,174 KEITH MUELLER, GO AHEAD. 6979 04:33:32,174 --> 04:33:34,309 >> MY FAVORITE IS #2. 6980 04:33:34,309 --> 04:33:36,144 SPEAKING ON BEHALF OF RURAL 6981 04:33:36,144 --> 04:33:38,146 POPULATIONS, THAT SPEAKS TO ME 6982 04:33:38,146 --> 04:33:39,648 VERY LOUDLY, THE A POPULATION 6983 04:33:39,648 --> 04:33:41,483 THAT IS NOT ALWAYS CONSIDERED. 6984 04:33:41,483 --> 04:33:45,420 AND WITHIN THAT, REALLY KIND OF 6985 04:33:45,420 --> 04:33:47,756 HONED IN ON OBJECTIVE 2.1 TO 6986 04:33:47,756 --> 04:33:50,993 WORK TOWARD BROADER INCLUSION 6987 04:33:50,993 --> 04:33:53,295 OF PATIENTS, FAMILIES AND 6988 04:33:53,295 --> 04:33:54,029 CAREGIVERS AS PARTICIPANTS IN 6989 04:33:54,029 --> 04:33:59,368 TRANSLATIONAL SCIENCE. 6990 04:33:59,368 --> 04:34:03,505 I THINK OF THAT, AS ONE OF THE 6991 04:34:03,505 --> 04:34:04,306 SISTER ORGANIZATIONS, SCIENCE 6992 04:34:04,306 --> 04:34:06,341 BEGINS WITH EVEN ASKING THE 6993 04:34:06,341 --> 04:34:08,643 QUESTION EVEN BEFORE THE STUDY 6994 04:34:08,643 --> 04:34:11,079 DESIGNS AND GOALS ARE WRITTEN. 6995 04:34:11,079 --> 04:34:13,115 SO THAT'S A CHALLENGE, I THINK 6996 04:34:13,115 --> 04:34:15,250 THAT IS INHERENT IN OBJECTIVE 6997 04:34:15,250 --> 04:34:16,551 ONE THAT DIDN'T COME RIGHT OUT 6998 04:34:16,551 --> 04:34:22,324 FROM THE LANGUAGE ON THE PAPER. 6999 04:34:22,324 --> 04:34:23,525 >> Joni Rutter: GREAT, THANK 7000 04:34:23,525 --> 04:34:24,426 YOU FOR THAT FEEDBACK. 7001 04:34:24,426 --> 04:34:27,362 THAT'S FANTASTIC. 7002 04:34:27,362 --> 04:34:34,436 OKAY, SO WE HAVE TWO FOR #2. 7003 04:34:34,436 --> 04:34:39,908 ANYONE ELSE? 7004 04:34:39,908 --> 04:34:41,743 >> I WILL DO A LITTLE LIKE 7005 04:34:41,743 --> 04:34:43,311 SERGIO AND PICK TWO. 7006 04:34:43,311 --> 04:34:45,814 I WILL SAY MY FAVORITE IS 7007 04:34:45,814 --> 04:34:48,683 PROBABLY #3. 7008 04:34:48,683 --> 04:34:50,819 I WOULD LIKE SPECIFICALLY 7009 04:34:50,819 --> 04:34:52,154 OBJECTIVES 3.1 AND 3.2. 7010 04:34:52,154 --> 04:34:56,958 I THINK THEY ARE VERY NCATS-IAN. 7011 04:34:56,958 --> 04:34:58,460 IF YOU THINK OF GENERALIZABLE 7012 04:34:58,460 --> 04:35:01,196 PROBLEMS. 7013 04:35:01,196 --> 04:35:03,031 #2. 7014 04:35:03,031 --> 04:35:03,698 WHICH IS MY SECOND FAVORITE 7015 04:35:03,698 --> 04:35:08,070 GOAL. 7016 04:35:08,070 --> 04:35:09,204 >> Joni Rutter: THAT'S A GREAT 7017 04:35:09,204 --> 04:35:10,405 COMMENT. 7018 04:35:10,405 --> 04:35:13,442 IN MANY WAYS MANY OF THESE 7019 04:35:13,442 --> 04:35:14,543 FEEDBACK ON ONE ANOTHER, WHICH 7020 04:35:14,543 --> 04:35:15,811 IS KIND OF THE BEAUTY OF IT AS 7021 04:35:15,811 --> 04:35:17,579 WELL. 7022 04:35:17,579 --> 04:35:22,017 ADVANCES IN ONE AREA WE HOPE 7023 04:35:22,017 --> 04:35:23,051 WILL PROVIDE ADVANCES IN 7024 04:35:23,051 --> 04:35:23,718 OTHERS, THAT'S WHAT WE EXPECT 7025 04:35:23,718 --> 04:35:24,352 TO SEE. 7026 04:35:24,352 --> 04:35:25,954 THANK YOU FOR THAT. 7027 04:35:25,954 --> 04:35:29,791 ANYONE ELTS? 7028 04:35:29,791 --> 04:35:32,127 -- ELSE? 7029 04:35:32,127 --> 04:35:32,494 KELLY McVEARRY. 7030 04:35:32,494 --> 04:35:36,264 S 7031 04:35:36,264 --> 04:35:38,600 >> KELLY: I LIKE THE WAY ONE, 7032 04:35:38,600 --> 04:35:41,002 TWO, AND THREE MIRROR WHAT YOU 7033 04:35:41,002 --> 04:35:41,837 HAVE CONSISTENTLY SAID, JONI, 7034 04:35:41,837 --> 04:35:43,572 WHEN YOU HAVE BEEN OUT THERE 7035 04:35:43,572 --> 04:35:44,739 ENGAGING COMMUNITIES. 7036 04:35:44,739 --> 04:35:50,112 I JUST LIKE THE WAY YOUR GOALS 7037 04:35:50,112 --> 04:35:58,086 LINEUP WITH YOUR CORE MESSAGE 7038 04:35:58,086 --> 04:35:59,588 AND HOW IMPORTANT, CONSISTENT 7039 04:35:59,588 --> 04:36:01,123 AND INCLUSIVE IT IS. 7040 04:36:01,123 --> 04:36:03,358 THIS IS REALLY TAKING THE 7041 04:36:03,358 --> 04:36:05,560 FUTURE MISSION OF NCATS, ARE 7042 04:36:05,560 --> 04:36:09,898 JUST AMPLIFYING A MESSAGE OF 7043 04:36:09,898 --> 04:36:10,799 INCLUSIVITY IN TRANSLATIONAL 7044 04:36:10,799 --> 04:36:11,433 SCIENCE AND I'M GRATEFUL TO SEE 7045 04:36:11,433 --> 04:36:12,534 THAT. 7046 04:36:12,534 --> 04:36:13,435 >> Joni Rutter: FANTASTIC. 7047 04:36:13,435 --> 04:36:13,735 THANK YOU. 7048 04:36:13,735 --> 04:36:15,170 OKAY. 7049 04:36:15,170 --> 04:36:22,210 SO NOW THAT WE HAVE YOUR 7050 04:36:22,210 --> 04:36:23,411 FAVORITES, I'M HEARING #2, I 7051 04:36:23,411 --> 04:36:26,248 THINK, IS WINNING. 7052 04:36:26,248 --> 04:36:29,718 AND IT SOUNDS LIKE THEY ARE ALL 7053 04:36:29,718 --> 04:36:30,352 REPRESENTED IN WHAT ARE TALKING 7054 04:36:30,352 --> 04:36:32,521 ABOUT. 7055 04:36:32,521 --> 04:36:35,257 PERHAPS GOAL #4 IS A LITTLE 7056 04:36:35,257 --> 04:36:38,593 LESS TANGIBLE BECAUSE IT'S SO 7057 04:36:38,593 --> 04:36:40,028 CROSS-CUTTING MAYBE THAT'S WHY 7058 04:36:40,028 --> 04:36:41,029 IT WASN'T NECESSARILY CALLED 7059 04:36:41,029 --> 04:36:42,531 OUT SPECIFICKLY. 7060 04:36:42,531 --> 04:36:44,399 BUT I THINK THAT MAKES A LOT OF 7061 04:36:44,399 --> 04:36:47,702 SENSE IN MANY WAYS. 7062 04:36:47,702 --> 04:36:49,304 IT'S IMPORTANT TO THAT COST TO 7063 04:36:49,304 --> 04:36:52,007 NATURE, I WILL TELL YOU WHEN I 7064 04:36:52,007 --> 04:36:55,076 WAS REALLY EXCITED WHEN I HAD 7065 04:36:55,076 --> 04:36:57,078 THE ENGAGEMENT WITH THE IC 7066 04:36:57,078 --> 04:37:02,217 DIRECTORS THEY WERE EXCITED 7067 04:37:02,217 --> 04:37:07,088 ABOUT GOAL #5 ADVANCING 7068 04:37:07,088 --> 04:37:09,291 TRANSLATIONING SCIENCES. 7069 04:37:09,291 --> 04:37:14,930 I HOPE WE CAN REALLY LIVE UP TO 7070 04:37:14,930 --> 04:37:16,298 THE PROMISES WE EXPECT 7071 04:37:16,298 --> 04:37:17,499 OURSELVES TO MAKE ON THESE 7072 04:37:17,499 --> 04:37:19,534 ACTIVITIES. 7073 04:37:19,534 --> 04:37:21,636 I LIKE TO SAY, THESE ARE BIG 7074 04:37:21,636 --> 04:37:22,704 GOALS. 7075 04:37:22,704 --> 04:37:24,839 AND WE ARE PROBABLY GOING TO 7076 04:37:24,839 --> 04:37:26,875 FAIL ON SOME ASPECTS OF THEM. 7077 04:37:26,875 --> 04:37:28,176 WE MAY NOT HIT THE MARK ON ALL 7078 04:37:28,176 --> 04:37:29,177 OF THEM. 7079 04:37:29,177 --> 04:37:30,645 BUT WE ARE GOING TO BE TRYING 7080 04:37:30,645 --> 04:37:31,846 FOR THEM. 7081 04:37:31,846 --> 04:37:34,649 AS LONG AS WE ARE TRYING FOR 7082 04:37:34,649 --> 04:37:35,984 THEM, THEY WILL BE MOVING 7083 04:37:35,984 --> 04:37:37,786 FORWARD, THAT MEANS WE WILL 7084 04:37:37,786 --> 04:37:39,788 FAIL FORWARD AND LEARN FROM 7085 04:37:39,788 --> 04:37:41,256 THAT AND REDIRECT AND HOPEFULLY 7086 04:37:41,256 --> 04:37:43,959 CONTINUE MAKING PROGRESS. 7087 04:37:43,959 --> 04:37:46,695 AND I THINK MATT HALL SAID THIS 7088 04:37:46,695 --> 04:37:47,896 IN HIS PRESENTATION TOO, WANT 7089 04:37:47,896 --> 04:37:50,131 TO TAKE THE MIND SET THAT WE 7090 04:37:50,131 --> 04:37:51,833 CAN FAIL AND WE CAN FAIL 7091 04:37:51,833 --> 04:37:54,336 FORWARD AND THAT'S THE WAY WE 7092 04:37:54,336 --> 04:37:55,770 WILL MAKE THOSE ADVANCES IN A 7093 04:37:55,770 --> 04:37:57,005 WAY THAT WILL BE VERY VALUABLE 7094 04:37:57,005 --> 04:37:57,973 TO THE COMMUNITY. 7095 04:37:57,973 --> 04:38:00,208 SO THANK YOU FOR THAT INPUT. 7096 04:38:00,208 --> 04:38:01,576 ARE THERE ANY OTHER COMMENTS 7097 04:38:01,576 --> 04:38:05,680 THAT YOU HAVE? 7098 04:38:05,680 --> 04:38:07,549 ANYTHING MISSING THE MARK? 7099 04:38:07,549 --> 04:38:09,884 OR ANY SPECIFIC GOALS YOU WANT 7100 04:38:09,884 --> 04:38:11,786 TO CALL OUT WHILE WE HAVE YOU 7101 04:38:11,786 --> 04:38:18,793 HERE FOR THIS DISCUSSION? 7102 04:38:18,793 --> 04:38:20,929 >> JONI, MAYBE I CAN ADD A 7103 04:38:20,929 --> 04:38:21,830 COUPLE THINGS WHILE FOLKS ARE 7104 04:38:21,830 --> 04:38:24,366 THINKING ABOUT THAT. 7105 04:38:24,366 --> 04:38:26,268 LIKE YOU, I'M NOT SURPRISED #4 7106 04:38:26,268 --> 04:38:27,702 WAS THE HARDEST FOR US TO TRY 7107 04:38:27,702 --> 04:38:28,870 TO FIGURE OUT HOW TO DO. 7108 04:38:28,870 --> 04:38:31,139 SO ONE OF THE THINGS I LOVE 7109 04:38:31,139 --> 04:38:33,241 BEING AT NCATS AND I WILL 7110 04:38:33,241 --> 04:38:36,344 DISCLOSE THIS IS MY SIXTH OR 7111 04:38:36,344 --> 04:38:39,080 SEVENTH IC AT NIH, I HAVE BEEN 7112 04:38:39,080 --> 04:38:43,451 IN SOME OTHER PLACES. 7113 04:38:43,451 --> 04:38:45,387 BUT I THINK IS HOW WE DON'T 7114 04:38:45,387 --> 04:38:47,589 SILO, RIGHT? 7115 04:38:47,589 --> 04:38:48,189 THAT'S SOMETHING WE ACTIVELY 7116 04:38:48,189 --> 04:38:49,224 WORK AGAINST. 7117 04:38:49,224 --> 04:38:50,325 SOMETHING WE HEARD FROM OUR 7118 04:38:50,325 --> 04:38:51,493 CONSTITUENTS. 7119 04:38:51,493 --> 04:38:52,961 SO IT'S REALLY NICE WHEN YOU 7120 04:38:52,961 --> 04:38:55,730 CAN HAVE A STRATEGIC PLAN THAT 7121 04:38:55,730 --> 04:38:57,232 MAPS PERFECTLY TO YOUR 7122 04:38:57,232 --> 04:38:58,667 ORGANIZATION, RIGHT? 7123 04:38:58,667 --> 04:39:01,102 AND WE WERE TRYING TO DO BOTH 7124 04:39:01,102 --> 04:39:02,804 THINGS, RIGHT IS THIS SEE HOW 7125 04:39:02,804 --> 04:39:04,639 WE DO THINGS AS A TEAM. 7126 04:39:04,639 --> 04:39:06,741 MATT SORT OF CHIMED IN ON THIS 7127 04:39:06,741 --> 04:39:08,176 IN HIS PRESENTATION ABOUT, HE 7128 04:39:08,176 --> 04:39:09,678 HAS GOT A STRUCTURE BUT THEN 7129 04:39:09,678 --> 04:39:11,579 PEOPLE CROSS THAT ALL THE TIME 7130 04:39:11,579 --> 04:39:12,647 TO SOLVE THE PROBLEMS THAT WE 7131 04:39:12,647 --> 04:39:13,815 ARE WORKING ON. 7132 04:39:13,815 --> 04:39:15,750 SO WE ARE TRYING TO REFLECT 7133 04:39:15,750 --> 04:39:17,285 THAT IN OUR PLAN. 7134 04:39:17,285 --> 04:39:19,254 WHICH MAKES IT HARD BECAUSE 7135 04:39:19,254 --> 04:39:21,790 THERE'S A DESIRE TO WANT TO PUT 7136 04:39:21,790 --> 04:39:23,425 THEM IN ONE PLACE AND THEY ONLY 7137 04:39:23,425 --> 04:39:24,459 LIVE IN THAT ONE PLACE OR THAT 7138 04:39:24,459 --> 04:39:25,527 ONE GOAL. 7139 04:39:25,527 --> 04:39:28,263 BUT WE DO SEE THIS AS A LIVING 7140 04:39:28,263 --> 04:39:29,931 BREATHING DOCUMENT WHERE THE 7141 04:39:29,931 --> 04:39:31,199 GOALS, ESPECIALLY THE 7142 04:39:31,199 --> 04:39:31,833 OBJECTIVES UNDER #4 WILL CROSS 7143 04:39:31,833 --> 04:39:32,934 CUT. 7144 04:39:32,934 --> 04:39:34,636 AND OTHER THINGS WILL TOO, WE 7145 04:39:34,636 --> 04:39:37,372 PICKED SOME PLACES, ESPECIALLY 7146 04:39:37,372 --> 04:39:39,374 IN GOALS 1-3 TO PUT THEM THERE 7147 04:39:39,374 --> 04:39:40,909 BECAUSE WE FELT THE MAJORITY OF 7148 04:39:40,909 --> 04:39:43,011 THE WORK WE ARE DOING OR 7149 04:39:43,011 --> 04:39:45,013 ENVISION DOING OVER THE NEXT 7150 04:39:45,013 --> 04:39:46,781 5-10 YEARS WOULD BE IN THAT 7151 04:39:46,781 --> 04:39:48,683 SPACE BUT NOT WITH THE THOUGHT 7152 04:39:48,683 --> 04:39:50,452 WE WOULD BE LIMIT TO OURSELVES 7153 04:39:50,452 --> 04:39:51,319 AND TO OUR COMMUNITIES IN THAT 7154 04:39:51,319 --> 04:39:52,220 WAY. 7155 04:39:52,220 --> 04:39:53,621 SO THAT WAS ONE POINT. 7156 04:39:53,621 --> 04:39:55,557 THE OTHER THING I WANTED TO 7157 04:39:55,557 --> 04:39:56,658 REITERATE I KNOW WE TALKED 7158 04:39:56,658 --> 04:40:00,095 ABOUT BEFORE WITH THE PLAN IS, 7159 04:40:00,095 --> 04:40:01,996 YOUR VIEW, JONI, AND MINE AS 7160 04:40:01,996 --> 04:40:03,331 WELL IS NOT SUPPOSED TO BE 7161 04:40:03,331 --> 04:40:05,433 SOMETHING THAT IS JUST PUT ON 7162 04:40:05,433 --> 04:40:07,035 THE SHELF, WE'RE DONE NOW, WE 7163 04:40:07,035 --> 04:40:09,270 ARE GOING TO RELEASE IT 7164 04:40:09,270 --> 04:40:10,472 PERMANENTLY AND WE ARE 7165 04:40:10,472 --> 04:40:11,106 TARGETING JULY, OKAY, YOU KNOW. 7166 04:40:11,106 --> 04:40:12,807 NO. 7167 04:40:12,807 --> 04:40:14,909 WE VERY MUCH ARE GOING TO PLAN 7168 04:40:14,909 --> 04:40:16,277 AS PART OF THE IMPLEMENTATION 7169 04:40:16,277 --> 04:40:18,279 TO BE EC WHICHING IN WITH 7170 04:40:18,279 --> 04:40:20,548 OURSELVES AND WITH YOU ALL HOW 7171 04:40:20,548 --> 04:40:22,817 WE ARE MAKING PROCESS. 7172 04:40:22,817 --> 04:40:24,252 THAT'S HOW TO JONI'S POINT WE 7173 04:40:24,252 --> 04:40:27,856 WILL KNOW IF WE ARE FAILING, IF 7174 04:40:27,856 --> 04:40:29,457 WE ARE MAKING THE MARK, IF WE 7175 04:40:29,457 --> 04:40:31,493 ARE NOT, AND WHAT WE ARE 7176 04:40:31,493 --> 04:40:33,328 LEARNING AT THE SAME TIME. 7177 04:40:33,328 --> 04:40:34,796 YOU WANT US TO KNOW THAT'S PART 7178 04:40:34,796 --> 04:40:36,164 OF THE GAME PLAN AS WELL. 7179 04:40:36,164 --> 04:40:38,800 >> Joni Rutter: OKAY, THANK YOU. 7180 04:40:38,800 --> 04:40:41,236 I SEE KELLY McVEARRY'S HAND IS 7181 04:40:41,236 --> 04:40:42,203 UP. 7182 04:40:42,203 --> 04:40:43,338 NOT SURE IF THAT WAS LEFT OVER. 7183 04:40:43,338 --> 04:40:44,439 >> NO. 7184 04:40:44,439 --> 04:40:45,840 >> Joni Rutter: SHE WAS VERY 7185 04:40:45,840 --> 04:40:48,676 CLEAR ABOUT HER NO. 7186 04:40:48,676 --> 04:40:51,312 AND SERGIO, PLEASE GO AHEAD. 7187 04:40:51,312 --> 04:40:53,181 >> SERGIO: KELLY, ARE YOU GOING 7188 04:40:53,181 --> 04:40:57,786 TO SHARE? 7189 04:40:57,786 --> 04:41:00,054 >> Joni Rutter: SHE SAID HER 7190 04:41:00,054 --> 04:41:03,224 COMMENT WAS FROM BEFORE. 7191 04:41:03,224 --> 04:41:04,826 >> SERGIO: OH. 7192 04:41:04,826 --> 04:41:06,561 WELL, THERE ARE SO MANY 7193 04:41:06,561 --> 04:41:07,162 POSITIVE THINGS IN STRATEGIC 7194 04:41:07,162 --> 04:41:08,997 PLAN. 7195 04:41:08,997 --> 04:41:10,799 I'M GOING TO ENDEAVOR TO READ 7196 04:41:10,799 --> 04:41:13,234 IT EVEN MORE CAREFULLY. 7197 04:41:13,234 --> 04:41:16,237 BUT ONE IMPRESSION THAT I GOT 7198 04:41:16,237 --> 04:41:22,076 BY READ IT THE WAY I DID, IN 7199 04:41:22,076 --> 04:41:24,646 THE QUESTION ARE ANY MISSING 7200 04:41:24,646 --> 04:41:28,283 THE MARK IS THAT I FELT THAT 7201 04:41:28,283 --> 04:41:31,553 THERE WAS NOT ENOUGH EMPHASIS 7202 04:41:31,553 --> 04:41:33,188 IN LOCAL COMMUNITIES, FOR 7203 04:41:33,188 --> 04:41:38,092 EXAMPLE, IN NEIGHBORHOODS. 7204 04:41:38,092 --> 04:41:46,367 AND YOU KNOW, THE FACTORS, FOR 7205 04:41:46,367 --> 04:41:50,538 EXAMPLE, THAT, YOU KNOW, ARE 7206 04:41:50,538 --> 04:41:52,440 CONTRIBUTE TO DISEASE. 7207 04:41:52,440 --> 04:41:55,543 KIND OF AN OPPORTUNITY TO 7208 04:41:55,543 --> 04:41:57,879 ASSESS AND INTERVENE IN THE 7209 04:41:57,879 --> 04:42:00,782 MANY FACTORS, ONCE AGAIN THAT 7210 04:42:00,782 --> 04:42:02,016 IMPACT HEALTH AND LEAD TO 7211 04:42:02,016 --> 04:42:03,051 DISPARITIES. 7212 04:42:03,051 --> 04:42:05,954 AND I THINK THIS IS IMPORTANT 7213 04:42:05,954 --> 04:42:08,156 IN TWO LIGHTS. 7214 04:42:08,156 --> 04:42:09,491 AND THAT'S THE OTHER PIECE THAT 7215 04:42:09,491 --> 04:42:10,825 I WANT TO BRING TO YOUR 7216 04:42:10,825 --> 04:42:15,063 ATTENTION. 7217 04:42:15,063 --> 04:42:20,268 I WAS POSITIVELY IMPRESSED WHEN 7218 04:42:20,268 --> 04:42:23,738 DR. BERTAGNOLLI, YOU KNOW, 7219 04:42:23,738 --> 04:42:31,813 JOINED US IN THE PREVIOUS. 7220 04:42:31,813 --> 04:42:32,947 I WAS IMPRESSED BECAUSE OF 7221 04:42:32,947 --> 04:42:34,449 SEVERAL REASONS. 7222 04:42:34,449 --> 04:42:36,351 ONE OF THEM IS HER BACKGROUND 7223 04:42:36,351 --> 04:42:38,653 AND EXPERIENCE. 7224 04:42:38,653 --> 04:42:39,254 LIVED EXPERIENCE ON COMMUNITY 7225 04:42:39,254 --> 04:42:39,554 ENGAGEMENT. 7226 04:42:39,554 --> 04:42:41,523 YOU KNOW. 7227 04:42:41,523 --> 04:42:44,025 IT WAS REALLY INSPIRING. 7228 04:42:44,025 --> 04:42:47,495 ONE OF THE THINGS SHE STARTED 7229 04:42:47,495 --> 04:42:54,335 WITH, THAT REALLY HAS RESONATED 7230 04:42:54,335 --> 04:42:56,638 WITH ME IS ABOUT THE BIG, BIG 7231 04:42:56,638 --> 04:42:58,706 PICTURE, WHAT IS GOING ON IN 7232 04:42:58,706 --> 04:43:01,309 THE U.S., DESPITE THE U.S. 7233 04:43:01,309 --> 04:43:03,411 INVESTING, WHAT 19% OF THE 7234 04:43:03,411 --> 04:43:04,212 GROSS DOMESTIC PRODUCT IN 7235 04:43:04,212 --> 04:43:06,481 HEALTH, THAT WE ARE NOT DOING 7236 04:43:06,481 --> 04:43:07,515 THAT WELL, COMPARED TO ANOTHER 7237 04:43:07,515 --> 04:43:13,555 NATIONS. 7238 04:43:13,555 --> 04:43:14,222 YOU KNOW, MORTALITY RATES, 7239 04:43:14,222 --> 04:43:15,557 MORBIDITY RATES. 7240 04:43:15,557 --> 04:43:16,224 SHE DECIDED TO SHARE THAT 7241 04:43:16,224 --> 04:43:22,697 INFORMATION WITH US. 7242 04:43:22,697 --> 04:43:23,298 BECAUSE OBVIOUSLY IT WEIGHS 7243 04:43:23,298 --> 04:43:28,269 IMPORTANTLY ON HER. 7244 04:43:28,269 --> 04:43:36,144 AND I WAS REMINDED ALSO OF WHAT 7245 04:43:36,144 --> 04:43:37,679 ROB GAELIS, FDA DIRECTOR NOW, 7246 04:43:37,679 --> 04:43:41,816 USE TO BE P.I. OF DUKE 7247 04:43:41,816 --> 04:43:43,117 UNIVERSITY, CTSA, THAT WHEN HE 7248 04:43:43,117 --> 04:43:45,954 PRESENTED TO US IN ONE OF THE 7249 04:43:45,954 --> 04:43:46,621 NATIONAL MEETINGS, IT WAS 7250 04:43:46,621 --> 04:43:47,655 EXACTLY THE SAME THING. 7251 04:43:47,655 --> 04:43:48,289 THE SAME TOPIC. 7252 04:43:48,289 --> 04:43:52,193 YOU KNOW. 7253 04:43:52,193 --> 04:43:53,494 OF ALL THE THINGS HE COULD HAVE 7254 04:43:53,494 --> 04:43:55,330 PRESENTED. 7255 04:43:55,330 --> 04:43:57,265 THOSE ARE BIG PICTURES THAT I 7256 04:43:57,265 --> 04:44:02,403 WOULD LOVE TO SEE THEM INCLUDED 7257 04:44:02,403 --> 04:44:03,438 IN THE STRATEGIC PLANNING, IN 7258 04:44:03,438 --> 04:44:07,909 SOME WAYS. 7259 04:44:07,909 --> 04:44:09,811 BIG PICTURES, BUT YOU KNOW, WE 7260 04:44:09,811 --> 04:44:10,812 ARE CONTRIBUTING TOWARDS THAT 7261 04:44:10,812 --> 04:44:18,853 AND WE COULD BE PART OF THE 7262 04:44:18,853 --> 04:44:20,021 SOLUTION FOR MEGATRENDS THAT 7263 04:44:20,021 --> 04:44:25,994 ARE HAPPENING IN THE U.S. 7264 04:44:25,994 --> 04:44:27,662 RELATED TO HEALTH, MORTALITY, 7265 04:44:27,662 --> 04:44:28,262 TRUNCATED LIFE EXPECTANCY, ET 7266 04:44:28,262 --> 04:44:35,737 CETERA. 7267 04:44:35,737 --> 04:44:39,807 >> Joni Rutter: THANK YOU VERY 7268 04:44:39,807 --> 04:44:40,675 MUCH, SERGIO, I COMPLETELY 7269 04:44:40,675 --> 04:44:41,242 AGREE, AND APPRECIATE YOUR 7270 04:44:41,242 --> 04:44:41,776 COMMENTS. 7271 04:44:41,776 --> 04:44:43,578 IT'S AN OPPORTUNITY FOR US. 7272 04:44:43,578 --> 04:44:44,646 WHEN WE DEVELOPED THE STRATEGIC 7273 04:44:44,646 --> 04:44:50,284 PLAN WE DIDN'T HAVE THE SORT OF 7274 04:44:50,284 --> 04:44:51,085 LUXURY OF HAVING DR. 7275 04:44:51,085 --> 04:44:51,686 BERTAGNOLLI'S VISION AT THE 7276 04:44:51,686 --> 04:44:53,454 TIME WE STARTED. 7277 04:44:53,454 --> 04:44:55,456 BUT WHAT WE NOW HAVE IS THE 7278 04:44:55,456 --> 04:44:57,258 OPPORTUNITY TO ENSURE WE ARE 7279 04:44:57,258 --> 04:44:57,759 INTEGRATING THAT IN OUR 7280 04:44:57,759 --> 04:44:58,993 THINKING. 7281 04:44:58,993 --> 04:44:59,927 I THINK THERE'S OPPORTUNITIES 7282 04:44:59,927 --> 04:45:01,496 FOR US TO DO THAT TO GET TO 7283 04:45:01,496 --> 04:45:03,464 YOUR POINT. 7284 04:45:03,464 --> 04:45:05,967 AND RECOGNIZING IT'S A BIG 7285 04:45:05,967 --> 04:45:07,168 PICTURE BUT CERTAINLY AS PART 7286 04:45:07,168 --> 04:45:13,541 OF WHAT WE ARE DOING IN 7287 04:45:13,541 --> 04:45:14,642 ADDRESSING HER VISION, YOU 7288 04:45:14,642 --> 04:45:15,643 KNOW, WORKING WITH HER CLOSELY 7289 04:45:15,643 --> 04:45:18,279 ON THAT, I THINK WE HAVE A VERY 7290 04:45:18,279 --> 04:45:20,281 GOOD OPPORTUNITY TO THINK ABOUT 7291 04:45:20,281 --> 04:45:26,254 HOW WE WORK MORE CLOSELY WITH 7292 04:45:26,254 --> 04:45:27,989 PRIMARY CARE NETWORKS IN 7293 04:45:27,989 --> 04:45:29,057 FEDERALLY QUALIFIED HEALTH 7294 04:45:29,057 --> 04:45:30,758 SYSTEMS AND HEALTH CENTERS. 7295 04:45:30,758 --> 04:45:33,428 AND HERE I SEE A REAL VALUE IN 7296 04:45:33,428 --> 04:45:34,028 THE COMMUNITY ADVISORY BOARD 7297 04:45:34,028 --> 04:45:38,466 MEMBER SHIP. 7298 04:45:38,466 --> 04:45:40,501 AND PERHAPS IN SOME WAY IS 7299 04:45:40,501 --> 04:45:42,437 EXTENDING SOME OF THE WORK THAT 7300 04:45:42,437 --> 04:45:44,238 THEY DO IN HELPING TO RAISE 7301 04:45:44,238 --> 04:45:46,574 VOICES AND HOW THEY WORK WITH 7302 04:45:46,574 --> 04:45:48,309 THEIR OWN COMMUNITIES WITHIN 7303 04:45:48,309 --> 04:45:49,110 THE CTSA PROGRAM. 7304 04:45:49,110 --> 04:45:51,212 I WOULD LOVE TO SEE WAYS IN 7305 04:45:51,212 --> 04:45:51,846 WHICH WE COULD REALLY ENHANCE 7306 04:45:51,846 --> 04:45:52,513 THAT. 7307 04:45:52,513 --> 04:45:55,383 I THINK THERE ARE A VARIETY OF 7308 04:45:55,383 --> 04:45:56,350 OPPORTUNITIES OF HOW WE CAN GET 7309 04:45:56,350 --> 04:45:58,786 THERE. 7310 04:45:58,786 --> 04:46:01,022 DID YOU SAY PERHAPS WHERE THAT 7311 04:46:01,022 --> 04:46:03,257 MIGHT, YOU THINK THAT IS 7312 04:46:03,257 --> 04:46:04,625 PROBABLY MOSTLY IN GOAL #2? 7313 04:46:04,625 --> 04:46:05,526 I THINK THAT MAKES A LOT OF 7314 04:46:05,526 --> 04:46:05,760 SENSE. 7315 04:46:05,760 --> 04:46:10,998 >> YES. 7316 04:46:10,998 --> 04:46:13,134 I'M THINKING ON GOAL #2. 7317 04:46:13,134 --> 04:46:18,072 ALONG WITH, ONCE AGAIN THE 7318 04:46:18,072 --> 04:46:20,108 EMPHASIS ON BUILDING TRUST AS, 7319 04:46:20,108 --> 04:46:24,645 YOU KNOW, WE ENGAGE WITH ALL 7320 04:46:24,645 --> 04:46:27,081 THAT CAN POTENTIALLY BENEFIT. 7321 04:46:27,081 --> 04:46:30,051 AND THAT ALSO, I THINK THAT IN 7322 04:46:30,051 --> 04:46:32,320 #5. 7323 04:46:32,320 --> 04:46:34,255 >> Joni Rutter: #5, YEAH. 7324 04:46:34,255 --> 04:46:35,957 >> SERGIO: WHICH IS AT THE 7325 04:46:35,957 --> 04:46:40,194 HEART OF WHAT WE ARE DOING. 7326 04:46:40,194 --> 04:46:44,899 THE TRANSLATIONAL WORK WE HAVE 7327 04:46:44,899 --> 04:46:46,400 BEEN ENGAGED WITH. 7328 04:46:46,400 --> 04:46:47,401 THOSE ARE THE PLACES. 7329 04:46:47,401 --> 04:46:49,437 AND I WILL CONTINUE TO SEND 7330 04:46:49,437 --> 04:46:50,271 SOME COMMENTS. 7331 04:46:50,271 --> 04:46:50,905 >> THAT WOULD BE GREAT. 7332 04:46:50,905 --> 04:46:51,706 >> Joni Rutter: THAT WOULD BE 7333 04:46:51,706 --> 04:46:53,174 GREAT. 7334 04:46:53,174 --> 04:46:54,542 ACTUALLY, IF YOU WOULD LIKE, 7335 04:46:54,542 --> 04:46:56,144 PLEASE ALSO, WE HAVE CERTAINLY 7336 04:46:56,144 --> 04:46:57,812 TAKEN A LOT OF NOTES. 7337 04:46:57,812 --> 04:47:00,014 I'VE WRITTEN DOWN A VARIETY OF 7338 04:47:00,014 --> 04:47:02,316 THINGS BUT IF YOU WOULD LIKE TO 7339 04:47:02,316 --> 04:47:04,552 ALSO SEND US A NOTE AS WELL TO 7340 04:47:04,552 --> 04:47:05,186 FOLLOW-UP, THAT WOULD BE 7341 04:47:05,186 --> 04:47:06,287 FANTASTIC. 7342 04:47:06,287 --> 04:47:08,289 PLUS YOU HAVE THE BENEFIT OF 7343 04:47:08,289 --> 04:47:09,490 HEARING THE CONVERSATION AND 7344 04:47:09,490 --> 04:47:12,627 HAVE UNTIL THE MIDDLE OF JUNE 7345 04:47:12,627 --> 04:47:14,529 UNTIL THEY ARE FINALIZED BEFORE 7346 04:47:14,529 --> 04:47:17,765 WE WRAP IT UP AND HOPEFULLY GET 7347 04:47:17,765 --> 04:47:21,335 THIS POLISHED AND THEN OUT TO 7348 04:47:21,335 --> 04:47:22,570 THE PUBLIC FOR THE FINAL 7349 04:47:22,570 --> 04:47:24,038 STRATEGIC PLAN. 7350 04:47:24,038 --> 04:47:25,306 >> AND THEN GETTING TO THE 7351 04:47:25,306 --> 04:47:28,576 STRATEGIC DOING. 7352 04:47:28,576 --> 04:47:29,811 >> Joni Rutter: THAT'S RIGHT. 7353 04:47:29,811 --> 04:47:31,779 STRATEGIC PLANNING IS IMPORTANT. 7354 04:47:31,779 --> 04:47:33,147 BUT I REALLY WANT TO GET TO THE 7355 04:47:33,147 --> 04:47:35,049 STRATEGIC DOING. 7356 04:47:35,049 --> 04:47:39,387 OKAY. 7357 04:47:39,387 --> 04:47:40,054 ANY OTHER COMMENTS BEFORE WE 7358 04:47:40,054 --> 04:47:42,323 END HERE? 7359 04:47:42,323 --> 04:47:44,091 YEAH, DR. MUELLER? 7360 04:47:44,091 --> 04:47:49,397 >> A COUPLE MORE COMMENTS ON 7361 04:47:49,397 --> 04:47:50,965 GOAL #2, OBJECTIVES #2 AND #3, 7362 04:47:50,965 --> 04:47:53,334 I GUESS IT IS. 7363 04:47:53,334 --> 04:47:55,469 THING THAT'S ARE BOTH EXCITING 7364 04:47:55,469 --> 04:47:57,605 AND INCREDIBLY CHALLENGING. 7365 04:47:57,605 --> 04:47:58,806 ENGAGING CONSTITUENTS THAT ARE 7366 04:47:58,806 --> 04:48:02,210 HARD TO REACH IN HARD TO REACH 7367 04:48:02,210 --> 04:48:02,710 COMMUNITIES, THAT'S IN 7368 04:48:02,710 --> 04:48:05,279 OBJECTIVE 2.2. 7369 04:48:05,279 --> 04:48:07,682 AND AN IMPORTANT APPROACH OF 7370 04:48:07,682 --> 04:48:10,017 USING DIGITAL HEALTH 7371 04:48:10,017 --> 04:48:10,518 TECHNOLOGIES TO SUPPORT 7372 04:48:10,518 --> 04:48:11,519 DECENTRALIZED TRIALS. 7373 04:48:11,519 --> 04:48:13,154 THE THIRD OBJECTIVE. 7374 04:48:13,154 --> 04:48:14,655 AND I I'M THINKING OF WORK WE 7375 04:48:14,655 --> 04:48:17,458 ARE DOING RIGHT NOW WITH OUR 7376 04:48:17,458 --> 04:48:18,893 NATIONAL ADVISORY COMMITTEE ON 7377 04:48:18,893 --> 04:48:20,428 RURAL HEALTH AND HUMAN SERVICES 7378 04:48:20,428 --> 04:48:22,430 OF THE USE OF TECHNOLOGY TO 7379 04:48:22,430 --> 04:48:24,232 OVERCOME SOME OF THE ACCESS 7380 04:48:24,232 --> 04:48:26,601 BARRIERS WE HAVE IN RURAL AND 7381 04:48:26,601 --> 04:48:29,804 UNDERSERVED COMMUNITIES. 7382 04:48:29,804 --> 04:48:31,973 AND I THINK ABOUT THE 7383 04:48:31,973 --> 04:48:33,441 DISCUSSIONS WE HAD HERE ABOUT A 7384 04:48:33,441 --> 04:48:35,309 PRIZE OF DEVELOPING THE RIGHT 7385 04:48:35,309 --> 04:48:36,544 TECHNOLOGY IN THE CONTEXT OF 7386 04:48:36,544 --> 04:48:38,212 EVERYTHING THAT NCATS DOES. 7387 04:48:38,212 --> 04:48:39,580 WE TALKED ABOUT THAT MODEL A 7388 04:48:39,580 --> 04:48:43,451 LITTLE BIT TO TRY TO GET 7389 04:48:43,451 --> 04:48:45,253 TECHNOLOGY THAT GOT RURAL 7390 04:48:45,253 --> 04:48:48,990 PATIENTS AND RURAL PERSONS MORE 7391 04:48:48,990 --> 04:48:49,857 ENGAGED WITH THE HEALTHCARE 7392 04:48:49,857 --> 04:48:52,159 DELIVERY SYSTEM. 7393 04:48:52,159 --> 04:48:53,794 BOTH APPLAUDING PUTTING THESE 7394 04:48:53,794 --> 04:48:56,797 THINGS IN THE OBJECTIVES AND 7395 04:48:56,797 --> 04:48:57,832 THROWING OUT THE BIG YELLOW 7396 04:48:57,832 --> 04:48:58,733 FLAG OF WHAT WILL BE DARNED 7397 04:48:58,733 --> 04:49:00,001 DIFFICULT. 7398 04:49:00,001 --> 04:49:01,836 A LOT OF US WILL BE RIGHT THERE 7399 04:49:01,836 --> 04:49:03,437 WITH YOU TO TRY TO GET THAT 7400 04:49:03,437 --> 04:49:03,971 ACCOMPLISHED. 7401 04:49:03,971 --> 04:49:04,705 >> Joni Rutter: THANK YOU FOR 7402 04:49:04,705 --> 04:49:05,673 THAT. 7403 04:49:05,673 --> 04:49:07,508 AND THANK YOU FOR RECOGNIZING 7404 04:49:07,508 --> 04:49:09,744 THE DIFFICULTIES OF THAT TOO, 7405 04:49:09,744 --> 04:49:11,579 THIS IS ALSO WHY WE WANTED TO 7406 04:49:11,579 --> 04:49:12,780 CO-DESIGN THIS. 7407 04:49:12,780 --> 04:49:15,983 WE NEED ALL OF YOUR HELP TO 7408 04:49:15,983 --> 04:49:17,919 MAKE IT AS SUCCESSFUL AS IT 7409 04:49:17,919 --> 04:49:19,153 POSSIBLY COULD BE. 7410 04:49:19,153 --> 04:49:22,056 SO IF YOU SEE YOURSELF IN THE 7411 04:49:22,056 --> 04:49:23,791 PLAN ITSELF, THAT WILL HELP US 7412 04:49:23,791 --> 04:49:25,092 ACCOMPLISH MORE TOGETHER. 7413 04:49:25,092 --> 04:49:28,296 AND YOU SHARE YOUR PASSION WITH 7414 04:49:28,296 --> 04:49:30,298 THE RURAL HEALTH AND THE RURAL 7415 04:49:30,298 --> 04:49:33,434 DELIVERY SYSTEMS TOO. 7416 04:49:33,434 --> 04:49:36,904 SINCE I SHARE MY ROOTS IN THE 7417 04:49:36,904 --> 04:49:38,439 RURAL COMMUNITY, SO I THINK 7418 04:49:38,439 --> 04:49:43,778 THAT'S INCREDIBLY IMPORTANT. 7419 04:49:43,778 --> 04:49:45,613 SO THANK YOU FOR THAT. 7420 04:49:45,613 --> 04:49:52,553 ANY OTHER COMMENTS FROM COUNCIL? 7421 04:49:52,553 --> 04:49:55,089 SERGIO? 7422 04:49:55,089 --> 04:49:56,991 >> SERGIO: JUST A VERY BRIEF 7423 04:49:56,991 --> 04:49:59,860 COMMENT TO THE EXCELLENT 7424 04:49:59,860 --> 04:50:00,661 COMMENTS THAT DR. MUELLER JUST 7425 04:50:00,661 --> 04:50:02,630 SHARED WITH US. 7426 04:50:02,630 --> 04:50:07,702 AND THAT IS, I USED TO USE 7427 04:50:07,702 --> 04:50:10,438 ALSO, FOR YEARS, I USED THE 7428 04:50:10,438 --> 04:50:14,175 HARD-TO-REACH POPULATIONS. 7429 04:50:14,175 --> 04:50:18,579 BUT I'M NOW CONVINCED THAT, AND 7430 04:50:18,579 --> 04:50:19,780 PREFER TO USE HARDLY REACHED 7431 04:50:19,780 --> 04:50:22,149 POPULATIONS. 7432 04:50:22,149 --> 04:50:26,287 IF WE USE HARD-TO-REACH, WE PUT 7433 04:50:26,287 --> 04:50:27,655 THE ONUS ON THOSE POPULATIONS, 7434 04:50:27,655 --> 04:50:29,824 WHEN THE ONUS IS ON US WHAT 7435 04:50:29,824 --> 04:50:31,092 EFFORTS CAN WE MAKE TO REALLY 7436 04:50:31,092 --> 04:50:33,294 GET TO THEM. 7437 04:50:33,294 --> 04:50:35,663 BECAUSE I'M THOROUGHLY 7438 04:50:35,663 --> 04:50:36,597 CONVINCED, ESPECIALLY DURING 7439 04:50:36,597 --> 04:50:37,498 THE PANDEMIC THAT WE CAN REACH 7440 04:50:37,498 --> 04:50:39,834 THEM. 7441 04:50:39,834 --> 04:50:49,210 IF WE JUST ENDEAVOR OURSELVES 7442 04:50:49,210 --> 04:50:50,644 AND PUTTING OUR RESOURCES TO 7443 04:50:50,644 --> 04:50:53,981 IT, I'M STOPPING NOW. 7444 04:50:53,981 --> 04:50:55,449 >> Joni Rutter: THANK YOU, I 7445 04:50:55,449 --> 04:50:57,718 WAS THINKING THE SAME THING. 7446 04:50:57,718 --> 04:50:59,720 IF WE HAVEN'T REACHED IT'S 7447 04:50:59,720 --> 04:51:01,222 BECAUSE PERHAPS WE HAVEN'T 7448 04:51:01,222 --> 04:51:03,357 TRIED TO REACH HARD ENOUGH. 7449 04:51:03,357 --> 04:51:05,893 I THINK THIS OFFERS US AN 7450 04:51:05,893 --> 04:51:08,329 OPPORTUNITY FOR BEING A LITTLE 7451 04:51:08,329 --> 04:51:11,065 MORE CREATIVE HOW WE THINK 7452 04:51:11,065 --> 04:51:11,766 ABOUT THOSE COMMUNITIES WE 7453 04:51:11,766 --> 04:51:12,666 THINK ARE HARD TO REACH. 7454 04:51:12,666 --> 04:51:14,268 THANK YOU FOR THAT. 7455 04:51:14,268 --> 04:51:15,903 I THINK WE ARE DEFINITELY 7456 04:51:15,903 --> 04:51:19,140 HAVING A MIND MELD THERE, I 7457 04:51:19,140 --> 04:51:19,673 APPRECIATE THE COMMENTS 7458 04:51:19,673 --> 04:51:21,475 BRINGING THAT UP TOO. 7459 04:51:21,475 --> 04:51:24,512 I TOOK JUST HIGH LEVEL THINKING 7460 04:51:24,512 --> 04:51:27,815 ABOUT TRUST BEING SORT OF, IT'S 7461 04:51:27,815 --> 04:51:30,051 CERTAINLY IN THIS DOCUMENT AND 7462 04:51:30,051 --> 04:51:32,553 INFUSED PERHAPS A LITTLE MORE 7463 04:51:32,553 --> 04:51:33,254 RECOGNITION AROUND BEING 7464 04:51:33,254 --> 04:51:35,523 TRUSTWORTHY TO THE COMMUNITY. 7465 04:51:35,523 --> 04:51:37,825 AND, THINKING ABOUT A LITTLE 7466 04:51:37,825 --> 04:51:39,060 MORE INTEREST ABOUT THE 7467 04:51:39,060 --> 04:51:40,261 IMPORTANCE OF THE LOCAL 7468 04:51:40,261 --> 04:51:43,597 COMMUNITY AND FOCUSING ON THE 7469 04:51:43,597 --> 04:51:44,432 SOLUTIONS WITH THOSE MORE LOCAL 7470 04:51:44,432 --> 04:51:45,699 COMMUNITIES. 7471 04:51:45,699 --> 04:51:47,001 INFUSING SOME OF THE IDEAS THAT 7472 04:51:47,001 --> 04:51:49,737 WE ARE HEARING A LITTLE BIT 7473 04:51:49,737 --> 04:51:52,239 MORE FROM THE NIH STRATEGIC 7474 04:51:52,239 --> 04:51:54,308 DIRECTION IN THINKING ABOUT THE 7475 04:51:54,308 --> 04:51:55,042 PRIMARY CARE DIRECTION AND 7476 04:51:55,042 --> 04:51:57,945 REALLY ENGAGING THAT PIECE OF 7477 04:51:57,945 --> 04:52:04,185 THE COMMUNITY, SO THAT WE DON'T 7478 04:52:04,185 --> 04:52:06,220 CONTINUE TO, EXPAND INEQUITIES 7479 04:52:06,220 --> 04:52:09,023 BUT REALLY ADDRESS THE 7480 04:52:09,023 --> 04:52:11,292 INEQUITIES SO WE ARE GEARING 7481 04:52:11,292 --> 04:52:12,960 MORE TOWARDS HEALTH EQUITY. 7482 04:52:12,960 --> 04:52:16,197 AND THEN THINKING ABOUT HOW THE 7483 04:52:16,197 --> 04:52:18,799 MORE QUICKLY SIDE OF THINGS IN 7484 04:52:18,799 --> 04:52:26,540 3.1 AND 3.2. 7485 04:52:26,540 --> 04:52:29,376 PAUL MENTIONED THOSE ARE VERY 7486 04:52:29,376 --> 04:52:30,478 NCATSIAN. 7487 04:52:30,478 --> 04:52:33,347 LINING UP WITH THE CORE MISSION 7488 04:52:33,347 --> 04:52:35,349 OF INCLUSIVITY AROUND ALL OF 7489 04:52:35,349 --> 04:52:37,151 THE DIFFERENT MESSAGES AND I 7490 04:52:37,151 --> 04:52:38,853 THINK THAT WAS KELLY'S COMMENT 7491 04:52:38,853 --> 04:52:41,689 ABOUT THIS SORT OF MORE 7492 04:52:41,689 --> 04:52:43,624 TREATMENTS FOR MORE PEOPLE MORE 7493 04:52:43,624 --> 04:52:45,259 QUICKLY, I THINK TO SAY THESE 7494 04:52:45,259 --> 04:52:52,900 GOALS QUICKLY. 7495 04:52:52,900 --> 04:52:54,735 BUT ALSO MESSAGING THE 7496 04:52:54,735 --> 04:52:59,073 INCLUSIVENESS THAT IT TAKES TO 7497 04:52:59,073 --> 04:53:01,275 DO IT, IT'S TIME THAT GENERATES 7498 04:53:01,275 --> 04:53:04,044 THE MOST PRODUCTIVE SCIENCE. 7499 04:53:04,044 --> 04:53:05,246 THE HARDLY REACHED POPULATIONS 7500 04:53:05,246 --> 04:53:07,148 WE SHOULD PROBABLY ADDRESS THAT. 7501 04:53:07,148 --> 04:53:09,283 THE USE OF TECHNOLOGY AND 7502 04:53:09,283 --> 04:53:10,985 ACCESS BARRIERS AND PERHAPS 7503 04:53:10,985 --> 04:53:12,219 LOOKING TO RURAL COMMUNITIES TO 7504 04:53:12,219 --> 04:53:13,921 HELP US ADDRESS AND ANSWER 7505 04:53:13,921 --> 04:53:15,656 THOSE CONCERNS FROM BOTH THE 7506 04:53:15,656 --> 04:53:20,127 HEALTH SIDE AND THE DELIVERY 7507 04:53:20,127 --> 04:53:21,395 SIDES. 7508 04:53:21,395 --> 04:53:23,130 SO THOSE ARE SOME HIGH LEVEL 7509 04:53:23,130 --> 04:53:24,098 COMMENTS BUT I KNOW WE TOUCHED 7510 04:53:24,098 --> 04:53:25,533 ON MORE. 7511 04:53:25,533 --> 04:53:28,369 I WANT TO REITERATE, WE ARE 7512 04:53:28,369 --> 04:53:30,771 OPEN STILL FOR INPUT ON THE 7513 04:53:30,771 --> 04:53:33,207 STRATEGIC PLAN FOR JUNE 14th. 7514 04:53:33,207 --> 04:53:35,075 PLEASE TELL ALL YOUR FRIENDS 7515 04:53:35,075 --> 04:53:39,013 AND FAMILY, IF YOU REALLY WANT 7516 04:53:39,013 --> 04:53:41,282 TO TELL YOUR FAMILY TO WEIGH 7517 04:53:41,282 --> 04:53:42,416 IN, THAT WOULD BE GREAT, THEY 7518 04:53:42,416 --> 04:53:44,351 ARE PART OF THE COMMUNITY. 7519 04:53:44,351 --> 04:53:45,553 WOULD APPRECIATE YOUR 7520 04:53:45,553 --> 04:53:46,420 ENGAGEMENT WITH YOUR COLLEAGUES 7521 04:53:46,420 --> 04:53:49,290 AND FRIENDS TOO. 7522 04:53:49,290 --> 04:53:53,227 SO WITH THAT, I THINK, IF THERE 7523 04:53:53,227 --> 04:53:55,229 ARE NO OTHER POINTS OF 7524 04:53:55,229 --> 04:53:55,963 DISCUSSION, WE CAN GO AHEAD AND 7525 04:53:55,963 --> 04:53:57,264 MOVE ON. 7526 04:53:57,264 --> 04:53:58,632 I BELIEVE THAT IS REALLY 7527 04:53:58,632 --> 04:53:59,900 WRAPPING UP TODAY. 7528 04:53:59,900 --> 04:54:03,003 AND WE ARE JUST A LITTLE OVER 7529 04:54:03,003 --> 04:54:04,338 FIVE MINUTES OVER. 7530 04:54:04,338 --> 04:54:06,440 SO WE DO HAVE ONE THING THAT'S 7531 04:54:06,440 --> 04:54:07,975 NOT ON OUR AGENDA TODAY THAT I 7532 04:54:07,975 --> 04:54:15,082 WANTED TO TURN IT OVER TO ANNA 7533 04:54:15,082 --> 04:54:15,416 TO INTRODUCE. 7534 04:54:15,416 --> 04:54:17,851 >> THANK YOU, JONI. 7535 04:54:17,851 --> 04:54:21,088 SO AS IS CASE FOR OPEN SESSIONS 7536 04:54:21,088 --> 04:54:23,624 THE FEDERAL ADVISORY COMMITTEE 7537 04:54:23,624 --> 04:54:24,625 MEETINGS WE DO HAVE AN 7538 04:54:24,625 --> 04:54:25,960 OPPORTUNITY TO HEAR FROM THE 7539 04:54:25,960 --> 04:54:28,095 PUBLIC, I WOULD LIKE TO EXTEND 7540 04:54:28,095 --> 04:54:30,197 AN OFFER TO A MEMBER OF THE 7541 04:54:30,197 --> 04:54:32,733 PUBLIC WHO HAS JOINED US TODAY, 7542 04:54:32,733 --> 04:54:38,372 SHE IS HEADING TO THE MIC, DR. 7543 04:54:38,372 --> 04:54:41,075 CATHERINE KREBS, WHO IS THE 7544 04:54:41,075 --> 04:54:41,609 PHYSICIANS COMMITTEE FOR 7545 04:54:41,609 --> 04:54:44,812 RESPONSIBLE MEDICINE. 7546 04:54:44,812 --> 04:54:54,989 >> HELLO. 7547 04:54:55,489 --> 04:55:00,728 HELLO, OKAY, HI, I'M CATHERINE 7548 04:55:00,728 --> 04:55:01,595 KREBS. 7549 04:55:01,595 --> 04:55:02,863 THANK YOU FOR OPPORTUNITY TO 7550 04:55:02,863 --> 04:55:05,566 PROVIDE INPUT. 7551 04:55:05,566 --> 04:55:16,043 THE COMMITTEE COMMENDS THE 7552 04:55:17,811 --> 04:55:18,379 SPECIFIC NON-ANIMAL RESEARCH AT 7553 04:55:18,379 --> 04:55:18,946 THE NIH, INCLUDING ONGOING 7554 04:55:18,946 --> 04:55:19,580 NCATS PROGRAM, NEWLY APPROVED 7555 04:55:19,580 --> 04:55:20,114 COMPLIMENTARY COMMON FUND 7556 04:55:20,114 --> 04:55:20,347 PROGRAM. 7557 04:55:20,347 --> 04:55:20,881 GREAT PROGRESS TO ADVANCE 7558 04:55:20,881 --> 04:55:21,448 WE WANT TO HIGHLIGHT THE 7559 04:55:21,448 --> 04:55:22,516 IMPORTANT ROLE THAT SCIENTIFIC 7560 04:55:22,516 --> 04:55:29,089 REVIEW PLAYS IN THE SUCCESSFUL 7561 04:55:29,089 --> 04:55:32,693 USE AND DEPLOYMENT OF NAMS AND 7562 04:55:32,693 --> 04:55:35,896 FEW MEASURES THAT CAN HELP 7563 04:55:35,896 --> 04:55:37,865 ENSURE NAMS ARE EVALUATED AND 7564 04:55:37,865 --> 04:55:41,835 SKRUKTIVE AND EQUITABLE MANNER. 7565 04:55:41,835 --> 04:55:43,904 LIKE SPECIFIC REVIEW CRITERIA 7566 04:55:43,904 --> 04:55:44,405 IN FUNDING OPPORTUNITY 7567 04:55:44,405 --> 04:55:48,175 ANNOUNCEMENTS. 7568 04:55:48,175 --> 04:55:55,783 BROADENING THE POOL OF NAM'S 7569 04:55:55,783 --> 04:55:56,283 EXPERTISE AVAILABLE FOR 7570 04:55:56,283 --> 04:56:01,121 SCIENTIFIC GROUPS. 7571 04:56:01,121 --> 04:56:05,159 TSR IS ALREADY WORK ON THIS BY 7572 04:56:05,159 --> 04:56:07,361 EXPANDING BIAS AWARE PS AND 7573 04:56:07,361 --> 04:56:09,997 MITIGATION TRAINING TO INCLUDE 7574 04:56:09,997 --> 04:56:10,464 INFORMATION AND ABOUT 7575 04:56:10,464 --> 04:56:12,599 SCIENTIFIC BIAS. 7576 04:56:12,599 --> 04:56:14,435 BROADER EFFORTS TO COMMUNICATE 7577 04:56:14,435 --> 04:56:15,269 THE VALUE OF TRANSLATIONAL 7578 04:56:15,269 --> 04:56:16,937 SCIENCE ARE LAID OUT IN THE 7579 04:56:16,937 --> 04:56:19,073 NCATS DRAFT AND STRATEGIC PLAN, 7580 04:56:19,073 --> 04:56:24,478 WE SUPPORT THIS GOAL AND 7581 04:56:24,478 --> 04:56:27,448 ENCOURAGE NCATS TO CLARIFY THE 7582 04:56:27,448 --> 04:56:30,484 RORNT ROLE OF SCIENTIFIC REVIEW 7583 04:56:30,484 --> 04:56:32,820 IN ADVANCING NAMS AND 7584 04:56:32,820 --> 04:56:33,420 TRANSLATIONAL SCIENCE IN THE 7585 04:56:33,420 --> 04:56:36,156 STRATEGIC PLAN. 7586 04:56:36,156 --> 04:56:40,194 LASTLY WE ENTHUSIASTICALLY 7587 04:56:40,194 --> 04:56:42,196 SUPPORT AND CAST EXEMPLARY 7588 04:56:42,196 --> 04:56:43,030 STRATEGIC PLANNING ACTIVITIES 7589 04:56:43,030 --> 04:56:45,833 WHICH INCLUDE OPEN AND 7590 04:56:45,833 --> 04:56:48,168 COMPREHENSIVE GATHERING OF 7591 04:56:48,168 --> 04:56:50,304 STAKEHOLDER INPUTS AND GROUND 7592 04:56:50,304 --> 04:56:52,673 PEOPLE DISCUSSIONS ON RFI ON 7593 04:56:52,673 --> 04:56:55,042 THE DRAFT STRATEGIC PLAN 7594 04:56:55,042 --> 04:56:56,143 FRAMEWORK AND RFI ON THE 7595 04:56:56,143 --> 04:56:58,278 STRATEGIC PLAN. 7596 04:56:58,278 --> 04:57:01,482 WE ENCOURAGE NCATS TO SHARE THE 7597 04:57:01,482 --> 04:57:03,517 SUCCESS OF THESE APPROACHES 7598 04:57:03,517 --> 04:57:05,652 WITH THE ICO'S AND THE NIH WIDE 7599 04:57:05,652 --> 04:57:07,421 STRATEGIC PLAN TEAM TO SIN 7600 04:57:07,421 --> 04:57:07,955 SPIRE SOME MORE EFFORTS. 7601 04:57:07,955 --> 04:57:09,089 >> THANK YOU. 7602 04:57:09,089 --> 04:57:10,391 >> Joni Rutter: WONDERFUL. 7603 04:57:10,391 --> 04:57:15,062 THANK YOU SO MUCH FOR THOSE 7604 04:57:15,062 --> 04:57:16,864 COMMENTS AND JOINING US HERE 7605 04:57:16,864 --> 04:57:18,499 TODAY. 7606 04:57:18,499 --> 04:57:20,134 SO CATHERINE, OOPS I DID THE 7607 04:57:20,134 --> 04:57:22,803 WRONG THING HERE. 7608 04:57:22,803 --> 04:57:24,505 I'M NOT SURE WHAT I DID. 7609 04:57:24,505 --> 04:57:25,572 SHE ENDED IT, SO I THINK WE ARE 7610 04:57:25,572 --> 04:57:26,974 OKAY. 7611 04:57:26,974 --> 04:57:29,343 I WANTED TO RECOGNIZE THE 7612 04:57:29,343 --> 04:57:29,877 PHYSICIANS COMMITTEE FOR 7613 04:57:29,877 --> 04:57:32,613 RESPONSIBLE MEDICINE. 7614 04:57:32,613 --> 04:57:35,649 THEY SENT US A LETTER PENNED BY 7615 04:57:35,649 --> 04:57:36,950 CATHERINE KREBS. 7616 04:57:36,950 --> 04:57:38,318 THEY SENT US A LETTER FOR 7617 04:57:38,318 --> 04:57:40,921 PUBLIC COMMENT. 7618 04:57:40,921 --> 04:57:42,823 AND BECAUSE IT IS FOR PUBLIC 7619 04:57:42,823 --> 04:57:44,658 COMMENT AND FOR OUR COUNCIL, I 7620 04:57:44,658 --> 04:57:45,759 WANT TO FIRST ALL THANK THEM 7621 04:57:45,759 --> 04:57:47,361 FOR THE COMMENT AND THE LETTER. 7622 04:57:47,361 --> 04:57:49,863 AND MAKE SURE THAT FOR THE 7623 04:57:49,863 --> 04:57:50,898 COUNCILMEMBERS FOR YOU ALL TO 7624 04:57:50,898 --> 04:57:52,232 SEE THE LETTER WE WILL BE 7625 04:57:52,232 --> 04:57:55,402 MAKING SURE YOU HAVE IT IN YOUR 7626 04:57:55,402 --> 04:57:58,939 INBOX, RELATIVELY SOON. 7627 04:57:58,939 --> 04:58:01,375 AS SOON AS COUNCIL IS OVER SO 7628 04:58:01,375 --> 04:58:03,744 YOU HAVE THAT AND THAT WILL 7629 04:58:03,744 --> 04:58:05,145 REFLECT THE LETTER IN THE 7630 04:58:05,145 --> 04:58:06,246 COMMENTS AND IN OUR MINUTES 7631 04:58:06,246 --> 04:58:07,748 FROM THE COUNCIL TODAY. 7632 04:58:07,748 --> 04:58:09,183 THANK YOU AGAIN. 7633 04:58:09,183 --> 04:58:11,685 AND WITH THAT, I BELIEVE WE CAN 7634 04:58:11,685 --> 04:58:12,920 ADJOURN. 7635 04:58:12,920 --> 04:58:14,955 AND SO I WILL GAVEL US OUT. 7636 04:58:14,955 --> 04:58:16,323 THANK YOU, AGAIN FOR A 7637 04:58:16,323 --> 04:58:26,667 SUCCESSFUL MEETING. 7638 04:58:27,501 --> 04:58:37,778 [ END 4:38 P.M. ET ]